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Abstract 
 
Jenni Burt                  2010 
 
Equity, need and access in health care: a mixed methods investigation of 
specialist palliative care use in relation to age 
 
The equitable provision of care is a core principle of the NHS. Previous 
research suggests that older cancer patients may be less likely to use 
specialist palliative care than younger patients, but studies have failed to 
fully define and measure clinical need. The aim of this study was to examine 
use of specialist palliative care in relation to age, after controlling for need. I 
used a mixed methods approach, grounded in a pragmatic philosophy and 
drawing upon a health capability account of equitable healthcare.  
 
I undertook a focused ethnography of three specialist palliative care services, 
using documentary evidence, observation of meetings, and interviews to 
investigate conceptualisations of need for care. I derived two models of need. 
The first ‘aspirational’ model encompassed physical, psychological, social 
and spiritual care for patients and carers. However, with limited resources, a 
predominantly physical model of need was applied. Additionally, 
observations suggested that care may vary in relation to patient 
characteristics including age.  
 
To locate a suitable measure of need, I conducted a systematic literature 
review and critical and content appraisal of health-related quality of life 
instruments. I chose the EORTC QLQ-C30 instrument as the indicator of 
need in a cross-sectional survey of patients and carers, conducted to measure 
use of specialist palliative care in relation to age. 252 patients and 137 carers 
attending four outpatient lung cancer clinics participated. 39% received 4 
 
specialist palliative care. Age was not associated with use of specialist 
palliative care; metastatic disease, global quality of life (‘need’) and the clinic 
where treatment was provided were.  
 
These findings suggest equitable use of specialist palliative care. However, a 
comprehensive account of equity must consider both use and quality of care. 
There were some suggestions that, within a resource-limited context, the 
quality of care may vary. Future equity research should prospectively 
consider variations in use and quality of specialist palliative care for different 
patient groups across all care settings, and from diagnosis to death.  5 
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Chapter 1 
 
Introduction 
 
The appointed day, 5 July 1948, brought not one extra doctor or nurse. What it did 
was change the way in which people could obtain and pay for care. They ceased to 
pay for medical attention when they needed it, and paid instead, as taxpayers, 
collectively. The NHS improved accessibility and distributed what there was more 
fairly. It made rational development possible, for the hierarchical system of command 
and control enabled the examination of issues such as equity.  
 
Geoffrey Rivett. From Cradle to Grave: fifty years of the NHS. 1 
 
 
The equitable provision of care was a founding principle of the National 
Health Service (NHS). Its creation was intended to enable access to high 
quality medical care for all, according to their need. 2 Today, the allocation of 
health care on the basis of clinical need alone remains a central tenet of the 
service. As the NHS Plan states: 
 
Everyone – no matter how much they earn, who they are, how old they are, where 
they come from or where they live – should have the health care they need for 
themselves and for their families. 3 
 
The principle of equitable care is further reinforced in the NHS Constitution 
for England. The first principle of the Constitution declares that the NHS will 
provide a comprehensive service to all, regardless of their socioeconomic 
characteristics, gender, ethnicity, disability, age, sexual orientation, religion 
or belief. 4 The rights of patients recorded within this document include the 
right to access NHS services, and the right not to be unlawfully 
discriminated against in the provision of care, including on the basis of age. 4 
 17 
 
The pursuit of equitable health care is founded on the Government’s 
commitment to principles of social justice. Social justice is concerned with 
the fair distribution of goods and resources within society, frequently 
aligned to egalitarian goals. The current Government argues that equality is 
both a right and a necessity; that ‘fairness is the foundation for individual 
rights, a prosperous economy and a peaceful society.’ 5 However, recent 
Government health care policy also prioritises the needs of the most 
disadvantaged in society in their pursuit of reductions in inequalities in health. 6 
The Government’s notion of fairness may thus incorporate both egalitarian and 
prioritarian ideals.  
 
This dual concern, to ensure equality as well as reduce disadvantage within 
society, is reflected in recent Government efforts to improve the treatment of 
older people within the NHS. Acknowledging gaps in treatment between 
older and younger patients, and the deprivation suffered by many people as 
a result of older age, in 2001 the Government published the National Service 
Framework (NSF) for Older People. 7 This aimed to provide a cohesive 
strategy for the delivery of high quality health care to older people, and 
outlined steps to tackle age discrimination throughout the NHS. Standard 
one of the NSF stated that ‘NHS services will be provided, regardless of age, 
on the basis of clinical need alone’. 7 A 2006 review of the impact of the NSF 
concluded that, whilst explicit age discrimination in access to NHS services 
had declined, ageist attitudes and practices persisted. 8 A more recent report 
into the treatment of older people within health and social care reinforced 
these findings, suggesting that action was still required to address implicit 
discrimination and negative attitudes. 9 
 
Cancer care is one of several clinical areas where concerns about inequitable 
use of services by age have arisen. Cancer is predominantly a disease of 18 
 
older people; in 2006, two thirds of cancers and three quarters of cancer 
deaths occurred in people aged 65 and over. 10 Lower use of cancer services 
by older people has been reported along the entire disease course, from 
diagnosis through to treatment and supportive care. 11;12 The NHS Cancer 
Plan and the more recent Cancer Reform Strategy acknowledged that there 
were variations in the treatment patients received according to their age, and 
stated that such variations were unacceptable. 13;14  
 
Current evidence suggests inequalities in access to and use of cancer care 
persist up until death. Systematic reviews of palliative care use have 
concluded that older patients are less likely to receive these services 
compared to their younger counterparts. 15-17 The NSF for Older People 
highlighted concerns that older people may have more limited access to 
palliative care. 7 This policy message was reinforced by the publication of a 
World Health Organisation (WHO) report on palliative care for older people, 
which suggested that older age may be a barrier to end of life care. 18  
 
Alongside their cancer care reform programme, the Government have aimed 
to improve the funding and provision of palliative care services. Publication 
of guidance on supportive and palliative care by the National Institute for 
Clinical Excellence (NICE) in 2004 was followed by the End of Life Care 
Strategy in 2008. 19;20 Under this strategy, PCTs are required to conduct a 
comprehensive assessment of the end of life care needs of their population, 
with a particular aim of providing high quality care to all regardless of age 
and other patient characteristics.  
 
Current policy thus strongly supports efforts to ensure older people receive 
the health care they need, including end of life care. Efforts to reduce 
acknowledged variations in access as a result of age will be further 19 
 
reinforced by the introduction of the Equality Bill currently before 
Parliament. 21 The Equality Bill would explicitly ban age discrimination 
against adults in the provision of goods, facilities and services. This would 
legally require the same medical care to be given to people with the same 
condition, regardless of age, unless age-based variations in care were 
justifiable.  
 
However, the Government has acknowledged that further methodological 
developments and research are required to develop understanding of 
inequities in access to health care. As a result, it has established a National 
Cancer Equality Initiative to advise on future research, and to develop an 
action plan to reduce inequalities in cancer care. Research into the fair 
distribution of healthcare is dependent on a number of important factors. 
The first of these is the accurate definition and measurement of need. 22 This 
is essential if we are to assess equity (variations in use between groups which 
cannot be attributed to variations in need) rather than simply equality of use. 
23 There are a number of different approaches to defining need for healthcare, 
but within public health, need for health care is commonly classified as a 
person’s capacity to benefit from that health care. 24;25 This may encompass 
not just physical, but social, emotional and other outcomes. 26 Such holistic 
approaches to need measurement may be particularly relevant to palliative 
care, which aims to improve quality of life across all its dimensions. 27 
 
To date, studies on variations in use of palliative care have not 
comprehensively investigated and controlled for patients’ need for care. 
Typically, studies have looked at use without considering need, or have 
approximated need to the existence of a cancer diagnosis or the presence of a 
physical symptom such as pain. 15 Furthermore, studies have rarely 
considered the needs of carers as well as patients in determining use of care, 20 
 
in spite of the stated aim of palliative care to improve quality of life for 
patients and their families. 27 Definitions of palliative care need are 
complicated by the division of palliative care into that that provided by 
generalists in their everyday work (such as GPs and district nurses), and that 
provided by specialists (such as consultants and clinical nurse specialists in 
palliative medicine). 28 In this model, specialists offer advice and care to 
patients with more complex and persistent problems, which generalists may 
not have the skills to deal with effectively. 19 However, there is currently little 
evidence on how providers distinguish a need for specialist as opposed to 
generalist palliative care.  
 
Accurate data on use are also essential if we are to draw firm conclusions 
about the distribution of health care. Previous studies of the use of palliative 
care have often drawn on incomplete and inaccurate data on use, in part as 
most have taken a retrospective approach. Cross-sectional and prospective 
methods offer a more rigorous way of gathering high quality data on service 
referral and use.  
 
A comprehensive investigation into health care inequalities will thus define, 
operationalise and accurately measure need in relation to use, as well as 
considering the reasons why any variations in use arise. Mixed methods 
represent a particularly suitable approach to achieving this, combining 
qualitative and quantitative techniques to formulate and measure concepts 
of need for care and assess access in relation to this need. Mixed methods are 
frequently partnered by a pragmatic philosophy, particular concerns of 
which are the clarification of ideas through consideration of their practical 
consequences, and the acknowledgement of the influence of the beliefs of the 
researcher on the matter at hand. 29 Such ideas are particularly relevant to 
research into inequalities, which may stem from a belief that differences in 21 
 
the use of health care which do not reflect differences in need are unjust, and 
must be reduced.  
 
The aim of this study is to examine use of specialist palliative care (SPC) 
services, in relation to age, after controlling for need. There are three core 
objectives: 
 
1.  To explore, using documentary evidence, qualitative observation and 
interviews, how SPC providers define and conceptualise patients' 
need for care. 
 
2.  To systematically identify health-related quality of life (HRQL) 
instruments developed for use in palliative care and lung cancer 
patient populations, and to appraise their validity for use as indicators 
of need for SPC. 
 
3.  To conduct a cross-sectional survey to measure use of SPC in younger 
versus older lung cancer patients, in relation to need. 
 
I start the thesis with an overview of relevant conceptual issues, including 
theories of social justice, equity and need; current evidence of use of SPC by 
age; and potential explanations for variations in the use of health care in 
older people. I then consider theoretical and methodological issues in mixed 
methods research, giving a detailed account of the development and 
structure of this study including its grounding in a pragmatic approach. The 
background sections of the thesis close with a detailed description of the 
context and setting of the study, including further details of the nature of 
palliative and lung cancer care. Descriptions of the empirical work 
undertaken then commence with my ethnographic study of three SPC 22 
 
providers to consider how need for care may be conceptualised. I move on to 
present the methods and findings of a systematic literature review and 
critical appraisal of existing HRQL instruments used within cancer and 
palliative care, and their relevance for use as indicators of need. The final 
empirical work presented is a cross-sectional survey of lung cancer patients 
and carers assessing use of SPC in relation to age, after controlling for need. 
In the closing chapter, I draw these elements together to present inferences 
derived from this research, my conclusions, and my recommendations for 
further research and future policy developments. 23 
 
Chapter 2 
 
Conceptual overview 
 
Youth is full of sport, 
Age’s breath is short, 
Youth is nimble, Age is lame: 
Youth is hot and bold, 
Age is weak and cold. 
 
William Shakespeare. From The Passionate Pilgrim. 30 
 
 
Current Government policy supports equal access to SPC regardless of age. 
Why is this? What principles are used to determine the distribution of health 
care? Further, if differences between older and younger people in the use of 
SPC are seen as unfair, how might such differences arise?  
 
In this chapter I outline concepts of social justice, equity and need for health 
care, although I reserve further analysis of these accounts for my 
conclusions. I consider issues in defining and measuring need for SPC, and 
current evidence for variations of use of SPC by age. Finally, I present 
explanations for lower use of SPC by older patients. 
 
2.1 Social justice, equity and need 
The NHS was founded to be universally available, comprehensive and free 
at the point of use. 31 The concept of a publicly financed health care system, 
available to all on the basis of clinical need rather than ability to pay, was 
revolutionary at the time. 32 Despite major reorganisations and changes over 
the years, most notably the more recent introduction of the principles of 
patient choice and provider competition, the founding principles of the NHS 24 
 
remain strong. 33 The current Government recently reaffirmed its 
commitment to these, set out in a new NHS Constitution published in 2008 
following Lord Darzi’s Next Stage Review. 4;34 The Constitution sets out 
seven core principles of the NHS, which include access on the basis of 
clinical need, and the provision of a comprehensive service available to all. 
These principles are underpinned by core values, including respect and 
dignity, commitment to quality of care, and compassion.  
 
Social justice and health care 
The UK Government’s adherence to equitable principles within health care 
stems from an ongoing commitment to social justice. Theories of social 
justice are concerned with how goods and resources are shared amongst 
members of society. Philosophical debates about which principles of 
distributional justice should guide access to health care underpin the public 
health literature on equity of care, and thus are reviewed briefly below.  
 
The most influential theory of social justice, ‘Justice as Fairness,’ was 
proposed by John Rawls in 1971. 35 In his theory, he argues that rational 
persons would choose two general principles of justice to structure society: 
 
1.   Each person is to have an equal right to the most extensive total system of 
equal basic liberties compatible with a similar system of liberty for all. 
2.   Social and economic inequalities are to be arranged so that they are both: [2a] 
to be attached to offices and positions open to all under conditions of fair 
equality of opportunity; [2b] and to be to the greatest benefit of the least 
advantaged members of society (the difference principle). 36 p266 
 
The first principle has priority over the second principle, whilst within the 
second principle, the principle of fair equality of opportunity (2a) takes 
precedence over the difference principle (2b). A person’s advantage 25 
 
(essential to applications of the difference principle) is defined by social 
primary goods, which Rawls classifies into five groups: 
 
(a) basic rights and liberties; 
(b) freedom of movement and choice of occupation; 
(c) powers and prerogatives of offices and positions of authority and responsibility; 
(d. income and wealth; 
(e) the social bases of self-respect. 36 p386 
 
Rawls did not explicitly include health or health care as one of the basic 
social goods which should be distributed equally. However, the influence of 
Rawlsian arguments is such that they have subsequently been applied to 
health care, albeit in different ways. 37;38 Philosopher Norman Daniels 
extended Rawls’ ‘fair equality of opportunity’ principle (his second 
principle) to decisions about the distribution of health care. He argues that 
the primary function of health care is to maintain normal species 
functioning, and thus the range of opportunities that are open to individuals. 
The achievement of this principle requires universal access to appropriate 
health care, not based on ability to pay. 37 However, Daniels also 
acknowledges that health care is not the only social good to be distributed, 
and so in his formulation of justice rationing and prioritisation are inevitable. 
39 This includes the restriction of health care in some circumstances to older 
patients. Ethicist Ronald Green, by contrast, draws on Rawls’ first principle 
of justice to support his argument that health care is one of the basic social 
goods. 40 He contends that access to health care is instrumental to the pursuit 
of other values held to be important, and that there is a right of equal access 
to the best quality health care that a society can afford. 41 These and other 
approaches to the distribution of health care are summarised in Figure 2.1. 
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Rawlsian principles of social justice have been criticised by proponents of the 
capability approach. In particular, Amartya Sen argues that the use of 
primary social goods to identify advantage or disadvantage is insufficient to 
account for differences between people, and in particular people’s abilities to 
convert primary goods into what they wish to be and to do with their lives. 
We should instead focus on people’s capabilities to function. 42 Capabilities 
represent different combinations of functionings (doing and being) with 
resources (that which are used to achieve functionings). Sen himself has 
refrained from defining what these capabilities are, but another influential 
capability theorist, Martha Nussbaum, has committed herself to providing a 
list. 43 This comprises ten capabilities which she argues are essential for a 
good life, and which capability-based theories of social justice should 
promote:  
 
1.  normal life span 
2.  bodily health 
3.  bodily integrity 
4.  senses imagination and thought 
5.  emotions 
6.  practical reason 
7.  affiliation 
8.  other species 
9.  play 
10. control over one’s environment 
 
Whilst, as with Rawls, capability approaches did not at first directly include 
health, their influence has spread to the debate about the distribution of 
health care. 44 Sen has set out the centrality of illness and health to any 28 
 
discussion of social justice and equity, and argued for a multidimensional 
concept of health equity. 45 This is concerned with: 
 
...the achievement of health and the capability to achieve good health, not just the 
distribution of health care. But it also includes the fairness of process and thus must 
attach importance to non-discrimination in the delivery of health care. 45 p31 
 
Ruger has further developed a capability view of health and access to health 
care (the ‘health capability account’) and outlined its implications for public 
health policy. 46-48 In her theoretical framework, health policy should aim to 
support individual’s capabilities for health functioning by providing the 
conditions in which individuals can meet their health needs. 46 The goal of 
health systems is to reduce disparities in health capabilities in the most 
efficient manner. This should be achieved through both procedural 
mechanisms and by reference to a substantive, capability approach with its 
focus on removing barriers to both process and opportunity aspects of 
freedom. Aiming for equal access to high quality evidence-based care, 
making efforts to expand individual’s health agency (their ability to navigate 
the health care system), and taking a shared responsibility between 
individuals, providers and institutions to achieve health goals all stem from 
this approach. 46 Further, Ruger argues for the moral importance of health 
care quality, as differences in the quality of health care available to 
individuals are unjust in their impact on individual’s capability for health 
functioning. 48 A final dimension of Ruger’s theoretical argument for equal 
access to health care is the requirement for society to seek to remove any 
social disadvantages (including reduced access to health care) that may 
result from social exclusion. 48 Thus, social norms towards, for example, 
older adults, must be inclusive, ensure dignity and grant each individual 
equal moral worth. 48 
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The major distinction between Rawlsian and capability approaches is that 
the former emphasises outcomes, whereas the latter emphasises the means to 
achieve outcomes. Thus, Sen argues for a focus on the ability of people to 
choose between opportunities, whereas Rawlsian approaches (including that 
of Daniels) are focused on the opportunities themselves. As Sen writes: 
 
Equality of freedom to pursue our ends cannot be generated by equality in the 
distribution of primary goods. We have to examine interpersonal variations in the 
transformation of primary goods (and resources more generally) into respective 
capabilities to pursue our ends and objectives. 49 p87 
 
The concepts of social justice outlined above are predominantly egalitarian. 
None are strictly egalitarian. This would require all health care to be 
distributed equally, regardless of whether this forces everyone to be worse 
off than they may have been in an unequal society (an outcome known as 
‘levelling down’). 50 Instead, conditional egalitarianism incorporates 
efficiency principles alongside egalitarian principles. Thus, under Rawls’ 
difference principle, an expansion of inequality may be just as long as it is 
not detrimental to the less advantaged. Such an outcome is known as a 
Pareto improvement: a distributional decision which makes one individual 
better off without making any other individual worse off. 
 
There are further, alternative formulations of social justice, primarily based 
either on prioritarian or on sufficiency principles. 51 Prioritarian principles, 
such as those set out by Derek Parfit, are founded on the argument that 
improving the position of the worst off is of greater importance than 
achieving equality. 52 Whilst both prioritarians and egalitarians might 
support the moral importance of benefitting the worst off, Parfitt asserts that 
these concerns arise from differing underlying beliefs. Thus, he argues that 
an egalitarian is concerned with relative wellbeing, whilst a prioritarian is 30 
 
concerned with absolute wellbeing. 52 His view is a variation of 
utilitarianism, in that improving the situation of the most deprived will bring 
about the greatest gain in social utility or well-being.  
 
By contrast, sufficiency principles question whether everyone has ‘enough’, 
and are concerned with maintaining people above a critical threshold of 
advantage. 53;54 Casal identifies two formulations of the sufficiency thesis. 51 
In its positive and moderate form, sufficiency is simply concerned with 
eliminating deprivation, a widely supported goal which is compatible with 
additional distributional principles. By contrast, the negative formulation of 
sufficientarianism focuses entirely on ensuring that everyone has enough, 
and explicitly rejects egalitarian and prioritarian principles. Thus, as long as 
everyone has reached the threshold of sufficiency, it is seen as of no moral 
importance if others have more. 53 As Crisp states: 
 
The Compassion Principle: absolute priority is to be given to benefits to those below 
the threshold at which compassion enters. Below the threshold, benefiting people 
matters more the worse off those people are, the more of those people there are, and 
the greater the size of the benefit in question. Above the threshold, or in cases 
concerning only trivial benefits below the threshold, no priority is to be given. 54 
 
There is a lively, ongoing debate within the philosophical literature about the 
detail, respective merits, and compatibility of egalitarianism, prioritarianism 
and sufficientism (see for example Campbell Brown 55and Ole Norheim 56). 
Thus, principles of social justice underpinning health care provision remain 
contested, with no clear consensus emerging. For this reason, Daniels has 
argued that in the absence of agreement on guiding principles of 
distribution, a focus on procedural principles is increasingly important [see 
Figure 2.1, page 26, for an illustration of these]. 39 As he states:  
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Access to health care cannot be considered equitable if it is much more difficult for 
some people to get care than it is for others, even if people make adjustments to the 
burdensomeness of the process and get the amount of care they need. 57  
 
His formulation, together with Jim Sabin, of ‘accountability for 
reasonableness’ sets four conditions to ensure fairness in setting priorities for 
health care, and places procedural rather than distributional justice at the 
heart of the debate: 58 
 
•  Relevance – evidence and values used to make priority setting 
decisions must be relevant 
•  Publicity – priority setting decisions and the reasons behind them 
must be made public and accessible 
•  Revisability – decisions must be reviewed in the light of new evidence 
and public opinion 
•  Enforcement – the above conditions must be met 
 
Philosophical criticisms of the accountability for reasonableness approach 
centre on the lack of clarity about which criterion of ‘fairness’ Daniels is 
appealing to. 59 Additionally, Ruger has argued that this emphasis on fair 
procedures may allow differential access to health care between different 
areas or health plans as long as each has satisfied the conditions for 
accountability for reasonableness, a situation a capability approach would 
not support. 48 Practical criticisms highlight the fact that the authors have not 
suggested how institutions might actually operationalise the model. 60  
 
Some of this criticism reflects a wider concern that philosophical debates on 
justice take place at an abstract level which renders their application to 
practical policy making decisions almost unworkable. 61 This has been taken 
up by philosophers Jonathan Wolff and Avner de-Shalit, who set out to 32 
 
formulate an egalitarian theory which was applicable to social policy. They 
argue that the crucial issue facing governments, in the light of restricted 
resources, is simply ‘to identify the worst off and take appropriate steps so 
that their position can be improved’. 62 p3 They acknowledge the importance 
of both distributional and social equality, but aim to weave these together to 
provide a model to guide the relief of disadvantage. In doing so, they draw 
on the capability approach of Sen and Nussbaum. Using this as a 
springboard, the major modification they propose is that what matters to an 
individual is not only the level of functionings they have at any particular 
point, but their likelihood of sustaining that level of functioning. They 
summarise their overall proposition as follows: 
 
...the interaction of your internal resources and your external resources with the 
social and material structure within which you find yourself, determines your 
genuine opportunities for secure functionings, creating for you paths of varying cost 
and difficulty. In short, your resources are what you have to play with; the structure 
provides the rules of the game. 62 p 173 
 
Opportunities for addressing disadvantage therefore exist at the level of 
internal resources (including medical intervention), external resources 
(including cash compensation or resource enhancement) and social 
structures (including changes in the law or social attitudes). 62 In the 
formulation of Government policy, according to Wolff and de Shalit, priority 
should be given to the least advantaged: however, this does not mean that 
the least advantaged will always receive priority. Thus, if doctors must 
decide between offering a heart transplant to one of two patients, they are 
still likely to decide the recipient on the basis of clinical norms rather than 
purely on the basis of which patient is the least educated or otherwise 
disadvantaged. Whether the hospital receives sufficient resources in the first 
place to offer heart transplants will, however, be in part decided by whether 33 
 
this is a component of an efficient package of measures aimed at improving 
the position of the least advantaged overall.  
 
As Wolff and de-Shalit recognise, the importance attached to social justice by 
the Government demands that decisions are made about how best to offer a 
system of health care regarded by society as fair (and, typically, equitable). I 
therefore turn now to consider the definition of equity within health care 
theory and policy. 
 
Equity of health care 
In 1992, Margaret Whitehead published an influential paper on equity and 
health that defined health inequities as differences in health which were 
unnecessary, unfair and unjust. 23 She went on to offer three possible 
definitions of equity in health care: 
 
1.  Equal access to available care for equal need 
2.  Equal use for equal need 
3.  Equal quality of care for all 
 
The distinction between equity and equality is important: equity, unlike 
equality, is essentially a normative concept. 63 Not all health care inequalities 
may be judged to be unjust or unfair – however, Whitehead does not go on 
to specify how such judgements should be made. 64  
 
The distinction between access and use emphasised by Whitehead is also an 
important one. 65;66 Access is concerned with the availability of suitable 
opportunities to use health care. Whether individuals and groups actually 
gain access to (use) the health care services they need depends on issues such 
as the affordability, physical accessibility and acceptability of services, not 34 
 
just the sufficiency of supply. 67 The opportunity to use health care may thus 
not be converted into actual use, whether for social, cultural, practical, 
attitudinal or other reasons. Differences in use which arise as a result of 
differences in individual preferences are unlikely to be regarded as 
inequitable, although the attribution of use to individual choice or other 
factors external to an individual is difficult. 68 Access to health care is 
perhaps a more conceptually important measure than use of health care, as it 
is the equal opportunity to use health care that is the central concern of 
health care systems pursuit of equity, even if that opportunity is not taken 
up. 26 However, in practice, use is the measure that is employed by most 
researchers, for the simple reason that it is more easily determined. 69  
 
Whitehead’s third definition of equity of health care, that of quality, moves 
away from outcomes to consider the nature of care provided. Systematic 
differences between particular groups of people in the speed with which 
they receive care, the quantity or intensity of the care received, and the 
humanity with which care is delivered may all therefore be aspects of 
inequity of care. Thus, it is not only entry into the health care system which 
must be monitored if we are concerned about the achievement of equity, but 
also what occurs as people travel through the system. This again highlights 
the importance of procedural justice; whilst we may accept the outcome of 
the chosen distributional principle, concerns could remain if the process by 
which these outcomes are achieved is considered unfair. Thus, as outlined 
above, Norman Daniels has argued that access to health care cannot be seen 
as equitable if it is more difficult for some people to get that care, even if they 
are adequately treated in the end. 57 Sen has also reiterated the importance of 
process equity, alongside outcomes (such as improved health) and the 
capability to achieve these outcomes. 45 
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There are two important dimensions of equity, originating in Aristotelian 
theories of justice. The first principle, known as horizontal equity, requires 
the equal treatment of individuals who are equal in relevant respects (for 
example, there should be equal use for equal need). The second, related 
principle requires the proportionately unequal treatment of individuals 
unequal in relevant respects (for example, unequal use for unequal need). 
This is known as vertical equity. A comprehensive examination of equity of 
health care will incorporate both measures, as the presence of horizontal 
equity does not necessarily imply the presence of vertical equity. 70 For 
example, whilst both older and younger cancer patients with an advanced 
stage of disease may be equally likely to receive a particular course of 
treatment, it does not necessarily follow that there is equal access to 
treatment by age group at a less advanced stage of cancer.  
 
A slightly different perspective on vertical equity is given by economist 
Gavin Mooney, who argues that vertical equity is essentially about positive 
discrimination. 71 Acknowledging that, thus far, a concern with delivering 
equitable health care has done little to narrow the gap between the 
advantaged and disadvantaged, Mooney suggests a community approach to 
deciding the relevant claims on care of each social group. 72 Consequences of 
care (such as an improvement in health) may be less important than the 
process by which care is decided. 71 Mooney’s work moves the concept of 
vertical equity away from egalitarian principles and towards prioritarian 
principles. Although not explicitly stated, it is apparent that in his support of 
efforts to provide fairer health care by reducing differences in health, access 
to and use of health care, the underlying concern becomes not relative 
wellbeing, but absolute wellbeing.  
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Whilst both dimensions of equity are important if assessments are to be 
comprehensive, in research practice to date the focus has predominantly 
been on horizontal equity. 73 This is most commonly defined as ‘equal use for 
equal need’. 69 If this is the case, the question arises as to what is meant by 
need.  
 
Need for health care 
The nature of need has been the subject of much debate. I do not intend to 
present an extensive summary of the literature on human need, but a 
diversion into aspects of this debate is presented as a foundation to ideas of 
need for health care.  
 
At its most fundamental, the argument on the nature of human needs centres 
on whether these may be classified as objective and irrefutable, or subjective 
and contestable. 74 Abraham Maslow’s influential hierarchy of human needs 
defines ‘basic needs’ which must be fulfilled in pursuit of the ultimate goal 
of self-actualisation. Arguing for the universality of these needs, Maslow 
stipulates that the fulfilment of these basic needs is a necessary prerequisite 
for health. 75 Similar formulations in relation to health needs include that of 
Doyal and Gough, who define physical health as a basic, and objective, need 
which must be met to fully participate in social life. 76 
 
If ‘true needs’ exist, it follows that they may be distinguished from ‘false 
needs’. 74 However, the determination of both true and false needs on an 
empirical basis alone is criticised by those who argue that value judgements 
are involved in the definition of needs. 77 If this is the case, it is the current 
social and political context which will influence which needs are judged as 
legitimate. 74  
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Below, I review four major approaches to defining health care need, as 
categorised by a philosopher, Per-Erik Liss. 78 The four groups defined by 
Liss are ill health; supply; normative; and instrumental. 
 
Donabedian’s ill health notion of need is that a need for health care exists 
when there are some deficiencies in health that require health care. 79 A 
criticism of this perspective is that a person’s need for health care should in 
fact depend on the existence of an effective or acceptable treatment for that 
person’s illness or disability. That is, a person cannot need health care if 
there is no service or technology available to improve their health. In this 
situation, a person may have a need for health, but they do not have a need 
for health care. 70 This perspective forms the basis of the supply notion of 
need for health care: a need exists when there are both deficiencies in health 
and an effective treatment available. Acheson added to this approach by 
arguing that definitions must account for the limited availability of 
resources, arguing that a need exists only when effective interventions can be 
provided ‘at reasonable cost’. 80;81  
 
Normative notions of need stress that there is a need when someone (for 
example, a patient, or a doctor) believes that health care should be provided 
to an individual or population. In such formulations, medical professionals 
are typically identified as the ones to decide ‘objective’ health care needs. 
These needs are then contrasted with ‘wants’ or ‘demands’, reflecting the 
health care individuals or the public at large feel they ought to receive 
(correctly or otherwise). 82;83 Magi and Allender recognised the unequal 
power balance between doctors and patients in determining need under 
such approaches. They argued that both perceived need (from an 
individual’s perspective) and medically defined need (from a doctor’s 
perspective) incorporate values and norms. 84 38 
 
Bradshaw’s influential taxonomy of social need, widely used within social 
policy, includes the concept of normative need. 85 He defines ‘normative 
need’ as that decided by a group of experts, reflecting the ‘desirable 
condition’ within that society. As such, normative need is based entirely on 
value judgements and will change with changing social values. Three other 
components of need make up Bradshaw’s concept of ‘total need’: felt need 
(as experienced by individuals), expressed need (felt need which is acted 
upon or demand) and comparative need (based on comparing groups or 
individuals within a population). 85 
 
Finally, instrumental notions of need for health care suggest that health care 
is necessary to achieve a particular end state, such as ‘health’. 25;57;86 
Instrumental approaches derived from health economics additionally 
introduce ideas of efficiency to the concept of need alongside an examination 
of the change in state as the result of an intervention.   
 
It is an instrumental definition of need for health care that has come to 
dominate current public health thinking and research. This is economist 
Tony Culyer’s formulation of need for health care as ‘capacity to benefit’ 
from that health care. 25 In practice, capacity to benefit is often equated to 
health status. Thus, in epidemiologically based needs assessments used to 
inform decisions about expenditure within a health system, data are 
gathered on disease burden and cost effectiveness to measure need for care. 
87 This approach separates out need from demand (what people might be 
willing to pay for, or wish to use in a system of free health care), and from 
supply (what is actually provided). 88 Further, need tends to be categorised 
into a dichotomy of need/no need, or into groups representing different 
levels of need, rather than conceived as a continuum.  
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Culyer’s formulation follows supply notions of need in requiring that health 
care must be effective for a need to exist: if there is no expected health gain, 
there can be no capacity to benefit. Benefits may be drawn widely and 
encompass social, emotional and other outcomes. 26 However, as Culyer 
himself has demonstrated, the application of ‘capacity to benefit’ alone as a 
definition of need may lead to difficulties in the equitable distribution of 
care. 24 Thus, in his later work, Culyer refined his formula to include 
resources: 
 
A need for health care is the minimum amount of resources required to exhaust a 
person’s capacity to benefit. 24 
 
He argues that this definition incorporates essential aspects of need in that it 
is instrumental, with a moral objective (Culyer states this to be ‘health for 
flourishing’), sets out what is needed (resources), and additionally defines 
the amount required (that which will exhaust capacity to benefit) without 
setting limits to this. 88 
 
Culyer’s influential formulation of need, with its focus on quantitative 
approaches to assessment, has been criticised for excluding consideration of 
human behaviour (see e.g. James 1999 89). This criticism may be particularly 
relevant to health care specialties such as SPC, where decisions about relative 
need involve assessment over multiple domains. Purely quantitative 
approaches risk excluding the complexities of individual behaviour, social 
circumstances and cultural norms from approaches to defining and assessing 
need. Furthermore, they do not identify or provide a value framework 
through which consensus may be sought as to which needs are accepted as 
needs by society. 72;89  
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Alternative approaches to the formulation of need come from the emerging 
sociological literature on micro-rationing. 90 For example, research into the 
acceptance of patients for cardiac surgery and neuro-rehabilitation found 
clinical decisions were influenced by implicit moral concepts of 
‘deservingness’ rather than clinical ability to benefit, with age, smoking 
habits, and other social factors appearing to affect admission to care. 91 In 
making such decisions, staff moved from a ‘technical’ to a ‘social’ discourse 
when a characteristic such as the older age of a patient came into focus, with 
attitudes displayed reflecting those of the wider public. 92  
 
Further, observations of mental health team meeting discussions have found 
that, for all patients regardless of age, rationing of care was more likely to 
take place by reducing the intensity of treatment on offer, delaying access to 
care or re-defining cases as inappropriate, rather than explicitly refusing 
access. 93 This highlights the importance of considering ‘need’ as a 
continuum rather than the more typical dichotomy of present/absent 
suggested by economic formulations.  
 
Whether formulations of need are derived from an economic or sociological 
stance, the crucial point is that any study of health care use explicitly defines 
and operationalises a model of need. Goddard and Smith list a number of 
key assumptions often made when investigating the use of health care. 26 
Firstly, studies have disregarded need completely, equivalent to assuming 
that levels of need are the same in each patient group being studied. 
Secondly, studies have assumed that morbidity may suffice as a measure of 
need, without investigation as to whether this is sufficiently comprehensive 
for the service under study. Finally, studies have assumed area-level 
characteristics can be applied to individuals as a proxy of their need. 26 The 
practice of most studies which do consider ability to benefit is to rely on the 41 
 
measurement of individual health status, which may be an incomplete 
measure of need for some health care.  
 
Furthermore, capacity to benefit – the most commonly used definition of 
need within public health – may vary in relation to individual characteristics 
such as age, diagnosis, prognosis, comorbidity, family support, living 
conditions, socio-economic status, religious/spiritual beliefs, and access to 
other services. All these may therefore be relevant when considering 
variations in the use of health care. If Culyer’s definition of need is to be 
strictly applied, questions also arise about the measurement of resources. For 
example, should resources be measured cross-sectionally or longitudinally 
when considering need for care? That is, do early presenters to health care 
have a greater need (requirement for resources to reduce their capacity to 
benefit to zero) than late presenters? Time may have a varying influence 
depending on the health problem of concern. Furthermore, Culyer’s 
approach requires services to be effective in order for them to be needed. 
This leads to the question of whether there are particular situations or 
patient characteristics which make services more effective, and if this is the 
case, what the implications of this are for the level of need. 
 
Approaches to the definition and measurement of need are, as highlighted 
above, varied and contested. Inevitably, the requirement for quantitative 
needs assessment in research and planning means that the complexities of 
how need is conceived and shaped within a clinical encounter may be lost in 
its measurement. However, as Goddard and Smith highlight, studies must at 
least state their approach to the definition and measurement of need, even if 
this is acknowledged to be limited. 26  
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Following this overview of equity and need, I turn to consider how these key 
concepts have been employed within policy and practice in recent years. 
 
Theory and policy: the current Government’s position 
Since the election of the Labour Government in May 1997, public health 
policy and healthcare funding has focused on reducing health inequalities 
and improving access to health care for disadvantaged groups. 94 Thus, 
access to healthcare is explicitly linked to an impact on health inequalities. 
As the Government reiterated in their 2009 response to the Health Select 
Committee’s report on health inequalities: 
 
Resource allocation to PCTs is designed to ensure equal access for equal need and 
help to reduce health inequalities. It aims to target resources to where health care 
need is greatest. 95 
 
The Government’s pursuit of better health and better health care for all, and 
the narrowing or elimination of inequalities, has led to policies specifically 
targeting disadvantaged areas and groups. In 2004, the Department of 
Health announced a list of ‘Spearhead PCTs’ in which they would focus 
efforts to reduce health inequalities. 96 These PCTs (currently there are 62) 
were selected as their populations were in the lowest fifth of local authorities 
for at least three of the five following measures: life expectancy at birth in 
males and in females, mortality rates from all circulatory disease and cancer 
in people aged under 75, and the average score in the Index of Multiple 
Deprivation 2004. Spearhead PCTs were given additional funding, and a 
number of national initiatives aimed at reducing health inequalities (such as 
enhanced stop smoking services) and improving access to health care were 
piloted in these areas. 6 Arguing that increasing access to primary care is one of 
the most effective ways of improving population health, the Government has also 43 
 
funded additional GP practices in areas identified as lacking in provision and high 
in disadvantage. 97  
 
Lord Darzi recently argued that ‘a fair NHS must continue to be equally 
available to all, taking full account of personal circumstances and diversity.’ 
97 He went on to state: 
 
To create a fairer NHS, we have to focus on improving access to health and social 
care services for people in disadvantaged and hard-to-reach groups and those living 
in deprived areas. 97 
 
Thus, in both theory and policy, recent Government approaches to the 
distribution of care appear to be based both on egalitarian and prioritarian 
principles. Access to the NHS should be based on equal need, but priority 
(and thus extra resources) should be given to those in most need. Donald 
Franklin, economic adviser to the Department of Health, has suggested that 
current Government policy and practice reflects a pragmatic adaptation of a 
broadly utilitarian agenda which aims to maximise the net benefit of health 
care. 98 Recognising that historical distributions of care have been biased 
against particular groups, he argues that an efficient approach to maximising 
utility is to target health care delivery towards the disadvantaged. The result 
is policies with a concern for health inequalities based on the belief that 
improving health is a means to increase utility (in this case, by preventing or 
removing pain and suffering). However, Franklin also identifies 
inconsistencies within Government rhetoric. He suggests that documents 
such as Saving Lives: Our Healthier Nation outline a broader notion of health, 
the improvement of which is valued not just its utilitarian good, but also for 
its capacity to enable us to lead lives of value: 
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We believe that good health, like good education, should be within reach of all. [...] 
Better health is vital in itself, leading directly to longer, more active and more 
fulfilled lives. 94 
 
The approach of the current Government echoes Wolff and de-Shalit’s 
argument that targeting the worst off is the only sensible tactic in the face of 
limited resources. 62 However, the doctrine behind Government policies 
(whether prioritarian, egalitarian, sufficientarian or some combination of the 
above) is never explicitly stated. Anand has argued that the Government’s 
stance represents a moral hybrid. 99 He contrasts the utilitarian approach to 
priority setting with the prioritisation of patient autonomy and choice at the 
clinical level, suggesting that this is more reflective of a capabilities approach 
with its emphasis on the opportunities individuals have. ‘Fairness’ in 
practice may thus be concerned with reaching out to those suffering the 
most, striving to bring everyone over a particular threshold of quality of life, 
and making sure everyone in the same situation gets the same. The challenge 
is to connect this with a coherent theoretical basis for action.  
 
The concept of vertical equity – unequal use for unequal need – is also 
particularly relevant to current Government policy. As Mooney argues: 
 
...positive discrimination is needed if health services are to be capable of meeting the 
call to provide fairer health care in such a manner as to have some impact on the gaps 
in health, access or use that exist between the better off in societies and the worse off. 
71 
 
The Government concern with narrowing the gap between the advantaged 
and the disadvantaged may have consequences for the definitions of need 
they use to make decisions about the allocation of care. If a fundamental 
health care policy goal is a reduction in health inequalities, this requires an 
understanding both of the impact of health care on health, and of how best to 45 
 
target this health care to the greatest benefit of disadvantaged populations. 
100 In deciding resource allocation within health care, this approach may lead 
the Government away from an explicit commitment to equal access for equal 
clinical need, towards a commitment to equal access for some concept of 
equal social need. 100 That is, preferential access may be offered not simply on 
the basis of disease severity, but also with consideration of personal 
characteristics, to target care towards vulnerable groups such as the poor or 
the old. However, this stance has not yet been explicitly acknowledged by 
the Government.  
 
Following this consideration of the wider context of equity theory and 
policy, I move on to look at how these issues apply specifically to specialist 
palliative care.  
 
2.2 Examining equity of specialist palliative care 
Investigations into the fair distribution of health care must account for the 
nature of the service under investigation. SPC has a number of dimensions 
which render it particularly interesting for investigations of equity: its 
provision across multiple settings (at home, in hospitals and hospices), the 
split between NHS and voluntary providers, and its multidisciplinary 
nature. Furthermore, SPC makes claims about its holistic nature which may 
make it challenging to formulate and measure a concept of need for care. 
Below, I consider how studies have considered need for SPC, and the 
evidence on use of SPC by age they have generated.  
 
Need for specialist palliative care  
To date, studies involving need for SPC have suffered from a number of the 
limitations outlined by Goddard and Smith. 26 Firstly, studies may not define 
what need encompasses. For example, one US report on the differences in 46 
 
palliative care needs in older versus younger patients compared the groups 
on the basis of diagnosis, recommendations on advance care planning and 
symptom management, and decisions about withholding or withdrawing 
treatment, without explaining how these may signify need for care. 101  
 
Alternatively, need for SPC is equated directly with diagnosis. Thus, 
individuals with the diagnosis of interest, typically cancer, are identified 
using administrative health data (e.g. 102) or reports of bereaved relatives (e.g. 
103), and their use of SPC analysed in relation to characteristics of interest 
such as age. This assumes that all individuals with cancer require SPC, 
which is unlikely to be the case. A small refinement of this approach was 
employed by Currow et. al., who used a survey of bereaved relatives to 
obtain data on diagnosis, reported receipt of SPC, usefulness of SPC, and 
reasons for not receiving SPC. 104 Use of SPC was then compared to 
perceived benefit of SPC by patient characteristics including diagnosis and 
age, and an estimate of unmet need according to these characteristics 
derived. This assumes that the proportion of individuals with a particular 
diagnosis estimated by relatives to have found SPC useful represents the 
proportion of patients who need such care. It is doubtful that measuring 
perceived usefulness is equivalent to measuring capacity to benefit.  
 
Patient surveys of groups including advanced cancer patients are another 
approach used to measure need for SPC. Such surveys tend to use much 
more comprehensive formulations of need, questioning respondents on 
prevalence and intensity across areas including physical symptoms, 
emotional, psychological and social problems, and activities of daily living. 
105;106 However, full psychometric testing of the instruments used in these 
surveys has not been undertaken. Thus, whilst their content validity may be 
high, reliability is unknown. Another study used interviews with advanced 47 
 
cancer patients already under the care of SPC teams to identify eleven needs 
over five areas: psychological (emotional support, self-fulfilment, emotional 
closeness, communication, occupational functioning), health related 
(symptom control, nutrition, and sleep), instrumental (personal care), 
financial, and informational. 107  
 
Surveys of health care professionals have also been used to identify patients 
who have a need for SPC. Gott and colleagues conducted a week-long census 
of all patients in one hospital, asking medical and nursing staff to identify 
patients under their care who, in their view, either met the offered definition 
of palliative care (‘Palliative care is the combination of active and 
compassionate therapies intended to comfort and support individuals and 
families who are living with, or dying from, a progressive life-threatening 
illness, or are bereaved’) and/or were terminally ill (defined in advance as 
having a life expectancy of 3 months or less). 108 Using this approach, the 
authors found a discrepancy between patients identified as needing SPC 
according to nursing versus medical staff, and versus their own case note 
review. A broader formulation of SPC need was used in another survey of 
hospital health care professionals, in which equity of access, pleasant 
surroundings, flexibility of visiting hours and discharge planning were 
included alongside pain and symptom management, psycho-social and 
spiritual support. 109 These factors were used as an indicator of palliative care 
needs which were not being addressed by current services, but suggest a 
lack of understanding of the differences between access and need, and 
between need and service provision.  
 
Finally, a small number of papers have focused on one aspect of need, 
including theoretical and empirical formulations of aspects of spiritual SPC 48 
 
need 110;111, and the needs of families of patients within the palliative care 
phase of disease. 112  
 
Routine data, bereaved relative report, patient report and health care 
professional report are thus all used to approximate need within research 
studies. A recent review of definitions and approaches to needs assessment 
in SPC identified three approaches: epidemiological (based on routine 
population data), corporate (involving engagement with the public) and 
comparative (a comparison of the provision of care between areas), and 
argued that a combination of these would be necessary for defining a 
population’s need for care. 113 The authors argue that the definition of need 
as ‘the ability to benefit from health care’ is useful for SPC, and that this may 
include reassurance, supportive care, and relief of carers as well as clinical 
benefit. However, they offer no further advice on how this definition may be 
operationalised and measured.  
 
So, much of the research conducted to date suffers from a lack of clarity of 
the nature of need for care, and explicit definitions of need for SPC. As SPC 
claims to benefit patients over multiple domains, not just physical, any 
definition of need for SPC may be expected to reflect the holistic approach of 
the service. This is rarely the case.  
 
This review of theory and research to date leads me to suggest the following 
questions relevant to the current study:  
 
1.  How is need for SPC conceptualised and applied within day to day 
clinical decision-making? 
2.  Is need for SPC a singular concept, or do multiple versions exist for 
different purposes or in different contexts? 49 
 
3.  How can need for SPC best be operationalised and measured within 
research studies? 
 
The question of need for care is essential to investigations of equity, but so is 
the characteristic by which we are assessing equity – in this case, age. Below, 
I briefly consider how we may define older age, before assessing the current 
evidence on how older age is related to the distribution of SPC.  
 
Old age and use of specialist palliative care 
Beliefs about when ‘old age’ commences are dependent on our own age. A 
survey of nearly 2000 people conducted on behalf of Age Concern found that 
the reported start of old age varied from 55 years amongst 16-24 year olds to 
just over 70 in those aged 75 and over themselves. 114 Within the UK, older 
age is commonly defined in Government policies such as the NSF for Older 
People as being the age of 65 or above. 7 However, this chronological 
definition of old age is currently under challenge due to medical advances 
and rising life spans. 115 As a result of the ageing population, finer categories 
of older age have been developed and applied within medical and other 
research. Thus, we may categorise older persons into the ‘oldest old’ (aged 
85 and above), ‘mid-old’ (aged 75 to 85), and ‘young old’ (aged 65 to 75).  
 
Chronological definitions offer only one approach to considering older age. 
Biological, social and psychological theories of old age offer different 
perspectives on the defining influences of such categorisations. 116 Of 
particular import for health research, self-perceived age, rather than 
chronological age, may be a better indicator of health, psychological and 
social characteristics. 117 However, in this study, I focus on chronological age. 
This is because my assessment of age equity (or inequity) stems from the 50 
 
requirements of Government policy, which uses age in years rather than 
other markers of the ageing process. 
 
Four separate reviews have investigated factors influencing access to 
palliative care, including one specifically on age conducted as background to 
this thesis. 15-17;118 These reviews have consistently concluded that the use of 
SPC services varies according to age. Below, I briefly summarise the 
currently available evidence on use of SPC in relation to age for patients with 
cancer.  
 
The majority of studies conducted in this area to date have been 
retrospective cohort studies using administrative data, ranging in size from 
521 119 to 170,136 participants [Table 2.1]. 120 Three cross-sectional surveys 
using retrospective reports of service use from proxy respondents (usually 
carers) have also been conducted. They included 96, 121 1271 122 and 2074 123;124 
participants respectively. Two further studies have been conducted – one 
used a retrospective case-control design 125 and one was a retrospective 
review of a palliative care service’ records, with comparisons to the wider 
population of cancer deaths. 126 Studies covered deaths occurring from 1979 
to 2003. Two studies restricted participants to patients aged 65 years and 
above at death, and one to 67 years and above; the remaining restricted 
participants to adults, or had no stated age restrictions.  51 
 
Table 2.1 Current evidence on use of SPC by age   
Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
Retrospective cohort studies 
Burge 2008 
127 
Retrospective 
cohort study 
using 
administrative 
data 
Canada 
To re-examine the 
relationship between age 
and palliative care use 
among cancer patients and 
identify the multiple 
indicators contributing to 
these inequalities. 
7511 cancer deaths 
(1998 to 2003) identified 
from death certificates in 
two district health 
authorities in one 
province.18 years and 
over.  
Referral to the 
municipality palliative 
care programme. 
Determined from clinical 
records of the services. 
Over 65 less 
likely to receive 
care 
Over 65 less likely 
to receive care, 
particularly those 
aged 85 and over 
Burge 2002 
128 
Retrospective 
cohort study 
using 
administrative 
data 
Canada 
To determine whether 
previously determined low 
palliative care programme 
referral rates for the elderly 
have been overcome in 
recent years. 
4376 cancer deaths 
(1992 to 1997) identified 
from death certificates in 
one municipality. No 
stated age restrictions. 
Referral to the 
municipality palliative 
care programme. Not 
stated how determined. 
Over 65 less 
likely to receive 
care 
Over 65 less likely 
to receive care 
Costantini 
1993 
129 
Retrospective 
cohort study 
using 
administrative 
data 
Italy 
To identify the 
characteristics of patients 
who received palliative 
home care compared to the 
general population of 
patients who died of cancer. 
12,343 cancer deaths 
(1986 to 1990) identified 
from local department of 
statistics in one city. 18 
years and over. 
Use of the palliative 
home care service. 
Determined from clinical 
records of the service. 
Over 75 less 
likely to receive 
care 
- 52 
 
Table 2.1 Current evidence on use of SPC by age   
Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
Evans and 
McCarthy 
1984 
126 
Retrospective 
cohort study 
(with external 
control group) 
using 
administrative 
data. 
UK 
To describe the first year’s 
work of a terminal care 
support team. 
125 patients (referred 
between May 1982 and 
June 1983) identified 
from the clinical records 
of the service and who 
received continuing 
care. 437 cancer deaths 
(1982) in one district 
identified from the death 
records of the Office of 
Population Censuses 
and Surveys.  
Receipt of continuing 
care from the 
multidisciplinary terminal 
care support team. 
Over 65 less 
likely to receive 
care 
- 
Gray and 
Forster 
1997 
119 
Retrospective 
cohort study 
using 
administrative 
data 
UK 
To identify and compare 
adult residents dying of 
cancer during 1991 who 
received SPC and those 
who did not. 
521 cancer deaths 
(1991) identified from 
death register held by 
the Director of Public 
Health. Participants 
included if postcode of 
residence within District 
Health Authority; cancer 
recorded as a causal or 
contributory factor in 
death. 16 years and 
over 
Receipt of care from one 
or more SPC agencies, 
last 12 months of life. 
Determined from in-
patient and day hospice 
records; Marie Curie and 
Macmillan nurse' case 
load diaries 
Users mean age 
at death 66.6 
Non-users mean 
age at death 73.0 
- 53 
 
Table 2.1 Current evidence on use of SPC by age   
Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
Hunt and 
McCaul 
1996 
130 
Retrospective 
cohort study 
using 
administrative 
data 
Australia 
To compare the population 
of hospice cancer patients 
with non-hospice cancer 
patients in terms of age, 
sex, marital status, primary 
site of malignancy, survival 
time from diagnosis to 
death, country of birth and 
religion of residence. 
2800 cancer deaths 
(1990) identified from 
Central Cancer Registry 
(CCR) database. Deaths 
attributable to a non-
cancer cause – based 
on State death records – 
excluded. No stated age 
restrictions. 
Use of one of South 
Australia's inpatient 
hospice or outreach 
palliative care services. 
Determined from lists 
provided by all hospice 
and palliative care 
services of their patients 
who died in 1990. 
Over 80 less 
likely to receive 
care 
Over 80 less likely 
to receive care 
compared to 
under 40 
Hunt 2002 
131 
Retrospective 
cohort study 
using 
administrative 
data 
Australia 
To determine the extent of 
coverage by designated 
palliative care services of 
the population of terminally 
ill cancer patients in South 
Australia, and to identify the 
types of patients who 
receive these services and 
the types who do not. 
3086 cancer deaths 
(1999) identified from 
State Cancer Registry 
database. No stated age 
restrictions. 
Use of one of South 
Australia's inpatient 
hospice or outreach 
palliative care services. 
Determined from lists 
provided by all hospice 
and palliative care 
services of their patients 
who died in 1999. 
Over 80 less 
likely to receive 
care  
Over 80 less likely 
to receive care 
compared to those 
under 60 
Johnston 
1998 
102 
Retrospective 
cohort study 
using 
administrative 
data 
Canada 
To assess the degree to 
which cancer patients 
resident in the region who 
may need palliative care are 
being referred to the 
comprehensive palliative 
care program. 
14,494 cancer deaths 
(1988 to 1994) identified 
from death certificate 
data included in the 
Cancer Registry in one 
region. 20 years and 
over. 
Referral to a 
comprehensive Palliative 
Care Program (PCP) 
based in one Infirmary. 
Inpatient unit, hospital 
consultation, clinic follow-
up, home consultation 
and bereavement 
support. Determined from 
clinical records of the 
service. 
Over 75 less 
likely to receive 
care 
Over 75 less likely 
to receive care 54 
 
Table 2.1 Current evidence on use of SPC by age   
Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
Keating et. 
al 2006 
132 
Retrospective 
cohort study 
using 
administrative 
data 
US 
To evaluate the relative 
importance of patient 
characteristics, physician 
characteristics, individual 
physicians, and local health 
centres in explaining 
variations in hospice 
enrolment. 
3805 lung, colorectal, 
breast, or prostate 
cancer deaths (January 
1996 to June 2001) 
identified from one 
regional integrated 
health care delivery 
system 
Enrolment in the hospice 
care programme. 
Determined from health 
plan records. 
No age difference  
Over 75 more 
likely to receive 
care 
Lackan 
2003 
133 
Retrospective 
cohort study 
using 
administrative 
data 
USA 
To assess the use of 
hospice by women dying 
with breast cancer as a 
function of time period, 
geographic area, and 
patient characteristics. 
25,161 breast cancer 
deaths (1991 to 1996) 
identified from 
Surveillance, 
Epidemiology and End 
Result (SEER) Medicare 
databases - population-
based registry for 
incident cancer cases. 
SEER areas represent 
about 14% of the US 
population. Diagnosed 
with breast cancer 
between 1986 and 
1996. Aged 65 years 
and over. 
Receipt of hospice care. 
Determined by existence 
of a hospice claim in the 
hospice standard analytic 
file [Medicare claims]. 
Over 75 less 
likely to receive 
care 
- 55 
 
Table 2.1 Current evidence on use of SPC by age   
Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
Lackan 
2004 
120 
Retrospective 
cohort study 
using 
administrative 
data 
USA 
To examine whether use of 
hospice has changed over 
time, as a function of 
sociodemographic 
characteristics, geographic 
location, type of insurance 
and year of death. 
170,136 breast, 
colorectal, lung and 
prostate cancer deaths 
(1991 to 1999) identified 
from Surveillance, 
Epidemiology and End 
Result (SEER) Medicare 
databases - population-
based registry for 
incident cancer cases. 
Diagnosed with cancer 
between 1991 and 
1996. Aged 67 years 
and over. 
Receipt of hospice care. 
Determined by existence 
of a hospice claim in the 
hospice standard analytic 
file [Medicare claims]. 
Over 75 less 
likely to receive 
care 
- 
Sessa 1996 
134 
Retrospective 
cohort study 
using 
administrative 
data 
Switzerland 
To describe the 
characteristics of a 
consecutive series of 
cancer patients seen in the 
referral centre. 
993 cancer deaths 
(January 1991 to July 
1993) identified from 
clinical data of referral 
centre for medical 
oncology (SOC) in one 
region. Included patients 
whose treatment had 
been taken over by the 
SOC, or for whose 
treatment the advice of 
the SOC was regularly 
being sought. No stated 
age restrictions. 
Use of palliative home-
care program in one of 
five districts - in two 
districts of the study area 
this home care includes 
more nursing and clinical 
staff and is called 
'hospice'. Determined 
from clinical records of 
the service. 
Over 70 more 
likely to receive 
care 
- 56 
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Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
Virnig 2002 
135 
Retrospective 
cohort study 
using 
administrative 
data 
USA 
To determine disease-
specific rates of hospice 
use before death, and 
whether hospice use varies 
across cancer diagnoses or 
by ethnic group, age or sex. 
388,511 deaths from 
one of seven cancers 
(1996) identified from 
the National Center for 
Health Statistics’ Report 
of Final Mortality 
Statistics. Aged 65 
years and over.  
Use of hospice care. 
Determined from 1996 
hospice claims data 
submitted to the Health 
Care Financing 
Administration.  
Over 85 less 
likely to receive 
care 
- 
Proxy surveys             
Addington-
Hall 1998 
123 
Retrospective 
survey of 
proxies 
UK 
To investigate how cancer 
patients who receive 
hospice inpatient care differ 
from those who do not in 
terms of their socio-
demographic 
characteristics, site of 
cancer, symptom 
experience and 
dependency levels in the 
last year of life. 
2074 of 2094 (71% 
response rate) cancer 
deaths randomly 
sampled from 20 self-
selected health 
authorities. Deaths 
occurring in last quarter 
of 1990. For each death, 
the best informant about 
the deceased’s last 12 
months of life sought, 
and interviewed using a 
structured 
questionnaire. 
Receipt of hospice 
inpatient care. 
Determined by 
respondent’s recollection 
of the names of hospitals 
and hospices to which 
the deceased was 
admitted. Names cross-
checked with the 1990 
Directory of Hospice 
Services. 
Over 65 less 
likely to receive 
care 
Over 75 less likely 
to receive care 57 
 
Table 2.1 Current evidence on use of SPC by age   
Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
Addington-
Hall 2000 
124 
Retrospective 
survey of 
proxies 
UK 
To explore the factors 
associated with receiving 
care from community SPC 
nurses (CSPC) 
2074 of 2094 (71% 
response rate) cancer 
deaths randomly 
sampled from 20 self-
selected health 
authorities. Deaths 
occurring in last quarter 
of 1990. For each death, 
the best informant about 
the deceased’s last 12 
months of life sought, 
and interviewed using a 
structured 
questionnaire. 
Receipt of CSPC 
nursing. Determined by 
respondent’s reports of 
use of these services – 
no further details. 
Over 65 less 
likely to receive 
care 
Over 85 less likely 
to receive care 
Beccaro et. 
al 2007 
122 
Retrospective 
survey of 
proxies 
Italy 
To estimate the distribution 
of places of care for Italian 
cancer patients during the 
last three months of their 
lives, the proportion 
receiving palliative care 
support at home and in 
hospital, and the factors 
associated with referral to 
palliative care 
1271 of 2000 (67% 
response rate) of cancer 
deaths randomly 
sampled from country. 
Deaths occurring 
between March 2002 
and June 2003. Non-
professional carer 
interviewed using 
structured 
questionnaire. 
Receipt of care from 
home or hospice 
palliative care team. Use 
of palliative care 
determined from 
palliative care records. 
Over 85  less 
likely to receive 
care 
No effect of age 58 
 
Table 2.1 Current evidence on use of SPC by age   
Study  Methods  Location  Stated aim  Participants  Outcome 
Effect of age 
on use: 
univariable 
analysis 
Effect of age 
on use: 
multivariable 
analysis 
McCusker 
1985 
121 
Retrospective 
survey of 
proxies 
USA 
To identify factors 
associated with the use of 
home care, including home 
hospice, by patients with 
terminal cancer 
133 cancer deaths 
randomly selected from 
deaths in one county, 
December 1979 to 
January 1980. Surviving 
relatives contacted and 
interviewed (96/133 – 
72% response rate). 
Use of the county home-
hospice programme.  
Over 65 less 
likely to receive 
care 
- 
Retrospective case-control study 
Grande 
2002 
125  
Retrospective 
case-control 
study 
UK 
To investigate variables 
associated with referral to a 
Hospital at Home (HAH) 
palliative care service.  
121 cancer patients 
referred to HAH from 
June 1994 to June 1995 
(cases) and 206 cancer 
deaths randomly 
sampled from the area 
Cancer Registry who 
were not referred to 
HAH (control). 
Referral to the Hospital at 
Home palliative care 
service. Not stated how 
determined. 
Users mean age 
70.5 
Non-users mean 
age 74.7 
- 
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Four studies focused specifically on the receipt of SPC at home. 121;124;125;129 The 
remaining included one or more services providing SPC across a range of 
settings (e.g. home, hospital, and hospice). Studies based their outcome 
ascertainment on records kept or provided by the SPC service of interest, 
except two of the surveys of proxy respondents, which relied on 
participant’s reports of the deceased’s use of services. 
 
The majority of the studies reported a statistically significant lower use of 
SPC among older patients at a univariable level. 102;119-131;133;135 One study 
reported a statistically significant higher use of palliative home care among 
the older age group (70 and over) 134 and one found no effect of age. 132  
 
Ten studies included a multivariable regression analysis to investigate the 
effect of age on referral to or use of SPC, after controlling for potential 
confounding factors. 102;120;122-125;127;128;130-132 Of these, seven reported older adults 
were significantly less likely to use SPC services. 102;123;124;128;130;131 However, age 
group cut-offs and variables included in regression models varied between 
studies, making direct comparison between them difficult. In Grande et al’s 
(2002) case control study, the effect of age disappeared after controlling for 
other variables, including use of cancer and district nursing services. 125 As 
the authors acknowledged, if age is related to use of other health care 
services, its relationship with hospice use may have been disguised in their 
analysis. The effect of age on use of domiciliary palliative care services also 
disappeared in Becarro et al.’s study of bereaved carers, after controlling for 
patient and caregiver characteristics including gender, education, marital 
status, place of residence, primary tumour, and caregiver's relationship, age, 
gender and education. 122 Significantly higher use among cancer patients 
aged 75 and over compared to those younger than 55 was reported in 60 
 
Keating’s retrospective administrative data analysis, which had found no 
effect of age at a univariable level. 132  
 
The majority of studies conducted to date therefore suggest that older cancer 
patients are less likely to use SPC services. However, this evidence comes 
from retrospective study designs alone. The widespread use of retrospective 
approaches in this area is attributable in part to the ease with which 
researchers can assemble a sample of relevant patients to assess service use 
within the final few months of life. Additionally, retrospective approaches 
enable all such patients to be studied, including those who may not 
prospectively have been identified as approaching death. They thus facilitate 
the efficient study of the end-of-life experiences of a wide range of patients. 
136 However, a number of important limitations of this approach must be 
recognised. 
 
Firstly, reliance on routine data and retrospective proxy reports is likely to 
reduce the accuracy and completeness of outcome ascertainment. Referral to 
or use of SPC has been shown to be inconsistently recorded in patient 
medical records; 106 the validity of responses about service use from proxies 
such as carers is uncertain; 137 and questions asked of proxy respondents to 
determine use of SPC are often insufficiently comprehensive. 121 
Retrospective studies therefore risk over- or under-estimating use of SPC 
services. If the recording or recall of service use varies systematically in 
relation to patient age, bias will be introduced. 
 
Secondly, the availability of data on important predictor factors is limited to 
that available within medical records, or based on the recall of significant 
others. Details of symptoms, functional status, and psychological and 61 
 
spiritual concerns may be lacking or inaccurate. 138 The ability to ascertain 
patient need for care is therefore severely limited.  
 
Finally, retrospective study designs of use of services in relation to age and 
other characteristics have been criticised for risking an over-estimation of 
differences between older and younger patients. 139 Systematic bias may be 
introduced due to the shorter survival time of older patients following the 
diagnosis of a terminal illness; older patients may therefore appear to have 
received less treatment during the last months of life. However, these 
arguments are more applicable to studies considering the intensity of care, 
rather than the presence or absence of referral to a service.  
 
Aside from the limitations applicable to all retrospective studies, there are a 
number of quality issues pertinent to the research studies summarised 
above. Firstly, studies often gave an insufficient description of the location of 
SPC (home or hospital) and nature of the service. 120;128;131;133 As SPC services 
vary widely in their organisation and scope, accurate descriptions of the 
nature of care are essential in understanding the generalisability of findings. 
Secondly, the statistical analysis undertaken within studies was often 
limited. Five studies conducted no multivariable analysis, drawing 
conclusions about the relationship between age and use of palliative care 
based on univariable analysis alone. 119;121;126;134;135 Thirdly, within those 
studies which did conduct multivariable analysis, critical factors which may 
be associated with both age and use of SPC, including comorbidity and 
symptom experience, were not included (with four exceptions 123;124;127;132).  
 
Of most concern in the work conducted to date is the lack of assessment of 
equity, rather than equality, of use. Only one of the studies described above 
explicitly defined, investigated, or controlled for need for SPC. This, the most 62 
 
recent study, responded to criticism of earlier work and created proxy 
variables for need using data available from administrative databases. 127 The 
study authors constructed variables for disease burden and severity using 
type of cancer, comorbidities and length of inpatient stays. However, as they 
themselves acknowledge, this cannot match approaches which gather data 
directly from patients.  
 
2.3 Explaining variations in use of palliative care by age 
Reduced access to all health care for older patients may arise as a result of 
rationing, lower need for care, differences in patient preferences or implicit 
prejudice. These factors are summarised in relation to SPC below.  
 
Explicit rationing of health care by age has been defended on the basis that, 
as everyone ages, no particular group is being discriminated against in an 
unacceptable manner (as opposed to, say, rationing by gender or ethnic 
group). 140 Thus, ageism is argued to be ‘value-neutral’, and is simply an 
outcome of different stances on the distribution of care derived by health 
economists. 141 There are three main types of explicit ageism by which care 
for older people may be denied or limited: ‘health maximisation ageism’, 
‘productivity ageism’, and ‘fair innings ageism’. 142 These concepts may be 
used to deny access to care, as well as to guide decisions about the amount of 
a particular health care service that could be offered to older people.  
 
Under the ‘health maximisation’ approach, decisions about the distribution 
of health care resources are based on the assignation of a constant value to a 
year of life, irrespective of age. As younger people are likely to experience 
health gains for a greater number of years than older people, by default they 
are likely to be given priority. The key influence here is life expectancy, 
although this is of course heavily dependent on a patient’s age.  63 
 
The second approach, ‘productivity ageism’, relates the value of health gains 
at particular ages with the expected productivity at that age. Productivity 
may peak during the middle years of life, and fall towards old age, thus 
leading to limitations on access to care for older adults.  
 
The final approach, ‘fair innings’, considers health over the course of an 
entire lifetime, for example by deciding on a certain number of Quality-
Adjusted-Life-Years (QALYs) which people may expect to enjoy. Decisions 
on resource allocation are then made on the basis of achieving the ‘fair 
innings’, which may lead to the prioritisation of a young person over an 
older person.  
 
However, the application of such approaches to decisions about the 
distribution of SPC may be limited, due to SPC’s focus on improving quality 
rather than length of life. Calculations about the benefits accrued by patients 
receiving SPC are not easily captured by an approach focusing on life-years 
gained. Thus, within the rationing debate, SPC has often been seen as an 
entity separate from other health care services, one that can be offered when 
access to expensive health technologies has been denied. A leading 
proponent of age-based rationing, Daniel Callahan, suggested that over a 
certain age people should receive only palliative and symptom-relieving 
care. 143 However, palliative care must still compete against other health care 
services within any resource-limited health care system. It must also 
therefore face rationing, and some form of priority-setting. In later work, 
Callahan argued that, whilst palliative care should be provided at some 
minimal level to all those in need, the highest priority should be given to 
palliative care for the elderly, as the older a patient is, and the closer to 
death, the greater the likelihood that it may be all that medicine can offer 
them. 144 In a survey of preferences for the receipt of treatment by younger or 64 
 
older patients, members of the public favoured younger age groups to 
receive a life-saving procedure, but showed no preference between younger 
and older groups to receive palliative care. 145  
 
Variation of benefit in relation to age as a reason for the explicit rationing of 
care is upheld by NICE. A recent consultation document published by NICE 
on the use of social value judgments in allocation decisions suggested that 
‘where age is an indicator of benefit or risk, age discrimination is 
appropriate’. 146 A reduced ability to benefit from SPC may therefore be one 
explanation for reduced access to care. Evidence of benefit in relation to age 
is, however, often limited, due to the widespread exclusion of older people 
from clinical trials. 147;148 This is particularly problematic in SPC, where there 
is a paucity of evidence of effectiveness. 149 What evidence there is, based 
upon the presence and impact of symptoms, is limited and conflicting.  
 
One post-bereavement survey of carers found that patients of all diagnoses 
over 85 years had a greater number of symptoms than patient under 65, but 
symptoms in the older group were less likely to ‘very distressing’. 150 By 
contrast, a secondary analysis of a retrospective survey of carers of cancer 
patient suggested that both the number of symptoms and the proportion 
perceived to be ‘very distressing’ declined with age, whilst the level of 
functional dependency did not vary. 151 The finding that older palliative care 
patients may have fewer interventions for symptom control, suggesting a 
lower need for care, 101 has been related to a tendency for older patients to 
under-report pain. 152  
 
It has been argued that the need for SPC should be determined by social, 
emotional and spiritual concerns as well as by health status. 153 Across a life 
span, patients’ health, social and economic status (including the presence of 65 
 
dependent children or partners, the likelihood of living alone and 
employment status) fluctuates. It is therefore possible that the need for SPC 
will vary with age. Older cancer patients may have fewer and less severe 
psycho-social problems than younger patients, and experience less 
disruption and carer burden. 154 If need for SPC is assessed on this basis, 
older patients may have a lower use of these services.  
 
A further reason for a reduced use of SPC in relation to age is that the needs 
of older adults may be more likely to be met by other services. General 
practitioners, district nurses and hospital doctors and nurses are all 
providers of generalist, rather than specialist, palliative care. It is possible 
that older cancer patients are sufficiently cared for by these professionals. 
However, evidence to support this argument is lacking. Policies state that all 
those with complex needs should have access to SPC, and it remains 
uncertain whether older patients are more or less likely to have ‘complex 
needs’, howsoever defined. 19 One small UK study has shown that patients 
not referred to a palliative hospital at home scheme were also less likely to be 
receiving other forms of care such as district nursing, suggesting age may be 
a barrier to all types of care at the end of life. 125  
 
Differences in patient attitude and choice may lead to differential use of 
services. However, one UK survey of adults aged 55 and over found no 
differences between older and younger groups on attitudes to hospice and 
palliative care, or the belief that younger patients should take priority. 155 
 
Finally, variations in the use of SPC may arise because of prejudicial 
attitudes amongst those who refer patients to or accept patients into SPC. 
Stereotyping and stigmatisation of the elderly was first referred to as ageism 
in the 1960s by Robert Butler, a US geriatrician who attributed such 66 
 
behaviour to younger peoples’ revulsion and fear towards growing old, 
disease, disability and death. 156 Ageism relates to stereotyping of and 
prejudice against older people, arising from the belief that people are less 
productive, attractive and intelligent as they age. 157 Age discrimination may 
occur as a result of ageist attitudes, and describes behaviour in which older 
people are treated unequally. 114 However, such behaviour is not necessarily 
always negative. Compassionate ageism may lead to older patients being 
offered more care due to perceptions they are needier. This contrasts with 
conflictual ageism in which elderly people are perceived to be burdensome 
or less deserving, and are thus avoided or sidelined. 158 Callahan’s views on 
prioritising SPC access for the elderly demonstrate the former approach. 
Evidence that older people are less likely to be offered SPC suggests the 
latter, more negative view.  
 
Ageism may not be confined to the attitudes of (normally younger) health 
care professionals towards older patients. Older adults may themselves hold 
negative views about their own age group, known as ‘self-stereotyping’. This 
has been attributed to the internalisation of a lifetime’s exposure to cultural 
attitudes (usually negative) towards the elderly. 159 Such attitudes may lead 
to the attribution of symptoms of illness to ageing rather than disease, and 
reduce the likelihood of seeking or accepting medical care. 160 
 
The effect of negative attitudes on clinical decision-making is difficult to 
ascertain. As Dey and Fraser state: 
 
Precisely because clinical judgement is meant to involve a holistic assessment of 
individual needs, it is no easy matter to assess the way age is used at the clinical 
level. If clinical decisions involve age-based rationing, they are likely to be covert. 161 
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Research suggests that the influence of ageist attitudes on such decisions 
may not even be recognised by the decision-maker themselves. ‘Implicit 
ageism’ is defined as thoughts, beliefs and feelings about the elderly ‘that 
exist or operate without conscious awareness, intention or control’. 162 
Measures of ageist attitudes tend to find a lower proportion of negative 
views on explicit compared to implicit measures. 162 Individuals may not 
even be aware that stereotyping of older people is influencing their 
behaviour, and may attribute decisions to withhold or restrict treatment to 
alternative explanations which sit more comfortably with their self-
conception as a non-ageist individual. 163  
 
Perhaps due to difficulties in researching this area, suggestions of ageism 
within palliative and cancer care are based predominantly on extrapolations 
from evidence of treatment disparities, rather than measures of perception. 
11;164 However, one UK survey of the attitudes of oncology professionals 
(medical, nursing and radiography staff) towards older patients has found 
consistently negative views were held. 165 This suggests the possibility that 
such attitudes may be present within SPC too. 
 
Summary 
This review of social justice, equity and need has shown how access to health 
care is shaped by societal and individual preferences about the distribution 
of goods to individuals. Whilst Government policy is strongly supportive of 
equal use of SPC, regardless of patient age, there is a suggestion that 
prejudicial attitudes and discrimination may remain. Additionally, the 
Government commitment to prioritising care for particular patient groups to 
reduce inequalities adds a further dimension to observations of the process 
by which care is distributed at all levels. SPC is a particularly interesting 
topic of investigation into the fair use of care, as its holistic nature challenges 68 
 
the methods frequently used to define and measure need for care. It is also, 
therefore, particularly important that the context in which decisions are 
taken, and the influences on such decisions, are acknowledged and explored 
to comprehensively investigate whether care is provided equitably.  
 
In this thesis I base my ethnography of SPC provision within the dominant 
theory of need within public health, the capacity to benefit from health care, 
exploring its relevance to the definition, operationalisation and measurement 
of need for SPC. I consider how my survey findings relate to accounts of 
equal access to health care, both ‘equal opportunity’ and ‘capability’ views, 
and the relevance of each to the field of SPC.  
 
In the next chapter, I turn to the particular methodological underpinnings of 
the thesis. I explore how mixed methods research originated and developed, 
and the major controversies in the integration of qualitative and quantitative 
methods. I then explain how I applied these methods to the design and 
conduct of this research study, and provide full details of the planned phases 
of work.  69 
 
Chapter 3 
 
Methodological overview 
 
And if the world were black or white entirely 
And all the charts were plain 
Instead of a mad weir of tigerish waters, 
A prism of delight and pain, 
We might be surer where we wished to go 
Or again we might be merely 
Bored but in the brute reality there is no 
Road that is right entirely. 
 
Louis MacNeice, ‘Entirely’ 166 
 
 
This project set out to investigate variations in the use of SPC, and in 
particular whether older age leads to a reduction in use of these services. The 
central question, therefore, is whether the use of SPC is equitable in relation 
to age. Within the NHS, need for care should determine use. Therefore, to 
unpick this question, I also wished to examine how need for SPC is 
conceptualised, and which factors might cause this conceptualisation to 
change in the minds of providers. Additionally, once I had an idea of what 
constituted need for SPC, I wished to consider how I could measure such 
need to assess use.  
 
The most appropriate methods for answering these questions are mixed. 
Qualitative techniques are particularly suited to exploring conceptualisations 
of need. Yet quantitative techniques are the appropriate approaches for 
measuring use in relation to need. The combination of both approaches 
enables the full range of questions to be explored and answered. 
Additionally, it enables findings from one phase of work to influence other 70 
 
phases, generating a holistic and comprehensive investigation into the area 
of concern.  
 
To trace the development and conduct of this research, within this chapter I 
present in detail the methodological approach taken, and its relationship 
with the research question. It opens with an overview of the field of mixed 
methods research. I then explore the history of mixed methods and key 
current questions in its application, with particular reference to the 
philosophical underpinnings of this approach. Drawing upon the theoretical 
justifications for the methods chosen, I then demonstrate how I developed 
the study design. Finally, the linkages between qualitative and quantitative 
methods in this study are explored.  
 
3.1 The nature of mixed methods research 
The combination of quantitative and qualitative data within one study is not 
a new phenomenon. 167 However, it is only in the last twenty years or so that 
‘mixed methods’ has gained momentum and prominence as a distinct 
movement within social science research. As a new and developing 
approach, considerations of philosophy, theory, values, methodology and 
methods are still being debated. Whilst it is essential for all researchers to 
pay attention to the clarification of and justification for their approach, in the 
still emerging discipline of mixed methods research this is particularly 
important. To provide a clear foundation for my work, within this and the 
following sections I review current thinking, and state my particular stance, 
across six key issues in mixed methods research: 168 
 
1. Definitions 
2. Utility 
3. Philosophical basis 71 
 
4. Design considerations 
5. Inference 
6. Logistics 
 
What is mixed methods research? 
Mixed methods research has been defined as: 
 
…the type of research in which a researcher or team of researchers combines elements 
of qualitative and quantitative research approaches (e.g. use of qualitative and 
quantitative viewpoints, data collection, analysis, inference techniques) for the broad 
purposes of breadth and depth of understanding and corroboration. 167 
 
Therefore, the inclusion of both quantitative and qualitative approaches 
within a study is the traditional basis for mixed methods. 
 
Why undertake mixed methods research?  
Greene, Caracelli and Graham devised an influential scheme summarising 
different (although potentially overlapping) purposes for mixed methods 
research: 169 
 
•  Triangulation: looking for convergence or corroboration by using 
different methods 
•  Complementarity: using results from one method to elaborate or 
clarify results from another method 
•  Development: using results from one method to develop or inform the 
other method 
•  Initiation: using different methods to look for contradictions or new 
perspectives on results or questions 
•  Expansion: using different methods for different components of a 
study to extend the range of inquiry 72 
 
Justifications for why methods should be combined may vary depending on 
authors’ aims, beliefs and values. A number of protagonists who argue that  
mixed methods are the ‘best’ way to conduct research claim that it can 
answer research questions not amenable to quantitative or qualitative 
approaches alone; that it can provide stronger (‘better’) inferences; and that it 
enables the presentation of a greater diversity of views. 170 Other authors 
who do not subscribe to the thesis that mixed methods are the only way 
forward have argued that the incorporation of more than one method simply 
enables a broader understanding to be developed, if required. 171 
 
In practice, the reasons for using mixed methods are more diverse, and 
sometimes less obvious, than conceptualisations suggest. Following a review 
of published mixed methods studies, Bryman identified 18 possible reasons 
for methods to be combined, with complementarity (as defined by Greene et. 
al. 169) being the most common. 172 However, stated rationales for mixing 
methods did not always correspond with subsequent practice, and Bryman 
warns researchers to be aware that the outcomes (and thus the rationale 
behind) mixed methods studies may not always be predictable as studies 
progress.  
 
Whilst consideration of the purpose of mixed methods research helps clarify 
its aims, the rigid schemes put forward (as Bryman demonstrated) are not 
straightforwardly applied to practice. In particular, multiple reasons for 
mixing methods may be viable within one study, as methods and results 
interact with each other. The importance is in clarifying that mixed methods 
are the appropriate approach to answering the research question at hand, 
and to clearly state how, and why, the methods and results are to be 
combined.  
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3.2 Philosophical considerations in mixed methods research 
As an emerging approach, mixed methods researchers are engaged in 
ongoing debate amongst themselves and with researchers from other 
approaches as to the appropriate philosophical underpinning for mixed 
methods research. This debate is heavily tied to claims for the legitimacy of 
mixed methods, which depend on arguing that quantitative and qualitative 
approaches and methods can be logically combined. Such claims have been 
fiercely resisted on philosophical grounds. In practice, the debate on 
combining quantitative and qualitative approaches operates at two levels: 
the philosophical, and the technical (method). 173 In this section I clarify the 
origins of this debate, its current status, and how this relates to research 
practice. 
 
Key definitions 
Firstly, though, a note on definitions is required. Terminology used in the 
debate about quantitative, qualitative and mixed methods approaches is 
often employed with different intentions and meanings. A key term in these 
debates is ‘paradigm’. Originating in Kuhn’s work on revolutions in 
scientific knowledge, there are multiple concepts of paradigms. One 
summary of the different definitions in use is outlined by Morgan, who 
argues they may be nested within each other, as adapted in Figure 3.1. 174 
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The broadest definition of paradigms is as world views, covering our 
thoughts and beliefs about, potentially, everything. The next definition in use 
associates paradigms with belief systems, and thus has a narrower focus on 
epistemology or philosophy of knowledge (one part of a world view). In this 
conceptualisation, stances such as positivism and constructivism are 
paradigms. This is a commonly used concept of paradigms, and one on 
which the incompatibility debate (the impossibility of combining 
quantitative and qualitative approaches, discussed in more detail below), is 
based. Morgan’s third paradigm definition is that of the set of beliefs shared 
by particular communities of researchers; which research questions should 
be asked, and how can they best be answered? Finally, a little-used idea of 
paradigms, although one that Kuhn himself was particularly interested in, is 
one that sees paradigms is ‘exemplars’ for best research practice. 
 
Discussion of paradigms inevitably relies on ideas about ontology, 
epistemology and methodology. Ontology can be defined as concerning the 
nature of reality. Epistemology concerns the nature of knowledge; 
methodology concerns how to generate this knowledge. 174 Whilst 
Paradigms as world views 
Paradigms as epistemological stances 
Paradigms as shared beliefs 
among members of a specialty 
area 
Paradigms as model examples 
of research 
Figure 3.1 Morgan’s definitions of paradigms 75 
 
methodology is commonly accepted as being about more than just methods, 
the two are sometimes conflated 175. Conversely, ideas of methodology are 
also on occasion pushed as far as being synonymous with epistemology. 176 
Method is defined as the actual techniques of doing; the practical data 
collection and analysis.  
 
Quantitative, qualitative and the rise of mixed methods approaches 
A number of key phases in the history of methodological approaches in 
social and behavioural sciences have been posited, stretching back well over 
one hundred years. 177 A brief review of these is useful to understand where 
mixed methods approaches, and their philosophical underpinnings, came 
from. If we take the idea of paradigms as epistemological stances, the initial, 
dominant paradigm was that of positivism, with its tenets of objectivism and 
use of quantitative, hypothesis-driven methods. From the start of the 20th 
century, purist (logical) positivism was at first challenged, and then 
overturned, by an emerging qualitative research paradigm drawing on 
constructivist/interpretivist stances of subjectivism and inductivity. In 
response to these new ideas, positivism morphed into post-positivism, with 
its acceptance that true objectivity is an impossible ideal. Alongside this, 
however, also came new emerging qualitative philosophies such as post-
structuralism. Adherents of the new qualitative and quantitative approaches 
became enmeshed in a sometimes strident debate (often referred to as the 
‘paradigm wars’) about the incompatibility between the two, discussed in 
detail below. With its early roots in the late 1960s, this debate gave rise to the 
pragmatist paradigm, alongside the explicit use of mixed methods. 
 
By using this version of methodological history, quantitative and qualitative 
approaches are characterized as two distinct entities. This is problematic, as 
the binary conception of ‘quantitative/qualitative’ is a false dichotomy. 76 
 
Qualitative inquiry is not one tradition, but many; the categorisation of non-
positivist research as ‘qualitative’ was a way of enabling diverse researchers 
to claim their place in the mainstream under one banner. 175 Additionally, the 
distinctions between ‘quantitative’ and ‘qualitative’ are often over stated. 
Instead, it has been argued that research approaches lie on a continuum, 
with only a few ‘purists’ marking either end of the spectrum [Figure 3.2]. 178 
 
 
 
However, I follow the stance of Johnson et. al. in distinguishing quantitative 
and qualitative approaches for the purposes of this discussion, broadly 
aligned to post positivism and constructivism respectively, whilst 
acknowledging that the ‘real life’ position is not as clear as this usage would 
suggest. 167  
 
Adopting the concept of ‘quantitative’ and ‘qualitative’ approaches, then, 
how might these be defined, and what are the key differences between them? 
Reichardt and Cook provided a useful summary of the attributes of 
traditional ‘quantitative’ and ‘qualitative’ approaches, as adapted in Table 
3.1. 179 
Quantitative 
(post-positivist) 
Qualitative 
(constructivist) 
Figure 3.2 The epistemological continuum 77 
 
 
Table 3.1 Qualitative and quantitative approaches 
Qualitative inquiry  Quantitative inquiry 
Advocates the use of qualitative methods  Advocates the use of quantitative methods 
Interpretivism/constructivism  Positivism/post-positivism 
Naturalistic and uncontrolled observation  Obtrusive and controlled measurement 
Subjective  Objective 
Close to the data: the “insider” perspective  Removed from the data: the “outsider” 
perspective 
Grounded, discovery-oriented, exploratory, 
expansionist, descriptive and inductive 
Ungrounded, verification-oriented, 
confirmatory, reductionist, inferential, and 
hypothetico-deductive 
Process-oriented  Outcome-oriented 
Valid; “real”, “rich” and “deep” data  Reliable; “hard”, and replicable data 
Ungeneralisable: single case studies  Generalisable: multiple case studies 
Holistic  Particularistic 
Assumes a dynamic reality  Assumes a stable reality 
 
Four major differences between quantitative and qualitative approaches can 
be outlined, based on: 
 
1.  Their differing epistemologies (positivist versus constructivist) 
2.  The perceived purpose of their research (explaining facts and causes 
versus understanding social phenomena) 
3.  Their approach to research (experimental versus observational), and 
4.  The role of the researcher (detached versus immersed). 180  
 
Within the quantitative approach, a move away from positivism’s rigid 
belief in objectivism (that reality exists and is measurable) led to post-
positivism, a more moderate version which none the less still adheres to 
central tenets of cause and effect, reductionism (the selecting and testing of 
particular variables), empirical observation, and theory verification. 181;182 
Constructivism (often used as an over-arching term to encompass 
interpretivism, naturalism and phenomenological approaches) contends that 
reality is socially constructed, and thus multiple, subjective and liable to 78 
 
change. The emphasis is on developing understanding and exploring 
relationships and values inherent in the research process. 183  
 
The presence or absence of a link between quantitative and qualitative 
epistemologies and particular methods is fervently debated, and will be 
discussed more below. The quantitative paradigm is typically associated 
with methods involving ‘numbers and statistics’ such as cross-sectional 
surveys with closed questions, and the qualitative paradigm with ‘words 
and narratives’ such as in-depth interviews and focus groups. 181 The 
association of these epistemologies with particular methods formed the basis 
for the so-called ‘paradigm wars’ which occurred within the social sciences, 
particularly educational research, and which subsequently influenced the 
development of mixed methods approaches. 
 
The ‘paradigm wars’ and the emergence of mixed methods 
The basic tenet of the debate which has been referred to as the ‘paradigm 
wars’ is whether quantitative and qualitative approaches are 
incommensurate or not. The ‘incompatibility thesis’ states that the 
quantitative and qualitative research paradigms are and should remain 
totally separate. 183 Advocates of this approach argue that the ontological, 
epistemological and methodological gulf between quantitative and 
qualitative research precludes any combination of these approaches. 184 As 
Guba’s oft-quoted phrase summarises:  
 
the one [paradigm] precludes the other just as surely as belief in a round world 
precludes belief in a flat one. 185  
 
Thus, in its early stages, the paradigm debate was characterised by a clear 
quantitative versus qualitative divide. 186;187 However, with the rise of the 79 
 
‘compatibility thesis’, the argument was made that the deliberate 
combination of quantitative and qualitative approaches was not only 
possible, but should be encouraged. 183 Consequently the idea of a ‘third 
paradigm’, that of mixed methods research, was raised. 29 As mentioned 
above, the debate actually took place on two levels or over two issues; 
whether different quantitative and qualitative methods can be combined, 
and/or whether different epistemologies or philosophies prevent or enable 
the combination of quantitative and qualitative approaches. 
 
Teddlie and Tashakkori provide one view of the debate as it currently 
stands, defining six different schools of thought on quantitative, qualitative, 
and mixed methods research. 188 A consideration of these different 
approaches emphasizes that the debate on the combination of methods is by 
no means resolved. It has continued to be confused by differing concepts of 
paradigms; as worldviews, as epistemologies, or as shared sets of beliefs 
among researchers. Clarity over whether the combination is of methods 
alone, or of something greater than methods (requiring the use of different 
philosophical approaches, or a new philosophical approach, for example), is 
required both at the level of methodological debate, and when developing 
and designing a mixed methods study. The different schools are 
summarized below: 
 
1. The ‘a-paradigmatic’ stance. 
This stance argues that methods and epistemology are not linked in ‘real 
world’ research. Research should continue independently from the paradigm 
debates, with methods employed without reference to wider metaphysical 
considerations. One study found that this often was the case, with mixed 
methods academics usually not considering ontology or epistemology at all 
in their work. 189 The author’s assertion that such academics were taking a 80 
 
‘pragmatic’ approach is, however, a potential source of confusion within the 
mixed methods debate – there can be a difference between a philosophical 
stance based on pragmatism and a ‘doing what works’ attitude, discussed in 
more detail below. Finally, the ‘a-paradigmatic’ stance is not found in the 
work of the leading exponents of mixed methods research, who argue 
strongly for a philosophical basis to all work to foster high quality research 
underpinned by deep methodological understanding. 29;170 
 
2. The incompatibility thesis. 
As already discussed, this stance states that quantitative and qualitative 
approaches are fundamentally incompatible due to their different 
epistemologies, which are strongly linked to particular methods; they (and 
their methods) may not, therefore, be mixed. Teddlie and Tashakkori argue 
that this concept is now discredited, but in fact it can still be found. 184;190  
 
3. The complementary strengths thesis 
Adherents of this view believe that it is possible to mix methods, but 
researchers who do so must retain the assumptions of each paradigm. Under 
this stance, either qualitative or quantitative methods will be the driving 
force behind a study, and dictate the epistemological stance used. Other 
methods may be used to triangulate results only, and must be kept separate 
from the other strands of work until then. 171 
 
4. The single paradigm thesis 
Following on from the links made between quantitative methods and post-
positivism and qualitative methods and constructivism, many protagonists 
have suggested a single paradigm to support the mixed methods approach. 
Pragmatism has been suggested as the philosophical basis for mixed 
methods by a number of commentators. 170;174;176;183; due to its prominence in 81 
 
the debate, this will be discussed in more detail below. The transformative-
emancipatory approach has also been suggested as the underpinning for 
mixed methods approaches, although its focus on disadvantaged groups and 
power dynamics may limit its appeal. 191 
 
5. The dialectic stance 
The dialectic stance, as advocated by Greene and Caracelli, embraces 
multiple stances and paradigms within one study, emphasising the 
importance of juxtaposing viewpoints and exploring the tensions that arise 
from this within mixed methods research. 192 As they themselves admit, the 
practice of such an approach within a mixed methods design can be 
challenging, due to the complexities of incorporating different philosophical 
perspectives within the same project.  
 
6. The multiple paradigm stance 
Creswell, amongst others, has argued for the use of multiple paradigms, 
dependent on the mixed methods design being employed, but with only one 
paradigm within a particular study. 193 Such an approach means that post-
positivism might be the approach taken within one study with a quantitative 
focus, whilst interpretivism might be favoured in, for example, a 
predominantly qualitative study. This approach thus links differing 
paradigms with particular research designs rather than methods, a variation 
on the traditional epistemology/methods partnership. It differs from the 
complementary thesis approach in allowing mixing to take place at any stage 
of the design and conduct of a study, rather than being confined to the 
triangulation of results from one dominant approach. It places pragmatism 
as just one of a number of possible approaches which may be taken within a 
‘toolkit’ of epistemologies. 193 
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Another strand of the debate on the compatibility, or otherwise, of 
quantitative and qualitative approaches is the efforts made, mainly by mixed 
methods researchers, to find similarities between the two traditions. For 
example, Johnson and Onwuegbuzie argue that both approaches use 
empirical observations, make efforts to maximise validity or trustworthiness, 
and attempt to make assertions about people and their environments. 194 
This, they assert, means the approaches are not as different from each other 
as might be suggested. 
 
Amongst the debate outlined above, an alternative foundation for mixed 
methods research has been proposed, the philosophy of pragmatism. 
Pragmatism’s role in shaping current debate on the combination of 
quantitative and qualitative methods is considered below. 
 
The pragmatic approach and mixed methods research 
Classical pragmatism originated with late nineteenth/early twentieth century 
early philosophers such as Charles Sanders Pierce, William James, John 
Dewey, George Herbert Mead, and Arthur F Bentley. 176 Whilst there are 
many versions of pragmatism, and thus no one definition which can be 
offered, one common central tenet (the ‘pragmatic maxim’ of Pierce) is that 
the meaning of ideas should be clarified by considering their practical 
consequences. 195 Thus, pragmatic research is guided by its anticipated 
consequences; where we want to end up will govern what questions we are 
interested in researching, and how we wish to do this. Pragmatists view 
research as taking place in particular contexts (social, historical and political), 
and thus what is ‘right’ now may not be ‘right’ at another time. 174 
Pragmatism embraces the concept of the existence of ‘the real world’, but it 
does not believe you would ever know if you had got at ‘reality’ or not; that 83 
 
is, it rejects foundationalism. 195 Finally, pragmatism acknowledges the role 
of beliefs and values in decisions made by researchers. 29  
 
One particular criticism of pragmatism and its focus on providing validation 
for beliefs is that our beliefs may all be consistent yet incorrect, or that there 
may indeed be bodies of beliefs that differ between themselves, but which 
are all internally consistent. In defending the pragmatic approach within 
qualitative research from this charge, Avis argues that to develop 
understanding of a situation or problem there must exist some shared beliefs 
between the researcher and the researched. 196 As researchers do apparently 
successfully manage to interpret other’s behaviours and norms, he asserts 
that, from a pragmatic point of view, it seems unlikely that our systems of 
beliefs are incommensurable or entirely false.  
 
Pragmatism formed the underpinning for Howe’s influential ‘compatibility 
approach’, supporting the thesis that quantitative and qualitative stances 
were compatible at both the method and epistemological level. 183 Teddlie 
and Tashakkori subsequently made six points about the utility of a link 
between pragmatism and mixed methods research: 188 
 
1.  Pragmatism rejects the incompatibility thesis, and supports both 
quantitative and qualitative approaches in the same study. 
2.  The research question is of primary importance, subsuming the 
methods chosen or the paradigm that might underlie that method. 
3.  Pragmatism also rejects the ‘forced choice’ between post 
positivism and constructivism, instead embracing both points of 
view. 84 
 
4.  Decisions about the use of methods (mixed, quantitative or 
qualitative) are dependent on the current research question and 
the developing research project. 
5.  Pragmatism rejects the emphasis on metaphysical concepts 
(‘truth’, ‘reality’) that have previously driven much of the debate. 
6.  Pragmatism is practical and applied. 
 
As pragmatism has developed with the work of authors such as Rorty 197 and 
Cherryholmes, 195;198 new strands are emerging. 176 In particular, three aspects 
(or levels of application) of neo-pragmatism can be defined.  
 
1.  Epistemological pragmatism locates pragmatism as a theory of 
knowledge, arguing that inquiry (the development of knowledge) 
cannot be guided by any particular set of rules, but instead by the 
impact of experience on thinking and the consideration of 
consequences of thought.  
 
2.  Meta-methodological pragmatism uses pragmatic principles to 
examine concepts within research methodology. Maxcy locates 
Howe’s use of pragmatism in his compatibility thesis, and the 
subsequent justification of mixed methods, within this tradition. 176 
The neo-pragmatism of Richard Rorty, with its rejection of any 
attempt to find a set of rules or develop one ‘reliable method’, is also 
seen as part of this level of pragmatic thought. 199  
 
3.  Methodological pragmatism takes two forms. In the first, pragmatism 
itself can be a method for choosing research methods. In this, the best 
method is one that is found to be most effective (‘what works’); that is, 
pragmatic concepts guide choice. 188 This approach is consistently 85 
 
encountered within mixed methods. In the second form of 
methodological pragmatism, pragmatism becomes a broad method of 
inquiry in itself. Accepting that research, and researcher, are located 
within particular contexts, pragmatic approaches are used to explore 
the most valuable methods, and the meaning these have within that 
context.  
 
The link between pragmatism and mixed methods research has been 
criticised by some qualitative researchers, who argue that pragmatism is a 
position available within any paradigm (e.g. post-positivism, 
constructivism), and as used by mixed methodologists is in fact post-
positivist in nature. 181 In part, this is a reaction against the perceived ‘loss of 
ground’ by qualitative researchers who feel quantitative researchers have 
embraced qualitative methods to subsume them within their approach to 
research. 175 In partial agreement with this, Maxcy has acknowledged that 
methodological pragmatism, in its first form, comes close to post-positivist 
perspectives, with the potential for reliance on empirical notions of 
effectiveness. 176  
 
An alternative position to this debate is offered by sociologist David Morgan. 
He rejects the use of ‘paradigm’ as a useful term, and instead proposes a 
pragmatic approach to methodology defined by three major themes: 174 
 
1.  An abductive approach to connecting theory and data 
2.  An intersubjective relationship with the research process 
3.  An emphasis on transferability in making inferences from data 
 
This contrasts with the inductive-subjective-contextual approach of 
qualitative research and the deductive-objective-generalising approach of 86 
 
quantitative research, both of which he acknowledges continue to be useful. 
Morgan argues that abductive reasoning (moving back and forth between 
theory and actions to examine those theories) is familiar to anyone who 
combines quantitative and qualitative methods sequentially. Subjectivity and 
objectivity he views as unrealistic ideals; intersubjectivity incorporates 
different frames of reference without conflict. Finally, Morgan rejects the 
dichotomy between all knowledge being context-specific, or being universal, 
setting out instead the importance of reflecting on the utility of results in 
other contexts. 
 
Pragmatism and/or mixed methods (the terminology varies, although the 
proposed link between the two does not) have been argued to form a ‘third 
paradigm’ by a large proportion of mixed methods researchers. 188 This has 
been aggressively promoted as the ‘best’ way to do research by those who 
wish to see the end of ‘purist’ quantitative and qualitative research as 
separate approaches. 177 However, there is still a lack of clarity about how 
pragmatism shapes mixed methods. If pragmatism is to form a true and 
useful basis for mixed methods, we perhaps need to move away from 
previous paradigmatic debates. Morgan offers a moderate and, in my view, 
useful approach here by attempting to reorient the issue outside of confining 
terminology, thus providing a fresh look at how we can approach different 
research questions. This draws on pragmatism as both a philosophical and a 
practical approach, offering a holistic framework within which to conduct 
research, whether using quantitative, qualitative or, of course, both methods. 
I have therefore drawn upon Morgan’s approach in the design and conduct 
of this study, using in particular the concept of abductive reasoning to 
consider the links between theory and data. 
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Having considered the philosophical framework of mixed methods 
approaches, and identified pragmatism as a useful basis for this, I turn to 
briefly consider suggested mixed methods designs and issues of inference 
and quality.  
 
3.3 The design and conduct of mixed methods research 
A key consideration in the design of mixed methods studies is the nature of 
the combination which takes place. Is the mixing in the methods alone; or 
does it take place in the formulation of the research questions, methods, 
analysis and inferences made? 200 There is an increasing consensus that 
mixed methods designs must aim to fully integrate quantitative and 
qualitative findings to make useful inferences. 167 Studies which use both 
methods within a program of work, but keep the designs, results and 
discussions from quantitative and qualitative strands entirely separate, are 
not therefore seen as integrated mixed methods approaches. Labels such as 
‘partially mixed’ versus ‘fully mixed’ are suggested to distinguish potentially 
‘insufficiently’ mixed studies. 201 However, the debate over how quantitative 
and qualitative methods and analysis may actually be combined continues.  
 
Within this debate, a particular emphasis has been placed on the 
development of mixed method design typologies to guide researchers. In 
2007, Creswell identified twelve different typologies of mixed methods. 202 
As Morse noted, this plethora of typologies reflects in part a search for the 
definitive design taxonomy for mixed methods. 203 A review of suggested 
typologies reveals four major dimensions of interest: 172 
 
1.  The timing of quantitative/qualitative aspects of a study (whether 
concurrent or sequential) 88 
 
2.  The emphasis placed on quantitative and qualitative methods 
(quantitative dominant, qualitative dominant or equal status).  
3.  The reason for the integration (e.g. complementarity, triangulation) 
4.  The stage at which mixing occurs (e.g. during data collection, data 
analysis, data interpretation). 
 
However, most of these typologies have been developed theoretically, and 
they do not necessarily relate to the actual conduct of mixed methods 
research. 172 Cresswell, for example, argues that his suggested designs (such 
as the sequential exploratory design or concurrent triangulation design) 
should not be combined, but there is no practical justification for such an 
assertion, and studies may require a complex web of interactions between 
data, analysis and inference to answer the research question. So, whilst 
typologies (or the common dimensions of typologies) are useful as guiding 
considerations in the design of a mixed methods study, I believe that the 
appropriate design should be dictated by the research problem which is to be 
addressed. 
 
Inference in mixed methods research 
An additional important aspect of mixed methods studies is the inferences 
which are made as a result of conducting such research. A distinction may be 
made between the results of a study, and the inferences that are made from 
these findings. 188 Results are the product of data collection and analysis; 
inferences are the interpretation of these results by the researcher, whether 
derived inductively or deductively (or, as Morgan would argue, 
abductively). To move away from terminology used exclusively within 
quantitative or qualitative approaches, Teddlie and Tashakkori suggest the 
use of the term inference quality to refer to the internal validity (a 
quantitative term) and/or credibility (a qualitative term) of a study. 188 89 
 
Inference quality can be further divided into design quality (referring to 
standards for methodological rigour) and interpretive rigour (referring to 
standards for the accuracy of the conclusions). Whilst this terminology is still 
debated, the underlying principles offer a useful framework for designing 
and concluding a study firmly founded in a mixed methods approach.  
 
Of course, quality judgements about methodology and the derivation of 
conclusions within a mixed methods study draw upon the same key issues 
as those in a qualitative or quantitative study. Questions such as the 
relevance of the design to the research question, the appropriateness and 
application of the data analysis techniques used, and the consistency of 
inferences with current knowledge and theory can be applied to any 
methodological approach. The issue here is not that mixed methods require a 
different approach to assessing quality and rigour, but that to create clarity 
within studies drawing upon multiple research traditions, different 
terminology may be required. 
 
A major issue for mixed methods studies is how inferences based on 
qualitative and quantitative approaches may be combined or contrasted to 
develop a holistic view of the issue under investigation. As a result of this 
challenge, ‘rules of integration’ for quantitative and qualitative results have 
been suggested by Erzberger and Kelle. 204 They argue that the combination 
of quantitative and qualitative results to examine a specific research question 
may lead to three situations: 
 
1.  Convergence 
2.  Complementariness, or 
3.  Divergence or contradiction 
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In the first instance, the convergence of quantitative and qualitative results 
may lead to the same inferences being drawn, based on both data sets. In the 
second, quantitative and qualitative findings may relate to different aspects 
of a phenomenon, but be complementary, enabling them to be used to 
supplement each other. In the final situation, qualitative and quantitative 
results may be completely divergent, or contradict each other. 
 
These situations require different approaches to the integration of data, 
based above all on hypothesised linkages between theoretical considerations 
on the phenomenon of study, and the empirical data at hand. 205 In aiming to 
integrate results, therefore, expectations of convergence or 
complementariness should be clarified in advance of the study. In a situation 
where findings diverge from or contradict each other, consideration must be 
given to whether this is as a result of a lack of rigour in study conduct, or a 
mistake in the original theoretical and empirical assumptions, which may 
then need to be cautiously revised and re-tested. Pragmatic considerations, 
as advanced by Peirce, form a central aspect of these approaches, applying 
logical reasoning in the light of theory and previous experience to the 
empirical data.  
 
The logistics of mixed methods research 
Finally, then, following this overview of the origination, philosophical 
underpinnings and current debates in mixed methods research, what are the 
implications for the actual ‘doing’ of such studies? There are as yet few 
published mixed methods studies which use pragmatism as a specifically 
defined approach, in spite of its dominance in the methodological literature. 
In health services research, studies drawing on dual approaches of post-
positivism and constructivism have encountered problems with drawing 
upon both stances, or with conflicting results. 206;207 This suggests that the use 91 
 
of a pragmatic framework to guide the choice of research question and study 
design may be helpful, albeit challenging. 181 As Bryman has noted, mixed 
methods studies in practice otherwise risk being separate quantitative and 
qualitative studies with no integration. 189  
 
The next sections apply these considerations to set out the approach and 
overall study design I used in this project. 
 
3.4 Mixed methods and the design of this study 
A vital consideration in pragmatic mixed methods research is the 
relationship between the research question/s and chosen study design. Once 
the area of research has been refined, this will drive the choice of methods to 
obtain the best ‘fit’ between question and design. The emphasis within 
pragmatism is therefore on using whichever methods will generate suitable 
data for the research question, rather than asking questions which only fit 
particular epistemological viewpoints, methodologies and methods.  
 
As the introduction to this thesis highlighted, the goal of this piece of work 
was to provide high-quality data on use of SPC services, in relation to need. 
To accomplish this, it was also necessary to undertake a comprehensive 
assessment of how need for SPC is operationalised by those who provide 
such care. This section briefly reiterates the aims of the study before 
explaining the overall study design developed to meet these aims. 
 
Overview of study aims and objectives 
The aim of this work was to examine providers’ conceptualisations of need 
for SPC, and the extent to which use of SPC services in lung cancer patients 
varies according to age. To clarify the areas of investigation, the pathway to 92 
 
use of SPC was visualised and potential areas of investigation mapped onto 
it [Figure 3.3].  
 
 
Patient with diagnosis of lung 
cancer 
IDENTIFYING NEED 
- How is need for SPC identified by 
referrers and patients/carers? 
- Are there systematic differences in 
the identification of need, for example 
because of the context of care (e.g. 
chest or oncology clinic) or patient 
characteristics? 
BARRIERS TO REFERRAL FOR 
THOSE WITH IDENTIFIED NEED 
- What are the barriers to making 
referrals to SPC? 
- Are referrals to SPC refused and if so 
why? 
- Are there systematic differences in 
the acceptance of referrals? 
Presence of need for SPC 
Referral made to SPC 
Acceptance of referral to SPC 
Need for SPC identified by 
potential referrer and/or 
patient/carer 
USE 
- Is SPC used in relation to need? 
- Are there systematic differences in 
the use of SPC after controlling for 
need? 
- What factors in the pathway 
contribute to these differences? 
- Are there refusals of the offer of SPC, 
and if so why? 
CONCEPTUALISING NEED 
- How is need conceptualised by 
providers of SPC? 
- Are there systematic differences in 
the conceptualisation of need as a 
result of factors such as the context of 
care provision (e.g. NHS or voluntary 
sector) or patient characteristics? 
- How can need be measured? 
STAGES IN DETERMINING USE 
OF SPC FOR PATIENTS WITH 
LUNG CANCER 
Use of SPC 
CONTEXTUAL FACTORS 
- What other factors influence the 
pathway to use of SPC for lung cancer 
patients? 
- How and why are these factors 
influential? 
POTENTIAL AREAS OF 
INVESTIGATION 
Figure 3.3 The pathway to use of SPC and key research areas 93 
 
Following this schema, four specific objectives for this study were derived: 
 
1.  To explore providers’ conceptualisations of need for, and factors 
influencing use of, SPC for cancer patients. 
2.  To explore existing methods and instruments which may be used to 
identify and measure need for SPC in lung cancer patients.  
3.  To measure use of SPC services in younger versus older lung cancer 
patients, in relation to need. 
4.  To examine demand and supply side factors influencing referral to 
and uptake of SPC services in lung cancer patients. 
 
The suitability of mixed methods 
Mixed methods approaches are ideally suited for research with multiple, 
inter-related objectives. The objectives above have very different 
requirements, exploring, locating and appraising, and measuring different 
aspects of the problem; namely, whether there are systematic differences in 
the use of SPC services, and if so why. It was apparent that (a) each objective 
required different methods, but also that (b) each objective could not be 
achieved in isolation. That is, data generated for each objective would be 
required to feed into other objectives. The utility of mixed methods 
approaches in answering this overall research question was therefore related 
both to complementarity (using results from one method to elaborate or 
clarify results from another method) and development (using results from 
one method to develop or inform the other method). This will be detailed 
further below. 
 
Approach taken 
This research is situated within a pragmatic epistemology. Pragmatism 
rejects the notion that knowledge represents reality or, alternatively, that 94 
 
reality is constructed entirely through social interaction (and thus, as per 
social constructivist perspectives, there are multiple social realities with their 
own knowledge which may only be fully understood from within). 
Pragmatism asserts that we cannot (and should not) wish to know whether 
our beliefs correspond with an independent reality. However, as it is at least 
possible to provide objective criteria to enable a distinction between which 
beliefs are true or false at that time, the purpose of research is to provide 
such validation for our beliefs. So, pragmatic inquiry is concerned with 
examining the strength of the arguments underpinning a particular belief, 
based on empirical evidence. 
 
Pragmatism does not adhere to the idea that there are fundamental 
epistemological divides between techniques concerned with human 
experience and those concerned with ‘facts’. All forms of inquiry may be 
used to add to our body of knowledge (that is, our system of justified 
beliefs). In this way, and as discussed previously, pragmatism is a natural 
partner for mixed methods research. 
 
Study design 
Study design in mixed methods research has been defined as encompassing 
the procedures for collecting, analysing and reporting research. 208 To 
address every aspect of the research question, the study design was 
conceptualized in three inter-related phases [Figure 3.4].  
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In the terminology of mixed methods approaches, the study was a sequential 
‘qual ￿ quan ￿ qual’ design using a variety of methodologies (ethnographic 
approaches, systematic reviewing and survey research) and methods 
(qualitative observation, interviews, systematic literature review, and 
questionnaires). In the first phase of work, I explored the perspectives of SPC 
providers on need for their services. Building on this work, I then located 
and appraised established instruments used to measure HRQL to devise a 
valid method for measuring need (objectives 1 and 2). In the second phase, I 
used a cross-sectional survey to investigate whether referral to SPC services 
by lung cancer patients varied according to age, after controlling for their 
need for this care (objective 3). Finally, in a third phase I planned to examine 
MEASURING EQUITY 
Cross-sectional survey of lung cancer 
patients and carers: assess use of 
SPC in relation to need 
UNDERSTANDING DEMAND AND 
SUPPLY INFLUENCES ON USE 
Interviews with lung cancer patients 
and health care professionals 
Systematic literature review and critical 
appraisal of HRQL instruments used in 
cancer and palliative care 
DEFINING NEED: 
Documentary analysis, observation of 
SPC meetings, and interviews with 
providers 
MEASURING NEED 
Choice of HRQL instrument/s as 
indicator of need for SPC, guided by 
observation and interviews 
PHASE ONE 
PHASE TWO 
PHASE THREE 
Figure 3.4 The three-phase study design 96 
 
both demand side (patient) factors and supply side (health service) factors 
which may influence referral to, use of and/or need for SPC (objective 4). For 
reasons which will be explained in greater detail below, this third phase of 
work was not undertaken. However, as it formed an integral part of plans 
for addressing the research question in full, I continue to show its envisaged 
place within the overall design in this chapter. 
 
A vital aspect of mixed methods research is integration at all stages of the 
study, with quantitative and qualitative approaches informing and drawing 
on each other. Figure 3.5 provides details of the study design, and highlights 
the inter-relationships between the three planned phases of this study at the 
level of design, method and analysis. As this figure demonstrates, there are 
six key relationships between the different methods, determined a priori, 
demonstrating both development and complementarity: 
 
1.  Results from a thematic analysis of phase one data (based on 
documents, qualitative observation and interviews) were used to 
finalise the design of phase two (cross-sectional survey). For example, 
results from phase one determined that carers, and not just patients, 
should also be surveyed.  
2.  Results from a content analysis of phase one data were used to guide 
selection of the most suitable HRQL instrument to measure need in 
the phase two survey.  
3.  The thematic analysis of phase one data was also used to inform 
multivariable analysis of the survey data by identifying key variables 
influencing use of palliative care to include in our model. 
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PHASE 1: 
PROVIDERS’ CONCEPTS 
OF NEED FOR SPC 
PHASE 2: 
EQUITY OF USE OF SPC 
PHASE 3: 
PATIENTS’ AND 
REFERRERS’ VIEWS ON 
USE OF SPC 
Objective:  
To explore providers’ 
conceptualisations of need 
for SPC, and factors 
determining the offer of 
care 
Methods:  
Documentary analysis, 
qualitative observation and 
interviews with three SPC 
service providers.  
Analysis:  
Thematic and content 
analysis of transcripts of 
observed meetings; 
thematic analysis of 
interviews and fieldnotes 
Objective:  
To investigate equity of use 
of SPC by lung cancer 
patients in relation to age 
Methods:  
Cross-sectional survey of 
lung cancer patients and 
carers attending outpatient 
clinics at four hospitals 
Analysis:  
Statistical (multivariable) 
analysis of questionnaire 
and medical records data 
Methods:  
Qualitative interviews with 
lung cancer patients and 
health care professionals 
referring to SPC 
Objective:  
To explore demand and 
supply side factors 
influencing referral to and 
use of SPC 
Analysis:  
Thematic analysis of 
transcripts of interviews 
QUAL  QUAN  QUAL 
Design: 
Ethnography 
Design: 
Cross-sectional survey 
Design: 
Semi-structured interview 
study 
Thematic analysis 
informs design of 
survey 
Content analysis 
guides choice of 
HRQL instrument 
used in survey 
Thematic analysis 
helps determine 
variables in 
multivariable analysis 
Analysis to  
help explain/further 
explore results 
Sub-sample of survey 
participants; purposive 
sampling based on 
survey data 
Figure 3.5 Study design and relationships 
PHASE 1b: 
MEASURING NEED FOR 
PALLIATIVE CARE 
Systematic literature review 
and critical appraisal of 
HRQL instruments used in 
cancer and palliative care 98 
 
4.  In the planned phase three (interviews with patients and health care 
professionals) sampling would be guided by data from the phase two 
survey, for example with patients being selected on the basis of 
quantitative variables such as HRQL scores. 
5.  Thematic analysis of phase three data was also planned to feed into a 
revised multivariable analysis of the survey data in the light of any 
new themes identified as determining use of SPC. 
6.  Finally, the results of all phases of the study undertaken were woven 
together to illuminate differing aspects of the research question, 
covering concepts of equity, need and use. 
 
The study was designed to take place within one cancer network in England. 
Cancer networks bring together health service commissioners and providers, 
the voluntary sector and local authorities to oversee implementation of the 
NHS Cancer Plan and other policy initiatives within their area. There are 34 
cancer networks in England, each covering a population of between one and 
two million people. The decision to conduct the study within one cancer 
network was taken to allow me to develop an in-depth understanding of 
referral procedures and service use across an entire organizational system. 
Cancer networks routinely use standardised referral procedures and 
documentation across the Trusts within their domain, and thus provide a 
stable environment in which to study variations in referral and use of 
services. A detailed description of the chosen cancer network is given in 
Chapter 4. 
 
As outlined above, the study was planned with three inter-linking phases to 
address differing facets of the research question. Phase three, interviews with 
a purposive sample of lung cancer patients and their health care 
professionals, was planned to take place immediately after phase two. I have 99 
 
discussed this final qualitative phase to demonstrate how the study was 
originally conceived, and the utility of linking quantitative and qualitative 
approaches and data across all aspects of the research question. The 
documentation for this phase was drawn up and ethical and research 
governance approval obtained. However, for the personal reasons outlined 
in the preface to this thesis, phase two data collection was interrupted, 
delaying the completion of recruitment to the survey. To achieve a 
comprehensive and rigorous analysis of data from the first two phases of the 
study within the time available, the decision was taken not to go ahead with 
the final phase of work. 
 
Summary 
Mixed methods research is an emerging discipline, but one that offers an 
appropriate and useful approach to many health services research questions. 
The philosophical and theoretical foundations of mixed methods are open to 
ongoing debate and development. This necessitates clarity about the 
philosophical stance (such as pragmatism) taken within a project. Clarity, 
too, is required to deal with logistical and practical considerations inherent 
within mixed methods approaches, particularly the combining of inferences 
from quantitative and qualitative data. Within this study, mixed methods 
were used to approach the question of equity of use of SPC services. By 
combining different methods (in this case, ethnography, systematic review, 
and survey techniques) I was able to devise a thorough investigation of the 
issues at hand, exploring, measuring and assessing the need for and use of 
SPC in a particular patient group.  
 
The central concerns of this thesis, theoretical and conceptual, are inevitably 
contested and fluid. Dimensions of and debates about equity, need and use, 
pragmatism, and age, have been considered and dealt with in this and the 100 
 
previous chapter. The next section returns to more concrete ground to 
provide the practical context in which the more abstract concerns are 
situated. In the following chapter I give a detailed description of the setting 
of the study, and the clinical subject matter at hand: the nature of SPC, and 
the diagnosis, prognosis, and treatment of lung cancer.  101 
 
Chapter 4 
 
The study in context: specialist palliative care, lung cancer, and the 
research setting 
 
The setting holds the key: met out of context 
A face is nameless, or if daily seen, 
Confused in memory by its many frames.  
 
So, though we treat the landscape as a background,  
Without it we are – nowhere. 
 
Anne Ridler. ‘Leaving Ringshall: A quodlibet of voices in one self’ 209  
 
 
The theoretical and practical context within which a study takes place is a 
key influence both on the results obtained, and on interpretation of those 
results. Detailed study development takes place with reference to the area in 
which it is to be conducted. At a study’s conclusion, reflections on bias and 
generalisability must be made with consideration of how the data were 
generated. To provide a framework within which results may be considered, 
a summary of palliative care, lung cancer and the study setting is provided 
within this contextual chapter. 
 
Firstly, I focus on palliative care. A brief overview of the development of 
palliative care and key current debates is given, including the distinction 
within the UK between generalist and specialist palliative care. Evidence of 
effectiveness of SPC, and patient experiences of receiving such services, are 
summarised. Next, I turn to consider lung cancer, including the different 
types of lung cancer and the epidemiology of this disease. A brief 
explanation of the treatment options for lung cancer is given, highlighting 
the important role of palliative treatment in the context of poor prognosis 102 
 
and high symptom burden. Finally, I describe the setting in which this study 
took place. I start with an overview of the geographical area and its 
population, including the epidemiology of cancer and lung cancer within the 
region. I then outline the lung cancer and palliative care services available 
for patients within the study setting, and the inter-relationships between 
these. Figures reported are those most relevant to the time period during 
which this study was conducted, where available. 
 
4.1  Specialist palliative care 
 
In the midst of caring for people who are dying, we are also celebrating life in all its 
richness and variety. 210 
 
The development and definition of palliative care 
Palliative care is a relatively recent phenomenon, a discipline whose research 
and practice base is still developing from its origins in the UK in the 1960s. 
The foundation of this now-worldwide movement is traditionally ascribed to 
the original vision of one woman, Dame Cicely Saunders. Saunders died in 
2005 aged 87 at the hospice she founded in 1967, St Christopher’s, in 
Sydenham, South London. At this, the first ‘modern hospice’, end of life 
clinical care, teaching and research were combined for the first time with the 
aim of improving relief of cancer patients’ symptoms, both physical and 
emotional. Previously, whilst there were a number of hospices caring for the 
dying (usually established and run by religious foundations), the focus was 
on providing nursing care alone for those in the final stages of life.  
 
The establishment of an extensive research programme at St Christopher’s 
led to influential advances in care, particularly in the area of terminal pain 
control. From the 1970s onwards, the principles of ‘hospice care’ began to be 
rolled out into other settings, including hospitals and the community. 211 103 
 
Whilst the hospice movement had started (and remains) predominantly 
within the voluntary sector, during this time NHS services were also being 
developed. 212 With increased availability and continued developments in 
practice, a particular philosophy of care coalesced which focused on 
physical, social, psychological and spiritual support, delivered by a multi-
disciplinary team: palliative care. 211 By the late 1980s, palliative medicine 
was sufficiently developed in the UK that it was established as a subspecialty 
of general medicine, thereafter becoming a specialty in its own right.  
 
Today, the provision of palliative care is widespread, and is offered on an in-
patient basis (in hospitals and hospices), as day care, and as home care for 
patients in the community. By 2006 in England, Wales and Northern Ireland, 
there were a total of: 
 
•  288 services providing care in the hospital setting  
•  187 inpatient units providing palliative care (with 2774 beds) 
•  216 providers of day care services, and 
•  295 providers of community care 213 
 
All services are expected to meet standards set down in guidelines issued by 
NICE covering the organisation and delivery of supportive and palliative 
care for patients with cancer. 19 These guidelines form part of recent 
Government initiatives to improve the quality of cancer care. 13 They require 
providers to work with commissioners to address key recommendations on 
service co-ordination and approach, and represent a milestone in the 
regulation and standardisation of minimum palliative care provision. 214 
Palliative care is now a central aspect of UK Government cancer policy, and 
the development of an end-of-life care strategy has widened this approach to 
all life-threatening conditions. 20 104 
 
In response to developments both in the UK and other countries, a formal, 
internationally accepted, definition of palliative care was first offered by the 
WHO in 1989. This has been revised through the years, and the 2002 version 
states that: 
 
Palliative care is an approach that improves the quality of life of patients and their 
families facing the problems associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychological and 
spiritual. 215 
 
Other definitions of palliative care have been offered; all focus on the holistic 
nature of palliative care and the aim of improving quality of life. For 
example, one definition of palliative nursing states that: 
 
All life-threatening illnesses – be they cancer, neurological, cardiac or respiratory 
disease – have implications for physical, social, psychological and spiritual health, for 
both the individual and their family. The role of palliative nursing is therefore to 
assess needs in each of these areas and to plan, implement and evaluate appropriate 
interventions. It aims to improve quality of life and to enable a dignified death. 216 
 
The NICE guidance on supportive and palliative care adopts a WHO 
definition of the nature of palliative care, 27 but additionally it divides 
palliative care into two types: generalist and specialist. 19 
 
Generalist and specialist palliative care 
Under the WHO definition, all patients with cancer and other life-
threatening illnesses could be said to have an ability to benefit from 
palliative care. This very broad formulation of need, based on diagnosis, is 
commonly employed in studies of use of palliative care. 119;123;124 However, 
within the UK in recent years the provision of palliative care has increasingly 
been distinguished as two types of care – that provided by generalists in 105 
 
their everyday work (such as GPs and district nurses), and that provided by 
specialists (such as consultants and clinical nurse specialists in palliative 
medicine). 28 In this model, specialists offer care only to particular patients 
with more complex and persistent problems, which generalists may not have 
the skills to deal with effectively. 19 
 
The National Council for Palliative Care (NCPC) has set out the components 
of a SPC service, as provided by a dedicated multidisciplinary team. 217 These 
teams should include palliative medicine consultants, palliative care clinical 
nurse specialists, social workers, physiotherapists, occupational therapists, 
dieticians, pharmacists, and staff members qualified to offer spiritual and 
psychological support. According to the NCPC, SPC services will: 217 
 
•  Assess, advise and care for patients and families in all care settings, 
including hospitals and care homes.  
•  Offer specialist in-patient facilities (in hospices or hospitals) for 
patients who may benefit from specialist input.  
•  Offer home support for patients with ‘complex needs’ who would like 
to be cared for at home. Specialist services will work alongside GPs 
and district nurses, most commonly as an advisory service. Some 
services will offer more intensive, hands-on nursing and medical care, 
usually referred to as ‘hospice at home’.  
•  Offer day care facilities to assess and review patients’ needs, provide 
physical, psychological and social interventions, and frequently offer 
creative and complementary therapies.  
•  Provide advice and support to all the people involved in a patient’s 
care.  
•  Provide bereavement support for the people involved in a patient’s 
care following the patient’s death.  106 
 
•  Offer education and training in palliative care.  
 
Generalist care, by contrast, may be referred to as the provision of a 
‘palliative care approach’ by non-specialists in the field. These might include 
hospital doctors and nurses, GPs and other members of the primary care 
team. Whilst some of these health care professionals, particularly 
oncologists, GPs and district nurses, may have regular contact with patients 
with advanced cancer, such care does not form the major component of their 
professional role. As set out in the NICE guidelines, generalist palliative care 
encompasses: 19 
 
•  information for patients and carers, with ‘signposting’ to relevant 
services 
•  accurate holistic assessment of patient needs  
•  co-ordination of care teams in and out of hours and across boundaries 
of care 
•  basic levels of symptom control 
•  psychological, social, spiritual and practical support 
•  open and sensitive communication with patients, carers and 
professional staff. 
 
The guidance stresses that generalists must seek advice from specialists 
when necessary. However, in spite of the division into generalist and SPC, 
and clarification of what these both involve, there is little guidance given as 
to which patients will require or benefit from specialist intervention.  
 
Evidence of effectiveness of specialist palliative care 
The effectiveness of SPC in improving patients’ and carers’ quality of life, 
managing pain and other symptoms and addressing psychological, social 107 
 
and spiritual concerns has been debated in the light of limited research 
evidence. 218 The challenges of conducting randomised controlled trials 
(RCTs) within palliative care have been well documented; problems include 
poor recruitment, patient attrition, ethical concerns and a lack of rigorous 
outcome measures. 219-221 With few RCTs completed, systematic reviews of 
the impact of SPC have included a large proportion of observational studies. 
218;222 Whilst drawing attention to the lack of high quality studies on 
effectiveness, these reviews have concluded there is some evidence that SPC 
has a small but positive effect on the control of pain and other symptoms, 
and on patient satisfaction, when compared to conventional care. 218;222 A 
more recent systematic review of research evidence conducted to inform the 
NICE guidance concluded that SPC improved outcomes for cancer patients 
across all settings – at home, in hospital and in hospices. 223 However, its 
impact in areas such as psychological and spiritual support is less well 
documented. 
 
SPC defines itself as being aimed at informal carers as well as patients. 
Meeting the needs of both patient and family may be challenging, but it is 
regarded as a fundamental aspect of the role of SPC providers. 224 Again, 
however, evidence on the effectiveness of interventions in cancer and 
palliative care to support informal caregivers is limited. 225  
 
Patient experiences of specialist palliative care 
There is limited research on patients’ perspectives of SPC. Studies tend to be 
small scale and are frequently opportunistic. However, from research which 
has been conducted it is clear that palliative care is frequently perceived by 
patients and carers to focus on terminal care and death; as a result patients 
report being upset or shocked by their own referral to the service. 226;227 Yet, 
once they are receiving care from a SPC team, patients quickly come to value 108 
 
their specialist knowledge of symptom, especially pain, control. 228 Patients 
often perceive that SPC teams have more time to devote to their care, 
offering ‘someone to talk to’ about their experiences. 229 Building up a 
relationship with key SPC staff, and knowing that they can contact someone 
for advice at any time, leads to a feeling of security and safeness for patients 
which in many cases had previously been lacking. 228 As a result of these 
factors, satisfaction with SPC services is often high. 230;231  
 
Current debates in palliative care 
Today, palliative care is firmly established as a medical and nursing 
specialty, and integrated within primary and secondary care services. 
Further development of palliative care centres on two main issues – a move 
away from terminal care to care at all stages of disease, and a widening of 
focus from providing cancer care alone to caring for patients with other life-
threatening illnesses. 215;232 The first debate is briefly highlighted here as it 
impacts on concepts and definitions of need for palliative care as addressed 
in this thesis. 
 
Following the establishment of palliative care as a specialty in its own right, 
practitioners began to consider how this approach may benefit cancer 
patients at all stages of the disease. Empirical studies showed that cancer 
patients may have need for symptom, psychological and other support (as 
provided by the palliative care approach) from diagnosis rather than only in 
the end stages of disease. 105 Greater understanding of symptom 
development and control led to the conclusion that problems at the end-of-
life may have their beginnings much earlier in the disease trajectory. 215 
Palliative interventions could therefore benefit patients with progressive, 
life-limiting illnesses alongside attempts at curative treatment. 233 
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The move from a ‘traditional’ end-of-life care concept to a more integrated 
approach has been shown diagrammatically [Figure 4.1]. 234 Incorporating 
palliative care earlier in the disease trajectory offers two possibilities; (i) the 
use of a generalist palliative care approach by all medical staff from the 
diagnosis of cancer and/or (ii) the involvement of SPC providers to provide 
advice and support for the patient and family from diagnosis or shortly 
afterwards. This model is now widespread within the literature, and is 
commonly referred to as the ‘Sheffield’ model after its place of origination. 235 
However, whether this theoretical view is reflected in clinical practice is 
questioned. 233 SPC providers may become involved only at the switch from 
curative to palliative interventions, and when there is a recognition a patient 
has a limited time left to live. For example, in the USA the criteria for the 
receipt of palliative care under Medicare for the over-65s remains the 
certification by two clinicians that life expectancy is six months or less. 236 
 
 
 
Anti-cancer treatments  Palliative / 
terminal care 
Anti-cancer treatments 
Palliative care  Grief 
Sheffield model of care 
Traditional model of care 
Diagnosis  Death 
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SPC has developed rapidly over a short period of time, although there 
continues to be a deficiency of evidence of effectiveness and a lack of clarity 
over its content and future direction. 233 In particular, whilst the organisation 
and nature of SPC services are clearly agreed, the specific patients who may 
need this type of care are poorly defined in policy and literature. For those 
who do receive such services, palliative care enjoys a high reputation.  
 
As a result of the heavy symptom burden of lung cancer, such patients are 
often seen as ideal candidates to receive SPC. 237 The following section briefly 
summarises the nature of this disease. It highlights its high incidence and 
poor prognosis, considers the treatments on offer (both curative and 
palliative), and gives a brief insight into the reported experiences of people 
diagnosed with lung cancer. 
 
4.2  Lung cancer 
 
We still have a considerable way to go until we have achieved optimal management 
for the patient with lung cancer. 238 
 
Development, types and symptoms 
Primary lung cancer is the development of a malignant tumour within the 
lungs. It is divided into two main types, which behave and respond to 
treatment in different manners. These are small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). About 25% of diagnosed lung cancers 
are SCLC, and 75% NSCLC (239 p. 63). NSCLC is a grouping of three cancers, 
divided according to the histology of the tumour: 
 
1.  Squamous cell carcinoma 
2.  Adenocarcinoma 
3.  Large cell carcinoma 111 
 
As all lung cancers develop, they may cause a variety of symptoms 
including: 
 
•  Persistent or worsening cough 
•  Dyspnoea (shortness of breath) 
•  Chest pain 
•  Haemoptysis (coughing up blood) 
•  Hoarseness 
•  Recurrent chest infections 
•  Fatigue 
•  Weight loss 
 
Research suggests that lung cancer patients experience a high symptom 
burden. 240 One study found that lung cancer outpatients reported a greater 
degree of symptom severity than patients with other cancer diagnoses. 106 
Pain, fatigue and dyspnoea have been identified as causing particularly high 
levels of distress. 241;242 Symptoms are frequently compounded by the high 
prevalence of comorbidity, especially cardiovascular diseases and chronic 
obstructive pulmonary disease (COPD), amongst patients with a diagnosis of 
lung cancer. 243 
 
Incidence and mortality 
In 2006, there were a total of 39,027 reported cases of lung cancer within the 
UK (22,381 (57.3%) in men and 16,646 (42.7%) in women), accounting for 13% 
of all cancer diagnoses. 244 Incidence is greater in the north of the UK, and 
highest in Scotland, reflecting historical variations in smoking rates across 
the country.  
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Lung cancer is primarily a disease of older adults, with 85% of lung cancer 
cases diagnosed in people aged 60 and over. Peak incidence falls between 75 
and 79 for both men and women [Figure 4.2]. 244 
 
 
 
 
Lung cancer has a high mortality rate, causing 22% of all cancer deaths in 
England and Wales. 245 It is the most common cause of cancer death in men, 
(24% of all cancer deaths) and the second most common cause of cancer 
death in women (19% of all cancer deaths), following breast cancer. 245  
 
Staging and treatment 
NSCLC is staged using the TNM system: 
 
•  T to indicate the size and location of the primary tumour 
Figure 4.2 Lung cancer incidence and age specific incidence rates, by sex, UK 2006 113 
 
•  N to indicate spread to regional lymph nodes 
•  M for distant metastasis 
 
These are then classified into stage groupings ranging in severity from stage 
I to IV. Whilst SCLC can in theory also be classified using the TNM system, 
in practice it is grouped into two stages, limited or extensive disease. Limited 
disease is defined as being where all detectable tumour can be encompassed 
within a radiotherapy port. Extensive disease includes patients with 
metastatic lesions in the other lung, and those with distant metastatic 
involvement.  
 
NICE guidelines on the diagnosis and treatment of lung cancer set out 
recommended treatment approaches. 237 Options include surgery, radical 
radiotherapy, palliative radiotherapy, chemotherapy, and best supportive 
care. Full details of standard treatment regimes are in Appendix I.  
 
Which treatments do patients receive? 
Accusations of ‘therapeutic nihilism’ (a reluctance to investigate or treat) 
have been levelled at physicians caring for lung cancer patients, in part 
attributed to the typically older age of lung cancer patients at diagnosis. 246 
However, whilst surgery rates in lung cancer remain low (in the main due to 
the high proportion of patients who are diagnosed at later stages of the 
disease), the use of chemotherapy and radiotherapy has increased in recent 
years. 247 In London in 2004, 11% of patients with lung cancer were reported 
to have received surgery; 23% received chemotherapy and 25% received 
radiotherapy in the first six months following diagnosis. 248 For 23% of 
patients, no treatment was recorded. Slightly different figures were derived 
from an audit of lung cancer patients in one cancer unit in the UK from 1998 
to 2001 [Table 4.1]; for this earlier time period, these show that the most 114 
 
common approach for NSCLC patients was best supportive care only 
(defined in this instance as excluding the receipt of any treatment). 249 
 
Table 4.1 Initial treatment for lung cancer in a UK cancer unit, 1998-2001 
249 
NCSLC  n (%) 
Surgery  84 (12) 
Radical radiotherapy  24 (4) 
Palliative radiotherapy  225 (32) 
Chemotherapy  57 (8) 
Best supportive care  255 (36) 
Missing data  57 (8) 
SCLC  n (%) 
Palliative radiotherapy  6 (5) 
Chemotherapy  75 (56) 
Best supportive care  28 (21) 
Missing data  24 (18) 
 
With a frequently short survival time and heavy symptom burden, SPC is 
argued to play a central role in the management of lung cancer patients and 
families. 250 Symptoms amenable to SPC intervention which are particularly 
prevalent in lung cancer patients include dyspnoea, pain, and fatigue. 242;251;252 
Whilst one study concluded that 83% of lung cancer outpatients reported 
one or more issues which could benefit from SPC care, 106 the proportion of 
patients who actually receive such services is likely to be much lower. 253  
 
Survival 
Lung cancer is frequently diagnosed at a late stage. Only a small proportion 
of patients are therefore deemed eligible for curative treatment, and overall 
survival rates are subsequently low. In the UK, about 25% of patients 
diagnosed with lung cancer are alive one year later, and only 7% are alive at 
five years. 254 
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Survival is related to stage of disease at diagnosis and the treatment patients 
receive. A review of lung cancer patients diagnosed between 1998 and 2001 
at one UK cancer centre reported median survival for NSCLC patients as 
being 18.1 months for stage 1 patients, 13.4 months for stage II, 7.4 months 
for stage III, and 2.1 months for stage IV. 249 When analysed by treatment 
received, the following median survival times were reported: 
 
•  Surgery – 52.4 months 
•  Radical radiotherapy – 21.6 months 
•  Palliative radiotherapy – 6.2 months 
•  Chemotherapy – 8.3 months 
•  Best supportive care only – 1.8 months. 
 
Even with the receipt of curatively aimed treatment such as surgery, survival 
may be poor. One study reported that five year survival following surgery 
varies widely according to stage of disease, with reported rates of 69% in 
stage IA, 52% in IB, 45% in IIA and 33% in IIB. 255 For patients with stage I 
and II disease receiving radical radiotherapy, a systematic review reported 
overall five-year survival of only 17%, substantially worse than patients 
receiving surgery. 256  
 
Survival also varies with patient age, with five year survival in males falling 
from 9% at aged 40-49 to 2% at ages 80 and above, and in females from 13% 
at 40-49 to 1% at ages 80 and above [Figure 4.3].  
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Figure 4.3 Five year relative survival by age, England and Wales, adults diagnosed 1996-
1999 and followed up to the end of 2001 
254  
 
Patient experiences 
 
The fear and the anxiety don't go away. There isn't a day when I don't think, you 
know, “I've got cancer, why did this happen? This is horrible, it's terrible. What 
does it mean in terms of life expectancy?” 
 
54 year old male diagnosed with SCLC, recounting his experiences for 
patient information website Healthtalkonline. 257  
 
Lung cancer has been referred to as the ‘Cinderella of common solid 
tumours’, as despite its high incidence and poor prognosis it is one of the 
least-researched and least-discussed cancers. 246 This dearth of understanding 
extends to the experiences of people diagnosed with lung cancer. Studies 
which have been conducted in this area are summarised briefly below.  
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Delays in the diagnosis of lung cancer, and the subsequent prevalence of 
advanced disease at diagnosis, have long been a source of particular concern. 
258 A small exploratory UK study found that a median of 7 months passed 
between patients’ first recalled changes in health and the onset of the 
symptom or event that finally led them to seek medical care and receive a 
diagnosis of lung cancer. 259 Reasons for the delay in seeking care included 
uncertainty over what may be normal, with the attribution of symptoms to 
‘everyday causes’, or to other co-morbid diseases. 260 Additionally, patients 
had either not considered the possibility of lung cancer, or had suppressed 
this as a possibility. 
 
Once patients have sought help, reactions to a diagnosis of lung cancer may 
include shock, relief or resignation. 261 Following diagnosis, patients may feel 
uncertain about where they ‘belong’ – not yet safely under the care of the 
hospital team, but no longer the responsibility of the GP. Such feelings can 
cause acute anxiety and distress for both patients and carers; feelings that 
may be repeated during the gaps which occur between completing treatment 
and subsequent follow-ups. 262 Further, perceived stigma attached to the 
diagnosis of lung cancer as a result of its strong association with smoking 
may cause anxiety in patients concerned they will be denied access to care. 263 
 
As previously highlighted, many lung cancers are diagnosed only at an 
advanced stage. Treatment options may be limited, and progression rapid. 
As Deborah Hutton, a women’s health journalist, wrote shortly before her 
death from NSCLC in July 2005 aged 49:  
 
It didn’t take long to find out that in the world of advanced cancer, stage IV is as bad 
as it gets. There is no stage V. 264  
 118 
 
Hutton, a fitness and health fanatic who had smoked briefly as a young 
adult, survived for less than eight months from diagnosis, during which time 
she received six cycles of chemotherapy to little effect.  
 
The final section of this chapter moves away from clinical considerations to 
focus on the setting in which my research took place. I firstly outline reasons 
for the choice of study location, and the strengths and limitations as a result 
of this. I then provide some contextual information on the setting, including 
its geography and population. Next I consider the morbidity and mortality 
profile of the population, particularly with reference to cancer and lung 
cancer. Finally, the palliative and cancer care systems within the area are 
explained.  
 
4.3  Study setting 
 
Cancer networks will work together to develop strategic service delivery plans to 
develop all aspects of cancer services – prevention, screening, diagnosis, treatment, 
supportive care and specialist palliative care. They will agree common protocols and 
service patterns to tackle variations and to make best use of resources. 13 
 
Rationale for choice of study setting 
The study took place within one cancer network in London, England. Cancer 
networks were first proposed as the most appropriate structure for the 
delivery of cancer care by the Calman-Hine report, published in 1995. 265 This 
influential report, commissioned by the Government to develop a policy 
framework for commissioning cancer services, envisaged a network of 
providers from primary care, through Cancer Units in District General 
Hospitals, to Cancer Centres in major teaching hospitals, all working 
together to deliver a uniform standard of care. Cancer networks were 
subsequently established as the organisational structure for the 119 
 
implementation of the NHS Cancer Plan and other policy initiatives within 
each region. 13 They bring together health service commissioners and 
providers, the voluntary sector and local authorities within a defined area. 
Originally tasked with reviewing current service provision, networks now 
focus on developing services in line with Government targets and 
expectations. Currently there are 34 cancer networks in England, each 
covering a population of between one and two million people.  
 
I decided to confine the study to one cancer network to promote an 
understanding of service use across an entire organizational system. Within 
networks, health care professionals use standardised referral forms for 
cancer and palliative care services with reference to criteria for making such 
referrals. This provides a degree of organisational cohesiveness within which 
investigations of variations in use may take place.  
 
The participating cancer network covers a population of about 1.5 million 
across six Primary Care Trusts (PCTs) in London. It was purposively chosen 
as the study setting due to its diverse population in terms of age, ethnicity 
and deprivation, its mix of both urban and suburban areas, wide variations 
between PCTs in the provision of cancer and SPC services, and a high 
incidence of lung cancer. Despite these variations, it operates a standardised 
referral system for cancer and palliative care services. Additionally, I had 
developed strong links and a good understanding of the cancer system 
within the network as a result of previous research. 
 
The restriction of the study to one cancer network may limit generalisability 
of the study findings as a result of the unique service provision and 
population characteristics within the area. Whilst the network covers both 
urban and suburban areas, it does not include any rural settings. The referral 120 
 
to and use of palliative care within rural settings may differ markedly, 
particularly for patients at home, as lengthy travel distances to isolated 
communities may lead to different organisational approaches to care being 
adopted. However, as the provision of SPC has largely developed within the 
voluntary sector, widespread variations in care exist across all areas with 
little reference to whether services are urban, suburban or rural. For 
example, some rural areas in England are exceptionally well provided for 
palliative care as a result of local fundraising and commitment to 
establishing such services, whilst some urban areas have very patchy 
coverage. 13 
 
An additional consideration for generalisability is the population contained 
within the network, discussed in detail below. Differing age structures of the 
population between this network and other regions, and variations in other 
key socio-demographic variables including deprivation, must be considered 
when extrapolating findings.  
 
Despite the potential restrictions on generalisability, the focus on one cancer 
network is beneficial in containing the study within one system of care with 
standardised guidelines for referral. Additionally, the confinement of the 
study to one geographical area enhanced the rigour with which data 
collection could be conducted within the available study resources.  
 
Geography and socio-demographics of the cancer network 
The participating network comprises six PCTs, all of which are coterminous 
with six Local Authority boundaries. According to the population estimates 
for mid-2005, the area had a total population of 1,524,600. 266 Whilst 
population numbers are relatively evenly spread across the six PCTs within 
the area, the characteristics of their populations vary widely. In particular, 121 
 
the three inner London PCTs within the network have a lower proportion of 
older residents compared to the London average, and a higher proportion of 
residents from black and ethnic minority groups [Table 4.2]. One explanation 
for the relatively young population structure of the inner London PCTs is the 
high level of migration within these areas. 267 Index of Multiple Deprivation 
(IMD) scores also reveal wide differences, with four of the PCTs being some 
of the most deprived boroughs in England.  
 
Table 4.2 Overview of PCTs 
PCTs   Location 
Population 
at census 
2001 
Proportion 
of over 75s 
1 
Minority 
ethnic 
population 
2 
Index of 
Multiple 
deprivation 
2004 
3 
A  Inner  266,169  4.2%  31.6%  13 
B  Inner  244,866  4.8%  37.0%  12 
C  Inner  248,922  5.3%  34.1%  38 
D  Outer  218,307  7.4%  8.6%  216 
E  Outer  295,532  8.2%  8.4%  252 
F  Outer  214,403  6.5%  22.9%  23 
 
[1] Estimates from the 2001 census. Proportion of 75s and over: England 7.5%, London 5.9% (Inner London 4.7%, 
Outer London 6.6%) 
[2] Estimates from the 2001 census. Percentage is that of all other categories apart from White. (England 9.1%, 
London 28.8%) 
[3] IMD 2004 rank of average of ward ranks - out of 354 districts, 1 = most deprived 
 
Mortality and morbidity in the cancer network 
Life expectancy for both males and females is lower than the England 
average in four of the PCTs [Figure 4.4]. As a result of their poor population 
health and high deprivation levels, these are designated part of the 
Spearhead group of local authorities and PCTs. 96 This group, set up to 
accelerate reductions in health inequalities in England as a result of the 
Public Health White Paper Choosing Health, 6 initially comprised 88 PCTs in 
the bottom fifth in England for 3 or more of the following indicators: 
 
•  Male life expectancy at birth 
•  Female life expectancy at birth 122 
 
•  Cancer mortality rate in under 75s 
•  Cardiovascular disease mortality rate in under 75s 
•  Index of Multiple Deprivation 2004 (Local Authority Summary), 
average score 
 
 
 
 
Table 4.3 shows key indicators for population health in the area. As would 
be expected in the Spearhead PCTs, these are all below the England average 
for the number of deaths from smoking, and the number of early deaths 
(below age 75) from cancer.  
Figure 4.4 Life expectancy in the cancer network 123 
 
 
Table 4.3 Key health indicators for PCTs 
PCTs  Deaths from 
smoking 
a 
Early deaths: 
cancer 
b 
Compared to 
England average 
A 
268  280.7  133.1  ￿ above 
B 
269  293.5  126.1  ￿ above 
C 
270  296.2  140.5  ￿ above 
D 
271  218.8  111.0  ￿ below 
E 
272  201.7  108.9  ￿ below 
F 
273  304.1  138.9  ￿ above 
England average  234.4  119.0  - 
England worst  366.5  168.0  - 
 
[a] Directly age-standardised rate/100,000 population aged 35 or over, 2003-2005 
[b] Directly age-standardised rate/100,000 population, under 75s, 2003-2005  
 
Cancer incidence and mortality 
There were a total of 5,762 cancer registrations in the network in 2004, a rate 
of 406.4 per 100,000 population in males and 341.6 per 100,000 population in 
females. 248 Lung was the second most common cancer in males in the region, 
behind prostate but ahead of colon – together these three accounted for 
44.7% of all cases. Lung was also the second most common cancer in females, 
with breast the most common and colon the third most common, together 
accounting for 49.1% of all cases [Table 4.4]. These figures echo the most 
common cancers in England in 2004; breast, lung, colorectal and prostate.  124 
 
 
Table 4.4 Cancer registrations in the network 2004 * 
248 
Female  Male 
Cancer site  Cases  Rate  Cancer site  Cases  Rate 
Breast  886  114.3  Prostate  576  84.7 
Lung  354  38.9  Lung  479  69.2 
Colon  200  21.1  Colon  209  30.3 
Uterus  140  18.3  Head and neck  148  22.7 
Ovary  122  14.8  Rectum  150  21.8 
Rectum  109  12.3  Bladder  124  17.4 
Head and neck  93  11.1  Non-Hodgkin's 
lymphomas  119  17 
Non-Hodgkin's 
lymphomas  88  10.5  Stomach  91  12.2 
Pancreas  93  9.6  Pancreas  79  11.8 
Cervix  71  8.6  Oesophagus  75  11.3 
Stomach  65  6.1  Melanoma of skin  45  6.1 
Melanoma of 
skin  52  5.8  All  2830  406.4 
Oesophagus  49  4.6       
Bladder  49  4.5       
All  2932  341.6       
 
* Numbers of registrations and age-standardised incidence rates per 100,000 European 
standard population. 
 
All-cancer mortality is higher than expected in PCTs D, A, and B [Table 4.5] 
compared to England as a whole, with Standardised Mortality Ratios (SMRs) 
for these PCTs of 112, 106 and 115 respectively. 125 
 
 
Table 4.5 All cancer mortality in the network 2003 to 2005 (pooled) 
274 
Indirectly standardised ratios (SMRs) 
PCTs   Observed 
mortality 
Standardised 
mortality ratio 
(SMR) 
SMR 95% confidence limits 
Lower  Upper 
A  1257  106  100  112 
B  1284  102  97  108 
C  1486  115  109  121 
D  1583  96  91  100 
E  2250  94  90  98 
F  1482  112  107  118 
Inner London  14198  101  99  102 
Outer London  28040  96  95  97 
London  42238  97  97  98 
England  379580  100  100  100 
 
Lung cancer incidence and mortality 
The cancer network has a high overall incidence of lung cancer compared to 
London and England, although there is great variation within the network. 
During 2001 to 2003, there were a total of 1,519 registered diagnoses of lung 
cancer in the network. Standardised registration ratios (SRRs: the ratio of 
observed to expected registrations in an area multiplied by 100) show that 
lung cancer incidence was significantly higher than expected in PCTs D, A, 
and B compared to England as a whole [Table 4.6]. Figures are not currently 
available separately for NSCLC and SCLC.  126 
 
 
Table 4.6 Incidence of lung cancer in the network 2001 to 2003 
274 
Indirectly standardised registration ratios (SRRs) 
PCTs   Observed 
incidence 
Standardised 
registration 
ratio (SRR) 
SRR 95% confidence 
limits 
Lower  Upper 
A  240  134  118  152 
B  251  136  120  154 
C  215  115  100  131 
D  267  111  98  125 
E  300  89  79  100 
F  246  132  116  150 
South East London  1519  116  110  122 
London  6611  105  103  108 
England  55053  100  99  101 
 
Consistent with a raised incidence, lung cancer mortality was also 
significantly higher than the English average in PCTs F, A, C and B [Table 
4.7].  
 
Table 4.7 Lung cancer mortality in the network 2003 to 2005 (pooled) 
274 
Indirectly standardised ratios (SMRs) 
PCTs   Observed 
mortality 
Standardised 
mortality ratio 
(SMR) 
SRR 95% confidence 
limits 
Lower  Upper 
A  321  131  117  146 
B  358  137  123  152 
C  325  122  109  136 
D  342  98  88  109 
E  481  96  88  105 
F  364  134  120  148 
Inner London  3473  119  115  123 
Outer London  5730  94  92  96 
London  9203  102  100  104 
England  80204  100  99  101 
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In the network as a whole, one-year survival in lung cancer patients is 
slightly lower than the overall proportion of patients surviving in London, 
although this difference is not statistically significant. When survival rates in 
London as a whole are compared to those in England, a larger proportion of 
patients are alive at one year post diagnosis, potentially reflecting the greater 
availability of cancer care in the capital. However, by five years post 
diagnosis only 6.2% of patients in the network are still alive, the same figure 
as for England [Table 4.8].  
 
Table 4.8 Relative survival for lung cancer in the network 
248 
Area 
Number 
of 
patients 
One-year survival 
a  Five-year survival 
b 
% 
95% confidence 
limits  % 
95% confidence 
limits 
Lower  Upper  Lower  Upper 
Network  2212  25.6  22.4  28.8  6.2  4.4  8.1 
London  9385  26.8  25.2  28.3  6.6  5.6  7.5 
England  76969  24.2  23.6  24.7  6.2  5.9  6.6 
 
[a] Patients diagnosed 1997-99 (followed up to 31 December 2000) 
[b] Patients diagnosed 1997-99 (followed up to 31 December 2004) 
 
Organisation of cancer and palliative care services in the cancer network 
There are six acute trusts serving the network. Four are designated cancer 
units and the remaining two jointly serve as the cancer centre for the 
network. Cancer units are usually District General Hospitals with a full 
range of support services for cancer patients, including designated clinics for 
specific common cancer sites such as lung cancer. Cancer centres offer 
diagnosis and treatment for all cancers, including rarer cancers referred from 
cancer units, and also provide specialist diagnostic and therapeutic 
techniques such as radiotherapy. 265 The cancer network therefore operates 
on a ‘hub and spoke’ basis, with the cancer centre providing the most 
specialised care. More details about the clinics, hospitals and SPC providers 
which participated in this study are given in chapters 6 and 7. 128 
 
The cancer network is also part of a Supportive and Palliative Care Network. 
This umbrella organisation brings together palliative care providers and 
commissioners to work towards enhancing provision and meeting standards 
including those set out in the NICE Guidance on Supportive and Palliative 
Care. 19 Within this area of the palliative care network, there are eleven 
providers of SPC, although additional services from outside the network 
area are also used. These can be summarised by setting: 
 
Hospital inpatient care 
Each of the six acute trusts operates a SPC team to offer care to hospital 
inpatients.  
 
Hospice inpatient care 
There are three hospices providing specialist inpatient care and other 
services to parts of the cancer network, with a total of 97 beds.  
 
Home care 
A total of seven providers, including three acute trusts, two of the hospices 
and two stand-alone services, operate SPC community teams to support 
patients in their own homes within the network.  
 
Figure 4.5 summarises the arrangements for cancer and palliative care 
service provision within the area.  
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Standardised referral procedures operate across the network for GPs to refer 
suspected lung cancer patients to a cancer unit or centre, and for all health 
care professionals to make a referral to one of the SPC services in the area. 
This requires referrers to complete the relevant referral form; the same 
clinical and personal details are therefore received by each provider of care. 
However, there are not standardised procedures across SPC providers in 
how they choose to respond to referrals.  
 
The network is a diverse urban area, encompassing six PCTs with varying 
levels of deprivation, morbidity and mortality. Cancer mortality, both overall 
and for lung cancer in particular, is higher than expected. The population is 
served by a number of different hospitals and palliative care providers, 
although these work together as a network with common referral procedures 
for cancer and palliative care services.  
 
Following this summary of the context within which this research project 
took place, I move on to present findings of the ethnographic study I 
conducted within three SPC providers in the network. This exploration of 
how need for SPC was defined and operationalised by providers of care had 
two broad aims: to understand in greater depth the nature and content of 
decisions to offer care, and to inform my approach to measuring need within 
a later study of use of SPC.  
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Chapter 5 
 
Defining need for specialist palliative care: ethnographic study 
 
As he came near death things grew shallower for us: 
We’d lost sleep and now sat muffled in the scent of tulips, the 
  medical odours, and the street sounds going past, 
  going away; 
And he, too, slept little, the morphine and the pink light the 
  curtains let through floating him with us, 
So that he lay and was worked out to the skin of his life and  
  left there, 
And we had to reach only a little way into the warm bed to 
  scoop him up. 
 
Roy Fisher. As He Came Near Death. 275 
 
 
Palliative care is defined by the World Health Organisation (WHO) as: 
 
The active holistic care of patients with advanced, progressive illness. Management 
of pain and other symptoms and provision of psychological, social and spiritual 
support is paramount. The goal of palliative care is achievement of the best quality of 
life for patients and their families. 27 
 
This statement suggests need for palliative care is a multidimensional 
concept. In spite of this, studies including palliative care need commonly use 
narrow definitions – a diagnosis of cancer, or the presence of pain. 276 This 
approach may arise in part due to insufficient consideration of the 
importance of assessing need to examine equity. Without an effective 
measure of need, studies of variations in use can only report on inequalities 
(differences in use) rather than inequities (differences in use which do not 
reflect differences in need). Further, studies of palliative care use have 
typically been based on administrative data or retrospective reports of 
bereaved relatives. As a result, they are limited in the reliability and 132 
 
comprehensiveness of data they may draw upon to define and assess need 
for care.  
 
Sen distinguishes between external and internal observations in assessments 
of equity. 277 External observations are those derived from ‘observation-
oriented’ subjects such as economics, and typically take a quantitative 
approach to measurement. Internal approaches come from ‘perception-
oriented’ subjects such as anthropology, and often draw upon qualitative 
methods. He argues that we need both perspectives to deepen our 
understanding of equity. A comprehensive examination of the process by 
which patients gain access to SPC thus requires a multi-method approach.  
 
Within SPC, as other health care specialties, the context in which decisions 
about need for and access to care take place is crucial. 278 Whilst guidelines 
and policies may clearly set out the parameters within which SPC services 
should operate, it is the day-to-day interpretation and implementation, or 
otherwise, of these which shape the nature of care received. 279 Definitions of 
need – in the eyes and actions of the providers – may be fluid. They may 
encompass a diversity of criteria, including economic, clinical, social, lifestyle 
and personal characteristics (including age). 280 As such, operational 
definitions of need for care may be more about the ‘deservingness’ of a 
patient rather than strict ‘objective’ medical criteria. 91  
 
However, there is currently little research evidence on how providers make 
decisions about which patients have a need for SPC. In particular, which 
aspects and levels of a patient’s physical, emotional and social well being, 
and functional ability, trigger providers to offer care? What are the 
contextual constraints within which these decisions are made? And how 133 
 
might patient characteristics, including age, influence use of and quality of 
care? 
 
This chapter outlines the ethnographic approach I took to explore SPC 
providers’ views about factors that are relevant when determining need for 
care. It describes the choice of study settings, entry into those settings, and 
the participant observation and other data collection undertaken. Procedures 
for recording and analysing data are set out, along with the ethical 
considerations and concerns which guided the conduct of this phase of work. 
I present my findings in two separate sections, based on an analysis of 
different data sources – documentary evidence, and observations of meetings 
and interviews undertaken. I develop two alternative models of need for 
SPC, and then move on to place the concept of need within the context of the 
day-to-day practices and decision-making of SPC providers. Finally, I briefly 
consider the role of age and other patient characteristics in determining the 
nature and level of care provided.  
 
5.1  Aims and objectives 
The aim of this component of my research was to develop an understanding 
of providers’ conceptualisations of need for SPC.  
 
The objective was to conduct an ethnographic study of SPC providers to 
explore their concepts of need for, and factors (including age) influencing 
use of, SPC. 
 
5.2  Investigation and choice of study design 
To gain an understanding of how need for SPC is conceived by providers of 
such services, and how need and other factors may be viewed as 
determining use, I chose to use an ethnographic approach. The term 134 
 
‘ethnography’ may refer both to a particular methodology, and to the end 
result of that methodology (a written report of the research). 281 Ethnography 
as a methodology originates in social anthropological research, with small 
scale studies of particular cultural groups. However, it offers a powerful 
approach in health care research, where the observational methods which 
form a central component of ethnography can be used to explore differences 
in action and explanation; what people actually do rather than what they say 
they do. 282 
 
A particular strength of the anthropological approach is its emphasis on 
exploring the nature of a phenomenon, rather than assuming it is 
unproblematic or focusing only on exploring beliefs about it. 282 In this way, 
ethnographic approaches are employed to question categories that are used 
within the study setting, considering what they mean, their content and 
form, how they originated and how they are used. This makes this approach 
particularly useful in considering how need for SPC is conceptualised by 
providers of that care.  
 
Ethnographic approaches draw upon a variety of methods, and may 
incorporate both qualitative and quantitative data. The defining aspect of 
any ethnography, however, is its focus on a particular culturally and socially 
defined context. 283 An ethnography is commonly situated within a naturally 
occurring group, whether that is a local community, a hospital or a multi-
disciplinary team. The second major aspect of ethnography, as mentioned 
above, is the use of observational techniques to explore the phenomena 
under study. This is fundamental in gaining insight into the actions and 
behaviours of individuals and groups, rather than simply the descriptions of 
these actions and behaviours which might be given. 284;285  
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Observation of the individuals under study within an ethnography is 
commonly known as participant observation. There is an ongoing debate 
about the precise nature of participant observation. 286 Definitions of 
participant observation often highlight a range of stances the researcher may 
adopt, with implications for their involvement in the study setting. For 
example, an influential taxonomy by Gold suggested that the researcher may 
be a full participant, participant as observer, observer as participant, or 
complete observer. 287 One determinant of the nature of participant 
observation undertaken in each study will therefore be the researcher 
themselves, including whether their background is, for example, clinical or 
nursing, their metaphysical stance, and their knowledge of or prior 
involvement in the study setting. 
 
Participant observation is regarded by some as a method, and others as a 
methodology. Those who argue for its methodological status assert that it 
can be linked to a number of different epistemological approaches, and so 
may not be used without reference to metaphysical beliefs. 286 It thus 
becomes an approach to generating knowledge, rather than a particular 
technique to obtain data. Reflecting the pragmatic philosophy within which 
this work is situated, in this study I define participant observation as a 
method. It is one of a range of techniques I use within the ethnographic 
approach of this phase of work (see below), and is therefore employed as a 
data collection tool. Thus, I chose participant observation as one approach to 
considering the construction of the category of need for SPC.  
 
Ethnographic approaches are being used increasingly within health services 
research as they enable context-specific understanding of behaviour and 
beliefs around health care delivery. Observation of team meetings has been 
used previously to gather data on decision-making relating to patient 136 
 
referrals and care. 288;289 By considering the context of care and the actual 
processes which take place, such approaches facilitate understanding of ‘real 
world’ health care organisation. This is vital in investigating variations in use 
of care, as it enables insights into the construction of need for care and how 
this might impact on use.  
 
5.3 Methods 
 
Ethnographic and theoretical approach taken 
To consider the nature of need for SPC from the perspective of providers of 
that care, I situated my ethnography within such services. I used a focused 
ethnographic approach, suitable for use where particular research questions 
are established prior to commencing fieldwork. 281  
 
Focused ethnographic approaches are characterized by their restriction to 
specific areas of study within the field; a ‘focus on the particular’. 290 The 
restriction of subject to a selected behavioural or belief area of study within a 
discrete community or organization also means focused ethnographies are 
frequently time-limited. 291 They are commonly found in nursing and public 
health research, where both time constraints and a desire to conduct research 
to understand and potentially change policy and practice are conducive to 
smaller-scale, but more tightly focused, ethnographic research.  
 
In such approaches, data collection is inevitably targeted. To explore the 
question at hand, the researcher may combine selective episodes of 
participant observation with a limited number of interviews with key 
informants, alongside the gathering of other sources of information such as 
documents and visual data. The use of audio-recordings and subsequent 137 
 
transcripts alongside fieldnotes is often a key feature of focused 
ethnographies.  
 
Knoblauch contrasted focused ethnographies with ‘conventional’ 
ethnographies to develop further the distinguishing aspects of this approach 
[Table 5.1]. 290  
 
Table 5.1 Ethnographic approaches 
Conventional ethnography  Focused ethnography 
Long-term field visits  Short-term field visits 
Experientially intensive  Data/analysis intensity 
Time extensity  Time intensity 
Writing  Recording 
Open  Focused 
Participant role  Field-observer role 
Notes  Notes and transcripts 
 
In this focused ethnography, I combined participant observation of SPC team 
meetings with formal and informal interviews and documentary analysis. I 
worked primarily within one SPC provider, expanding my data collection to 
two other providers to interrogate the concepts emerging from initial 
analyses. Taking one ‘index’ site and two ‘satellite’ sites enabled me to gather 
in-depth data at the first and more targeted data at the others, as is suited to 
a focused ethnographic method.  
 
My previous experience of SPC was as a researcher, including conducting a 
number of palliative care studies within the area in which this ethnography 
was situated. I have no clinical or nursing background, and no personal 
experience of palliative care provision as a result of illnesses of family or 
friends. My understanding of the nature of palliative care prior to this piece 
of research was thus through reading, and through previous conversations 
and interviews with providers of care. I had not been on a hospice ward, or 138 
 
seen first-hand the ways in which SPC teams worked. The experience of 
observing providers of care was thus completely new. This meant I entered 
the field with few ideas about how things worked within SPC. However, it 
also meant I had a steep learning curve to be able to ‘keep up with’ technical 
discussions I observed. I say more about my experience of conducting the 
research, and my potential impact on the data, later in this chapter. 
 
My ethnography was framed by the pragmatic philosophy which guided the 
entire research project. This requires qualitative inquiry to situate itself as far 
as possible within the empirical natural world, a task to which ethnography 
is particularly well suited. 292 Further, it highlights the importance of 
considering the interaction between agency and the environment; that is, 
between individuals (with all their motivations and aspirations) and the 
context in which they may express their agency. 292 Thus, an appreciation of 
the multiple levels at which concepts of need may be shaped and applied is 
essential.  
 
In considering the nature of need for SPC, I drew on the most common 
theory of need within public health, that of capacity to benefit from 
healthcare. 24 I thus approached my observation of staff meetings and other 
documentary sources with a framework already in place. I was aiming to 
operationalise this concept by considering which dimensions of a patient’s 
situation or the SPC service might relate to a capacity to benefit. Of course, it 
was possible that I might encounter sufficient challenges to this account to be 
forced to re-consider its relevance to SPC need, and I thus aimed to maintain 
a flexible outlook during the process of data collection and analysis.   
 
My focused ethnography was concerned with investigating provider-defined 
need. It is these views that dictate whether a patient, once referred, is offered 139 
 
SPC services. It therefore presents a narrow view of need, excluding patients, 
carers and referrers’ conceptualisations. However, it offers the most 
constructive approach for phase two of the study, where patients were 
assigned a level of need for SPC. By developing an idea of provider-defined 
need I applied, as far as possible, the same criteria to categorising patients as 
those aspired to by these specialists.  
 
In addition, I considered need for SPC for all, rather than specifically lung 
cancer, patients. Firstly, early discussions with SPC providers determined 
that the components of need for care were unlikely to vary according to 
diagnosis, although of course the level of these components might be 
dependent on the nature of the disease at hand. Therefore, a specific focus on 
lung cancer was unlikely to generate different definitions of need. Secondly, 
practical difficulties would render such an approach challenging, as only a 
small proportion of discussions within SPC providers’ meetings would relate 
to lung cancer patients. Therefore, this ethnography focuses on need for SPC 
as a whole, although the findings were applied to the later cross-sectional 
survey of lung cancer patients. 
 
A potential conflict arises between the requirement for ‘a definition’ of need 
to conduct a statistical analysis of use, and ethnographic data which may 
lead me to conclude definitions of need are lacking, unclear, contradictory, 
or ignored in practice. As discussed in chapter three, in mixed methods 
approaches such tensions require, as far as possible, prior consideration and 
exploration. The persistence of irreconcilable contradictions between 
findings derived from the use of different methods within a study may 
require the original assumptions to be revisited.  
 140 
 
It was partly to address this issue that I drew on a variety of data sources 
within the ethnography to explore the phenomenon of need. These included 
documents used by service providers to set out the parameters of their 
services. I was interested in the feasibility of using these in part to derive a 
‘public’ view of need. I wished to compare this with ideas of need apparent 
in working practices, using observational data to explore conceptualizations 
of this phenomenon in day-to-day life. A further aspect I wished to consider 
was the concept of need used to assess and accept referrals to SPC (perhaps 
reflected in service documents), and whether and how this varied from need 
in patients receiving ongoing care. This would also involve a focus on why 
and when patients may be discharged from SPC – one aspect of how 
providers may define a lack of need for care. I hoped to use these varying 
perspectives in developing a measure of need for the cross-sectional survey, 
reflecting how I felt SPC providers assessed need in patients referred to their 
care. I accepted, however, that this definition of need may not reflect 
conceptualisations of need for SPC throughout the entire patient and 
provider journey.  
 
Prior to the commencement of the study, I therefore expected to be able to 
derive a workable definition of need for quantitative measurement, but to 
subsequently consider the influence or otherwise of this concept in 
providers’ work, and the implications this may have for the equitable 
provision of care.  
 
Situating the study: participating SPC services 
 
Sampling and recruitment of sites 
It was essential to sample a diverse range of SPC providers to investigate 
conceptualisations of need for SPC, as these might vary between settings. I 141 
 
chose two key characteristics as factors which may influence approaches to 
the provision of SPC, and which therefore needed to be central to the 
sampling strategy. 
 
Firstly, SPC providers may be based within the voluntary sector or the NHS. 
As a result of their different funding sources and management or governing 
arrangements, NHS and voluntary providers may vary in their 
conceptualisations of SPC. Voluntary sector SPC providers, whilst in part 
funded by local NHS sources (typically one third to one half of their income), 
raise the rest of their running costs from charitable donations and other 
sources. As stand-alone organisations dedicated to the provision of SPC, this 
could mean they offer additional services and have a wider definition of 
SPC. By contrast, NHS services may have more limited budgets and be 
working within other, larger health care providers which place constraints 
on the nature of the care they provide.  
 
Secondly, the nature of SPC provision and the patients receiving care will 
vary whether it is provided in an inpatient or community setting. Inpatient 
hospice patients are usually admitted for symptom control, respite or 
terminal care, and have already been under the care of community SPC 
teams. In an inpatient hospital setting, patients referred for SPC input may or 
may not have already received community SPC care. In the community, 
patients referred to receive SPC from a home care team for the first time will 
not have received SPC previously, although they may have received 
generalist palliative care. These varying patient characteristics may lead to 
differing questions on need for SPC input by setting, as summarised below: 
 
a.  Community SPC – does the patient have a need for specialist, rather 
than generalist, palliative care? 142 
 
b.  Hospice inpatient care – does the patient have a need for inpatient 
SPC, requiring intervention, treatment or care which cannot be 
delivered by the community SPC care and/or in the home setting? 
c.  Hospital inpatient care – does the patient have a need for specialist, 
rather than generalist, palliative care and/or does the patient have a 
need for inpatient SPC at this time? 
 
Potential research sites were therefore chosen to ensure I included both 
voluntary and NHS sector providers, and providers offering care in inpatient 
hospice, inpatient hospital and community settings.  
 
Three providers of SPC were initially selected as potential research sites, 
based on the sampling strategy. These were: 
 
1.  A large, voluntary sector provider offering inpatient hospice and 
community care, as well as day care 
2.  An NHS team offering community care, based within one of the 
cancer network’s cancer centre hospitals 
3.  An NHS team offering inpatient hospital care, based within one of 
the cancer network’s cancer units 
 
The intention was to cover both voluntary sector inpatient and community 
care through site one, and NHS sector inpatient and community care 
through sites two and three. However, following initial contact to discuss the 
research project the medical director of the NHS inpatient hospital team felt 
that, as they were currently experiencing staffing difficulties, it was not 
appropriate to take part in a research project at this time. The selected NHS 
community team then suggested I could attend team meetings of a hospital 
team they were linked with, who were agreeable to participating in the 143 
 
project. A full description of the sites who therefore agreed to participate is 
given below. 
 
Details of sites 
The three sites taking part in this phase of work were [Figure 5.1]: 
 
1.  Research site one (RS1): a voluntary sector SPC provider with an 
inpatient hospice, day care unit and community care teams 
2.  Research site two (RS2): an NHS community SPC team, operating out 
of an NHS acute Trust. 
3.  Research site three (RS3): an NHS inpatient hospital SPC team, based 
at a different hospital site but with organisational links to RS2.  
 
 
 
Research site one (RS1) 
RS1 is a voluntary sector hospice which offers inpatient, day and home care. 
They serve a catchment area of around 1.5 million people and care for 
around 2,000 people each year. Currently, the NHS funds 40% of their 
running costs; the remainder is generated through fundraising, legacies, 
voluntary donations and commercial activities.  
 
RS1 
Voluntary sector 
 
• Inpatient hospice 
• Community care 
• Day care 
RS2 
NHS 
 
• Community care 
RS3 
NHS 
 
• Inpatient hospital 
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Inpatient care offers 48 beds spread across four wards, served by a dedicated 
inpatient nursing staff. Home care is provided by five home care teams, 
divided according to the geographical area they cover, with dedicated 
Clinical Nurse Specialists (CNSs) forming the core of each team. Home care 
is available 24/7, with on-call nurses covering the out-of-hours period. 
Medical staff work across both inpatient and home care, although only make 
home visits to patients on request of the nursing staff.  
 
All services are provided according to the hospice Admissions Policy. This 
states that: 
 
Patients are admitted into the service with advanced cancer, motor neurone disease, 
HIV or any other advanced, progressive and life limiting non-malignant disease. The 
complexity of the illness needs the services of a specialist team to achieve control of 
symptoms and to offer social, psychological and spiritual support to the patient and 
family. All referrals are prioritised based on reviewing the complexity of problems 
presented. 
 
RS1 was used as my ‘index’ site to generate core data on concepts of need 
and applications of these concepts to patients. It was chosen as the primary 
site due to it being a particularly rich source of data, with access to inpatient 
hospice and community care teams within the same organizational entity. I 
therefore focused my data collection on this site, spending the most time 
within the organisation. I used data from sites two and three to explore 
similarities and differences with themes from site one which may arise as a 
result of differing contexts (organizational, financial, and ideological). 
 
Research site two (RS2) 
RS2 is an NHS-funded community palliative care team based at one hospital 
site within a two-hospital NHS Trust. Together with their counterpart 145 
 
community team at the other hospital, they serve a catchment area across 
parts of three boroughs. 
 
They provide a nurse-led home visiting service between Monday and Friday 
from 9am to 5pm. Out-of-hours advice for patients under their care is 
available via telephone from 5pm to 11pm on weekdays and from 9am to 
11pm at weekends. Medical staff work across the community team and their 
linked hospital team, although nursing staff are dedicated home care 
providers. Care is provided according to their criteria for referral, as below: 
 
Most patients will have an advanced, progressive disease, where the focus of care will 
have changed from curative to palliative and the prognosis is limited. Some patients, 
who have complex specialist needs, can be referred at an earlier stage, from diagnosis 
onwards. Patients may be discharged if their condition stabilises. 
 
A demonstrable need for SPC services must be established. Appropriate reasons for 
referral may include potential / existing difficulties with the following: 
−  Pain and Symptom management 
−  Meeting the psycho-social needs of the patient & their family, and/or 
significant others 
−  Terminal Care/Dying 
 
Research site three (RS3) 
RS3 is an NHS-funded hospital palliative care team based within the same 
NHS Trust as, but at an alternative hospital to, RS2. They provide advice for 
inpatients and outpatients at the 900-bed hospital, with a weekly consultant 
ward round and outpatient clinic appointments. The criteria for referral to 
the service are the same as for RS2, and referred patients are scored on a 1 to 
4 scale for dependency by the CNSs as follows: 
 
1.  Professional colleagues contact palliative care team for advice or 
information. No direct patient contact is made. 146 
 
2.  Palliative care team member makes a single assessment visit at 
request of referrer. Referrer may or may not be present. No further 
intervention by the palliative care team thought appropriate. The 
patient may be re-referred at any time. 
3.  Palliative care team undertakes a short-term intervention with a 
review date, when the benefits of continuing palliative care 
intervention is considered. Further referrals may be needed. 
4.  Complex physical or psychological or social issues requiring intensive 
review and continuing assessment from the palliative care team. 
 
The three research sites thus present a broad range of SPC practice and 
caseloads across both voluntary and NHS sector providers.  
 
The process of negotiating entry into research sites began with my initial 
approach and meetings about the proposed work. This was facilitated by my 
prior acquaintance with key medical staff at the voluntary sector provider 
and the NHS hospital team, who I had met during the course of previous 
research work. I was therefore already known by some members of staff for 
my work within the area of palliative care, and this facilitated the 
arrangement of meetings to discuss the proposed project.  
 
To gain agreement to participate, at RS1 I met separately with the medical 
director, nursing management, and senior nursing staff. I then attended a 
research committee meeting, and two staff research meetings, to present the 
project to the wider medical and nursing staff. Following the granting of 
approval for the project to proceed, I organised a further round of meetings 
to discuss how best to introduce the project to staff and gain their consent to 
take part in the research. As I was proposing to observe all home care team 
meetings and inpatient admission meetings, information sheets and consent 147 
 
forms were circulated, through managers, to all medical staff, home care 
nursing staff, social work and relevant administrative staff.  
 
As the work involved my attendance at a large number of admissions and 
home care team meetings, I was offered a base in the medical office, where 
the medical team secretary and the junior medical staff were located. Once I 
had received full approval to go ahead with the research, I therefore 
attended the site on a daily basis; in the first week this enabled me to collect 
consent forms and finalise arrangements before commencing data collection 
and attending admissions and home care team meetings.  
 
At RS2 and RS3, entry into the research sites required attendance at a team 
meeting of both the hospital and community team to introduce the project 
and explain what would be involved. Information sheets and consent forms 
were distributed directly to staff at these meetings and received back via 
post. Once research governance approval had been gained, and an honorary 
contract issued, I attended the weekly team meetings to collect data. Contact 
with providers was therefore at much more of a distance than at RS1, where I 
was treated as a new member of staff and spent my working hours mainly 
on site.   
 
Data collection 
From June to August 2005, I spent a continuous period of eight weeks based 
at RS1. Data collection and analysis were conducted simultaneously, with 
further analysis ongoing following my disengagement from the research site. 
I then attended meetings at RS2 and RS3 from January to March 2006, but 
was not based full-time at these sites as I had been at RS1.  
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The primary focus of data collection was multi-disciplinary meetings held at 
the three participating providers to discuss patient referrals, care, discharges 
and deaths. At RS1 I also conducted both formal and informal interviews. 
For contextual information on the service I participated in the daily life of the 
doctor’s office, including attending ward rounds and ward meetings on 
occasion. Finally, at all sites I collected relevant policy documents and 
operational procedures for documentary analysis. Full details are given 
below; appendix II (page 387) contains all relevant study documentation.  
 
Observation of meetings 
At RS1, I observed 15 inpatient admissions and 12 home care team meetings. 
 
RS1 inpatient admissions meetings.  
Admissions meetings take place at 10am every day from Monday to Friday. 
Their role is to consider the referrals for inpatient admission that have been 
made to the hospice, to accept or refuse these referrals and, for those 
referrals which have been accepted, to prioritise these in relation to the 
availability of beds. 
 
There are usually two participants in the admissions meeting, one a 
representative from the admissions office (either the admissions officer or 
the assistant admissions officer), and one a representative from the senior 
nursing staff (either the inpatient matron, the nurse consultant or, on 
occasion, the director of nursing). This arrangement had only commenced 
shortly before the start of my study. Previously, the admissions meeting was 
attended by the admissions officer, the matron, a consultant physician, a 
representative from homecare (usually one of the home care team nurse 
managers) and a social worker.  
 149 
 
Occasionally, the admissions’ meeting is attended by extra personnel. 
During my period of observation, these included a student nurse, the finance 
officer for the hospice, and (at one Friday meeting) a doctor who was on-call 
over the weekend. 
 
RS1 home care team meetings 
These meetings, which take place three times a week for each of the five 
home care teams working out of the hospice, are used as forums to discuss 
new patients referred to the community service, to seek advice on issues or 
concerns surrounding current patients, to conduct formal reviews of current 
patients, and to decide whether patients should be discharged from the 
home care service.  
 
Arrangements for home care team meetings vary between teams. All have at 
least one full multi-disciplinary team meeting a week, attended by the team’s 
consultant in palliative medicine along with Specialist Registrar/s (SPRs), 
Clinical Nurse Specialists (CNSs) and the team’s social worker. Occasionally, 
other staff members, such as day centre workers, may be invited to the 
meeting to discuss a particular patient. Meetings are scheduled to last for 
one hour. All teams meet with their SPR on additional days of the week, to 
access medical advice on a more frequent basis.  
 
RS2 community team meetings 
At RS2, I attended five community team meetings over the course of two 
months (January to March 2006). These weekly multi-disciplinary home care 
team meetings comprise the core team (SPC consultant and CNSs), and 
occasionally members of the extended team (including SPRs, 
psychotherapists, social workers and others). The meeting is used to discuss 
all new patients referred to the team during that week and to recap on all 150 
 
recent deaths and discharges from the service. Additionally, any current 
patients with urgent needs or concerns requiring input from the team are 
presented for discussion. Finally, a selection of all current patients are 
presented for review at each meeting, with the aim of all patients being 
reviewed at a minimum of every two months.  
 
RS3 hospital team meetings 
Multidisciplinary hospital team meetings at RS3 also take place on a weekly 
basis. I again attended five of these meetings, over the same two month 
period as RS2. Meetings are attended by the consultant, SPRs, and CNSs and 
frequently the complementary therapist, psychotherapist, psychologist and 
pharmacist attached to the team. These meetings are used to discuss all 
current inpatients seen by the team, as well as all recent deaths and 
discharges which have occurred. 
 
Recording of meetings 
With the written consent of participants, all observed meetings were audio-
taped and transcribed to provide a detailed recording of events. I wrote 
detailed observation notes following each meeting, with a particular focus on 
how referral information about each patient was discussed by the team; what 
domains (such as symptoms, psychosocial and functional issues) were 
covered by the discussions; and on what basis decisions were made to accept 
or not accept referrals, or to make discharges from the service. This is 
covered in more detail in the fieldnotes section below. 
 
Formal interviews 
I also conducted five interviews with hospice staff members at RS1, three 
with senior nurses and two with doctors. To guide the conduct of each 
interview, I developed an interview guide sheet [see appendix II, page 393]. 151 
 
This set out the major topics of interest I wished to cover, with a list of 
prompts to facilitate exploration of each area. It did not include specifically 
worded questions. I opened each interview by asking about the participant’s 
role within the SPC service, to provide contextual information. I then moved 
on to ask about their broad views on definitions of palliative care and ideas 
of need for healthcare. The main body of the interview covered their views 
on accepting referrals to inpatient and home care services, reasons for 
rejecting referrals or discharging patients, the perceived benefit of SPC to 
patients, and how these benefits may vary between patients (including 
whether patient age was related to benefit). Finally, I focused on specific 
dimensions of need for SPC. All interviews were audio-taped, with written 
consent, and transcribed in full.  
 
Informal interviews 
During my time at RS1, I conducted a number of informal interviews and 
conversations with doctors, nurses and administrative staff including the 
two admissions officers. These were used to clarify points of procedure, raise 
queries about issues arising, and explore individual’s views on need for 
services, benefit from services, and patient characteristics on an ad-hoc basis. 
These conversations were recorded in my fieldnotes. Consent for the conduct 
and use of these interviews was negotiated with each participating 
individual, all of whom had read the information sheet and signed a consent 
form for participation in the study.  
 
Documentary sources 
The final source of data was documentary. For RS1, these documents 
included the admissions and discharge policies, which covered all services 
offered (inpatient, home and day care); the operational policy for the home 
care teams; the inpatient admissions scoring sheet and its accompanying 152 
 
guidance; and a blank patient notes file. For RS2 and RS3, which are 
governed by a common administrative structure, I obtained the joint 
operational policy (covering all aspects of the running of the services 
including referrals and discharges). I also acquired additional 
documentation covering the entire Palliative and Supportive Care Network, 
including the referral pathway and referral form.  
 
In addition to documentation from the participating sites, I also gathered a 
small amount of textual evidence from other SPC providers in England to 
provide a broader perspective on SPC work. To achieve this, I sampled one 
SPC provider from each of the nine regions in England covered by the 
‘Hospice Information’ directory. As I did not have ethical or research 
governance approval to gain confidential documents directly from 
providers, I was limited to publicly available information. I therefore visited 
the website for each sampled provider and downloaded or copied all text 
relating to their definitions of SPC, who they offered these services to, and 
their referral procedures. I also requested any further information they made 
available to members of the public on their services and operational 
procedures. All documents were converted into electronic form, as 
necessary, for analysis along with all other data [Table 5.2]. 153 
 
 
Table 5.2 Documents analysed from additional services 
SPC provider  Services provided  Documents analysed 
A 
Inpatient beds 
Home care 
Day care 
Website 
B 
Inpatient beds 
Home care 
Day care 
Website 
Referral form and guidelines 
C  Inpatient beds 
Day care 
Website 
Eligibility criteria 
Referral form 
D 
Inpatient beds 
Home care 
Day care 
Website 
Referral form and guidelines 
E  Inpatient beds 
Day care  Website 
F  Inpatient beds 
Day care  Website 
G  Inpatient beds  Website 
Referral form and guidelines 
H 
Inpatient beds 
Home care 
Day care 
Website 
Referral form and guidelines 
I 
Inpatient beds 
Home care 
Day care 
Website 
Referral form and guidelines 
 
Fieldnotes 
Fieldnotes were a key element of data collection. I did not write notes whilst 
observing meetings for two reasons. Firstly, a number of the meetings I 
attended were small, with only two participants, and I felt that to write notes 
would have re-emphasised the observation, potentially inhibiting the natural 
flow and the content of the meeting. Secondly, all meetings were audio-
taped and fully transcribed, so the verbal content, as well as other events 
such as the coming and going of participants, phone calls and so on, was 
recorded. However, fieldnotes were made immediately following each 
meeting and interview, as described below. 
 
Fieldnotes were created in three stages following Lofland’s and Lofland’s 
approach. 293 Mental notes were a way of focusing my observation whilst in a 154 
 
meeting, considering questions such as who was in attendance and their 
participation in the meeting, the procedure followed, and key discussions 
which related to ideas of need. Such notes were thoughts, not recorded at the 
time, and were an attempt to ’make sense’ of each situation I observed with 
reference to my major topics of interest. Mental notes were converted into 
jottings immediately after the meeting ended. Jottings were made directly in 
my notebook whilst in an inconspicuous place. At RS1 this was usually back 
at my desk in the medical office; at RS2 and RS3 this was on the way back to 
my office following an observation session. At this stage, I considered key 
words, quotes and points of discussion. Jottings also often contained rough 
sketches of the meeting room layout and participant location. At RS1 
admissions meetings, I also included in my jottings the contents of the 
admissions board at the beginning and at the end of each meeting, so I had 
an accurate record of the decisions that had been taken.  
 
I converted mental notes and jottings into full fieldnotes, which were my 
interpretation of everything that had taken place in that meeting and in me 
as I observed the meeting. Full fieldnotes were written up the same day of 
observation, directly into a computer file, with a separate file for each day 
(RS1) or meeting attended (RS2 and RS3). In these notes, I focused on key 
decisions which had been taken, particular phrases which had been used, 
and cases and concepts discussed. I also included emerging analytic ideas, 
and my own feelings. They therefore represent the full record of observation, 
and were treated as data and included within my analysis. I used a fieldnote 
notation system to distinguish between different sources of text [Table 5.3]. 155 
 
 
Table 5.3 Fieldnote notation system 
Exact recall of quotations  “quotations” 
Less certain recall of quotations or paraphrasing  ‘apostrophes’ 
Verbal material but no quotation / general observation  no markings 
Analytic ideas and inferences  (brackets) 
Emotions and opinions  [square brackets] 
 
Transcription 
All audio tapes of meetings attended were transcribed in full. I undertook 
the transcription of seven meetings myself; the remaining thirty meetings 
were transcribed by two professional transcribers, who were briefed on the 
confidential and sensitive nature of the data. Transcription commenced at 
the same time as data collection, to enable ongoing analysis, although owing 
to time constraints not all meetings were transcribed until after data 
collection had ceased. To ensure standardised and accurate transcription, the 
transcribers were given a detailed summary of the organisation and 
personnel of the three research sites, a full list of commonly used drugs in 
palliative care, a list of commonly used medical abbreviations (e.g. b.d. [bis 
die, twice daily]), guidance to commonly used terms (e.g. ‘mets’ to indicate 
cancer metastases), and the transcription conventions and format I wanted to 
be used. I did not require detailed transcription markings of pauses in 
speech and other aspects of discussions; I did however require inaudible 
speech and stage directions (e.g. [laughter]) to be recorded. 
 
The process of data collection 
The process of data collection at RS1 involved my immersion within the staff 
environment. For two months, I was based in the doctor’s office on site. I 
was given an honorary contract and went through the human resources 
procedures necessary for this, including being issued with a staff handbook 
and identity card. Yet I was not a new member of staff, I was an external 156 
 
researcher there to observe procedures and events. I felt drawn in as though 
I was starting a new job, and an urge to ‘fit in’ and build relationships. 
However, I was also acutely aware that I had no skills or knowledge relevant 
to this world, and that I wished to try and learn how things worked without 
losing my analytical stance. After several weeks of data collection, I took a 
short break, and it is interesting to look back and see the following in my 
fieldnotes: 
 
As I left the building, I felt quite sad that I wouldn’t be back for a while – it would be 
so easy to slip into that world for months at a time and probably quickly lose focus 
on the job in hand [...] it has definitely made me conscious of how attached I have got 
to RS1 and the characters in it and the set routine by which every day is run.  
Fieldnotes RS1 5 August 2005 
 
Immersion in the world of SPC provision also opened me up to the 
emotional consequences of hearing distressing details of patients’ condition 
and care. Listening to stories of pain, debilitation and emotional trauma was 
hard. At times this had a particularly strong impact on me as I felt frustrated 
I was not qualified or able to directly support any of these people. It 
sometimes made me feel inadequate, too; what was I achieving as an 
observer compared to those who were involved in providing care? My 
feelings certainly had an impact on me during my time at RS1:  
 
When I was walking out of the hospice today, I felt a rush of emotion that I just had 
to get out of the place. I was walking down the corridor away from the doctor's office 
and got a surge of overwhelming feeling that it was all about death and dying and I 
had had enough. [...] it is hardly like I am working directly with patients and carers - 
although I am listening, day in and day out, to all these terrible stories about faceless 
patients and their dreadful symptoms. I also felt that the hospice is slightly set apart 
from reality, existing blissfully in its own little world - no wonder [my colleague at 
work, a SPC registrar] once said to me she would never want to have a full-time 
consultant post at a hospice. 
Fieldnotes RS1 22 July 2005 157 
 
By contrast, my role at RS2 and RS3 felt very different. I primarily attended 
meetings of the teams, with little interaction outside of these times. I 
therefore maintained much more the role of observer, and my relationship 
with staff consequently stayed relatively distant.  
 
Inevitably, however, my presence had an impact on all those who 
participated in the study at each site. Whilst I tried to stress prior to 
attending meetings that staff should just carry on as usual, my first 
appearance usually invoked something similar to the following: 
 
Very aware of my presence and the microphone at first in this meeting – with the 
specialist registrar and one CNS both separately asking ‘is it on?’ about the 
microphone when they came into the room. The consultant also repeatedly referred to 
the microphone – joking that the CNSs hadn’t brought any patients because I was 
coming (it was a very quiet meeting). I noticed one CNS trying to pour coffee miles 
from the table so the microphone didn’t pick it up, and she also removed the box of 
tissues from the table so as not to make too much noise when pulling one out.  
Fieldnotes RS1 21 July 2005 
 
However, following initial self-consciousness, meetings tended to proceed 
without further reference to me or the microphone. At subsequent meetings, 
I felt that staff tended to be more relaxed from the outset. It is, of course, 
impossible to know how conversations may have been altered as a result of 
my attendance and the recording process. The fact that a substantial part of 
one meeting was taken up by a discussion of the previous night’s 
Eastender’s plot suggests that staff became relatively relaxed about how I 
might be viewing them and their work.  
 
Data analysis 
Fieldnotes, full transcripts of meetings and interviews, and documentary 
evidence were entered into QSR NVivo7 (later NVivo8) software to assist in 158 
 
analysis of the data. The analytical process is summarized in Figure 5.2, and 
described in detail below.  
 
 
My core qualitative analysis started concurrently with data collection. To 
guide my analysis I employed a system of coding and memoing developed 
by Lofland and Lofland. 293 This approach to qualitative data collection and 
analysis was developed in the USA by generalist, rather than medical, 
sociologists. Its typological approach to analysis is primarily characterised by 
an interest in classification and the derivation of categories for the 
phenomena of interest. It sets out a series of reflexive steps through which 
data are generated, coded, and re-coded, making particular use at all times 
of jottings and memos to aid analytical thinking. I chose this approach as it 
1. Core qualitative analysis 
Iterative coding and memoing. Focus 
on developing understanding of 
conceptualisations of need for SPC, 
and other aspects determining 
service use. 
2. Selected content analysis 
Counts of the number of occasions 
identified aspects of need for SPC 
were mentioned. Used to inform 
choice of HRQL instrument to 
measure need for SPC. 
3. ‘Quantitized’ analysis 
Dimensions of providers’ discussions 
and decisions summarized for each 
patient. Used to count frequency of 
particular coding categories by 
setting and type of patient. 
DATA COLLECTED 
1. All data 
2. RS1 
meeting 
data & all 
document
ation 
ANALYSES UNDERTAKEN 
Figure 5.2 Analyses undertaken on data collected 
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provides a robust and clear framework for analysis, which I felt was 
particularly well suited to guiding my thoughts within the focused 
ethnography.  
 
Firstly, I entered into a process of further familiarization with the transcripts 
and documents, reading and re-reading these and listening to taped extracts 
whilst considering ideas I had jotted down in the course of being at the 
research sites. In this initial stage I outlined some rough ideas about concepts 
of need and their role within SPC work. Pertinent excerpts within transcripts 
that illustrated these ideas were highlighted and assigned a code. At this 
stage coding was prolific, with new codes being used freely to highlight a 
wide range of potentially relevant elements. Codes initially remained in a 
long list rather than being grouped or placed into a ‘tree’ system. As I coded, 
I used memos to summarise and synthesise my work. These memos, from 
brief jottings to several pages of detailed musings, were created for each new 
code I assigned, as well as for potential overall themes or groupings of codes. 
I also used memos to record the process of analysis and my thoughts on this 
process. 
 
After the initial coding had been conducted across all data, I moved to a 
more focused period of iterative coding. Within this stage of the analysis, I 
rearranged, collapsed and sorted codes as I revisited the data and the 
literature and considered my direction of thinking. Themes were cross-
checked both within and between data sources to test and improve the 
validity of my emerging thoughts. Coding groups were developed, old codes 
deleted and new ones added. I began to pay more attention to questioning 
different emerging concepts of need based on the differing types of data I 
had collected. However, such questioning also led to confusion as a result of 
attempting to juggle the different contexts and dimensions within the data 160 
 
(inpatient versus community settings, new versus current patients, 
documentary versus observational data). Eventually, this led to the decision 
to temporarily set aside the analysis and consider how else I could 
interrogate my data to develop a cohesive analytic framework.  
 
Whilst the initial analysis was ongoing, I was also looking ahead to the next 
planned phase of the study, the cross-sectional survey of use of SPC by lung 
cancer patients. This required a measure of need of SPC. Full details of the 
choice of this measure are given in the next chapter; however, the analysis of 
data which guided this choice is discussed here. As already mentioned, I was 
aware that the derivation of dimensions of need for SPC to choose a measure 
of those dimensions may be complex in the light of other concepts thrown up 
by my observations and analysis. In my survey of use, I wished to employ a 
measure of need used by providers in assessing patients referred to their 
services. To achieve this, I conducted a content analysis, initially drawing on 
documentary evidence including admissions and discharge criteria and 
patient assessment tools to develop a coding framework. I then applied this 
to transcripts of inpatient admissions and home care meetings at RS1. Data 
collection at RS2 and RS3 was only just commencing at this stage. 
 
Content analysis as a term is currently used to describe a variety of 
approaches, from quantitative analysis of qualitative text to in-depth 
qualitative data analysis. 294 However, the original approach of content 
analysis was to investigate the existence and the frequency of ideas of 
interest (particularly words or phrases) within the data at hand. 295 
‘Qualitative content analysis’, as it is sometimes known, therefore involves 
coding data using inductively and/or deductively derived codes, and 
counting the occurrence of these codes within the data. 296;297 It is a 
particularly powerful approach in assessing the nature and relative 161 
 
importance of terms or concepts within the phenomena of interest, such as 
the components which may comprise concepts of need for SPC.  
 
Drawing on initial coding lists, a framework for potential aspects of need for 
SPC was compiled. This focused particularly on dimensions of importance 
highlighted by prioritization scoring systems and assessment tools, as well as 
elements discussed by staff when presenting or assessing new patients. This 
differed from the models presented later in this chapter by its detailed focus 
on specific concerns or complaints which were measured and addressed by 
SPC providers. The framework was then applied to RS1 transcripts to 
generate counts of the number of occasions on which these terms or concepts 
were used. The findings from this content analysis were used to help 
determine the choice of HRQL instrument to act as a measure of need for 
SPC, as described in full in Chapter 6.  
 
The conduct of a content analysis to inform the cross-sectional survey design 
subsequently inspired me to revisit my primary qualitative analysis using a 
different approach. Following the completion of all data collection, I 
therefore conducted an additional, adapted content analysis across the entire 
data set. I hoped that the re-arrangement and interrogation of the data using 
a quantitative perspective might help to resolve the disarray I felt my current 
codes and memos were in. This ‘quantitizing’ of qualitative data to conduct a 
secondary analysis is common within mixed methods studies, particularly 
where the frequency or intensity of observed phenomena is an important 
aspect of gaining understanding of events. 298 I wanted to use this approach 
to understand the distribution of potential dimensions of ‘need’ within 
discussions about each individual patient, and the nature and frequency of 
decisions that were taken in each case. I hoped that by considering the 
frequency and distribution of particular coding categories I would drive 162 
 
forward further understanding on my return to the main qualitative 
analysis.  
 
To achieve this, I created Excel charts with column headings based on key 
coding categories I had employed within my qualitative analysis. For each 
meeting transcript, I read through the text, creating a row in the spreadsheet 
for each patient who was discussed, and noting whether these patients were 
recently deceased, new to the service or current. For hospital team meetings 
patients who had been discharged from hospital care were also included. I 
excluded hospice inpatient admission meetings from this process as I wished 
to focus on potential aspects of need for SPC – rather than a need for hospice 
care by patients already receiving community or hospital palliative care.  
 
The dimensions of discussion for each patient were then summarized within 
the relevant column headings. At the end of this process, I had Excel charts 
for all home care and hospital team meetings detailing every patient 
discussed, the nature of these discussions, and any decisions that had been 
taken about the patient’s care. From these charts, I went on to produce 
summary graphics counting the frequency of discussion about particular 
dimensions of care, and decisions taken, according to the type of patient. In 
this way, I gained a different understanding of the nature and purpose of the 
observed meetings, and the emphasis participants placed on particular 
aspects of SPC.  
 
I thus returned to my primary qualitative analysis with new ideas for 
considering and interrogating the data. This energized a final phase of 
coding and memoing, in which codes were refined and arranged into 
hierarchical groups. I also began to present codes and code groupings in the 
form of models and diagrams to illustrate aspects of need, and the role of 163 
 
provider practices and social relations on these aspects. I also considered 
how patient characteristics, such as age, influenced the process of care. I paid 
particular attention to any contrasts between documentary and observational 
data. The process of analysis was further refined as I began to piece together 
the memos into larger documents and explanations of my findings. 
 
Data confidentiality and storage 
A number of steps were taken to ensure that data was stored securely, and 
that confidentiality was respected. All participants were allocated a 
pseudonym where appropriate, and only this was attached to transcripts 
from the audio tape recordings of interviews, and used in fieldnotes. All 
patient and carer initials used in the data extracts presented in this chapter 
are replacements for their actual initials. Tape recordings were listened to 
only by me and members of the immediate supervisory team, and by the 
transcribers. The transcribers signed a confidentiality agreement prior to 
commencing transcription. Following transcription, audio tapes were stored 
in a locked filing cabinet, and transcripts were kept on a password protected 
computer. 
 
Ethical considerations and concerns 
The conduct of ethnographic research raises a number of unique ethical 
considerations. Of overriding concern is the issue of informed consent for 
those who will become involved in the research project through their 
presence in the environment which the researcher is observing. This focused 
ethnography took as its key data source multidisciplinary meetings within 
the participating research sites. It was therefore essential to gain consent 
from all meeting participants, ensuring they had received full information 
about the study, and had been able to consider their participation and ask 
questions before agreeing to my presence in meetings. In preparation for the 164 
 
project, this issue was discussed with key staff at participating sites, and it 
was agreed that the researcher would take particular steps to stress to all 
potential participants the voluntary nature of taking part in the project. If a 
staff member objected, I would not attend the meetings at which they were 
present. In the event, this situation did not arise, and written consent was 
obtained from all known participants, including medical and nursing staff, 
social workers, administrative and other staff.  
 
Yet, in observational research, it is inevitably challenging to anticipate all 
ethical dilemmas which may arise within the field. 299 Consent is an ongoing 
process, rather than a simple signature on a consent form, and may need to 
be re-negotiated and adapted as the project develops and new situations 
arise unexpectedly. 300 It may also not always be possible to gain consent in 
advance. In my study, despite efforts to reach every staff member who was 
likely to attend meetings, I encountered a number of situations which gave 
rise to potential ethical difficulties. I give three examples here to illustrate 
some of the issues which arose. 
 
Firstly, mid-way through a home care team meeting I was observing and 
recording, an invited individual (from an outside organisation) arrived to 
join a particular discussion about a current patient. I was not aware this was 
to happen prior to the meeting commencing. The individual came into the 
meeting and immediately joined in the discussion; I was not introduced or 
acknowledged, yet the tape recorder was running. Should I interrupt the 
discussion to introduce myself and the study? Should I stop the tape 
recorder? In the event, I did not feel it was appropriate to interrupt the 
ongoing clinical discussion; nor did I wish to stop the tape recorder (which 
was in the middle of the table a long way away from my sitting position), as 
I felt this would inevitably also act as an interruption. I resolved to discuss 165 
 
the study with the individual after the meeting and to explore their views 
about participating, although I was anxious that such ‘retrospective consent’ 
was ethically difficult. In the event, the individual left prior to the end of the 
meeting. On reflection, I decided to excise the discussion which involved 
that individual from the subsequent transcript, and therefore exclude them 
from the study. 
 
On another occasion, I turned up to attend an inpatient admission meeting to 
find it was to include a student nurse on placement at the study site. I did 
not have any information sheets or consent forms about the study on my 
person. However, I did have the opportunity prior to the commencement of 
the meeting to introduce myself, the nature of the project, and gain a verbal 
agreement that the individual was happy to be recorded for the purposes of 
the study.  
 
Finally, a wider issue arose about the use of information gained outside of 
the meetings which were the primary focus of the research. Particularly 
during the time I spent at RS1, where I was based within the junior doctor 
and medical administration office, I was exposed to a large number of 
discussions of which I was not part, but which were on occasion relevant to 
my research. Consent had been obtained from all the present members of 
staff for me to observe the meetings which they attended, and to interview 
them if requested. I had not, however, obtained consent to conduct a wider 
observational study of the day-to-day activities within the service. I resolved 
that, without returning to the ethics committee which had approved the 
research, and re-negotiating consent with all staff members, it would be 
unethical to note or use such overheard conversations. That much was clear, 
although it is of course difficult to ‘forget’ things which I had overheard 
which shed light on the subject at hand. Aware of this dilemma, and with an 166 
 
increasing need to clarify or expand upon issues noted within meetings, I 
resolved to negotiate consent for ‘informal’ discussions/interviews with key 
members of staff. I therefore approached a number of individuals to ask if 
they were happy to discuss arising issues with me, and to have their 
comments incorporated within my fieldnotes. All those approached in this 
way were happy to cooperate, and most expressed surprise at my concern 
about what data I could or could not ethically use. From their perspective, 
they were aware that my overall aim was to investigate concepts of need for 
care, and knowing that I was conducting observational research they 
expected me to use multiple sources of data to this end, including my 
informal chats with them and my observations of the day-to-day running of 
the service.  
 
This situation in particular highlighted the challenges of following the 
consent procedures which are suggested and approved by ethics committees. 
Despite best efforts to clearly summarise the planned research within 
information sheets, and on consent forms, it is difficult to anticipate in 
advance of ethnographic research the course the project will take, and the 
dilemmas which arise. I would argue that judgment is required on an 
ongoing basis to determine whether individuals are aware of and freely 
participating in the research, and that written consent alone, obtained at the 
commencement of the study, is inadequate. As Hem et al argue, there is no 
simple solution to the ethical conduct of observational research, and 
researchers must be flexible yet aware at all times. 301 
 
A final ethical note is important here, on patient confidentiality. This issue 
arose in discussions with the approving ethics committee; namely, that by 
my presence in meetings I was party to information about patients, including 
their names and details on their medical conditions and social situations, 167 
 
without their express consent. It was not feasible for me to gain patients’ 
consent, as particularly in the inpatient hospital and hospice meetings 
referrals could be made right up until the start of the meeting. The ethics 
committee, on reflection, agreed that the study could go ahead, approving 
the safeguards I suggested preserving patient confidentiality. No transcripts 
or fieldnotes contained identifiable patient data such as their name or area of 
residence. Additionally, it was agreed that any other remaining details of 
data that could potentially allow identification of individuals would be 
removed prior to placing information from this project in the public domain. 
 
Ethical approval for this phase of work was sought and received from the 
relevant NHS Local Research Ethics Committee. Research governance 
approval was sought and received from the participating NHS Trust, and the 
equivalent from the participating voluntary sector provider. I had an 
honorary contract with each research site to conduct the research.  
 
5.4  Results 
 
Analysis of documentary data 
I first present findings derived from my analysis of documentary data. This 
is done to provide a clear counterpoint between conceptualisations of SPC 
derived from policy, and those derived from observations of practice. That is 
– what does SPC say it does, and what does it actually do? These distinctions 
became increasingly important throughout the course of my analysis, and 
presentation of findings in this manner helps clarify the importance of 
context in concepts of need.  
 
I identified a strong and consistent message about the aim and domains of 
SPC through my analysis of documents. Documents described ‘typical’ or 168 
 
‘ideal’ patients to receive SPC, and provided details as to how these patients 
may be prioritised in particular circumstances. 
 
The ‘holistic quartet’ of needs 
All documents examined clearly identified the primary purpose of SPC as 
improving quality of life: 
 
The aim is to achieve the best quality of life possible. 
[Hospice B website] 
 
The goal of enhancing quality of life was further clarified across all services 
by a focus on what I identified as the ‘holistic quartet’ of integrated SPC 
assessment and activity – physical, psychological, social, and spiritual needs. 
These terms were directly and repeatedly used in numerous documents. For 
example, RS1’s discharge policy states that discharge may occur when: 
 
The patient’s physical, social, psychological and spiritual needs have been responded 
to and do not require ongoing care. 
[RS1 Discharge Policy] 
 
A multi-dimensional conceptualisation of patient need, encompassing four 
key domains of life, is therefore routinely expounded. However, within such 
documents closer scrutiny revealed that it was common for the primary 
emphasis of work to be placed on physical symptoms such as pain and 
breathlessness. So, the operational policy for sites 2 and 3 separates out 
physical needs from other needs, stating: 
 
SPC needs include potential/existing difficulties with the following: 
(a) Pain and symptom management 
(b) Meeting the psychological, social and spiritual needs of the patient & their family 
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(c) Terminal care/dying 
[RS2 & 3 Operational Policy] 
 
Other documents repeat the dichotomy of ‘physical symptoms’ versus ‘other 
needs’. An RS1 form used for requesting transfers for patients from hospital 
to inpatient hospice care asks referrers to: 
 
Elaborate on reasons for transfer: 
(1) Physical 
(2) Emotional, psychological and spiritual needs of patient and/or carer 
[RS1 hospital transfer form] 
 
The centrality of families and carers 
A secondary aspect of the nature of SPC was an emphasis on the assessment 
and involvement of families and carers. Alongside patient care and then 
beyond into bereavement support, all services stressed the importance of 
meeting carers’ needs. It is particularly notable that the RS1 Admissions 
Policy specifically states that inpatient admission would be allowed for a 
terminal care patient if a family needs psychological support – even if the 
patient's symptoms are themselves stable. The inclusion of carers within the 
SPC approach is summarised succinctly on one hospice’s website: 
 
Palliative care is a term used, where the focus is to meet all the needs of the patient – 
physical, emotional, spiritual and practical. The aim of care is not to cure but to 
improve the quality of life, not just for the patient, but for family and close friends. 
[Hospice N website] 
 
The ‘ideal’ patient 
Suitable patients for the receipt of SPC were described as those with life-
limiting diseases which are no longer responsive to curative treatment. For 
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have ‘advanced incurable progressive’ disease; this focus on progressive and 
advanced illnesses was echoed in several other referral policies. Patient age 
or other characteristics were not mentioned as relevant in determining need 
for care in any documentation. Cancer was the key diagnosis for patients, 
with some services stating clearly that this was their main area of expertise. 
Other services either identified alternative eligible non-cancer diagnoses by 
name, or grouped them together to state ‘cancer and other’ patients would 
benefit from their services. RS1 states in its admissions policy: 
 
Patients are admitted into the service with advanced cancer, motor neurone disease, 
HIV or any other advanced, progressive and life limiting non-malignant disease. 
[RS1 Admissions Policy] 
 
There was less clarity on the stage of disease patients may be at when 
referrals to SPC were judged to be appropriate. Many services, including all 
three research sites, stressed that SPC would support patients at all stages of 
disease, from diagnosis onwards: 
 
We can provide care and advice from diagnosis to the final stages of a life- 
threatening illness. 
[Hospice D website] 
 
However, RS1 added the caveat that patients at an early stage would have 
‘uncontrolled symptoms’, whilst RS2 and 3 state that: 
 
Some patients, who have complex specialist needs, can be referred at an earlier stage, 
from diagnosis onwards. 
[RS2 and 3 Operational Policy] 
 
Thus, whilst stressing that patients may receive care at any stage of disease, 
services also wish patients to have ‘advanced’, ‘progressive’, ‘uncontrolled’ 171 
 
or ‘complex’ disease. This may well apply to patients who are diagnosed at a 
late stage of disease – for example, when cancer has metastasised widely – 
but the majority of patients diagnosed with ‘suitable’ diseases will not, at 
such a point, meet these other criteria. 
 
The debate about when in the disease trajectory support should be given is 
further highlighted in the Operational Policy for RS2 and RS3, which states 
that one of the criteria for discharge from the service may be that 
‘investigations reveal less advanced disease than previously thought’. A 
further criteria for discharge, identified by all three research sites as well as 
other services included in the documentary analysis, is the stability of the 
patient's disease. RS1's discharge policy gives the most explicit definition in 
this situation. Discharge may occur if: 
 
The patient’s disease is clinically stable and has remained so for a period two-three 
months. Given their disease status the patient is not expected to deteriorate in the 
following three months and the RS1 team no longer has an active role in their care. 
[RS1 Discharge Policy] 
 
This returns to the importance of ‘progressive’ disease in defining suitability 
for SPC.  
 
Finally, all documents analysed repeatedly highlighted that patients suitable 
for SPC interventions were those with ‘complex’ needs, illnesses or 
symptoms: 
 
The complexity of the illness needs the services of a specialist team to achieve control 
of symptoms and to offer social, psychological and spiritual support to the patient 
and family. All referrals are prioritised based on reviewing the complexity of 
problems presented. 
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However, no documents clarified how such complex needs or symptoms 
were identified or classified, or how ‘complex’ was to be defined in this 
situation. Thus, although complexity is viewed as a key determinant of 
eligibility or suitability for SPC intervention, this remains an ill-defined and 
vague concept within policy and procedure.  
 
Patient prioritisation 
As SPC providers are likely to receive more referrals than they can care for, 
some system of prioritisation may be used. In home care services, this may 
take the form of offering different levels of input (in terms of frequency and 
length of visits), rather than actually declining to accept referrals to care. 
However, within the inpatient hospice setting with a finite number of beds, 
prioritisation must occur when there are too few spaces for the number of 
referrals received – in this situation, referrals may be declined or deferred.  
 
RS1, and to a lesser extent RS2 and 3, operate formal scoring systems to help 
prioritise referrals. RS1’s scoring system, developed in-house, is used to 
assess referrals made for inpatient hospice care [Table 5.4]. A score is 
assigned to each patient by the referring professional. With a possible 
maximum of 14, the score covers three domains (physical symptoms, 
emotional/psychological problems [for both patient and carer], and 
social/practical care issues); it also takes account of the predicted likelihood 
of dying shortly. Under social/practical care issues, living alone, having 
children under 18 within the household, and having a current care package 
which is deemed insufficient will all lead to patients being scored more 
highly. The inclusion of emotional and spiritual problems for carers 
emphasises the perceived importance of family and friends in creating a 
need for inpatient SPC intervention. In this way, the scoring system covers 
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spiritual – as well as adding additional urgency for patients who are actively 
dying. Patient scores are used within the daily admissions meetings. 
However, the referral policy stresses that this system is simply to ‘assist with 
decision making’ and is ‘not an exact science’.  
 
Table 5.4 RS1 Admissions criteria score sheet 
Physical  Score 
Severe physical symptoms   3 
Moderate physical symptoms   2 
Some physical symptoms   1 
No physical symptoms   0 
Emotional/psychological   
Severe or many emotional/spiritual problems   3 for patient and 3 for carer 
Moderate emotional/spiritual problems   2 for patient and 2 for carer 
Some emotional/spiritual problems   1 for patient and 1 for carer 
No emotional/spiritual problems   0 for patient and 0 for carer 
Social/practical care issues   
Lives alone   1 
Children involved (under 18 years old)   1 
Current response insufficient (details please)   1 
Terminal care   
Patient is dying within 48 hours   2 
Patient is dying within 2 weeks   1 
  Total score out of 14 
 
RS2 and RS3 also operate a prioritisation system, one for hospital patients 
and one for home care patients [Table 5.5]. This takes a slightly different 
approach, using broad categories to define the level of input the services will 
provide to patients, ranging from minimal to frequent contact. 174 
 
 
Table 5.5 RS2 and RS3 dependency levels 
Levels of dependency for Hospital Patients 
1  Professional colleagues contact palliative care team for advice or information. 
No direct patient contact is made. 
2 
Palliative care team member makes a single assessment visit at request of 
referrer. Referrer may or may not be present. No further intervention by the 
palliative care team thought appropriate. The patient may be re-referred at any 
time. 
3 
Palliative care team undertakes a short-term intervention with a review date, 
when the benefits of continuing palliative care intervention is considered 
Further referrals may be needed.  
4  Complex physical or psychological or social issues requiring intensive review 
and continuing assessment from the palliative care team. 
Levels of dependency for Community Patients 
1  Minimal contact where existing support networks are in situ and patient has 
stable symptoms, but diagnosis indicates a probable short prognosis. 
2  Unstable symptoms requiring regular review from CNS, or where support 
network not established. 
3  Complex symptoms/terminal phase/rapid deterioration, requiring frequent 
contact by CNS. 
 
In spite of these formal systems for prioritising patients and/or the workload 
of the SPC teams, few documents referred specifically to how prioritisation 
decisions should be made; that is, how they would decide if one patient's 
need for SPC is greater than another's. RS1’s admissions policy states, for 
inpatient care, that; 
 
...occasionally the overall context of the presenting patient, even with a low score, 
may take priority. The Admissions Team is at liberty to change the score of the 
referrer. 
[RS1 Admissions Policy] 
 
However, it does not state what aspects of the ‘overall context’ may be 
considered. Only one document scrutinized offered any further details on 
the prioritisation of need: 
 
Please note that acceptance of a referral is based and prioritized on clinical risk issues 
alone. For example, if two patients have been referred to the in-patient unit and only 
one bed is available, the patients will be prioritized according to clinical need. If one 175 
 
is at home, alone and in pain, they would take preference over a patient who was in 
pain but in a hospital bed. In the hospital, the patient is at least safe and looked after. 
[Hospice D Referral Policy] 
 
This scenario suggests that ‘clinical need’ is portrayed as extending to social 
circumstances rather than physical symptoms alone.  
 
Overall, in spite of clear instructions within documents as to how patients 
may be scored or their level of required input assessed, no guidance is given 
as to the process of prioritization which should be undertaken, or on how 
scores should be actually used. There are therefore no clear criteria within 
policy and procedural documents to govern decision-making on levels of 
need.  
 
The documentary analysis presented above provides an insight into the 
public face of SPC, how its activities are defined and presented for staff, 
patients, families and a wider audience. The consistency of content between 
documents suggests a high degree of consensus on the nature of SPC 
amongst providers. Interviews conducted during the course of this work also 
supported this model of care. When asked what their idea of SPC was, 
providers universally presented the ‘holistic quartet’ concept of care: 
 
Well palliative care is a supportive approach to people who have life-threatening or 
life-limiting illnesses. And it ought to encompass the, not just the patient and their 
symptoms and their emotional well-being, but it ought to also cover the family that 
is close to them. And I think that's a philosophy, if you like, and an approach, that 
needs to be developed in healthcare generally. SPC I see as being, end of life care, for 
people who have slightly more complex emotional, social, physical symptoms. I am of 
the brigade increasingly, that palliative care in a way needs to start at diagnosis, the 
approach. But SPC needs to be limited to end of life care. 
Nurse 1 interview, RS1 
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Well I think everybody's perceptions about palliative care by now are shaped by the 
evolving WHO definitions of it. So, it's the care of people who have progressive, life-
limiting, incurable disease, that is causing symptoms, maybe physical, but may also 
be psychological. So they're people for whom death can be anticipated within a 
foreseeable period. 
Doctor 1 interview, RS1 
 
An initial model of need for SPC 
These ‘public’ statements and documents present a clear and consistent 
conceptualisation of need for SPC, illustrated in the model below [Figure 
5.3]. To be referred, patients must have an advanced, progressive illness with 
complex needs. SPC services will respond to a referral by taking a holistic 
approach to assessing a patient's, and their carer's, needs across four key 
domains - the physical, psychological, social and spiritual. Treatment and 
care from the multi-disciplinary SPC team will continue to focus on this 
‘holistic quartet’ throughout the patient's illness. Discharge will only be 
considered if a patient's disease and their symptoms are stable, or if the 
extent of their disease has lessened as a result of a good response to curative 
treatment.  
 
From this documentary analysis we therefore have a strong concept of need 
which suggests suitable patients will benefit from SPC in domains other than 
the physical, and which incorporates the needs of carers and families. 
Whether this model, or a different approach, is used in the observed practice 
of SPC is discussed in detail below.  177 
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Analysis of observational and interview data 
An alternative model of need for SPC emerged through my analysis of 
observational data. It is one in which the ‘ideal’ version of SPC has been 
winnowed down to a more focused and less holistic service within the 
context of resource limitations. The development of this model of need 
draws on a conceptualisation of SPC as a specialty built around the desire of 
its staff to ‘act’. ‘Doing’ something for patients involves a focus on critical 
and changing needs, usually physical, but at times psycho-social. Whilst 
initial assessments remain relatively true to the idealisation described within 
SPC literature and policy, ongoing treatment and care places the physical, 
and the pharmacological, first. 
 
I identified two key elements of need through my observations: the 
prevailing physical, and the critical psycho-social. These are assessed and 
responded to within an overall focus on the declining patient. Within this 
approach the physical domain is dominant, with patients requiring a certain 
severity of physical symptoms to enter into SPC. Furthermore, in practice 
any reference to spiritual needs is tokenistic. Thus the ‘holistic quartet’, 
whilst maintaining its presence in documentation, practice guidelines and 
even perhaps in the minds of SPC practitioners, becomes something very 
different in practice.  
 
The declining patient 
The declining patient was central to considerations of need for, and the 
practice of, SPC. As the documentary analysis showed, patients considered 
for care are those with advanced, incurable, progressive disease. This focus 
on change, on an inexorable path to death, was apparent in observed 
discussions of both new and existing patients. Decline was identified by 179 
 
practitioners through three primary, linked, areas – disease progression, 
deterioration in condition, and cessation of active treatment. 
 
The progression of a patient’s disease, with for example an increase in the 
size of a primary tumour or the development of secondary tumours, was a 
key piece of information in presenting patients for discussion, or clarifying 
their current status:  
 
R1:  Is the tumour growing? 
 
R2:  She hasn’t been rescanned recently, they haven’t really, the last scan they had 
for her was in June they said the disease had progressed and some of the mets 
in her lung have significantly increased in size, liver lesions have increased 
in size, the pelvic mass was unchanged and there is an overall progression of 
the disease. 
Home care meeting RS2 08Feb06 
 
‘Objective’ markers of disease progression such as these scan results were 
frequently linked to observed deteriorations in a patient’s symptoms, both 
physical and psychological: 
 
He was up and dressed and sitting in a chair, but he was obviously weaker, frailer, 
thinner. Very low, tearful, worried about how he was going to manage as the disease 
progressed, which it is, obviously. 
Home care meeting RS1 Team 1 18Jul05 
 
A final marker of change was the cessation of active treatment, usually 
commented upon in the context of explaining the role that SPC were now 
taking in a patient’s care: 
 
…so it was my first visit there yesterday, and she’s a lady who had a renal stent put 
in to hopefully improve her performance status to hopefully have some chemo and 
then she went back to clinic last week and they said, essentially, her performance 180 
 
status was unchanged and was unlikely to change and so they don’t want to see her 
anymore and it’s over to us now. 
Home care meeting RS1 Team 2 24Jun05 
 
The interest in deterioration and change is clearly in line with documentary 
evidence that services are for patients with advanced, incurable, progressive 
disease. Its central importance in defining need for SPC in practice as well as 
policy is further highlighted by the observed discontinuation of care for 
patients who lack progression of disease or symptoms. Stability was an 
overwhelming reason for discharging patients from SPC, for moving them a 
category of need for care to one of no need. Whilst aspects of this were 
recognised within the documentary analysis, my observations found that the 
‘progressive’ dimension often came to the fore when considering which 
patients should be receiving care. Patients discharged from the service 
frequently still had advanced, incurable disease, but if it was no longer 
worsening, their requirements for SPC may be questioned: 
 
… [palliative care] deals with people who by and large are changing quite rapidly. 
They're changing at least month on month, sometimes week on week. 
Doctor 1 interview 
 
Having the ‘potential to deteriorate’ was used as a reason to keep patients on 
the caseload for now, in anticipation of decline. Those, however, whose 
disease or symptoms were stable may not continue to receive care: 
 
Because I think actually CD probably we might be discharging, because he's got 
prostate with spinal cord compression, but actually he's not symptomatic and he 
looks like he could be around for a little while. 
Home care meeting RS1 Team 3 17Jun05 
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Decisions to more readily discharge a stable patient, even one with advanced 
disease, from SPC were linked by one senior doctor to the resource 
limitations under which services were now working: 
 
... because it's quite possible to have a group of people who are really very stable, and 
are trogging along just fine and all you do is go and have a cup of coffee with them 
once a month. Now, if you want to inflate your service numbers, that's one way to 
do it. But actually, viewed objectively, it's a waste of resources. 
Doctor 1 interview 
 
The prevailing physical 
Meetings concerned two different categories of patients, new patients and 
those already under the care of the service. There were clear differences in 
how discussion formed around these patients. Presentations about new 
patients varied according to the style of each staff member, but the 
paperwork they referred to in recounting their initial visits tended to give 
some uniformity to content. In particular, initial assessments routinely 
comprised the ‘holistic quartet’ of SPC concerns – the physical, 
psychological, social and spiritual – and were reported to the meeting as 
such. In spite of this guiding framework, however, staff tended to focus in on 
the physical needs of the patient, with details of symptoms forming the bulk 
of the information imparted and discussed. For current patients, the primacy 
of the physical was marked. Discussions and actions centred on physical 
symptoms and their control. Additionally, decisions to accept patients to the 
service (particularly notable for inpatient bed discussions) centred on the 
physical.  
 
This predominant focus on bodily functions and malfunctions was apparent 
within the diverse array of the symptom concerns which were discussed in 
observed meetings [Table 5.6]. The content analysis conducted to inform the 182 
 
choice of a measure of need for SPC (discussed further in Chapter 6) found 
that pain, breathlessness, nausea and/or vomiting and weakness were the 
most frequent focus of discussions across both community and inpatient 
settings. Fatigue and constipation were also major concerns with 
community-based patients.  
 
Table 5.6 Physical symptoms discussed in observed meetings 
Pain  Ascites  Anorexia 
Breathlessness  Fatigue  Sore or dry mouth 
Nausea and vomiting  Drowsiness  Jaundice 
Weakness  Cough  Bleeding 
Confusion  Diarrhoea   
Constipation  Oedema   
 
Some of these symptoms, particularly weakness, confusion and drowsiness, 
have a psychological component. However, the psychological and social 
components of these concerns were rarely discussed. Instead, reporting of 
physical problems usually led into discussion of appropriate 
pharmacological responses. Staff engaged in long debates on the prescribing 
of medication, to the extent that meetings could primarily be concerned with 
pharmacological approaches to physical needs. Medication concerns could 
be brought in very rapidly following the introduction of a patient for 
discussion, as the following extract from a new patient presentation shows: 
 
He’s a 78 year old man with an astrocytoma, grade 3, who became much less well in 
May and we then got involved. He basically became immobile and confused within 
the space of a week, and his GP put him on Dexamethasone but on a sort of gradual 
high dose. So he actually went up sort of from 4 mg to 10 mg to 14 mg, but he’s now 
been on 14 mg, since the end of May and he’s still bed bound. 
Home care meeting RS1 Team 1 23Jun05 
 
Depictions of patients’ symptoms and potential pharmacological responses 
to them were nearly always presented first to the meetings. This reflected the 183 
 
pattern of patient assessments, where physical information was routinely 
gathered prior to other domains of care, ensuring the physical was known 
even if other dimensions were missed: 
 
Because he can only speak for a limited amount of time before he vomits, I didn’t get 
onto spirituality, social, etc. 
Inpatient meeting RS3 26Jan06 
 
The dominance of the physical was further reinforced by the way in which 
staff controlled talk within meetings. Patient histories commonly started 
with the physical, briefly mentioned other aspects, and were then brought 
back round to the physical by the presenter. Interjections by other team 
members were also used to return the focus to the physical, in spite of other 
potential dimensions of need which may have been raised. In the following 
extract from a home care team meeting, a nurse only briefly presents a new 
patient’s psycho-social concerns (given in response to a routine question 
prompted by documentation requiring completion), before returning to the 
original topic of the patient’s pain and its control. The physical focus is 
further reinforced by another team member taking up the pharmacological 
topic as the crucial point of information for discussion. 
 
R1:  He’s got no real goals and expectations, except one long term goal of 
continuing to be. He’s going to his granddaughter’s 16th birthday party and 
a wedding. But we discussed his Oramorph. He said when he first started it 
he found that it was very helpful but as time’s gone on it doesn’t help so 
much. 
R2:  What’s happened to the dose over that time? 
Home care meeting RS1 Team 1 23Jun05 
 
Some staff interviewed argued that by focusing on and dealing with the 
physical aspects of a person’s illness (that is, by controlling their symptoms), 184 
 
they were more able to start addressing the more existential aspects of their 
illness experience. So, by an initial focus on the physical, SPC providers were 
freeing both themselves and the patient up to move on to address the more 
holistic psychosocial and spiritual dimensions of care. However, whilst one 
doctor felt that SPC should be multi-dimensional, he acknowledged that it is 
unlikely doctors would address all aspects of care: 
 
Well I think the thing about SPC, is that it is holistic, or should be. So that is should 
have the facilities to deal with people in the round. Now, for me, actually, the 
absolutely prime thing is the physical, because I'm a doctor. And so that's 
fundamentally what I am supposed to be good at. 
Doctor 1 interview 
 
If doctors concern themselves with the physical, other dimensions of SPC 
may be addressed by nursing and social work staff regarding these aspects 
as part of their role. This is, of course, the foundation of multi-disciplinary 
practice. However, my observations suggested that, regardless of the skill 
mix present, the primary focus of meetings remained on the physical.  
 
The critical psycho-social 
The prevailing physical orientation of work could, however, be disrupted by 
acute psycho-social concerns. In such situations, overwhelmingly urgent 
social or emotional situations became the focal point of SPC work. 
Addressing these psycho-social problems subsequently freed up provider’s 
ability to move back into the physical domain once the immediate crisis had 
passed. This, of course, is the opposite of that suggested above – that dealing 
with the physical enabled a switch in focus to other domains of need. In less 
volatile situations, psycho-social needs of patients were predominantly dealt 
with secondary to their physical needs.  
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Prioritisation of psycho-social needs typically came from crises related to a 
patient's housing, financial or family circumstances. These complex issues 
were time-consuming for SPC providers, both within meetings and on a day-
to-day basis, as they attempted to ameliorate the situation either themselves 
or with the help of other specialists. For example, one nurse was spending a 
large proportion of her time trying to work out how or if one of her patients 
could return to Portugal, from where he had recently arrived in the UK. His 
four young children were still in Portugal being cared for by a friend, his 
wife was with him in the UK but, like him, spoke little English, and they 
were both living with a friend whose children were sleeping in the living 
room to accommodate them in her flat. He was now mostly bed bound but 
did not wish to return to Portugal as he felt there was no treatment there – 
although his tumour was not chemo-responsive and he was not receiving 
active treatment in the UK either. In presenting the patient’s circumstances to 
her colleagues, the nurse first touched on his physical symptoms: 
 
…just his gross abdominal distension, really, it’s really, really taut, it’s quite hard 
and I presume very uncomfortable for him, really, stretched so his skin is really 
shiny, almost like it would just break and he’s quite emaciated. 
Home care meeting RS2 01Feb06 
 
However, the physical was dealt with swiftly to focus on how to resolve the 
multiple social issues: the need for effective translation, his uncomfortable 
living situation, the possibility of his return: 
 
Maybe, but I’m thinking will he afford the flight, will he afford the flight to go back 
because he doesn’t really have money […] I’ve been trying to find out what 
entitlements he would have, if any, as an EU national and I made a few calls, you 
know. 
Home care meeting RS2 01Feb06 
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Strained or problematic family relationships were also a common focus of 
attention. Whether these situations were heightened by the illness of a family 
member, or caused by the illness, they could become the dominant perceived 
need of the patient at that time. Discussions would then cover very detailed 
assessment and feedback of the relationship issue and suggested 
interventions to improve the situation. For example, one patient with 
advanced cancer and a young daughter was living with her mother as a 
result of her illness. Staff were concerned about the relationship between 
them and the impact it was having on her symptoms, and in the presentation 
to the meeting of her case her primary nurse outlined in some detail her 
assessment of the situation:  
 
She’s actually spending more than 50% of her day in bed. It’s difficult to tell 
whether that’s a direct result of the illness or not. I’ll discuss that when I get to her 
mother. […] She has a seven year old child and she’s living with, moved back with 
her mum for the time being, because she’s not well, and I spoke to her and her mother 
both separately, and they have never got on and they are arguing and a lot of the 
arguments are around her mother trying to discipline her [grand] daughter who’s 
misbehaving. […] Her mum sees [patient] as being very lazy, that she doesn’t make 
any effort to get up and do anything, [patient] says she doesn’t feel like it. But it’s 
difficult to know, you know, how much of it is directly due to the illness and whether 
some of it is perhaps due to psychological reasons, that she is perhaps depressed. 
Home care meeting RS1 Team 3 22Jul05  
 
A patient’s psychological needs could also become critical quite quickly and 
displace the focus on the physical, prompting more detailed assessment and 
referral to specialists. 
 
R1  So today I was trying to assess her psychological state because the nurses say 
she’s been in tears quite a lot. 
R2  For a week, they said. 
R1  […] when things go wrong she just bursts into tears and everything’s 
dreadful etc, etc, but I mean having said that, you know, she’s been whacked 
with a whole load of disease all at once, all very quickly, really, so I’m not 187 
 
surprised, I just think she’s probably not very good at expressing it, so I’ll 
make a referral to [psychologist]. 
Inpatient meeting RS3 01Feb06 
 
Psycho-social needs were not just confined to patients. Carers’ needs rose to 
the fore when they were identified as not coping, leading to outbursts or 
immediate difficulties requiring attention and support.  
 
She was hysterical, she was crying, she was screaming, she couldn’t cope because he 
had deteriorated so quickly over the weekend. The fact that he was incontinent and 
she couldn’t think of changing his pads, she couldn’t cope with that at all because 
he’s always been able to do things for himself. Anyway, I ended up having to help her 
to change him because she was just crying all the time. 
Home care meeting RS2 15Feb06 
 
The prevailing physical does not, therefore, entirely remove other domains 
of concern from provider’s attentions. I observed that psycho-social crises 
and complex issues were responded to sensitively and with energy. 
However, less visible psycho-social concerns of patients were not necessarily 
attended to in the same manner. As one nurse told me, the bi-monthly 
reviews of patients carried out in the MDT meetings were useful to ensure 
an issue was not missed for patients who were classified as just ‘chugging 
along’ (fieldnotes RS1 14 June 2005). For most patients who fell into this 
category, the domain of the psycho-social remained secondary to the 
physical.  
 
The tokenistic spiritual 
Discussions or assessments of patients’ spiritual needs were rarely observed, 
in spite of spirituality being such an integral part of the work of SPC as 
identified through documentary analysis. Within RS2 and RS3, computer 
records updated during each patient review require a set pro forma to be 188 
 
followed. This demands entries are made onto the patient record across all 
fields, including spiritual needs. The following two extracts reveal the usual 
response to this dimension: 
 
R1:  Spiritual, anything? 
R2:  To be assessed. 
R1:  OK. 
R2:  Difficult to get round to those kind of things. 
Inpatient meeting RS3 1Feb06 
 
R1:  Spiritual, continue to explore? 
R2:  Yeah, yeah. 
Home care meeting RS2 1Feb06 
 
When assessments of spirituality were reported, infrequently at best, these 
were associated with religious denominations. ‘Spiritually a Christian’ 
(inpatient meeting RS3 26Jan06) was a typical response. I did not observe 
mention of spirituality outside of discussions prompted by the requirements 
of record keeping.  
 
A new way of looking: quantifying the data 
Trying to decipher the way in which patients were being presented and 
discussed was rendered more complicated by the different services included 
in my observation, and the contrast between new and current patients. How 
concepts of need were being applied in such discussions, and the dimensions 
which were prioritized, was not always clear from the coding frame I had 
developed thus far. Having moved from freestanding codes to coding trees, 
re-developed and re-organised several times, quantification of some aspects 
of the qualitative data was used to offer an alternative way of thinking about 
the content of discussions.  
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An extract from the data tables generated as the first step in this approach is 
given in Table 5.7. This shows a sample of the summarized content of one 
observed meeting of the RS2 home care team. Each patient presented to the 
meeting is identified, and information about their diagnosis and treatment, 
as told to the meeting, abridged. These summaries focus on the identification 
of major domains of need for SPC (physical, psychological, social and 
spiritual), alongside additional dimensions such as pharmacological 
discussions and the decisions taken within the meeting about appropriate 
next steps or care.  
 
These tables clarified that talk tended to be concentrated on the physical and 
pharmacological domains of a patient’s needs, with other dimensions of care 
(social, psychological, spiritual) covered less frequently. This reinforced my 
idea that the ‘holistic quartet’ was not applied in practice as comprehensively 
as policy documentation suggested.  
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Table 5.7 Example patient summaries extracted from RS2 home care meeting 18 January 2006 
Patient  Type  Diagnosis  Treatment  Physical  Pharmacological  Psychological  Social  Spiritual  Carer/family  Decisions 
taken 
SW. 
Female. 
62. 
New  Breast cancer, 
liver and bone 
mets.  Pleural 
involvement. 
Hypertension. 
Had 
lumpectomy 
2001, chemo 
and radio. 
Further chemo 
and palliative 
radio. 
Pain (liver and 
jaw), poor 
sleeping, poor 
appetite, 
occasional 
nausea, 
constipation 
On Oramorph, 
Amytriptyline, Movicol 
Son died in car 
accident in 1996, 
husband died 2004 - 
withdrawn/depressed 
ever since. 
Does not 
speak 
English, son 
translates. 
Very 
socially 
isolated. 
Lives with 
son and his 
wife. 
-  Son involved - 
lives with her and 
translates 
To review by 
phone with son 
in two days 
time re pain 
and 
constipation. 
Chase GP to 
change 
Amytriptyline 
dose 
BJ. 
Female. 
47 
Current  Anal cancer 
(recurrent) 
Previous 
surgery. 
Considering 
radiotherapy - 
long delays in 
treatment 
unclear why 
Pain, 
uncontrolled, 
interferes with 
sleep 
On Amytriptyline, MST, 
Oramorph. Non-
compliant 
-  Lives with 
flatmate.  -  - 
Long 
discussion re 
pain meds. 
Considering 
home doctor 
visit - will 
review next 
week 
PD. 
Female. 
87. 
Current 
End stage 
cancer, end 
stage 
congestive 
cardiac failure, 
dementia 
makes it 
difficult to 
assess 
-  Denies pain. 
Breathless 
On continuous oxygen. 
Antibiotics. Something 
for rash 
 -  -   - 
Daughter gave 
up work to care - 
wanders at night, 
daughter v.  
stressed 
None in 
meeting - CNS 
update 
KC. 
Male. 
No age 
Current  Sinus cancer  - 
Severe 
uncontrolled 
pain.  
Have made many 
changes to pain meds   -   -   -    
None in 
meeting - CNS 
update 
JG. 
Male. 
70 
Current 
Colon cancer, 
liver and lung 
mets, suspicion 
lumbar mets (pt 
denies) 
Recent 
surgery. 
Potential offer 
of chemo 
Jaundiced. 
Potential 
infected 
abdominal 
abscess.  
Long discussion re 
meds [antibiotics] 
causing jaundice or not. 
Other meds noted. 
Possible denial of 
prognosis; anxiety re 
future. 
 -   -  Wife asks more 
re prognosis 
None in 
meeting - CNS 
update 191 
 
Representing patient summaries in graphical form helped to further clarify 
this. Using my a priori headings, graphs were constructed separately for new 
and for current patients in each research site to record the presence of talk 
within each domain [Figures 5.4 and 5.5]. These show clearly the importance 
of the physical and pharmacological, with staff discussing physical issues for 
100% of new patients, and around 90% of existing patients across all three 
research sites. 
 
There are notable differences in the prevalence of discussions around 
psycho-social issues for new patients and existing patients, with these issues 
receiving less attention for patients already under SPC. However, it is 
interesting that carers/families are discussed more frequently on average for 
existing patients than for new patients at RS1 and RS3. Variations between 
sites in the proportions of patients for whom the ‘secondary’ domains of 
need (social, spiritual) are discussed may be attributed in part to differences 
in the routine practices of each meeting. I now turn to consider the influence 
of these working practices on conceptualisations of need. 192 
 
 
 
 
 
Figure 5.4 Domains of discussion for new patients 
Figure 5.5 Domains of discussion for current patients 193 
 
Documentation and discussions 
As set out in the introduction to this chapter, contextual considerations are 
crucial when considering how concepts of need are derived. The process by 
which decisions about care are made or otherwise arrived at is a key factor in 
determining access. During the course of my research, I was therefore 
interested to see how practices between each research site varied, and the 
manner in which these practices shaped outcomes.  
 
Meetings within each setting had their own unique structure and rhythm. In 
the RS3 hospital team, notification and discussion of deaths and discharges 
preceded issues arising and routine reviews of each patient currently on the 
caseload. For the RS2 NHS community team, new patients, urgent problems 
with current patients, deaths and potential discharges were discussed, with 
each patient additionally being presented for review every two months. Both 
NHS settings were heavily influenced by the requirements to keep up-to-
date computer records for all patients, and each meeting took place in a 
board room with a computer to record changes as they were discussed. The 
community teams within the voluntary hospice (RS1) varied in their 
approaches to their weekly MDT meetings, but typically they discussed 
deaths and patients requiring immediate action or input, and then took it in 
turns to present patients for review. These often had a more informal 
atmosphere than the NHS meetings, taking place in the team’s own offices 
with comfy chairs drawn up and a tea tray set out.  
 
The order of discussion in each meeting, as set out above, was guided by the 
working policies of each setting. Additionally, the manner in which each 
patient was presented within the meeting was shaped by the setting’s choice 
of patient assessment tools and records. Thus, as each new patient was 
presented to the wider team by their primary nurse, their history was 194 
 
constructed with reference to notes taken at the time of initial contact. Staff 
recounted patients’ background and circumstances alongside detailed 
summaries of medical history, current treatment and symptoms. One 
example of this ‘new patient presentation’ is in Table 5.8. Throughout this 
presentation, questions from other team members are answered after 
checking the patient’s notes file for the relevant detailed information. As this 
particular history progresses, the nurse recounts symptoms directly from the 
assessment tools she used – thus, we hear her say ‘pain wise’, ‘breathing 
wise’ as she progresses through her file. These assessment tools 
comprehensively cover the ‘holistic quartet’ of needs. Here, we learn about 
the patient’s family, their feelings about his illness, his fears about the 
palliative care referral and his day-to-day living circumstances, as well as his 
current medication and treatment. Thus, for new patients the comprehensive 
ideal of need for care is reinforced by the choice of initial in-depth 
assessments and reference to the documentation of these.  
 
Table 5.8 Example new patient presentation 
Home care team meeting RS2, 18 January 2006 
OK, EF was a gentleman who was referred by his GP for palliative care. He’s been 
treated at [hospital] for cancer of his lower rectum. I’ve got very little information, 
I’m still trying to get some more information from the [hospital] on him, so most 
of my literature so far is based on what he’s told me […] 
 
When he was diagnosed with lower rectal cancer, it was decided that he wasn’t 
suitable for surgery or for chemotherapy because the chemotherapy may be toxic so 
he had radical radiotherapy which ended last year. […]  
 
They’d obviously discussed with him that he wasn’t able to have any more 
treatment and from what he, his son felt that he’d taken that very badly, really. It 
sounds like they’d already had a previous conversation with him about having 
more, having palliative referral to [hospice] and he’d taken that very badly I think 
and thought that he, um, was going to die rather imminently. Um… […]  
 
His wife, G, used to be practice nurse at the GP’s surgery […] And she did make 195 
 
it very clear to me that she was a nurse so some of the issues around care and stuff 
she actually wanted to do herself, so anyway.  
 
But the gentleman looks older, actually, than 74 because of all the different 
illnesses that he’s got and had. […]  
 
Pain wise, initially he said, oh no I don’t have any pain at all, I’m fine, no pain, 
then as we went on further it transpired that actually he has quite severe arthritis 
in both knees and he’s on Tramadol and Diclofenac for that, […] Breathing wise 
he’s got quite severe problems with angina, obviously his heart, and that causes 
him to have quite severe problems with getting about, if he does any exertion so he 
could only walk about 100 yards very slowly and then he really was very ill and 
short of breath. He is managing his activities of daily living except that he needs 
help getting in and out of the bath […]  
 
His appetite’s been… and he’s lost quite a lot of weight really in the last couple of 
months, about 6 kilograms […] He does feel nauseated at times, but his main 
problem which I think ties into that is that since the radiotherapy he’s had a 
problem with passing mucus and we had a long talk about how, you know, it’s 
difficult to decide whether someone’s constipated or got overflow or had diarrhoea, 
so I explained that his thing was that he probably had constipation with overflow 
problems rather than diarrhoea, and every now and then he passes some mucus 
which I think is harder to control. He had Loperamide but he hadn’t been taking 
much of that more recently, and he’s had Lactulose as a laxative and he had, um, 
not been using that very often, um, and that was about it and then he changed 
from Co-codamol to Tramadol […]  
 
Um, yes, so that was him really. He clearly had taken it badly that this 
appointment had been made, he talked quite a lot about that and how he had been 
very reluctant for his referral to palliative care so basically I just took it in a very 
practical sense […] 
 
He lives with his wife and also a son who is called, um, I think his name is H. His 
other son is married and lives in [county] with his children, and it sounds at some 
point they all talked about moving to be nearer to the son. It’s a very large house 
just off [road] and he’s getting DLAs which he’s been getting since his bladder 
operation […]  
 
Subsequent reviews of each patient’s needs are rarely so comprehensive, as 
Figure 5.5 (page 192) shows. Future discussions of patients are not rooted in 
the accepted norms of presentations of new patients, with their routine 196 
 
coverage of multiple domains of concern. Instead, subsequent presentations 
of patients to a meeting arise either because of pressing problems, or because 
they are due for review. In both these cases, the framework used for 
presentation is less formalized and more fluid. Thus, when the patient whose 
history is presented above [Table 5.8, page 194] comes up for discussion in 
future meetings, talk is focused on his immediate physical needs: 
 
I spoke to his wife on the 10th of the 2nd and they were very anxious because his 
faecal incontinence seemed to be getting worse […] I had arranged to go and visit 
them on Friday, then overnight, the weekend nurses got a call to say that he wasn’t 
very well and he’d got a rectal abscess so the doctor had been out and things like that 
and he was still leaking faecally and he’d probably had a stroke or something. 
Home care meeting RS2 15Feb06 
 
I observed that admissions meetings for inpatient hospice beds also relied on 
a routine of the comprehensive patient history as the basis of their decision 
making. However, with only a short referral form to refer to, and many 
patients to be reviewed and beds assigned, histories (whilst inclusive) are 
tightly worded and brisk: 
 
So, Mr JK. Um, very urgent referral, please consider as discussed on the phone. OK. 
This is a 72 year old gentleman. He's widowed. He's got inoperable pancreatic 
cancer. He speaks little English, so as an interpreter would be helpful but his son 
does speak good English. His next of kin is his son. He's being referred for pain and 
symptom control, emotional and psychological support, and carer support. Um, also, 
yeah, want to be admitted for terminal care. The patient is currently in hospital, 
bedbound. Referral asap. He is MRSA positive, he's got metastatic disease in his 
sigmoid colon. He's had a [inaudible] procedure. That's major surgery where they 
cut one bit out and they join with one of the ducts to the lower part of the colon so 
you bypass the mass. Hypertension and COPD as well. He's dying, he's in pain, 
he's got breathlessness. He's got fatigue and drowsiness, ascites, sore mouth, and not 
sleeping very well. The family and patient were desperate to go back to [country of 
origin]. Now realise he's too poorly and very keen for hospice admission. Oh, how 
sad. They've missed the boat. OK. 3 for severe physical, sorry, 2 for moderate 197 
 
physical symptoms, 2 for moderate emotional spiritual problems, and 3 for the carer, 
1 for lives alone, and 2 dying within 48 hours. 
Admissions meeting RS1 8Jul05 
 
The score assigned to each patient on aspects of need for care reduced the 
patient’s circumstances to a quantifiable urgency. It also typically 
represented the end of that patient presentation. Again, talk is here shaped 
by the requirements and coverage of documentation and policy.  
 
The most explicit examples of the impact of documentation on the content of 
meetings were observed at RS2 and RS3. Here, computer records on each 
patient were updated during meetings, leading to exchanges such as the 
following: 
 
R1:   [At computer] So physical, all I’ve got from [nurse] is p.r.n. Oxynorm for 
home. 
R2   You can wipe that off, say, um, some discomfort in his scapula, prefers to… 
on paracetamol t.d.s. and p.r.n. Oxynorm and total bed rest at the moment, I 
think that’s enough. 
R1:  Psychologically brighter. Citalopram 20mg started, aromatherapy, does that 
sound…? 
R2:  He’s having, yeah… 
R1:  So is he psychologically… 
R2:  He’s fine, pretty much. 
R3:  Maybe from last time. 
R1:  Yeah 
R2:  Compared to what he was last time, he came in said I’m depressed I do need 
something. 
R1:  But they’re both a little bit anxious you said. 
R2:  Oh they are, they’re talking about it, I think. They [inaudible] this time and 
whereas the wife was saying don’t give him the bad news, and she’s still 
saying, she’s more saying, stagger the information now rather than… which 
was quite interesting but I had a good chat with her. 
R1:  Mm hm, social, lives with wife, for benefits DS1500 refer back to 
[community SPC] team. 
R2:  Yeah, social just lives with wife. 
R1:  Mm hm. Um…  198 
 
R4:  We have done a DS1500 did we? 
R1:  No, I don’t think so. 
R2:  I need to check that, whether they have done. 
R1:  Spiritual to explore. 
R2:  Did you leave the DS1500 in that social one? Check DS1500? 
R1:  Is that to be done, check? 
R2:  Yeah. 
R1:  Yeah, spiritual, anything, or I’ve got to explore. Information needs, fully 
aware. 
R2:  Yeah. 
R1:  And then, under carer concerns from last week, wife is anxious, declined 
formal support, happy to talk to nurses when feels she needs to, doesn’t want 
him to have bad news [inaudible] on multiple bereavements in families in last 
few years. Is that still all applicable? 
R2:  Yeah, that has to stay on I think. 
R1:  OK. Done? 
R4:  Have you saved it first? 
R1:  Yes, I am doing it, both saving it and printing, it’s the printing that seems to 
be the problem. But yes. 
R4:  OK, the next one. 
Inpatient team meeting RS3 15Feb06 
 
These records are an important part of the care provided to patients. They set 
out what has happened to date, and guide what actions are taken in the 
future. Their content reflects the publicly agreed domains of action for a 
service. The choice of assessment tools, for example, will influence the nature 
of the information gathered about patients, and the subsequent course of 
their treatment and care. Thus, they both shape and record the actions taken 
outside meetings as well as the talk within meetings.  
 
Yet the comprehensive nature of both policy and practice suggested by these 
records does not necessarily translate to a consistently holistic approach 
throughout the trajectory of a patient’s care. Initial assessments are rarely 
revisited in the same depth, and domains which are seen as less urgent or 
important may receive only perfunctory mention. Whilst talk in meetings is 199 
 
underpinned by previously gathered information or the update of this 
information, these policies are not able to fully dictate practice. The typical 
content of a presentation about a new patient, a review and an urgent patient 
problem reveal how a practitioner’s focus may change throughout the course 
of a patient’s care, from getting to know and understand the situation to 
simply dealing with the immediate pressing concerns. The implications of 
this for ideas around need for care are considered further below.  
 
The importance of ‘doing’ 
Throughout my analysis of the data, I considered dialogue and events which 
may indicate ‘non-need’ for SPC: factors or components which in the minds 
of SPC providers meant patients did not require their input. As already 
noted, the unchanging physical (the stable patient) was the dominant factor 
in a patient being regarded as not having a need for SPC input. In my 
fieldnotes following one home care meeting, I wondered whether this link 
between stability and lack of need was about the staff’s expectations about 
their role – about the need for them to do, including the provision of advice: 
 
The first patient to be reviewed was very interesting as there was a query whether to 
discharge them or not. They had quite a long discussion about her diagnosis, 
treatment for cancer, and current situation. This time I picked up that discharge 
decisions are focused often on what the CNSs do when they visit. So – the question 
was that the CNSs didn’t do anything when they went to see her – therefore should 
she be discharged? This inability to do anything, backed with an understanding that 
her disease was not at this time actively progressing, resulted in the decision being 
made to discharge her. 
Fieldnotes RS1 28Jul05 
 
The displacement of a focus on the physical by psycho-social concerns when 
they are acute and pressing suggests that ‘doing’ is not confined to 
reviewing and addressing symptoms. My observations suggest that a 200 
 
definite focus of action – relieving the pain, improving breathlessness, 
sorting out an insecure living situation – is what motivates and rewards staff. 
More elusive dimensions of spiritual needs and concerns, harder to assess, 
address and to resolve in a situation of impending death, may not be 
encompassed by day-to-day actions in spite of claims to the contrary. There 
is also the issue of the expertise staff feel they have, discussed further below. 
 
Contextual constraints 
The diversity of aspects of care SPC aspires to address is ideally addressed 
by the complementary skills of a multi-disciplinary team. Such teams within 
the SPC setting may encompass social work, chaplaincy, psychotherapy, 
complementary therapy and psychiatry alongside medical and nursing 
expertise. However, at two of the research sites there were vacancies in social 
work at the time of data collection. Meetings observed were primarily 
attended by medical and nursing staff, and thus discussions centred on the 
competencies of these professionals. As one interviewee said: 
 
And I think here, in particular, there's been quite a lot of silo practice, in that the 
domains of care have sat very much with, you know, psycho-social sits with social 
work. And if there isn't a social worker member in the team meeting, then those 
needs are often not addressed. So whoever's not there, their particular profession 
doesn't get talked about. So it does become very symptom focused, because 
symptomatology is a, it's a tangible that nurses can work with. If they feel 
uncomfortable with psycho-social issues, they can hide behind it. 
Interview nurse 2 
 
The limitations imposed by a lack of staff were particularly severe within the 
NHS environment. High staff turnover and ongoing vacancies were 
compounded by a shortage of equipment and beds. Within the voluntary 
sector pressures were also evident, with very high bed occupancy and 201 
 
financial targets to be met. Additionally, a lack of information and poor 
communication could limit the care available to patients.  
 
The structural constraints on day-to-day working, along with role 
expectations, inevitably influence the orientation of SPC work. The potential 
for ‘fire fighting’, a focus on the dominant issue which requires attention, is 
more marked when staff do not have the luxury of unlimited time in which 
to address all aspects of care. This is of course a situation to be found across 
many if not all medical and nursing specialties. However, it is particularly 
apparent in the light of the claims that SPC is broad in approach.  
 
Maintaining such holism becomes increasingly challenging if the time is not 
available to address all areas of concern. Rather than a lack of care, providers 
may alter the dimensions or quantity of care to make ends meet. Visits may 
be less frequent and/or shorter to manage the caseload; requests for inpatient 
admission may be deferred until beds become available. And, of course, care 
may focus on the physical and the immediate if that is within the expertise 
and capabilities of the available staff on the SPC team: 
 
You know, you can always do more with more resources. 
Interview nurse 1 
 
Towards a new model of need for care 
The first model of need for SPC I derived presents SPC as holistic and multi-
dimensional, moving from referral through to initial assessment and ongoing 
care whilst maintaining an interest in and concern for all aspects of a 
patient’s, and their carer’s, needs. Based on observational data across all 
three settings, I now present a second alternative model which suggests a 
more narrow focus on ‘doing’. To enter into SPC, patients must clear a 202 
 
‘physical needs’ hurdle, with advanced disease and a high level of physical 
symptoms agreed by SPC providers as rendering that patient suitable for 
their care. The provision of SPC then primarily addresses physical needs, 
although it may also focus on psycho-social crises when these interfere with 
the ability to address the physical. Patients must be actively progressing to 
be seen as having a need for care, and must maintain this inexorable decline 
even in the face of constant interventions to improve their physical state. The 
role of resources is key, within both the voluntary and NHS services; 
limitations on the availability and skill-mix of staff, beds, and equipment 
constrain the delivery of care across all settings of care.  
 
This second model is illustrated graphically in Figure 5.6.203 
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The role of age and other patient characteristics 
When I started fieldwork for this study, I set out to investigate not only 
concepts of need for care, but also what other factors may influence access to 
and receipt of SPC. In my original formulation, I thought of these as ‘non-
need’ factors – dimensions which could not be assigned to ideas of need, but 
which even so may be influencing access to care. These included patient 
characteristics such as age. 
 
Of course, in the process of this research I quickly realized that ‘non-need’ 
was an almost impossible category to apply to such factors. Additionally, the 
dichotomy of need or no need was potentially unhelpful when services may 
respond to pressures by limiting the amount or quality of care provided, 
rather than simply denying care. The complexities of how patients were 
presented, categorized and responded to meant that it was entirely possible 
that characteristics such as age could form part of a provider’s concept of 
need, even if this formulation was not set out in policy or regarded as 
‘acceptable’ in the pursuit of equitable access. 
 
Within the meetings I observed, the age of each patient was routinely given 
at the start of any presentation about them, usually in the format of ‘[Patient] 
is a 74 year old lady with [diagnosis]’. This background information about 
age, whilst obviously perceived as an important piece of information, 
usually passed without comment. However, on a number of occasions where 
patients were younger, staff reactions implied a feeling of tragedy in relation 
to their age and circumstances: 
 
R1:  Um, [patient] was put in [hospice] yesterday afternoon but she’s died this 
morning. 
R2:  Oh, OK. 205 
 
R1:  And [nurse] has gone out there now because the family are distraught, it’s a 
45 year old. 
R2:  [Gasp] 
R1:  Mmm. 
R2:  Oh. OK. Oh dear. 
RS1 admissions meeting 07Jul05 
 
R1:  And then…this lady too.  
R2:  Yeah, she’s been on [hospice ward] before. 
R1:  Another youngish lady, isn’t she? 
R2:  Yeah, she is – very sad. 
RS1 admissions meeting 28Jun05 
 
Comments were infrequently made in relation to the older age of a patient. 
Where they were, it was usually to emphasise that the patient was, in spite of 
their age, still lively and active:  
 
R1:   How old is he? Sorry I missed that. 
R2:  He’s quite ancient. He’s 89 but doesn’t look it and is a bit of a charmer, you 
know, you can see that he’s obviously been a bit up to no good throughout his 
life. Um… 
R1:  Good for him. 
Home care team meeting RS1 Team 3 22Jul05 
 
Um, he was born 1921, so that makes him about 84, 85 – and he’s a very good 80 
year old. He’s very much out, walking - he goes away on holidays. 
Home care team meeting RS1 Team 4 16Jun 
 
There were was some suggestion within the meetings I attended that 
attitudes to age could translate to a greater level of care offered to younger 
patients once they were on the caseload of the palliative care team. A word 
of caution sounded by a consultant during one home care team meeting 
highlighted concerns that SPC may be requested to take on patients who had 
issues due to their age rather than their illness: 206 
 
R1:  Well we need to watch her because we haven’t got a confirmed diagnosis of 
cancer… 
R2:  we haven’t… 
R1:  …so she is an elderly lady like a lot of elderly ladies out there. So, much as   we 
can make a difference I think we need to also maybe on our first review sort of 
work out what our input’s been and what specialist palliative care side of 
things has been. 
Home care team meeting RS1 Team 4 16Jun05 
 
One interviewee directly stated that the palliative care service as a whole 
may be more likely to ‘make more of an effort for a younger person.’ They 
went on to say: 
 
I sometimes notice that we’re much more likely to try and put a younger person in a 
side room – oh yes, they’re young they’d want their privacy, but actually there’s no 
real logic behind that. Um, often you know – if there’s children involved then you 
know we think it’s nicer for them to be tucked away, but yeah – I certainly think 
there are inequalities there. 
Interview Doctor 2. 
 
This was borne out by my observations – as I wrote in my fieldnotes 
following one admissions meeting: 
 
The expectation was that a side room would be better for her – she was ‘a young 
patient’. [...] the very obvious message from [staff member] is that if she had a single 
room available she would put this patient into it and no reason was offered other 
than the fact she was ‘young’. 
Fieldnotes RS1 28Jun05 
 
This placement of patients – whether in a bay or in a private side room, and 
on which ward – was an important part of the admissions discussion process 
at RS1. The complexity of assigning the ‘right’ place to patients who had 
been referred for an inpatient bed led to often lengthy discussions about who 
should go where and when. Side rooms were conceived as a limited and 207 
 
valued resource for patients who had ‘something significant’ about them 
which may indicate a need for this level of service. Whilst reasons for the 
need for a side room were usually medical (the presence of open wounds or 
diarrhoea, for example) or social (young children), I also on one occasion 
observed the following exchange: 
 
R1:  Mmmmm. Mmmm. Think he’d be alright on a bay? 
R2:  Well – we’ve not got any choice. 
R!:  Yeah I mean or should we wait for a single room for him? 
R2:  Why? Because he’s a doctor? 
R1:  Mmmmm. Sorry! 
R2:  [laughs] Don’t apologise! I think we should give him the choice. 
R1:  OK. 
R2:  I think we should say there is a bed today but it is in a four-bedded bay. 
R1:  OK. 
R2:  We can’t guarantee a side room this week. 
R1:  Yeah, that’s fine. 
Admissions meeting RS1 30Jun05 
 
I was not able to gather statistical data on the proportion of patients who 
waited for access to inpatient SPC in relation to age. However, from 
attendance at admissions meetings my impression was that younger patients 
were commonly assigned a bed in preference to older patients with the same 
priority score. 
 
These observations demonstrate how patient characteristics, outside of the 
‘holistic quartet’, may determine the level of service offered to them. It is 
possible that aspects such as age, in the practitioner’s eyes, simply reflect 
different patient circumstances requiring different levels of input, such as a 
requirement for greater psycho-social support due to the loss of income for 
those who work or because of the needs of young children. Yet it is also 208 
 
possible that that there is a more subtle categorization at work, with 
characteristics forming part of implicit concepts of need for care.  
 
5.5  Discussion 
I have constructed two different concepts of need for SPC. My first, derived 
primarily from documentary sources, represents ‘the ideal’ (to use David 
Hunter’s terminology 302 p68) model of a clear pathway to and through 
holistic care. Patients requiring SPC will have an advanced, incurable and 
progressive disease with complex needs across a holistic quartet of domains: 
physical, psychological, social and spiritual. Need for care is thus comprised 
both of diagnostic and symptom dimensions, and the patient is viewed in 
totality along with their family and friends. 
 
My second model of SPC need is based predominantly on observations of 
the day-to-day decision making and workload management undertaken by 
SPC staff. It represents a more winnowed down and reactive approach 
driven by the immediate issue of concern, usually physical, sometimes 
psycho-social. Care focuses on the acute and the changing. In spite of SPC’s 
stated focus on holism, symptom control rises to the fore – a phenomenon 
observed in the wider medical approach to those with life-limiting illness. 303 
 
Additionally, there is some suggestion that patient characteristics, including 
age, may influence access to care, and in particular the quality of care on 
offer. However, the evidence provided for this in the current study is 
limited.  
 
Limitations 
My use of a focused ethnographic approach was well suited to the 
development of conceptualisations of need for care. Commencing with clear 209 
 
parameters of the phenomenon of interest enabled me to effectively target 
data collection to fulfil the study aim. Setting the focused ethnography across 
three providers enabled me to compare and contrast observations and 
develop a more rounded model. 
 
I developed good working relationships with staff at all sites, and this 
enabled me to undertake useful informal discussions as my ideas developed. 
Staff appeared to feel relaxed with me present and continued with their 
normal working routines, for example within the RS1 office. At meetings, 
initial self-consciousness about being recorded appeared to dissipate rapidly, 
although of course I cannot know if certain things were said or done 
differently as a result.  
 
The analysis undertaken used different analytical approaches to question the 
data from a number of angles. The challenges I felt in attempting to move 
beyond a purely descriptive analysis of the data to build a model of need 
were ameliorated by the freedom, within a pragmatic approach, to adopt 
new techniques (such as data quantification) to help me to answer the 
question at hand.  
 
Whilst ethnographies are by their very nature situated within one particular 
context, it is useful to understand how their findings may be generalisable to 
other settings. My primary research site was a large and relatively well 
resourced provider of care, which may perhaps have an impact on the model 
of need I built. Additionally, models of care may differ in rural areas where 
service provision is affected by the challenges of serving more disparate 
populations.  
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My analysis would be richer if I had drawn on additional sources of data. As 
is the nature of focused ethnographies, I concentrated on particular sources 
of information – documentary, staff meetings, and interviews. My work 
could have benefitted from further observation of the routine working 
practices of SPC staff. In particular, I observed that decisions on patient need 
are frequently taken by staff alone, without consultation with others. More 
in-depth interviews and observation of daily working life may have enabled 
me to question this further.   
 
Finally, time pressures did not permit me to return to participating providers 
to discuss and revise my data analysis in full. I held meetings with key 
members of staff to talk through my findings, but these did not form part of 
the analytical process. With hindsight, I feel my models of need would be 
stronger if SPC providers had been able to question my interpretations and 
offer their own. For example, teams may use a particular “shorthand” with 
each other when discussing patients, and their work may be more holistic 
than thus appears on the surface.  
 
Comparison with other studies 
There are few studies which have set out to conceptualise need for SPC. As 
discussed in Chapter 2, the majority of previous work has defined need in 
terms of diagnosis, the presence of symptoms such as pain or the perception 
of medical staff that patients are terminally ill. 102;103;304 These definitions are 
employed in spite of the recognition that need for SPC is likely to be 
multidimensional in nature. 113  
 
Findings from an ethnography conducted within an NHS hospice in 
Southern England suggested that resource constraints led to the 
prioritisation of patients with distressing physical symptoms and those in 211 
 
the terminal phases of illness, with a reduction in admissions for respite care. 
305 In a study of factors influencing inpatient admissions in one London 
hospice, the emphasis was again on the physical, with the majority of 
admissions taking place for symptom control. 306 However, I have not located 
any studies within SPC considering the context in which decisions about 
need are made, and the content of these decisions. 
 
Explanation for findings 
I discuss my findings in three sections. First, I explore possible explanations 
of the two concepts of need for SPC I derived. Second, I try to account for my 
observations on the potential influence of age within SPC decision making. 
Finally, I draw these together to offer a further model of the context in which 
SPC takes place, and the importance of this in investigations of need, equity 
and use. 
 
Need for specialist palliative care 
Holistic (‘ideal’) formulations of palliative care need may be linked to Cecily 
Saunders’ theory of ‘total pain’. This influential concept holds that pain is 
not just about the physical aspects of patients’ suffering, but encompasses 
mental distress, social problems, emotional problems and spiritual concerns. 
307 Recognising the multidimensionality of pain becomes the first step in 
relieving it. This requires a multidisciplinary effort in which the team 
approaches the patient as a whole person. 308 The total pain concept 
underpins much of the development and suggested practice of palliative 
care. 307 However, attempts to attain this ideal may be ambitious. One 
research team, in their analysis of the practice of SPC, suggested that: 
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Each caregiver involved in the caregiving process of terminally ill people must be 
ceaselessly concerned about the quality of the care… the quality of the moment is of 
utmost importance and should not be endangered by a caregiver’s shortcomings. 309 
 
The danger with such demanding requirements is that they cannot be 
realized in practice. Equipping individual caregivers with all the skills 
required to address ‘total pain’ is challenging. This is why multi-disciplinary 
teams form the basis for the SPC approach, with each staff member offering 
expertise in one or more areas (e.g. medical, nursing, spiritual, or 
psychological care). However, as my observations showed, SPC services do 
not always operate on a multi-disciplinary basis. In particular, difficulties in 
staff recruitment or funding in social work, psychology and spiritual care 
mean that needs in these areas are less likely to be recognised and addressed.  
 
As a result, need for SPC may be re-framed by what staff are equipped to 
respond to. As one of the interviewees stated, if the expertise of medical and 
nursing personnel lies in the relief of physical symptoms, this becomes their 
primary activity and their goal. Further, providing ongoing emotional 
support to patients and their families within palliative care may be 
challenging for SPC staff. One focus group study of the experiences of new 
SPC nurses found that the emotional difficulties of palliative care led them to 
question how long they would be able to remain within the specialty. 310 The 
need to protect themselves from emotional distress and maintain some 
distance between work and home life may also, therefore, reduce staff 
willingness to provide psycho-social support without receiving adequate 
support themselves. Thus, whilst the stated aims of SPC (and thus initial 
patient assessments) remain holistic, a focus on the physical domain of work 
may lead to an implicit re-negotiating of patient need to a narrower, more 213 
 
symptom-oriented concept. This is borne out by the perception of the Chief 
Executive of Help the Hospices, who in 2000 wrote: 
 
I read of increasingly short bed stays as complex physical problems are prioritized 
over other, equally complex but more drawn out and not so scientific social or 
psychological needs. Has it become the case that a carer driven to severe distress, if 
not near suicide or murder, and crying ‘help’, is less likely to obtain a bed for 
planned respite care for their loved one than is someone who needs to have their 
drugs balanced in order to control pain, particularly if the former is old and the 
latter young? 311 
 
However, Culyer and Wagstaff argued that a necessary condition for a 
service to be needed is that it should have a positive impact on the health or 
state of the individual. 312 This suggests that a need for care can only exist in 
domains to which staff can effectively respond. The evidence of effectiveness 
of SPC is limited; reflecting my observation above, what evidence there is 
tends to be confined to symptom relief. 223 This is not necessarily a problem. 
As a relatively new specialty, it is possible that SPC is in the process of 
working towards its aspirations of a holistic service, underpinned by high 
quality evidence of impact on all domains of patient and carer need. In the 
meantime, the work undertaken by the nurses and doctors who 
predominantly form SPC teams may have an excellent effect on the relief of 
pain and other important symptoms at the end of life.  
 
In considering additional explanations for the move from the ‘ideal’ to the 
‘actual’ model of need, I reflected on the process by which decisions are 
taken which shape need for care. Choices about care are made by providers 
within the context of managing their workload on a daily basis. 313 Such 
choices do not stand alone, as together they shape the course of care a patient 
receives. The direction and nature of the care which results reflects the 
practices that are routinely followed by the individual, the team and the 214 
 
service provider. Whilst providers may hold in their head a firm view of the 
nature of SPC, the realities of care may, explicitly or implicitly, force them to 
take a different direction. 
 
Insufficient staffing to manage the caseload at hand results in a pressurised 
working environment. The NHS services I observed, in particular, faced 
staffing shortages on a regular basis. Strategies to manage caseloads may 
include refusing care, delaying care, varying the level of care offered, and 
discharging from care. 314 To achieve the desired outcome (such as assigning 
a category of no need or a delayed need for SPC) and subsequently manage 
workload pressures, categories of need employed may vary.  
 
Observations of cardiac surgery and neuro-rehabilitation admission 
conferences show how complex negotiations take place between members of 
the multidisciplinary team as they ‘rule in’ or ‘rule out’ patients with a need 
for care. 91 Approaches to patient selection varied as a result of staffing mix, 
the organization of referrals, and attitudes to patient characteristics of a 
social or moral nature. However, the authors of this work identified two key 
points in decision-making about need. The first was the existence of implicit 
rules about which patients should receive care, and the level of care offered. 
The second was the nature of these rules, which may encompass both moral 
judgements and organizational criteria. 315 As staff explored each patient’s 
circumstances and constructed their need for care, they moved between 
medical and social discourses reflecting, respectively, professional norms 
and wider societal beliefs. Thus, concepts of ‘deservingness’ crept in to their 
decision-making. 92 
 
In my observations, implicit rules about need for care centred on the primacy 
of the physical. The requirement for patients to clear a ‘physical needs’ 215 
 
hurdle to gain entry to SPC reduces the number of patients staff may define 
as eligible for care. In spite of suggestions in documentary policy, patients or 
carers will not be considered for care on psycho-social grounds alone. This 
reflects the findings of a study into rationing of access to cancer genetics 
services. 316 Here, as a result of negotiations between staff members, 
previously defined categories of need for care such as inclusion criteria for a 
service (whether determined locally, regionally or nationally) became fluid. 
The flexing of these boundaries resulted from workload management 
pressures, and thresholds for care were set to contain the numbers of 
patients classified as requiring treatment.  
 
However, SPC provides ongoing support to patients, rather than a one-off 
procedure such as a surgical intervention or risk assessment. As such, my 
observations showed that the crucial concern in workload management was 
less likely to be defining a presence or absence of need, and more likely to 
focus on assigning a degree of need and subsequent intensity of service 
offered. It is in this area that the issue of age tentatively appeared.  
 
Age and SPC 
I did not observe patient care being withheld as a result of patient age. 
However, some of my observations suggest older patients may be perceived 
as less deserving of care (to use Hughes’ terminology 92). Thus, I observed 
older patients were more likely to wait for an inpatient bed, young patients 
were assigned a bed in a private side room rather than a bay if possible, and 
older patients were considered for discharge to a different service if their 
diagnosis was unclear, all apparently on the basis of their age.  
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Glaser and Strauss offered an explanation for the influence of age on medical 
staff’s attitudes and actions towards dying patients, based on a concept they 
termed ‘social loss’: 
 
The total of the valued social characteristics which the dying patient embodies 
indicates the social loss to family, occupation, and society on his death. 317  
 
In their work, age was a critical factor on which nurses caring for dying 
patients calculated a patient’s social loss. Older patients were seen as having 
enjoyed a full life, were currently contributing little to their family or society 
through employment, and had no future worth. 318.  
 
In their study, these implicit judgements resulted in perfunctory medical 
care with little attention given to the psychological or social needs of dying 
older patients. 318 I am not suggesting this reflects current SPC practice. 
However, as David Hughes’ work has shown, judgements about patients as 
a result of dimensions other than strict medical criteria do form a key part of 
implicit rationing. 90 There are glimpses within my data that SPC staff may 
make an extra effort for ‘young’ patients – do they regard these deaths as 
representing a greater social loss, and does this influence their categorisation 
of need? Decisions may therefore be taken to alter the quality or quantity of 
SPC as a result of age, but the impact of this on patients may be difficult to 
determine. 90 
 
The importance of context in determining need 
We are left, then, with three factors derived from the present study that may 
influence a move from the ‘ideal’ to an ‘actual’ model of need: 
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1.  The skills of available SPC staff (predominantly focused on the 
physical domain) 
2.  The number of available SPC staff (leading to workload management 
by refusing/delaying/reducing SPC, in part through a focus on the 
acute and the changing (predominantly in the physical domain)) 
3.  Rules of ‘deservingness’ including a patient’s age (leading to 
refusing/delaying/reducing SPC to reflect levels of deservingness) 
 
The third suggestion is tentative, as whilst this and previous research 
suggests issues in this area, these are not strongly identifiable throughout all 
data. 
 
Further, my findings suggest need for SPC is a continuous rather than 
dichotomous concept. The placement of patients on the continuum of need 
will vary during the course of their disease. Their position is likely to reflect 
their own situation and characteristics, and the competencies, availability, 
attitudes and interaction of SPC staff at each point in time. Classification of 
need for care will be reflected in the care offered. Thus, definitions of need 
for care should emphasise the importance of patient/provider interactions, 
rather than focus on the patient alone. This approach is in a way echoed by 
the concept of need for health care existing only where that care is effective. 
Staff provide what they are competent and able to provide, and in so doing 
shape their normative ideas of need.  
 
Rudolf Klein has argued that debates around access to care must take 
account of the nature of decision making, and how decisions at different 
levels relate to each other. 319 Allocation of resources and the setting of 
guidelines takes place at the macro level, with policy set at a governmental 
or regional level. However, it is the day to day decision making of medical 218 
 
staff at the micro level that determines that actual care that patients receive. 
As he states: ‘we must understand people accomplishing organisation in a 
multitude of locally situated interactions.’ 319  
 
In seeking to achieve equity, we must therefore consider the relationship 
between individual decision making and variations in access to care. Explicit 
guidelines such as those set down by NICE or Government strategy may aim 
to eradicate inequities in access to SPC. However, such strategies will be 
ineffective if decisions taken at the micro level enable patient characteristics 
such as age to determine the nature of the care offered. 320 It is, of course, 
widely acknowledged that medical staff must draw on their own experience 
and knowledge to respond to each individual patient’s circumstances, rather 
than simply make decisions as a result of criteria determined at a macro 
level. 321 The relationship between macro and micro is complex, and attempts 
to ensure fair decision-making at all levels are challenging. 322  
 
I suggest that the interaction between the macro and micro reflects the 
nature of the two concepts of SPC depicted here. The first, comprehensive, 
model of need is the ‘explicit’ model, reflecting publicly stated and agreed 
norms about the nature of SPC. The second is the ‘implicit’ model, revealing 
the actual nature of the services and the care they are able to offer. A 
pragmatic concern with ‘situated action’ requires the observation of dynamic 
interactions between individual agency and the environment, and 
consideration of how these contribute to the nature of the phenomenon 
under observation. 292 Drawing on this consideration, and on Eisenberg’s and 
Clark’s work on the interactional nature of clinical decision making, I 
developed a further model to reflect the spheres of influence within which 
care is determined [Figure 5.7]. 280;323  219 
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Figure 5.7 A model of the influences on specialist palliative care received 
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Whilst inevitably reduced to a static and relatively simplistic presentation, 
this model presents the concept of need as one which reflects an ongoing 
journey of multiple encounters between the patient and the SPC and wider 
medical system. Each encounter will add to the previous to determine the 
overall care pathway the patient follows. This reflects the fluid and 
contextual nature of the idea of need for SPC. All levels are influential within 
the subject of my study. Policies including the NICE guidelines on 
supportive and palliative care set out the parameters of SPC services 
nationwide. 19 These are subsequently reflected, along with professionally 
agreed norms of care, in the institutional policies and procedures of SPC 
providers. However, these are then modified by the pressures of the 
workplace, including staffing numbers and skill mix, and the attitudes and 
practices of individual staff members. The interactions of these staff with 
each other in discussing patients’ requirements, and with patients and carers 
themselves, then determine the model of need for care.  
 
5.6  Conclusions 
This study has shown that it is possible to formulate an idea of need for SPC. 
However, this is unlikely to be static. It is the result of complex interactions 
between patients and providers, within the context of wider social processes. 
My work here has shown that the categorization of patients within SPC is 
unlikely to be one of a dichotomous need/no need, but an ongoing process of 
variations in the nature of the service offered in the context of limited 
resources. I feel both models (the aspirational and the actual) are valid and 
useful. The first summarizes the ‘public’ face of SPC, and this may be useful 
at the macro level in population needs assessment and the quantification of 
those who may benefit from care. Estimates of need at this level may 
therefore provide evidence of all those who could benefit from care in a 
context of fully developed and resourced SPC services. However, the second 221 
 
model is a more realistic depiction of working practice and human 
judgement. Investigations of need at this level reflect the ongoing reality of 
care, and may present useful evidence on the influence of patient 
characteristics on the distribution of care.   
 
As outlined previously, data derived from this ethnography were also used 
to guide my choice of HRQL instrument as a measure of need for care. In the 
next chapter, I discuss previous approaches to measuring need for SPC, and 
why, in the absence of high quality SPC needs assessment instruments, 
existing HRQL questionnaires may provide a suitable alternative approach. I 
present the methods and results of a systematic review and critical appraisal 
of HRQL instruments used in lung cancer and palliative care, including how 
ethnographic data were used to inform an assessment of instrument content 
validity. Finally, I present detailed summaries of the shortlisted instruments 
and argue why two of these instruments may be suitable measures of SPC 
need within the cross-sectional survey of lung cancer patients.  
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Chapter 6 
 
Measuring need for specialist palliative care: location and critical 
appraisal of existing instruments 
 
And the arts of measuring and numbering and weighing come to the rescue of the 
human understanding – there is the beauty of them – and the apparent greater or 
less, or more or heavier, no longer have the mastery over us, but give way before 
calculation and measure and weight. 
 
Plato. The Republic of Plato. 324 
 
 
To evaluate equity of use of a health care service (whether there is equal use 
for equal need), need for that service must be measured. The first stage in 
measuring need is to operationalise it, by setting out a definition of need for 
care, and the domains this encompasses. Health care services will vary in the 
domains covered by concepts of need for that service. This is because the 
domains of need will differ according to the aim of the service, and on the 
benefits it will confer to the patient. For example, the need for a surgical 
procedure such as the removal of a suspected malignant melanoma may be 
determined purely by the presence of a suspicious mole (with an explicit 
definition of ‘suspicious’). Other factors, such as comorbidities or additional 
clinical considerations, may not be important in determining which patients 
will benefit from a biopsy, and which will not. By contrast, as the previous 
chapter highlighted, initial assessments of need for SPC may consider a 
diverse range of issues, including the patient’s symptoms, social 
circumstances, and their family’s anxiety. The definition of ‘need’ for these 
two services will therefore differ substantially, reflecting the varying 
domains in which patients will benefit from them.  223 
 
The second stage in measuring need is to choose a method by which to 
assess it. The method chosen to measure need will flow from the definition 
of need being applied, and in particular the domains which this 
encompasses. To return to our melanoma example, researchers may look to 
clinical guidelines on the type of moles which should be removed to classify 
those patients who do, or do not, have a need for a biopsy. Having set out 
the domains of need (in this case, covering clinical information alone) the 
decision must be then be made on how to gain information on the nature of 
the suspicious mole, and whether it meets the guidelines for removal. This 
could be achieved, for example, through a retrospective audit of medical 
records of dermatology services. However, with more complex definitions of 
need for care, such as those applied to SPC, a different approach is required 
to obtain comprehensive data on the domains of need being measured. For 
example, it may be that to understand a patient’s symptoms, social 
circumstances and the emotional state of themselves and their family, 
researchers may wish to gather new data directly from patients, rather than 
relying on medical records alone.  
 
All measurement of need must be conducted rigorously and systematically. 
Explicit criteria must be applied to each patient to determine their level of 
need, and these criteria must be transparent and reliable. This is where the 
requirements of research and the practice of day-to-day clinical decision 
making may differ radically. As the previous chapter showed, clinical 
decisions about a patient’s need for care may be based on criteria which 
differ from official guidelines, and be influenced by factors including the 
resource context within which practitioners are working. In SPC, explicit 
‘tick box’ lists are on occasion used, but more frequently these are employed 
to prioritise, rather than decide, need for care within patients, and not 
always consistently. As far as possible, research requires a thorough and 224 
 
replicable approach to determining patient need. In situations where this 
requires the collection of data directly from patients, such data must be 
obtained using instruments which are psychometrically robust and 
appropriate for use in the relevant patient groups.   
 
This chapter considers how to measure need for SPC to assess equity of use. 
It argues that need for SPC may be measured using an existing HRQL 
instrument. In doing so, it reviews definitions of HRQL and how this may 
relate to need for health care. The key properties of HRQL instruments are 
explained and discussed. It then reports on a systematic review and critical 
appraisal of HRQL instruments used in cancer and palliative care. Finally, it 
explains the choice of HRQL instruments suitable for use as indicators of 
need for SPC, based on data derived from the ethnographic study described 
in the previous chapter.  
 
6.1  Health-related quality of life, need, and specialist palliative care 
A number of instruments have been developed specifically to assess 
palliative care need and outcomes of care, detailed in systematic reviews of 
the field. 325-327 However, in spite of the prevalence of instruments for use 
with palliative care populations, two major criticisms have been made of the 
available options. Firstly, instruments frequently fail to determine and 
subsequently cover a comprehensive range of domains of need for care, 
often excluding dimensions such as spirituality. 325 Secondly, instruments 
have often undergone limited psychometric testing, and their reliability and 
validity cannot be ascertained. 327  
 
To address such concerns, the Problems and Needs in Palliative Care 
Questionnaire (PNPC) was developed. 328 Drawing upon interviews with 
patients and providers to develop a comprehensive model of need for care, 225 
 
this measure covers activities of daily living; physical symptoms; role 
activities; financial and administrative issues; social, psychological and 
spiritual issues; autonomy; information needs; and quality of care. It asks 
whether items are a problem, and whether professional help is required. A 
short version has also been developed. 329 Despite reaching reasonable levels 
of psychometric robustness, however, three concerns arise with this 
instrument in researching need for care. Firstly, it defines need for care as a 
wish to receive support for a problem. Thus, it focuses on what I would label 
demand rather than need. Secondly, it is designed for use as a clinical rather 
than a research tool. Thirdly, to date all psychometric testing has been 
undertaken in Dutch, and no English version has been validated. 
 
The PNPC draws heavily on concepts of HRQL in its content. 325 As the 
widely-used WHO definition of palliative care states, the aim of such 
services is ‘the achievement of the best quality of life for patients [with 
advanced, progressive illness] and their families.’ 27 Quality of life is, 
therefore, a major outcome of palliative care. 330 Considering the dearth of 
high quality instruments developed specifically to assess palliative care 
need, I therefore turned to consider the potential link between SPC need and 
HRQL, and the utility of using an existing HRQL instrument to measure 
need for care. 
 
Quality of life can be an ambiguous concept. There remains much debate 
about the meaning of quality of life (QL), and the linked, subsidiary concept 
of HRQL. 331-334 HRQL is acknowledged to be a narrower construct than QL, 
focusing on the effect of illness and subsequent health care on patients’ lives. 
335 Whilst it is agreed to be multidimensional in nature, a consensus on a 
single definition has yet to emerge. 335 Suggested domains of HRQL 
frequently include physical function, symptoms, global judgements of 226 
 
health, social well-being, cognitive function, role activities, personal 
constructs (such as life satisfaction and spirituality) and satisfaction with 
care. 336 For example, Bowling offers an overall definition of HRQL as; 
 
…optimum levels of mental, physical, role and social functioning, including 
relationships, and perceptions of health, fitness, life satisfaction and well-being. It 
should also include some assessment of the patient’s level of satisfaction with 
treatment, outcome and health status and with future prospects. 337 
 
Definitions of HRQL differ further according to the context and the 
population of interest. So, for example, in comparison to generic or other 
treatment areas, there is a greater emphasis on existential issues as central to 
HRQL in palliative care. 338 One definition for HRQL in palliative care which 
has been suggested is: 
 
QL in the context of advanced, progressive, incurable illness, is defined as the 
subjective experience of an individual living with the interpersonal, psychological, 
and existential or spiritual challenges, that accompany the process of physical and 
functional decline and the knowledge of impending demise. A person’s QL can range 
from suffering, associated with physical distress and/or a sense of impending 
disintegration, to the experience of wellness and personal growth arising from the 
completion of developmental work and the mastery of developmental landmarks. 339 
 
An association between HRQL and need for health care can only be made 
when the domains of HRQL are similar to the proposed domains of need for 
a service. This would not be the case for our suspected malignant melanoma, 
where clinical factors alone (the presence of a suspicious mole) may be 
enough to trigger an agreed need for a biopsy. Such a patient’s quality of life, 
although likely to be affected by their concern over the suspicion of skin 
cancer, may not be judged as relevant to their need for care. By contrast, 
need for SPC is multi-dimensional, encompassing physical symptoms, 
functional issues, psychological issues, and a patient’s social situation. These 227 
 
identified domains of need tie in with definitions of HRQL in palliative care, 
covering as they do physical comfort, psychological wellbeing, social 
functioning and wellbeing, spiritual wellbeing and meaningfulness of life, 
physical functioning, cognitive functioning, overall perceived quality of life 
and quality of dying of patient. 340 341 It may be possible, therefore, to 
consider HRQL as an indicator of need for SPC. 
 
HRQL has already been used to approximate patients’ need for healthcare 
where validated health care needs questionnaires are not available. 342;343 In 
taking such an approach, researchers can draw on an abundance of existing, 
psychometrically robust HRQL instruments. The use of existing instruments 
is recommended wherever suitable, as the development of new measures is a 
lengthy undertaking guided by strict procedures. 344 However, HRQL 
instruments are based on their author’s own definitions of HRQL. 
Definitions of HRQL within palliative care frequently follow the standards 
and scope set out for providing palliative care; again, an indication of the 
close ties between the aim of the service, need for the service, and measures 
of HRQL. 345;346 Yet these definitions do vary, and it is not possible to assume 
that any HRQL instrument developed for use with palliative care 
populations will closely match SPC provider’s concepts of need for their 
services.  
 
There is a further consideration in using HRQL instruments to indicate need 
for a health care service. Within clinical practice, decisions on need are most 
frequently taken by health care professionals, rather than patients. Patients’ 
perceived need may be expressed as demand for a service, but it remains the 
case that need is usually professionally-defined. HRQL instruments, by 
contrast, are now routinely completed by patients, rather than observers. 
This follows a number of studies showing that doctors and patients give 228 
 
widely differing reports of HRQL following treatment. 347-349 Within palliative 
care, it is still argued that proxy ratings of HRQL (given, by example, by 
close family or friends) may be necessary when a patient is too ill or frail to 
complete an instrument themselves. 350 However, the first choice of 
respondent remains the patient. In using HRQL instruments as an indicator 
of need for care discrepancies may, therefore, arise between the 
professional’s perceptions of need, and the patient’s rating of their HRQL.  
 
Ideally, of course, need for health care should be measured using an 
instrument designed specifically for that purpose. However, when need and 
HRQL are closely aligned (as they are within SPC) the use of an existing 
HRQL instrument may prove an effective way of obtaining valid and reliable 
data on need for care. Caution must, however, be exercised in choosing an 
appropriate HRQL instrument as an indicator of need for care. The author’s 
underlying constructs in developing the instrument, the psychometric 
properties it has, and its appropriateness for use in the intended population 
must all be considered. Fundamentally, the content of the HRQL instrument 
must be checked against the operationalised definition of need for that 
service which is being measured. The following section considers in detail 
the different types of HRQL instrument which are available, and the 
properties they must have to demonstrate robustness for use.  
 
6.2  Properties of health-related quality of life instruments 
HRQL instruments may be generic, disease or domain specific. Generic 
instruments are developed to be applicable across all respondents, to enable 
comparisons between healthy and ill adults, or between adults with different 
illnesses. Their utility is in the ability to compare HRQL scores across many 
different patient and non-patient groups, and for this reason they lend 
themselves well to cost-effectiveness studies. Disease-specific instruments 229 
 
are more sensitive, as they are able to include items relevant to the diagnosis 
of study, but they preclude the comparison of HRQL scores between 
different disease groups. Many clinical trials use both a generic and disease-
specific instrument for these reasons. 337 Domain-specific instruments do not 
measure HRQL, but only one or more dimensions of this (for example, 
physical symptoms or functional status), although they are frequently used 
as proxies for global HRQL.  
 
HRQL instruments must undergo extensive development and testing to 
ensure they meet adequate levels of reliability, validity, responsiveness, and 
acceptability. Guidelines have been published for the evaluation of the 
psychometric properties of instruments.336;337;351 These are briefly summarised 
below. 
 
Conceptual and measurement model 
All HRQL instruments should be based on a clear conceptual model of 
HRQL, stating the domains this is envisaged to encompass. The theoretical 
basis and methods used for developing the instrument’s content should be 
stated, as should the involvement of the target population in the 
development process. Measurement scales should measure a single distinct 
domain with sufficient variability of responses. This is to ensure that 
different scales within an instrument are measuring the stated domain of 
interest, and nothing else, and that the given response options are 
appropriate both to this item/domain of interest and to the target population. 
Additionally, the scale scoring system used should be clearly justified, with 
instrument authors explaining the rationale and methods for obtaining scale 
scores from raw scores, and for any transformations that are applied. This is 
essential if scale scores are to be meaningful and standardised across all 
users of an instrument.  230 
 
Reliability 
The reliability of a HRQL instrument is the degree to which it is free from 
random error. The two major aspects of reliability to be evaluated are 
internal consistency and reproducibility (test-retest).  
 
A. Internal consistency 
Internal consistency tests whether items in a scale are measuring the same 
concept. It reflects two aspects: the number of items in a scale, and the 
average correlation between these items. 352 Internal consistency is often 
tested for both the entire instrument, and the domains or sub-scales which 
make up the instrument, using the Cronbach’s alpha coefficient. The 
accepted standard is a coefficient of 0.70 or above, although higher figures 
are required if HRQL is being assessed on an individual, rather than a group, 
level. Low alpha scores indicate that the scale either has an insufficient 
number of items, or the items within the scale are not measuring a cohesive 
construct. 
 
B. Test-retest reliability 
Test-retest reliability is evaluated in respondents who are assumed not to 
have changed on the HRQL dimension of interest, and examines whether 
their scores remain stable over time as expected. It is assessed using either 
the Pearson or the intraclass correlation coefficients (ICC), with a minimum 
of 0.70 being deemed acceptable.  
 
Validity 
The validity of a HRQL instrument is the degree to which it measures what it 
claims to measure. There are three main ways of assessing validity – content 
validity, criterion-related validity, and construct validity. 
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A. Content validity  
Content validity is focused on whether an instrument covers all the relevant 
aspects of the construct it is claiming to measure. It is not possible to assess 
content validity statistically. Instead, the content of an instrument should be 
examined and adjusted in light of interviews with potential respondents, 
expert review, comparison to existing instruments, review of the literature, 
and pilot testing of draft versions.  
 
B. Criterion-related validity 
Criterion-related validity is the degree to which a HRQL instrument 
correlates with a criterion (gold-standard) measure. As criterion measures 
are not to be found easily in HRQL, this aspect of validity is rarely assessed.  
 
C. Construct validity 
Construct validity requires that the proposed interpretation of a measure’s 
scores is drawn from a theoretical underpinning of the constructs which are 
being measured. It is evaluated by testing hypotheses about how an 
instrument should ‘behave’ and about the expected relationships between 
the instrument and other variables or measures of the same construct. There 
is no single test for construct validity, and evidence for instruments is often 
gathered over a period of time and repeated use. There are a number of 
different aspects of construct validity, and it can be assessed internally, 
within the instrument, and externally, by comparison to other instruments. 
Internal and external construct validity are explained briefly below.  
 
Internal construct validity 
Internal consistency is assessed by determining that sub-scales are 
homogenous and valid. Scale inter-correlation is used to consider whether 
sub-scales are measuring separate, but related, constructs. Factor analysis 232 
 
can be used to explore the scaling structure used within an instrument – for 
example, to ensure that items are grouped as they should be. Known groups 
testing investigates whether scale or instrument scores vary as expected 
between respondents, when grouped by a characteristic also measured by 
the instrument. For example, do patients with a poorer reported global 
quality of life also have poorer scores in the symptom domain? 
 
External construct validity 
Convergent validity considers whether an instrument or sub-scales correlate 
as predicted with other measures, usually alternative HRQL instruments. 
Divergent validity is the opposite – whether an instrument or sub-scales 
correlate poorly as hypothesised with other measures. Known groups testing 
can also be conducted by comparing score differences between groups of 
respondents classified by an alternative, external measure. For example, do 
patients with poor performance status as measured by an alternative 
instrument also report greater symptom burden on the instrument being 
assessed?  
 
Additional properties 
 
Responsiveness 
Responsiveness refers to the degree to which an instrument is able to detect 
change over time. Whilst there is no one established method with which to 
assess responsiveness, the general principle is to calculate a measure of the 
magnitude of change in reported HRQL over a set period of time or after a 
specific event (such as treatment).  
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Interpretability 
Interpretability refers to the ability to assign qualitative meaning to an 
instrument’s quantitative scores. This may be facilitated, for example, by the 
use of population ‘norm’ scores for the instrument, or the comparison of 
scores to particular clinical conditions, known treatment needs or life events.  
 
Acceptability 
The degree to which an instrument places demands on respondents, and 
administrators, is an important aspect of an instrument’s suitability for use 
in its target populations. Respondent burden considers the time and effort 
required by patients to complete an instrument, and the impact completing 
the instrument may have on them. The ease of reading and length of the 
instrument should be suitable for the intended respondents and setting of 
administration. Respondent burden can be assessed by considering time to 
completion, but also indicators such as percentage completion rates, non-
response by item, and how responses are distributed across items and 
domains. Administrator burden considers the requirements of administering 
and scoring the instrument, and guidance should be provided by instrument 
developers for researchers on these points.  
 
Practical considerations (appropriateness) 
In addition to the psychometric aspects of instrument development and 
testing summarised above, a key aspect in evaluating and choosing between 
HRQL instruments is their appropriateness for the planned research study. 
Aspects to be considered include: 
 
A. Conceptual relevance 
Perhaps the most fundamental consideration in the choice of an instrument 
is the relevance of their content to the planned study. For example, if a 234 
 
particular outcome of interest is pain, does the instrument cover this in 
sufficient depth? Are items included which are irrelevant? And are items 
excluded which are relevant?  
 
B. Mode of administration 
Has the instrument been developed and validated to be administered in a 
face-to-face interview or by telephone, or to be completed by a patient in a 
clinic or at home after receiving it in the post? Psychometric properties must 
have been evaluated for each different mode of administration.  
 
C. Relevance to study population 
Is the instrument appropriate for the intended study population? Has it been 
validated in respondents of the correct age, diagnosis, and social situation? 
What assessment point has it been developed to cover – for example, was it 
developed for newly diagnosed cancer patients and has not been validated 
in advanced cancer patients? If study participants are predominantly older 
and retired, does the instrument include irrelevant or unsuitable questions 
about employment?  
 
Choosing a HRQL instrument 
The choice of a HRQL instrument must be guided by both psychometric and 
practical considerations, as outlined above. Importantly, instruments should 
meet basic criteria of validity and reliability. It is unlikely that a ‘perfect’ 
match will be found between an existing instrument and the aims, objectives 
and planned conduct of a study. Therefore, the final choice of instrument 
may involve a trade-off between psychometric standards, appropriateness 
and feasibility. 336 The process of finding and appraising a suitable 
instrument is outlined in the following section. 
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6.3  Systematic search for and critical appraisal of HRQL instruments 
To ensure all HRQL instruments which may be suitable for use in a study are 
located, a systematic search must be undertaken. The approach I took to 
identify HRQL instruments used in the fields of lung cancer and palliative 
care is outlined below. I also discuss the results of a critical appraisal of 
instruments for their psychometric robustness and appropriateness for use 
as an indicator of need for SPC.  
 
Aim and overview of methods 
My aim in this strand of work was to systematically identify and appraise 
critically HRQL instruments suitable for use in adult lung cancer and 
palliative care patient populations in the UK. I would then select an 
instrument based on psychometric properties and appropriateness of both 
content and administration to use as an indicator of need for SPC in the 
cross-sectional survey of lung cancer patients.  
 
I located HRQL instruments through a literature review using bibliographic 
databases, library catalogues, internet searching and discussion with experts 
in the field. My subsequent critical appraisal of these instruments was based 
on published guidelines and results from my ethnographic study. An 
overview of the process is given in Figure 6.1, and explained in more detail 
below. 
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Figure 6.1 Methods of review and critical appraisal of HRQL instruments 
Content of shortlisted instruments 
assessed against domains of need 
for SPC derived from ethnographic 
study: 
•  Physical symptoms 
•  Psychological issues 
•  Social issues 
•  Spiritual issues 
Shortlist of psychometrically robust 
instruments drawn up 
Instruments critically appraised for 
reliability, validity and 
appropriateness to cross-sectional 
survey. 
Instruments excluded: 
•  Observer completion 
•  Domain-specific (not HRQL) 
•  Not available in English 
Identified instruments screened 
against initial inclusion criteria: 
•  Patient completion 
•  Multi-dimensional HRQL 
•  Available in English 
Systematic review of literature 
conducted to identify HRQL 
instruments used in lung cancer 
and palliative care 
Instruments excluded: 
•  Poor reliability and validity 
•  Not appropriate for all stages 
of cancer 
•  Not appropriate to outpatient 
setting 
•  Not validated in all age groups 
•  Not validated in English 
Suitable HRQL instruments 
chosen to measure need for SPC 
Instruments excluded: 
•  Coverage of domains of need 
for SPC not extensive 
Identified instruments obtained in 
full where possible 237 
 
Search strategy 
I employed four strategies of searching. 
 
Firstly, I undertook a systematic search of bibliographic databases for studies 
published from 1966 (the earliest database listing) to the present. I conducted 
searches in Medline (Silverplatter, 1966 onwards), Embase (Ovid, 1980 
onwards), HMIC (Silverplatter, 1979 onwards) and SIGLE (Silverplatter, 1979 
onwards). I used a combination of text words and thesaurus terms for three 
major search concepts and their synonyms: quality of life, palliative care, and 
lung cancer. I developed the search strategy in Medline and adapted this for 
other databases [Table 6.1]. I carried out an initial search in December 2004, 
and repeated this in September 2005. All papers identified from each 
database search were imported into reference management software 
(EndNote v 6.0) and duplicate references deleted. I then scrutinised all 
identified citations against the inclusion and exclusion criteria (reported 
below) to determine whether the full paper should be obtained. I also 
examined bibliographies of full-text articles identified through database 
searching and meeting the initial inclusion criteria for further relevant 
studies. 238 
 
 
Table 6.1 Example search – Medline 
1. quality of life [tw] 
2. “quality of life” [MeSH] 
3. #1 or #2 
4. palliative* [tw] 
5. hospice* [tw] 
6. end of life [tw] 
7. terminal care [tw] 
8. supportive care [tw] 
9. "palliative care" [MeSH] 
10. "terminal care" [MeSH] 
11. “hospice care” [MeSH] 
12. #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 
13. lung cancer* [tw] 
14. lung neoplasm* [tw] 
15. lung tumour* [tw] 
16. lung tumor* [tw] 
17. lung carcinoma* [tw] 
18. "Lung Neoplasms" [MeSH] 
19. #13 or #14 or #15 or #16 or #17 or #18 
20. #12 or #19 
21. #3 and #20 
22. #21 limited to English 
 
Secondly, I used a library catalogue search, covering LSHTM, UCL and the 
British Library, to identify major relevant textbooks covering HRQL 
measures. Instruments identified through the text book search which had 
previously been used in palliative care or lung cancer patients were included 
in the review. 
 
Thirdly, I searched relevant internet websites for unpublished research in 
this field and further details on existing HRQL instruments: the Mapi 
Research Institute (www.mapi-research.fr) and their subsidiary site the 
Patient-Reported Outcome and Quality of Life Instruments Database 
(Proqolid: www.proqolid.org), the American Thoracic Society Quality of Life 
Resource (www.atsqol.org/) and TIME (Toolkit of Instruments to Measure 239 
 
End of Life Care: www.chcr.brown.edu/pcoc/toolkit.htm). Additionally, I 
entered the titles of all instruments located through the above three methods 
of searching into Medline, Embase and Google to identify any additional 
papers or information describing their development or use. 
 
Finally, I consulted with experts in the field of lung cancer, palliative care 
and quality of life for further recommendations on relevant instruments. 
 
Inclusion and exclusion criteria for papers 
To be included within the review, papers had to meet at least one of the 
following criteria: 
 
•  Containing information about the development, adaptation and/or 
psychometric properties of HRQL instrument/s for use with adult 
palliative care or lung cancer patients. 
•  Describing the validation of existing HRQL instrument/s for use with 
adult palliative care or lung cancer patients in different settings or 
populations 
•  Comparing the performance of existing HRQL instruments for use 
with adult palliative care or lung cancer patients. 
 
I excluded studies using HRQL instruments as process or outcome measures, 
such as clinical RCTs. Studies and reviews published in English in peer 
reviewed journals or grey literature were eligible for inclusion. 
 
Inclusion and exclusion criteria for HRQL instruments 
I obtained, where possible, the full text of all instruments identified through 
the papers located in the literature search. Generic, cancer, lung-cancer, and 
palliative-care specific instruments were all eligible for inclusion, if they had 240 
 
been used in lung cancer or palliative care populations. Instruments were 
subject to an initial brief assessment and exclusion criteria applied. 
Instruments were only taken forward for full critical appraisal if they were: 
 
•  Designed for completion by the patient (either self-administered or 
interviewer-administered), rather than observer-rated. 
•  Designed to make a comprehensive assessment of multiple domains 
of HRQL (physical, emotional and social well being, and functional 
ability), rather than one domain only (such as physical symptoms). 
•  Available for use in the English language. 
 
Critical appraisal of HRQL instruments 
HRQL instruments meeting the initial inclusion criteria (patient-rated, 
covering multidimensional HRQL and available for use in English) were 
subject to a critical appraisal of their psychometric properties, and 
appropriateness for the cross-sectional survey of lung cancer patients.  
 
I abstracted data on the psychometric properties of the HRQL instruments 
into a standardised critical appraisal form developed for this study, one form 
per instrument. As some HRQL instruments were identified and described 
across a number of different articles and books, forms therefore could 
contain data from a variety of sources. 
 
The form enabled me to summarise the key psychometric characteristics of 
each instrument: its reliability (internal consistency and reproducibility), 
validity (content and construct), and responsiveness [Table 6.2]. I noted 
further information on the instrument’s conceptual and measurement model, 
interpretability and burden. Finally, I abstracted descriptive information: the 
number of items, the domains covered, the mode of administration 241 
 
(interview or self-complete), the patient groups tested in (including age), the 
setting tested in, and the languages validated in, to further assist in decisions 
about the appropriateness of each instrument for the planned study setting. 
 
Table 6.2 Critical appraisal of HRQL instruments: key points 
1  Conceptual and 
measurement model 
What is the conceptual basis of the instrument? What is 
the measurement model used – does it include tests of 
scaling assumptions and floor and ceiling effects of 
items? 
2  Reliability  Is the instrument is free from random error? 
a) Internal consistency   Do items in the scale measure the same concept? 
b) Reproducibility (test-
retest and inter-rater) 
Test-retest: to what degree does the instrument 
reproduce stable scores over time in respondents who 
are assumed not to have changes on the domain being 
assessed?  
3  Validity  Does the instrument measure what it claims to 
measure? 
a) Content  Is the instrument comprehensive, without excluding any 
major areas deemed to be relevant? 
b) Construct 
What hypotheses are given about how the instrument 
‘behaves’ and what the expected relationships between 
the instrument and other measures of the same 
construct are? 
4  Responsiveness  Is the instrument able to detect clinically significant 
change over time? 
5  Interpretability  Can meaning be assigned to the quantitative scores 
derived from an instrument? 
6  Burden 
What is expected of the participant (respondent burden) 
in completing the form? What are the time implications 
for the researcher in e.g. scaling the responses? 
(administrator burden). 
7  Appropriateness to this 
study 
What patient groups and settings has the instrument 
been tested in? Is it culturally applicable? What is the 
method of administration? 
 
Content assessment of shortlisted HRQL instruments 
Following the first phase of critical appraisal, I drew up a short list of 
instruments based on the following criteria: 
 
1.  Good reliability and validity 
2.  Appropriate for use at all stages of cancer, including the recently 
diagnosed and those with advanced disease 
3.  Comprehensive coverage of physical, psychological and social 
dimensions of HRQL 242 
 
4.  Suitable for use in the outpatient setting 
5.  Validated in English 
6.  Validated in all age groups 
 
I then undertook a detailed assessment of the content of the shortlisted 
instruments. Items included within each instrument were compared against 
the domains of need for SPC derived through my content analysis of 
qualitative data conducted for this purpose. The methods used to derive 
these domains were outlined in Chapter 5. Briefly, I developed an initial 
coding framework from documentary evidence, particularly prioritization 
scoring systems and assessment tools reflecting potential dimensions of need 
for SPC. I then applied this to transcripts of home care team and inpatient 
admissions meetings from RS1 to generate counts of the number of occasions 
on which these terms or concepts were used. From this, I derived a 
framework covering the specific dimensions of need discussed and used by 
providers in assessing patients referred to their services [Table 6.3].  243 
 
 
Table 6.3 Framework for domains of need used to assess HRQL instruments 
Pain  Diarrhoea  Low mood 
Breathlessness  Confusion  Patient not coping 
Nausea/vomiting  Drowsiness  Thoughts of dying 
Weakness  Incontinence  Sleeping problems 
Fatigue  Urinary problems  Body image concerns 
Anorexia  Dry/sore mouth  Deteriorating condition 
Weight loss  Cough  Lives alone 
Ascites  Mobility difficulties  Financial issues/concerns 
Oedema  Patient anxiety/distress  Relationships with others  
Constipation  Depression  Carer anxiety and distress 
 
This framework is thus closely aligned to the ‘aspirational’ model of need I 
observed, rather than the narrower ‘actual’ model of need, as it was the 
aspirational model that was typically used to assess new referrals to the 
service and thus consider initial need for SPC. Additionally, this framework 
is derived from the detailed content of SPC providers’ discussions. So, 
instead of reference to an over-arching physical domain of care, the 
framework covers the specific symptoms SPC staff highlighted. It therefore 
contains all aspects of a patient’s needs addressed by staff in their first 
assessment. Having derived this framework, I used it to assess the relevance 
of each instrument’s content to provider’s conceptualisation of need for SPC. 
Additional items included within the instrument which were not part of the 
major dimensions of need for SPC were also assessed for their potential 
relevance to the target population.  
 
I also studied further important aspects of the short listed instruments. These 
included the conceptual model of HRQL on which they were based (if 
stated), and the scoring system used and its justification. The statement of a 
precise concept of HRQL on which an instrument is based is an important 
indicator of instrument quality and rigour. 351 Additionally, a consideration 
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each might be used as an indicator of need for SPC within a multivariable 
regression analysis.  
 
Following this assessment, and based on the outcome of all stages of 
appraisal, I decided which instruments were suitable to use as an indicator 
of patient need for SPC. 
 
Results 
 
Number of articles and instruments 
Bibliographic database searches returned a total of 9832 citations. Following 
deletion of duplicate references (n = 2254), I screened 7578 titles and abstracts 
against the inclusion and exclusion criteria [Figure 6.2]. Citations were 
primarily excluded as they reported the results of studies which had used 
HRQL instruments as process or outcome measures, with no description of 
their psychometric properties. 148 publications were retrieved in full text for 
further scrutiny.  245 
 
 
 
Scrutiny of the full text articles and their bibliographies led to the location of 
65 HRQL instruments suitable for use in lung cancer or palliative care 
populations. Following-up cited references was a particularly effective 
method of locating the original validation study for many instruments. I 
identified an additional two HRQL instruments through the manual text 
book search, and one more through expert recommendation, leading to a 
total of 68 instruments identified for appraisal. 
Potentially relevant references 
identified for retrieval – total from 
all databases (n = 9832) 
Duplicates excluded automatically 
(n = 1522). Duplicates excluded 
manually (n = 732). Total 
duplicates excluded (n = 2254) 
Potentially relevant references 
identified for assessment – total 
following deletion of duplicates  
(n = 7578)  References excluded with reason 
on basis of title (n = 7262) 
Publications retrieved for more 
detailed evaluation (n = 148) 
References excluded with reason 
on basis of abstract (n = 168) 
Potentially relevant titles identified 
for abstract scanning (n = 316) 
HRQL scales identified through 
bibliographic database search  
(n = 65) 
Figure 6.2 Flow chart of systematic search 246 
 
Initial brief assessment 
Following assessment of the identified HRQL instruments against the initial 
inclusion criteria (patient-rated; multi-dimensional in scope; and validated in 
the English language), I excluded 31 instruments from further appraisal 
[Table 6.4]. The largest category of exclusion (n = 22) was for instruments 
that did not cover multiple domains of HRQL. Instead, these were designed 
to capture a patient’s experience in only one area of HRQL, such as 
symptoms, functional status or existential issues. Seven instruments were 
designed to be completed by an observer based on their own judgements of 
the patient, rather than the patient’s own report. One instrument was only 
available in German and had not been translated to English.  247 
 
 
Table 6.4 HRQL instruments excluded from critical appraisal 
Not multi-dimensional HRQL 
Canberra Symptom scorecard 
353 
Cancer Patient Need Questionnaire 
354 
Cancer Patient Need Survey 
355 
Client Generated Index 
356 
Condensed Memorial Symptom Assessment Scale 
357 
Daily Diary Card 
358 
Demoralization Scale 
359 
Edmonton Functional Assessment Tool 
360 
Edmonton Symptom Assessment Scale 
361;362 
Herth Hope Index 
363 
Home Care Study – Patient Form 
364 
Hospice Care Performance Inventory – HCPI 
365 
Karnofsky Performance Status Scale – KPS 
366 
Life Closure Scale 
367;368 
Life Evaluation Questionnaire – LEQ 
369 
Meaning in Life Scale (ML) 
370 
Memorial Symptom Assessment Scale – MSAS 
371 
Mini-Mental State Questionnaire 
372 
Need Satisfaction Scale 
373 
Patient Information Survey 
374 
Quality of End of life care and Satisfaction with Treatment - QUEST 
375 
Symptom Distress Scale – SDS 
376;377 
Observer-rated 
Hebrew Rehabilitation Center for Aged QL (HRCA-QL) 
378 
INTERMED 
379 
Oncology Clinic Patient Checklist 
380 
Palliative Care Assessment – PACA 
381 
Resident Assessment Instrument for Palliative Care (RAI-PC).
382 
Spitzer Quality of Life Index 
383 
Support Team Assessment Schedule – STAS 
384 
Not available in English 
SELT-M 
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Full critical appraisal 
38 instruments therefore remained for full critical appraisal. These were 
divided into four categories – generic (9 instruments), cancer-specific (10 
instruments), lung-cancer specific (3 instruments) and palliative care specific 
(16 instruments), to reflect their different origins and application. Of the 38 248 
 
instruments identified, just under half (n=17, 44.7%) had been rigorously 
psychometrically evaluated on all dimensions of reliability (internal 
consistency and reproducibility) and validity (content and construct). 12 
(31.6%) had been tested for their responsiveness (ability to detect change 
over time). The instruments varied widely in their length (range of 6 to 139 
items) and the domains covered. This in part reflected the original purpose 
of their development, with shorter instruments designed to be used in 
palliative care populations. However, a number of instruments also had both 
long and short versions to address concerns of respondent burden in less 
healthy populations, such as those with advanced cancer.  
 
As a result of the critical appraisal, I shortlisted 6 of the 38 instruments for 
detailed consideration for use as an indicator of need. Brief details of the 32 
instruments excluded at this stage are given in Table 6.5, and in the 
commentary below. A detailed description of these instruments, including a 
full account of their psychometric properties (reliability, validity and 
responsiveness) and appropriateness for the purpose of this study is in 
Appendix III, page 396.  249 
 
 
Table 6.5 HRQL instruments critically appraised but not shortlisted 
Name of instrument  Reason for exclusion 
Generic instruments used in lung cancer or palliative care 
EQ-5D 
386  5 items. Limited coverage of HRQL 
dimensions; response options limited.  
Fox Simple Quality of Life Scale 
387 
25 items. No data on reproducibility and 
responsiveness published. Still in 
development.  
NHP  
(Nottingham Health Profile) 
388 
38 items. Evidence of conflation of pain 
and mobility domains.  
SEIQoL  
(Schedule for the Evaluation of Individual 
Quality of Life) 
389;390 
5 domains. Interviewer administered; 
acceptability in palliative care disputed.  
SEIQoL-DW  
(Schedule for the Evaluation of Individual 
Quality of Life – direct Weighting) 
389;390 
As above. 
SF-36  
(Short Form 36)  36 items. Limited coverage of symptoms.  
SIP  
(Sickness Impact Profile) 
391 
136 items. Psychometric properties in 
cancer uncertain. 
WHOQOL-100 
392;393  100 items. Acceptability in advanced 
cancer unknown. 
WHOQOL-Bref 
394  26 items. Acceptability in advanced cancer 
unknown. 
Cancer-specific instruments used in lung cancer or palliative care 
Care notebook 
395  24 items. Not psychometrically tested in 
English. 
CARES  
(Cancer Rehabilitation Evaluation System) 
396 
139 items. Acceptability in advanced 
cancer disputed. 
CARES-SF  
(Cancer Rehabilitation Evaluation System 
–Short Form) 
397 
59 items. Acceptability in advanced cancer 
disputed. 
QOL-CS  
(Quality of Life Instrument – Cancer 
Survivor Version) 
398;399 
41 items. Not suited to advanced cancer 
patients.  
QLI-C-FP  
(Ferrans and Power Quality of Life Index – 
Cancer version ) 
400;401 
66 items. Acceptability in advanced cancer 
unknown. 
FLIC  
(Functional Living Index – Cancer) 
402 
22 items. Reported poor acceptability with 
lung cancer patients.  
Quick-FLIC 
403  11 items. Reported poor acceptability with 
lung cancer patients. 
Padilla’s Quality of Life Index   14 items. Not tested in advanced cancer. 
Rotterdam Symptom Checklist 
404  38 items. Limited coverage of HRQL 
dimensions; focus on symptoms.  
Lung cancer specific instruments 
LCSS  
(Lung Cancer Symptom Scale) 
405-407 
9 items. Limited coverage of HRQL 
dimensions. 
Palliative care specific instruments 
AQEL  
(Assessment of Quality of Life at the End  19 items. Psychometric properties poor. 250 
 
of Life Instrument) 
408 
Brief Hospice Inventory 
409  17 items. Specific to patients receiving 
palliative care. 
EORTC QLQ-C15-PAL 
410  15 items. Still in development. 
HQLI  
(Hospice Quality of Life Index) 
411;412 
28 items. Specific to patients receiving 
palliative care. 
Initial Assessment of Suffering in Terminal 
Illness 
413  20 items. Still in development. 
Missoula-VITAS Quality of Life index 
339  26 items. Only suitable for patients with 
advanced disease. 
POS  
(Palliative Care Outcome Scale) 
414 
10 items. Limited coverage of HRQL 
dimensions. 
PQLI  
(Palliative Care Quality of Life Instrument) 
415 
28 items. Not psychometrically tested in 
English. 
Patient Evaluated Problem Score 
416  Unlimited list. Not psychometrically tested. 
PNPC  
(Problems and Needs in Palliative Care) 
328 
138 items. Not psychometrically tested in 
English. 
QUAL-E  
(Quality of life at the End of Life) 
417;418  31 items. Interviewer administered. 
Supportive Care Needs Survey 
419  61 items. Not used in UK populations.  
Therapy Impact Questionnaire 
420  36 items. Not psychometrically tested in 
English. 
 
A.   Generic instruments 
Whilst some of the generic instruments reviewed were extensively used 
within cancer research, particularly the SF-36, there were a number of 
limitations to their use as an indicator of need for palliative care. Firstly, their 
ability to discriminate between lung cancer patients with and without a need 
for SPC is likely to be low; few include symptoms other than pain and few 
have fine enough response formats to generate a range of responses in this 
group. Secondly, despite their use in lung cancer trials, the inclusion of 
domains such as work or the ability to walk long distances is redundant 
when applied in advanced disease. Thirdly, few include domains specific to 
the assessment of need for SPC, such as existential issues including concepts 
self, death and dying, and meaning of life. For these reasons, none were 
short listed for further consideration. 
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B.   Cancer-specific instruments 
Many cancer-specific instruments, such as the CARES, the QOL-CS and 
Padilla’s Quality of Life Index, have not proved suitable for administration 
in advanced cancer patients, limiting their utility in a cross-sectional survey 
of all stages of disease. The FLIC and Rotterdam Symptom Checklist 
excluded a number of important dimensions of HRQL, particularly 
psychosocial items. Finally, the Care Notebook has not been 
psychometrically tested in English speaking populations and is thus 
unsuitable for use until its validity and reliability have been confirmed in 
this language. 
 
C.  Lung-cancer specific instruments 
The LCSS, whilst it has shown good reliability and validity, is limited in its 
coverage of non-physical concerns. It additionally relies on being 
interviewer-administered; for these reasons it was not suitable to use in the 
planned cross-sectional survey.  
 
D.  Palliative-care specific instruments 
The largest group of instruments I identified were developed for use 
specifically in palliative care populations. However, this group also showed 
the greatest variation in the extent to which instruments had been 
psychometrically tested, with some showing little or no evidence of their 
reliability and validity. Additionally, instruments developed for use in 
palliative care populations varied widely in their content. A number – such 
as the Missoula-Vitas QLI and the Hospice Quality of Life Index – include 
items very specific to patients with a terminal illness, and are therefore 
unlikely to be suitable for use in patients in earlier stages of cancer.  
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6.4  Short listing and selection of HRQL instrument as indicator of 
need for SPC 
 
As a result of the critical appraisal, I short listed six potential instruments for 
more detailed consideration. These were: 
 
1.  EORTC QLQ-C30 
2.  EORTC QLQ-LC13 
3.  FACT-L 
4.  McGill Quality of Life Questionnaire 
5.  McGill Quality of Life Questionnaire – Cardiff short form 
6.  McMaster Quality of Life Instrument 
 
Details of the psychometric properties of these instruments are given in 
Table 6.6. The domains of need for SPC that I derived from my ethnographic 
data encompassed physical symptoms, functional issues, psychological 
issues, social situation, spiritual concerns, and change over time. To assess 
how comprehensively each short listed HRQL instrument covered these 
domains, instrument items were tabulated against identified domains of 
need [Table 6.7]. The results of the content appraisal of each instrument, 
along with full details of their characteristics and applicability, are discussed 
in detail below for each instrument in turn.  
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Table 6.6. Psychometric qualities of shortlisted HRQL instruments 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsiven
ess  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproducibi
lity  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
EORTC 
QLQ-C30 
421 
30 items; 
five 
functional 
scales 
(physical, 
role, 
cognitive, 
emotional 
and social), 
three 
symptom 
scales 
(fatigue, 
pain, and 
nausea & 
vomiting); 
plus global 
QL scale 
and 
additional 
symptom 
items 
Patient 
completion 
Four- 
and 
seven-
point 
categori
cal 
scales 
Domains 
Cronbac
h’s α .52 
to .89 
421 
- 
Literature
. 
Interview
s. Expert 
review. 
Pilot test. 
Divergent 
validity: 
scales 
distinct. 
Discriminant 
validity: able 
to distinguish 
between 
patients with 
different 
performance 
status  
Scores 
changed pre- 
and post-
treatment 
Time: 11 
minutes. 
Acceptabili
ty: 10% 
patients 
found one 
or more 
items 
confusing 
Inpatient 
Outpatien
t 
Communi
ty 
Cancer 
patients, 
all 
stages. 
Age 
range 
36 to 89 
English 
EORTC 
QLQ-LC13 
422 
13 items; 
Lung-
cancer 
related 
symptoms 
and 
treatment 
side-
effects. 
Supplemen
t to EORTC 
QLQ-C30 
Patient 
completion 
Four-
point 
categori
cal scale 
Domains 
α 
dyspnoe
a 
subscale 
.83; pain 
.54 
- 
Literature
. Expert 
review.  
Discriminant 
validity:  
symptom 
scores 
related to 
performance 
status. 
 
scale of 
instrument 
distinguished 
between 
patients with 
differing 
performance 
status 
Scores 
changed in 
expected 
direction 
during 
treatment. 
Time not 
known. 
Acceptabili
ty not 
known. 
Outpatien
t. 
Patients 
with 
non-
resectab
le lung 
cancer. 
Age 
range 
not 
known. 
English 
and 
other 
languag
es. 254 
 
Table 6.6. Psychometric qualities of shortlisted HRQL instruments 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsiven
ess  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproducibi
lity  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
FACT-L 
423 
44 items; 5 
domains 
plus 
‘additional 
concerns’: 
physical 
well-being, 
social/famil
y well-
being, 
relationship 
with doctor, 
emotional 
well-being, 
functional 
well-being. 
Patient 
completion 
Five-
point 
categori
cal scale 
Domains 
Cronbac
h’s α .53 
to 0.89. 
Lung 
cancer 
subscale 
α .68. 
- 
Patient 
and 
expert 
interview. 
Expert 
review. 
Pilot test. 
Factor 
analysis 
confirmed 
multidimensio
nal structure. 
Correlated 
with FLIC. 
Divergent 
validity: poor 
correlation 
with  
Marlowe-
Crowne 
Social 
Desirability 
Scale 
All domains 
but social 
desirability 
sensitive to 
change in 
performance 
status. 
Time: 8 
minutes. 
Acceptabili
ty not 
known. 
Outpatien
t. 
Patients 
with 
lung 
cancer. 
Age 
range 
36 to 80 
English 
and 
other 
languag
es 
McGill 
Quality of 
Life 
Questionna
ire 
338;424-426 
16 items 
plus single-
item global 
scale. 5 
domains; 
physical 
well-being; 
physical 
symptoms; 
psychologi
cal; 
existential 
well-being; 
support 
Patient 
completion 
Ten-
point 
categori
cal scale 
Overall 
Cronbac
h’s α .83. 
Subscale
s α .65 to 
.87 
Test-retest 
correlations 
.62 to .85 for 
subscales. 
N=100, 
time=2 days 
Literature
. Clinical 
experien
ce. 
Interview
s with 
patients 
Correlated 
with the 
single-item 
QL measure 
and Spitzer 
QL Index. 
Scores 
different on 
good, average 
and bad days. 
10 to 30 
minutes. 
Acceptabili
ty: 0.001% 
missing 
data (4 of 
3271 
items) 
Communi
ty. 
Inpatient. 
Outpatien
t. 
Cancer 
patients, 
all 
stages, 
includin
g 
palliativ
e care. 
All ages. 
English 
and 
French. 
McGill 
Quality of 
Life 
Questionna
ire – Cardiff 
Short Form 
427 
8 items; 3 
domains: 
physical 
symptoms, 
psychologi
cal and 
existential, 
plus global 
QL. 
Patient 
completion 
Ten-
point 
categori
cal scale 
Overall 
Cronbac
h’s α .68 
to .80. 
Subscale
s α .46 to 
.86 
Test-retest 
correlations 
.51 to .86 for 
items. 
n=48, time=1 
week 
Clinical 
experien
ce inc. 
use of 
original 
MQOL 
Items 
correlated 
with original 
MQOL 
domains and 
own domains 
 
1 to 8 
minutes 
(mean 3). 
Acceptabili
ty: 98.2% 
patients 
reported 
‘clear’ or 
‘very clear’ 
Inpatient. 
Outpatien
t. 
Cancer 
patients 
under 
palliativ
e care 
service. 
Age 
range 
27 to 88 
English 255 
 
Table 6.6. Psychometric qualities of shortlisted HRQL instruments 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsiven
ess  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproducibi
lity  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
 
McMaster 
Quality of 
Life 
Instrument 
428 
32 items; 4 
domains: 
physical, 
emotional, 
social and 
spiritual. 
Patient 
completion; 
carer and 
staff 
completion 
Seven-
point 
categori
cal scale 
Cronbac
h’s α 
subscale
s α .62 to 
.79 
Test-retest 
correlations 
.83 to .95 for 
subscales. 
Literature
. Clinical 
experien
ce. Pilot 
test. 
Correlated 
with the 
Spitzer QL 
Index 
Scores 
changed in 
relation to 
whether 
patients felt 
they had 
changed 
3 to 30 
minutes 
Inpatient 
Outpatien
t 
Communi
ty 
Patients 
under 
palliativ
e care 
services
. Age 
range 
29 to 
95.  
English 256 
 
Table 6.7 Content appraisal of short listed instruments against domains of need for SPC derived from content analysis 
  EORTC  
QLQ-C30 
EORTC  
QLQ-LC13  FACT-L  McGill *  McGill Short 
Form *  McMaster 
Pain  ￿  ￿  ￿      ￿ 
Breathlessness  ￿  ￿  ￿      ￿ 
Nausea/vomiting  ￿    ￿      ￿ 
Weakness  ￿           
Fatigue  ￿    ￿      ￿ 
Anorexia  ￿    ￿      ￿ 
Weight loss      ￿       
Ascites             
Oedema            ￿ 
Constipation  ￿          ￿ 
Diarrhoea  ￿          ￿ 
Confusion      ￿      ￿ 
Drowsiness            ￿ 
Incontinence             
Urinary problems             
Dry/sore mouth    ￿        ￿ 
Cough    ￿  ￿      ￿ 
Mobility difficulties  ￿          ￿ 
Patient anxiety/distress  ￿    ￿  ￿    ￿ 
Depression  ￿      ￿  ￿  ￿ 
Low mood  ￿    ￿  ￿  ￿  ￿ 
Patient not coping      ￿       
Thoughts of dying      ￿  ￿     
Sleeping problems  ￿    ￿      ￿ 
Body image concerns            ￿ 
Deteriorating condition             
Lives alone             
Financial issues/concerns  ￿          ￿ 
Relationships with others   ￿    ￿      ￿ 
Carer anxiety and stress             
* Requires respondents to list three most troublesome symptoms over the last two days 257 
 
EORTC QLQ-C30 and QLQ-LC13 
The EORTC QLQ-C30 is perhaps the most widely used cancer HRQL 
measure in Europe. It was originally developed for use in clinical trials, and 
has been widely tested and found to be valid, reliable and responsive in a 
range of populations, settings and stages of cancer, including advanced 
disease. 429 It is a recommended HRQL instrument within the Toolkit of 
Instruments to Measure End of Life Care (TIME), a large scale project aiming 
to assemble a battery of suitable questionnaires to measure quality of care at 
the end of life. 430 It is the core questionnaire of the EORTC’s modular 
approach to HRQL assessment, with optional disease-specific modules 
capturing diagnosis-related symptom issues in greater depth. The EORTC 
QLQ-LC13 is the lung-cancer specific instrument developed for use with the 
core EORTC QLQ-C30. 422 It covers lung-cancer related symptoms and 
treatment side-effects. It is extensively used in trials of lung cancer 
chemotherapy and radiotherapy and has strong evidence of reliability and 
validity at all stages of lung cancer. To measure multi-dimensional HRQL, 
however, it must be used in conjunction with the core questionnaire, forming 
a 43-item instrument.  
 
The EORTC HRQL measurement system is based on a multidimensional 
quality of life construct comprising core items relevant to all cancer patients, 
supplemented by diagnosis and/or treatment-specific items. 431 Within this 
modular approach, the core construct encompasses physical function, role 
function, cognitive function, emotional function, social function, key 
symptoms including fatigue, pain and nausea and vomiting, and financial 
impact of the disease. Guidance for the development of EORTC modules has 
been published; HRQL issues are generated through literature searches, 
interviews with health care providers, and interviews with patients, before 
these issues are operationalised into questions, piloted, and tested. 432 258 
 
The EORTC QLQ-C30 has 30 questions, arranged either as multi-item scales, 
or single items. It has five functional scales (physical, role, cognitive, 
emotional, and social), three symptom scales (pain, nausea and vomiting and 
fatigue), and a global health and quality of life scale. Additional single items 
cover symptoms including difficulties sleeping and shortness of breath, as 
well as the financial impact of the disease. The EORTC QLQ-LC13 (13 items) 
also uses a mixture of multi-item scales and single items to cover common 
lung cancer symptoms (cough, dyspnoea, haemoptysis) in more depth, 
together with treatment side effects. The time scale for both is how the 
respondent has felt during the last week. 
 
The EORTC group have published a manual to provide guidance on the 
correct scoring of the EORTC QLQ-C30 and LC13 instruments. 433 The QLQ-
C30’s five functional scales, three symptom scales, global QL scale, and six 
single-item symptom measures are scored from 0 to 100. Higher scale score 
represent a higher response level, meaning that high scores on symptom 
scales represent a high level of symptoms, but high scores on the functional 
scale indicate a high (good) level of functioning. The scoring procedure for 
each scale involves: 
 
1.  An estimation of the raw score (the mean of the items within each 
scale) 
2.  The linear transformation of the raw score to a range between 0 and 
100 using the appropriate formula (supplied by EORTC). 
 
The scoring system is applied in exactly the same way to the LC-13, which 
has one multi-item scale on dyspnoea, and single-items for other symptoms. 
For either instrument it is not possible to calculate a total score.  
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The EORTC system is widely used within cancer clinical trials. It is 
psychometrically robust, with a clear grounding in multidimensional 
concepts of HRQL, and has been subjected to a rigorous developmental 
process. It is also apparently comprehensive in its coverage of the concerns 
of lung cancer patients. However, when both instruments were compared 
against the items of need identified through the ethnographic study [Table 
6.7, page 256], they together covered 17 of the 30 different domains of need. 
They were particularly strong on key symptoms, with issues such as pain 
and nausea and vomiting being covered in depth by scales rather than 
single-items. They also covered key issues of need such as relationships with 
others and financial concerns. However, they did not cover other identified 
common symptoms such as urinary problems, ascites and oedema, or 
important psychological considerations such as coping ability, thoughts of 
dying and body image concerns.  
 
The scoring system of the EORTC may also restrict its suitability as an 
indicator of need for SPC. The EORTC QLQ-C30 alone generates 15 separate 
scores, which cannot be combined. Statistically, it may therefore be 
challenging to employ this instrument in a cross-sectional survey to grade 
levels of total need, unless the global quality of life score is used as the 
indicator of need. 
 
FACT-L 
FACT-L is a 44 item instrument also widely used in lung cancer research, 
formed of a core set of HRQL items (known as the FACT-G), with a further 9 
lung-cancer specific items. 423 Its domains encompass physical, social/family, 
emotional and functional wellbeing, as well as lung-cancer specific 
symptoms. It has undergone comprehensive psychometric testing, although 
its reliability and validity are not as robustly understood as with the EORTC 260 
 
QLQ-C30. Along with the EORTC, the FACT-G/L was also recommended for 
use as a HRQL instrument in palliative care populations by the TIME 
(Toolkit of Instruments to Measure End-of-Life Care) project. 430 
 
The FACT measurement system of which the FACT-L is part defines HRQL 
as having four major dimensions – physical wellbeing, emotional wellbeing, 
social wellbeing and functional wellbeing. Symptoms are part of, rather than 
something influenced by, HRQL. 423 Items for this instrument were generated 
through interviews with patients and health care professionals, and 
shortlisted by an expert panel. 423 
 
The current Version 3 of the FACT-L incorporates 44 items in six areas; 
physical, social, emotional and functional well-being, a respondent’s 
relationship with their doctor, and additional lung-cancer specific concerns 
including shortness of breath and weight loss. As with the EORTC, the time 
scale for the FACT-L is the previous seven days. 
 
The FACT-L can be used to calculate both a total score, and sub-scale scores 
(covering physical, emotional, social and functional wellbeing). Sub-scales 
are scored by adding or subtracting (depending on the wording of the 
question) scores for each item; the total score is a sum of each sub-scale score. 
Higher scores indicate a more positive quality of life. The maximum total 
score is 136.  
 
When the instrument items were compared against the domains of need for 
SPC, 14 of the 30 identified areas were included. FACT-L items focused on 
similar issues to the EORTC, in the main on key symptom concerns, and 
psychological problems including ability to cope.  
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The ability to calculate a total score for FACT-L makes it more feasible than 
the EORTC to use as an indicator of need for SPC, but its omission of 
important domains including financial concerns means it is not as 
comprehensive. 
 
McGill Quality of Life Questionnaire and the McGill Quality of Life Questionnaire 
– Cardiff Short Form 
Developed to be suitable for use at all stages of cancer and other life-limiting 
illnesses, although originally tested in advanced cancer patients, the 17-item 
McGill Quality of Life Questionnaire is widely used within palliative care 
research. 338;424-426 It has strong psychometric properties including 
responsiveness to change. A particular feature is its inclusion of a number of 
items to measure existential issues, seen by the authors as crucial to HRQL in 
patients with progressive disease. The McGill Quality of Life Questionnaire 
does not, however, ask about specific symptoms, instead requesting 
respondents to list and rate the three most troublesome symptoms for them 
over the last two days. In the context of the present study, this may prevent 
the assessment of the association of particular concerns such as pain and 
breathlessness with SPC use. A shortened version, the McGill Quality of Life 
Questionnaire – Cardiff Short Form – has also been recently devised and 
tested in patients receiving palliative care. 427  
 
The McGill Quality of Life Questionnaire covers four general domains of 
HRQL (physical, psychological, existential and support), and defines quality 
of life as subjective well-being. 338 As noted above, physical symptoms are 
not, however, explicitly defined; instead, respondents are requested to list 
the three physical symptoms which have been the biggest problem over the 
last two days. The instrument places a particular focus on the existential 
aspects of HRQL, with items covering concerns about death, freedom, 262 
 
isolation and meaning. It also considers both positive and negative 
influences on quality of life. 425 McGill items were derived from patient 
interviews, a literature review, and existing HRQL instruments including the 
FLIC. 338 
 
The McGill questionnaire can generate a total score. Firstly, item scores are 
recoded where necessary to ensure that a score of 0 indicates the least 
desirable state, and a score of 10 the most desirable. If respondents state that 
they have no, or less than three symptoms, a score of 10 is assigned to each 
symptom item which indicates ‘none’. Sub-scale scores (physical, 
psychological, existential and support) are calculated by determining the 
mean of the items contained within each sub-scale. The total score is 
calculated as the mean of the scores of the four subscales and the physical 
well-being item. Therefore, each item, sub-scale and the total score can range 
from 0 to 10. 338 
 
The McGill Quality of Life Questionnaire is widely used within palliative 
care. However, when items were compared against the listed domains of 
need for SPC, the long form covered only 4 of the identified areas of need, 
and its short form only 2. This was in large part accounted for by its lack of 
items on specific symptoms. Additionally, the McGill includes a number of 
extra items with a particular focus on how purposeful respondents feel their 
life is, how good they feel about themselves, and how much control they 
have over events. These were not identified as key domains of need for SPC.  
 
McMaster Quality of Life Scale 
Also developed to assess HRQL in palliative care patients, the 32-item 
McMaster Quality of Life Scale covers dimensions including physical 
symptoms, functional status, social functioning, emotional status, cognition, 263 
 
sleep and rest, energy and vitality, general life satisfaction and meaning of 
life. 428. It has good psychometric properties in patients with advanced 
disease; symptoms and issues were derived from monitoring patients under 
palliative care teams.  
 
The developers of the McMaster Quality of Life Scale define HRQL as 
covering four key dimensions: physical, emotional, social and spiritual. 428 
Items for the instrument were initially generated by an expert panel of 
palliative care specialists and a researcher, based on a review of the 
literature. Symptoms of palliative care patients were also monitored and 
included within the instrument before psychometric testing was undertaken.  
 
The instrument asks respondents to rate their experience over a list of areas, 
covering key physical symptoms (including pain, nausea and vomiting, 
breathlessness), activities of daily living, social interaction and issues such as 
meaning of life and future planning. Its time frame is the past day as the 
developers argue palliative care patients may change rapidly. 
 
The instrument generates a total score. Values on the 7-point response scales 
are recoded so that all items are rated in the same direction, with 1 being the 
most negative response and 7 the most positive response. An overall score 
can then be calculated by simple addition; scores for two subscales (physical 
and non-physical) can also be calculated. Adjustment was made by the 
instrument authors for missing items by dividing the total scores by the 
number of items rated, and then multiplying by 32, the maximum number of 
possible responses. 428 
 
Content appraisal of the instrument against the identified major domains of 
need for SPC found that the McMaster scale had the most extensive 264 
 
coverage, including 20 of the 30 need dimensions. This extensive coverage, 
together with the ability to calculate a total score, suggest this instrument 
may be well suited to use as an indicator of need.  
 
Choice of HRQL instrument as an indicator of SPC need 
Of the six shortlisted instruments reviewed above, inevitably none cover all 
the potential domains of need for SPC identified through my ethnographic 
study. Five domains of need are excluded from all instruments (ascites, 
incontinence, urinary problems, deteriorating condition, and living alone). 
Whilst the first three symptoms are not major indicators of need, the concept 
of a deteriorating condition is a powerful determinant of continuing SPC 
input. Living alone is also, in the presence of uncontrolled symptoms, a 
potential trigger of specialist care. However, it is possible that information 
on these latter two may be gathered from patient report and medical records. 
This is discussed further in the following chapter. 
 
Two instruments, the EORTC QLQ-C30/LC13 and the McMaster Quality of 
Life Instrument, cover the identified domains of need in most detail. 
However, the most comprehensive coverage is within the McMaster Quality 
of Life Instrument. Further, in comparison to the multiple scale scores 
derived from the EORTC QLQ-C30, the McMaster provides a total score 
which could more readily be used to reflect need for SPC. It is not as 
extensively tested or used as the EORTC, though its authors claim it reaches 
acceptable levels of reliability, validity, and acceptability. Thus, of the two, I 
decided to use the McMaster QLI as an indicator of need for SPC within the 
cross-sectional survey of lung cancer patients. However, its performance 
would require thorough testing through a piloting process to ensure it was a 
suitable instrument for use within this setting and population.  
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Assessing carer anxiety and distress 
I add a final note here on the role of carer anxiety and distress in determining 
need for SPC. Whilst carers’ issues were rarely central to discussions about 
referrals to SPC, they were a common and noticeable presence as the needs 
of patients were being considered. A carer who was not coping led to 
concerns about the unmet needs of patients. The role of carers was formally 
recognised in the referral scoring system used within RS1 to prioritise 
inpatient referrals, which included a score for carer emotional and 
psychological stress. A high carer score (the maximum of three) could ensure 
that a particular referral was prioritised for inpatient care over other 
patients. Thus, carer psychological needs form one, important, aspect of a 
patients’ overall need for SPC, and this was recognised within the 
framework of SPC need derived from my observations.  
 
The role of carer stress in determining need for SPC meant that I aimed, 
within the cross-sectional survey, to recruit carers as well as patients. I 
planned to use carer data in an exploratory analysis considering the 
association between carer stress and SPC use. Inevitably, carer stress is not 
assessed within HRQL instruments aimed at patients. A suitable instrument 
to measure carer stress was therefore required. A comprehensive systematic 
review of self-report caregiver instruments used in cancer had already been 
recently undertaken. 434 This identified 28 instruments in three categories: 
caregiver burden (17 instruments), caregiver needs (8 instruments) and 
caregiver quality of life (3 instruments). Following the appraisal of 
instruments for their psychometric properties and likely ease of 
administration, the authors made a number of recommendations for the 
most appropriate instruments to use in each category. In the area of 
caregiver quality of life, Weitzner’s Caregiver Quality of Life Index – Cancer 266 
 
(CQOLC) was recommended as being rigorously developed and extensively 
tested. 435;436 
 
The CQOLC is a 35 item instrument using a 5-point Likert scale. Items cover 
a multi-dimensional concept of quality of life, including emotional and 
psychological distress, activities of daily living, relationship with the patient, 
social support, and financial concerns. It has been demonstrated to have 
adequate validity, test-retest reliability and internal consistency. 435;436 
However, its development remains confined to the US hospice care system, 
and it has thus not been validated for use within a UK setting. Further, its 
ten-minute completion time may be excessive when the particular domain of 
need I wished to assess was caregiver stress, rather than a multi-dimensional 
concept of quality of life. 
 
In the light of these concerns, I therefore considered alternative instruments. 
Following discussion with experts and practitioners in the field, I decided 
that the General Health Questionnaire 12 item version (GHQ-12) was 
suitable to take forward into the piloting process. The GHQ was developed 
as a screening instrument to detect general psychological distress, and is 
used worldwide in both healthy and ill populations. 437 The shortest version, 
the GHQ-12, has been found to be as robust as longer versions. 438 It was 
designed to be self-administered, and comprises twelve questions covering 
the respondent’s experience of anxiety and depression, general level of 
happiness, and sleep disturbance. Its specific focus on psychological distress 
and its short completion time recommended it as the most suitable 
instrument within the exploratory study on carer stress and SPC use.  267 
 
6.5 Conclusions  
In this review and critical appraisal of HRQL instruments developed for use 
in lung cancer and palliative care populations, I considered the psychometric 
properties, conceptual relevance, and applicability of a range of instruments 
in searching for a valid and reliable indicator of need for SPC. Many 
instruments were poorly psychometrically tested, and were thus excluded 
from further consideration. Of those which met minimum standards of 
reliability and validity, few were suitable for use in cancer patients at all 
stages of disease, and covered a truly multidimensional concept of HRQL.  
 
However, through this review and appraisal I did locate more than one 
instrument which is both well matched to the identified criteria of need for 
SPC, and has undergone sufficient psychometric testing. I chose the 
McMaster QLI to take forward to the pilot study of SPC use. In spite of the 
existence of a number of instruments designed to assess the needs, burden 
and quality of life of carers of cancer patients, concerns with their validity 
and suitability led me to choose the GHQ-12 as an approach to assessing 
carer stress.  
 
In the next chapter, I describe the cross-sectional survey methods used to 
determine use of SPC in relation to age, after controlling for need. I explain 
the study setting, design and piloting of the study instruments. I then outline 
the conduct of the study, including determination of the sample size, 
recruitment, and data preparation and analysis. Finally, I present my 
findings on the equity of use of SPC within the study setting, and relate these 
to previous research on variations in use of SPC.  268 
 
Chapter 7 
 
Equity of use of specialist palliative care: cross-sectional survey 
 
All animals are equal but some animals are more equal than others. 
 
George Orwell. Animal Farm. 439 
 
 
The NHS Cancer Plan states that ‘all patients should have access to the 
specialist palliative care advice and services that they need.’ 13 The NSF for 
Older People highlighted concerns that older people may have more limited 
access to SPC services in comparison to younger patients. 7 This point was re-
iterated in later reports from the House of Commons Health Committee on 
Palliative Care, and WHO Europe. 18;440 A systematic review of referral to and 
use of SPC services in relation to age, conducted as background to this study, 
found that there was evidence of inequalities for older patients. 15 All of the 
studies included in the review reported a statistically significant lower use of 
SPC among older cancer patients (predominantly aged 75 and above) at a 
univariable level (crude odds ratios ranged from 0.33 (0.15 to 0.72) to 0.82 
(0.80 to 0.82)). 102;119-121;123-126;128-131;133;134 
 
However, these studies did not comprehensively investigate and control for 
patients’ clinical and psycho-social needs for care. Therefore, we cannot 
draw reliable conclusions about the extent to which use of SPC is equitable 
(reflects the need for care) for older patients. 22 Furthermore, studies have 
rarely considered the needs of carers as well as patients in determining use, 
in spite of the stated aim of SPC to improve quality of life for patients and 
their families. 27  269 
 
Prospective research on the use of SPC by cancer patients is challenging, due 
to the terminal nature of illness, fear of burdening participants, loss of data 
due to participants’ incapacity or death, and ethical considerations on 
research within such a vulnerable population. 441 Rather than the non-
investigation of this area, these complications necessitate the design of high 
quality research with careful data collection and analysis. 221 In particular, 
researchers need to pay special attention to the handling of missing data, 
which is frequently missing not at random due to the deterioration of study 
participants: the choice of imputation method and its effect must be reported 
in full. 442 The strongest observational study design, a prospective cohort 
study, enables data to be gathered on the whole patient pathway from 
diagnosis to death. This may be particularly important in examinations of 
use of SPC as (a) access may depend on treatment decisions made on 
diagnosis, and the subsequent care pathways patients follow, and (b) SPC 
may only be used in the terminal phases (even the last few days) of a 
patient’s illness.  
 
To achieve the most reliable and complete understanding of equity of use of 
SPC, I initially planned a prospective cohort study. I aimed to recruit and 
follow up older and younger groups of cancer patients, and their carers, to 
determine use of and need for SPC services over the course of their treatment 
and care. However, a series of meetings with cancer nursing professionals, 
and the observation of the conduct of two cancer outpatient clinics, raised a 
number of questions about the viability of conducting a cohort study [Table 
7.1].  270 
 
 
Table 7.1 Issues in the conduct of a prospective cohort study 
Design issue  Concern arising 
Optimal time to 
recruit patients 
Patients referred to SPC before definitive diagnosis would be 
excluded as already have outcome of interest at baseline. Sampling 
bias may arise if younger patients more likely to be referred at this 
stage 
Frequency of follow-
up 
Patients may be too ill or have died before first follow-up. A check on 
status would therefore be necessary with GP or lung nurse before 
each contact 
Conduct of follow-up 
Maintaining recruitment and follow-up within the necessary sample 
size may be difficult with only one researcher. Calculations show at 
peak data collection likely to be insufficient time to recruit and 
conduct follow-ups 
Measuring need 
Would have to use carer report on need during last stage of patient’s 
life, compared to patient report at earlier stages. Concerns include 
(a) ethical issues in discussing post-bereavement interviews at 
recruitment to study early in disease course, and (b) difficulties in 
reconciling carer versus patient reported need 
 
In the light of these challenges, I explored the alternative of a cross-sectional 
study. Cross-sectional studies determine a participant’s exposure and 
outcome of interest simultaneously, usually at one point in time. 443 They are 
frequently less resource-intensive than cohort studies. A cross-sectional 
study would involve the recruitment of older and younger groups of cancer 
patients to determine their current need for and use of SPC services at the 
time of participation. 
 
A major limitation of cross-sectional designs is the difficulty in establishing a 
causal relationship between the exposure and outcome of interest, as both 
are measured at the same point in time. 444 Difficulties in interpretation may 
arise as it is not possible to know the direction of the association; is the 
exposure responsible for the outcome, or is the outcome responsible for the 
exposure? However, for the topic under consideration, the primary exposure 
of interest is a personal characteristic (age). Difficulties in understanding the 
direction of any association do not therefore arise, as use of SPC cannot 
influence age. What cannot be assessed is whether there are delays in referral 271 
 
to or use of SPC in relation to age. However, within the available resources, a 
cross-sectional study became the chosen approach.  
 
In this chapter, I report in detail the design of my study to assess equity of 
use of SPC in relation to age. I outline the process of setting up the study, 
selecting outcome and explanatory variables, piloting instruments and 
approaches and calculating the required sample size. Full details of the data 
collection procedure and the data analysis undertaken are given. Next, I 
outline the major results from the survey, covering the characteristics of the 
sample, the proportion using SPC services, and the factors associated with 
the receipt of such care. Finally, I consider the strengths and weaknesses of 
the study, the results in comparison with existing literature, and offer a final 
summary and interpretation of the findings.  
 
7.1 Aim and objectives 
The aim of this phase of work was to investigate equity of use of SPC 
services in relation to age.  
 
I decided to conduct my research amongst lung cancer patients. This was for 
three simple reasons: lung cancer has a high incidence, a short prognosis, 
and a frequently heavy symptom burden. Ready access to a relatively large 
population of newly diagnosed patients (lung cancer diagnoses represent 
around 13% of all cancer diagnoses 254) enables a swifter achievement of the 
desired sample size. A short prognosis (around 25% of patients diagnosed 
with lung cancer are alive one year later 254) increases the likelihood that 
referrals to SPC will be made earlier in the disease course. Finally, the 
difficulties of managing lung cancer symptoms, which are often complicated 
by the presence of comorbidities such as COPD, suggest an important role 
for SPC in a large proportion of cases. 250 272 
 
The objective of this research was thus to conduct a cross-sectional survey to 
measure the use of SPC services by younger (< 75) versus older (≥ 75) lung 
cancer patients, after controlling for need.  
 
This aim is confined to horizontal equity (equal use for equal need) rather 
than vertical equity (unequal use for unequal need). Investigation of aspects 
of vertical equity – for example, the association of use of SPC with age after 
controlling for need at each level of severity of lung cancer – requires 
multivariable analyses with effect modification. Subsequently, a much larger 
sample size is required. Whilst comprehensive studies into equity should 
consider both dimensions, 70 due to time and resource limitations within the 
current research it was not feasible to include a vertical component.  
 
Further, I did not set out to investigate the relationship between age and 
need for SPC. One possible explanation for a lower use of SPC by older 
patients is that their need for SPC is also lower. Little research has been 
conducted in this area, and the specific relation of a measure of need to use 
of SPC would thus be useful. However, this would of necessity be secondary 
to the principal aim of this study, and be undertaken on an exploratory basis. 
The sufficiency of the proposed sample size to achieve this was questionable, 
and thus I decided to exclude this from the analysis.  
 
7.2 Study design 
 
Investigation and choice of setting 
As discussed in Chapter 4, the diagnosis and treatment of lung cancer can 
take a number of paths. To conduct a comprehensive study of variations in 
use of SPC by lung cancer patients, ideally recruitment would cover all 
potential settings, including primary care, A&E, inpatient hospital, and 273 
 
outpatient hospital [Figure 7.1]. This would ensure that, however patients 
were diagnosed and whatever subsequent treatment they received, they 
were included in the assessment of equity of use.  
 
However, to conduct a viable study of the use of SPC within the resources 
available, it was not possible to recruit lung cancer patients from multiple 
settings. NICE guidance on the diagnosis and treatment of lung cancer states 
that patients with suspected lung cancer should be referred to a member of 
the lung cancer multi-disciplinary team, usually a chest physician, for further 
investigation and diagnosis. 237 Unless the patient is already a hospital 
inpatient when the suspected diagnosis is raised, these referrals are routinely 
seen within the outpatient setting. To reflect NICE recommendations, I 
therefore chose to include only those patients attending outpatient lung 
cancer clinics. These clinics include both chest and oncology clinics, 
depending on whether patients are being diagnosed, treated or followed-up. 
I therefore excluded from this study all patients who did not attend lung 
cancer outpatient clinics. The limitations arising from this choice of study 
setting are considered further in the discussion at the end of this chapter. 
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Participating clinics 
I chose lung cancer outpatient clinics from within the cancer network in 
consultation with the participating cancer research network. As a Medical 
Research Council (MRC) funded project, the study was automatically 
included within the cancer research network’s official portfolio of research. 
GP  A&E 
Hospital 
Inpatient/outpatient 
Diagnosis 
Radiology/pathology/ 
bronchoscopy 
Active treatment 
Surgery/radiotherapy/ 
chemotherapy 
Palliative treatment 
Hospital/hospice/ 
community 
Follow-up  Discharge 
Recurrence 
Figure 7.1 Lung cancer diagnosis and treatment pathway 
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Studies within this portfolio are coordinated to avoid patients being over-
researched. Whilst there were no other epidemiological or health services 
research studies recruiting lung cancer patients at the same time as this 
study, there were a number of long-standing clinical trials recruiting from 
the two clinics which had a research nurse (the cancer centre and one of the 
cancer units). It was therefore agreed with the cancer research network that, 
whilst I could recruit from these clinics, I would not approach patients 
already participating in a clinical trial.  
 
There are six NHS Trusts providing lung cancer outpatient services within 
the network, organised as four cancer units and one cancer centre. Figure 7.2 
shows the lung cancer outpatient clinics chosen to participate in the study. 
The cancer centre spans two NHS Trusts, one of which has two hospitals. 
Within the cancer centre, dedicated lung cancer clinics take place at two of 
the three hospitals. I chose to recruit only from one of these hospitals, 
selecting the hospital which ran the major lung cancer clinic for the centre. 
Three of the four cancer units within the area were then selected to 
participate in the study, chosen to reflect different geographical locations 
within the network.  
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Each of the four participating sites varied in their lung cancer clinic 
organisation and the medical specialties available to treat patients. These are 
summarised in Tables 7.2 and 7.3.  
 
Table 7.2 Summary of lung cancer clinics at participating sites 
Site  Type  Chest clinic  Medical oncology 
clinic 
Clinical oncology 
clinic 
1  Cancer unit  ￿ weekly  ￿  ￿ weekly 
2  Cancer unit  ￿ weekly  ￿  ￿ referred to site 3 
3  Cancer centre  ￿ weekly  ￿ twice weekly  ￿ weekly 
4  Cancer unit  ￿ weekly  ￿  ￿ twice weekly 
 
 
CANCER 
UNIT: 
 
NHS 
TRUST 6 
 
CANCER 
UNIT: 
 
NHS 
TRUST 5 
 
CANCER 
UNIT: 
 
NHS 
TRUST 4 
NHS TRUST 2 
NHS TRUST 1 
CANCER CENTRE 
Hospital A  Hospital B 
 
CANCER 
UNIT: 
 
NHS 
TRUST 3 
Figure 7.2 Participating lung cancer clinics within the cancer network 
KEY: 
Participating 
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Table 7.3 Details of lung cancer clinics at participating sites 
  Site 1  Site 2  Site 3  Site 4 
Type of clinic  Cancer unit  Cancer unit  Cancer centre  Cancer unit 
Services 
offered 
Respiratory medicine & clinical 
oncology  Respiratory medicine  Respiratory medicine, clinical 
oncology, medical oncology 
Respiratory medicine & clinical 
oncology 
Times of 
clinics 
One day a week (morning lung 
clinical oncology list; afternoon 
clinical oncology and respiratory 
medicine) 
One day a week 
Three days a week. Main clinic 
runs all day: respiratory 
medicine, clinical & medical 
oncology. Second weekly 
oncology clinic. Third weekly 
oncology clinic for site 2 
referrals. 
 
Two clinics a week. Small 
clinical oncology list one 
afternoon; main respiratory 
medicine & clinical oncology 
clinic another day. 
 
Patients seen 
Suspected & diagnosed lung 
cancer patients. Other cancer 
site & respiratory patients seen 
occasionally. 
Mixed: suspected & diagnosed 
lung cancer patients and other 
respiratory patients.  
 
Mixed: suspected & diagnosed 
lung cancer patients and other 
respiratory patients.  
Thymoma & mesothelioma 
cases, although separate 
mesothelioma clinic also run.  
 
Mixed: suspected & diagnosed 
lung cancer patients and other 
respiratory patients. Clinical 
oncology not exclusively lung 
cancer; colorectal & some other 
cancer sites. 
Treatment 
offered 
Chemotherapy on site. 
Radiotherapy referrals to cancer 
centre.  
 
Chemotherapy only for SCLC 
patients. NSCLC chemotherapy 
& all radiotherapy referrals to 
cancer centre.  
 
Offers most possible 
chemotherapy &radiotherapy 
regimes. 
 
Chemotherapy primarily for 
SCLC patients. Most NSCLC 
chemotherapy & all 
radiotherapy referrals to cancer 
centre.  
 
Lung MDM  Lunchtime on clinic day.  Morning prior to clinic. 
 
Morning prior to main weekly 
clinic. 
 
Morning prior to main weekly 
clinic. 
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Due to clashes in the timing of clinics, I was not able to recruit from every 
clinic run at the research sites. In particular, sites 2 and 4 run their clinics on 
the same day. I therefore recruited from these in two phases, concentrating 
on recruiting from site 2 for three months before switching to recruit from 
site 4. Table 7.4 summarises the weekly timetable of clinics attended. 
 
Table 7.4 Timetable of attended lung cancer outpatient clinics 
  Monday  Tuesday  Wednesday  Thursday  Friday 
AM  Site 2 / Site 4  -  Site 1  -  Site 3 
PM  Site 2 / Site 4  Site 3  Site 1  -  Site 3 
 
Participants 
Patients were eligible for inclusion in the study if they had a histologically or 
clinically confirmed diagnosis of primary lung cancer (NSCLC or SCLC) and 
the ability to fully understand consent procedures and complete study 
instruments in English. 
 
I developed ineligibility criteria in consultation with clinic staff, to avoid 
distressing patients at particularly sensitive times. There were two categories 
of ineligibility; (i) patients ineligible at that point in time, who may become 
eligible in the future, and (ii) patients who were and would remain 
ineligible. The former category included patients receiving diagnoses or 
news on disease progression, or who required immediate medical attention. I 
did not feel it was suitable to approach these individuals at that point in 
time. However, on attendance at future clinics they were eligible to be 
approached. The latter category, those who were permanently ineligible, 
included patients attending participating clinics who were unable to 
communicate in English, who were participating in a clinical trial, or who 
did not have a diagnosis of primary lung cancer. Full details of the 
ineligibility criteria are in Table 7.5. 279 
 
Table 7.5 Ineligibility criteria 
Patients not approached but who may become eligible at a later clinic 
Category  Explanation 
Under investigation for lung cancer  If diagnosed, will become eligible at future clinic visits. 
New diagnosis of lung cancer 
It was not possible or appropriate to approach patients on the day of diagnosis. Additionally, it was not 
felt to be ethical to approach patients who were still unsure about their future course of treatment and 
likely prognosis. A small proportion of these patients will go on to have surgical intervention for their 
lung cancer and thus remain ineligible for the study.  
Lung cancer diagnosis but receiving 
test results on disease progression 
Those attending clinic for the results of tests as to whether their disease had progressed (e.g. the 
discovery of metastases or new metastases, or relapse following treatment) may be particularly 
anxious and distressed. It was not felt to be appropriate to approach them at this time.  
Lung cancer diagnosis but too ill or 
distressed 
This category included both physical and mental health issues which rendered patients unsuitable to 
approach for participation in the study. Patients in this category were usually identified by clinic staff, 
and included those with psychiatric issues. A small proportion of patients attend outpatient clinics 
requiring urgent medical attention and inpatient admission. In all cases, it was not appropriate to 
approach such patients about this study.  
Ineligible patients at time of screening for study: will remain ineligible 
Category  Explanation 
Non English speaker  It was not possible within the resources of the study to provide interpreters for those patients who were 
unable to communicate in English. 
Complete surgical resection of 
histologically confirmed lung cancer, 
with or without adjuvant therapy. 
Patients who had undergone surgery with the aim of cure. Patients who had previously undergone 
surgery but had relapsed were eligible for the study. 
Not aware of [usually clinical] 
diagnosis of lung cancer  If patients were unaware of their diagnosis, it was not possible to approach them about the study.  
Participating in a clinical trial 
Such patients do not receive standard care, as they are treated according to a strict protocol and are in 
regular contact with a dedicated research nurse. Therefore, their inclusion in an observational study 
would not be appropriate. 
Not lung cancer patients 
Patients with mesothelioma, with other primary cancers (including those with cancers which had 
metastasised to the lung), and with other respiratory illnesses also attended these clinics, and were 
excluded. 280 
 
The ethnographic work I conducted in phase one identified that informal 
carer’s needs may be taken into account when defining patient’s need for 
SPC. In particular, carer stress was included in documentary assessments of 
need for SPC. Therefore, I also approached informal carers (including 
spouses, partners, other family members or friends) who attended clinics 
with eligible patients to ask if they would participate in the study. 
 
Identification of eligible participants 
I identified potential participants prior to the start of each clinic from the 
clinic appointment list, and by additional screening of clinic notes [Figure 
7.3]. I marked eligible patients on the clinic clerk’s lists to alert them that I 
wished to approach these patients about the study. This helped in the 
identification of eligible patients as they arrived in the clinic. 
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Recruitment procedures 
I used identical recruitment procedures in all four clinics. On their arrival in 
the clinic waiting area I identified all eligible patients and their carers 
(sometimes with the help of clinic staff), and approached them to introduce 
myself and the study. I explained the aim and nature of the study verbally 
and answered any questions. Patients and carers who expressed an interest 
Clinic list obtained and patient 
names copied onto daily 
recruitment sheet 
Clinic list codes and/or 
‘comments’ screened 
EXCLUDED: 
• New patients – under 
investigation or new diagnoses 
Clinic list compared to print out 
of study database 
EXCLUDED: 
• Previous participants 
• Previously identified ineligibles 
Clinic list compared to multi-
disciplinary team meeting list 
for that week 
EXCLUDED: 
• Lung cancer but receiving test 
results re e.g. progression 
Medical notes of patients 
remaining on recruitment sheet 
screened 
EXCLUDED: 
• Not lung cancer 
• Still under investigation 
• Lung ca but curative treatment 
• Lung ca but not aware 
• Lung ca but too ill / distressed 
• Lung ca but non English 
speaking 
Final clarification of queries 
with clinic nurse or medical 
staff 
EXCLUDED: 
• Too ill / distressed 
• Receiving test results 
Figure 7.3 Determining eligible patients in each clinic 282 
 
in participating then received individual study information packs containing 
an information sheet, consent form and the relevant questionnaire. I asked 
patients and carers to read through the information about the study and 
complete the consent form and study measures whilst in the clinic, usually 
prior to seeing the doctor. Those who expressed an interest in participating, 
but wished to complete the instruments following the clinic, were provided 
with a freepost envelope to enable them to return questionnaires once 
completed. As far as possible, however, I obtained written consent from such 
participants whilst in the clinic, to enable me to extract data from their notes.  
 
I asked participants to complete the study measures themselves where 
possible. However, I offered patients or carers who had difficulties reading 
or writing due to visual impairment or disability the option of being read the 
questions and writing down their answers. This could be with a family 
member or friend who was attending clinic with them, or with me.  
 
Following completion of the study instruments by the patient, and the 
receipt of a completed consent form, I extracted further data from the 
patient’s medical notes using a form I developed and piloted for this purpose 
(Appendix V, page 460). Data extraction usually took place at the end of a 
clinic, after the patient had seen the doctor. This allowed for any decision to 
refer to SPC on that occasion to be noted, as the doctors wrote up all clinic 
encounters by hand in the patient’s notes. 
 
Consent 
I asked patients and carers to read through the information about the study 
and complete the study measures whilst in the clinic, if possible. Their 
consent to participate was recorded through their completion of a written 
consent form (see appendix V, page 435), including a section in which 283 
 
patients agreed to me obtaining additional demographic, diagnosis and 
treatment information from their medical records. This was a non-
intervention study involving the collection of basic demographic, health 
status and health service use data at one point in time only. Consent during 
attendance at the clinic followed the procedure of previous similar studies. 106 
I was present throughout every clinic and therefore available to answer any 
questions patients may have had. 
 
Ethical considerations and concerns 
There is ongoing debate about the ethical questions posed by research 
involving patients with palliative care needs, and their carers. Expressed 
concerns centre around the physical and emotional health of patients and 
their capacity to give informed consent; placing demands on their time at the 
end of their life; the probability of patients feeling ‘coerced’ to participate; 
and the likelihood for participants to directly benefit (or not) from the 
research. 445 However, the concern that research places an unacceptable 
burden on patients with palliative care needs is challenged by evidence that 
such patients and their carers welcome the opportunity to take part and use 
their experiences to potentially benefit others. 446;447 Additionally, it has been 
argued that patients nearing the end of life have the same rights to choose to 
participate in research as all other patients. 448 The skills of the researcher are 
frequently identified as crucial in ensuring palliative care research is 
conducted in an appropriate, sensitive and rigorous fashion. 449  
 
I endeavoured to involve health care professionals and patients in the design 
of the survey to ensure all ethical issues were highlighted and addressed. 
Lung cancer CNSs provided advice and support from an early stage. I also 
obtained advice from the User Involvement Partnership Facilitator in the 
cancer network as to how best to gain the advice of patients and carers, 284 
 
particularly on the planned recruitment procedures and the content of the 
study materials. Following her recommendations, I distributed information 
about the study to the local user involvement partnership groups, and more 
widely to users through the Cancer Voices Opportunities for Involvement 
Scheme. Despite these efforts, no patient or carer came forward locally to 
become involved. This perhaps reflects the particular challenges in involving 
patients with advanced cancer in research. 450 However, four patients 
recruited via Cancer Voices were able to offer advice on the proposed design 
and conduct of the survey.  
 
As I had not been able to consult with patients and carers as extensively as 
hoped in the initial design stages of the project, a pilot phase of the survey 
was used in part to test and amend the study information and instruments in 
consultation with patients and carers in the participating lung cancer clinics. 
The pilot testing was, as a result, more extensive than originally envisaged, 
and considered not only the study instruments but also the research 
processes put in place. The pilot, with 18 patients and 16 carers, found no 
major concerns from participants in the procedures used to explain the study 
and gain informed consent. It did, however, give rise to concerns about the 
HRQL instrument initially chosen as an indicator of need for SPC, the 
McMaster Quality of Life instrument; this is discussed further in section 7.3, 
below. Full details of the pilot methods and results are in appendix IV, page 
423. 
 
The information sheet used throughout the study covered the following: 
 
•  the purpose of the study 
•  the study methods, and what their participation would involve 285 
 
•  that participation was purely voluntary and that they were free to 
withdraw from the study at any time and without giving any reason 
•  that any decision they make about participation would not affect their 
future health care or work in any way 
•  that their data would be kept strictly confidential in accordance with 
the Data Protection Act 1998, and would never be used in a way 
which would identify them personally 
•  that the research had been given a favourable opinion by the 
appropriate Research Ethics Committee and that all research carried 
out within the study would conform to strict ethical guidelines 
 
Additionally, all participants had the opportunity to discuss any concerns 
prior to giving written consent. My presence in the clinic, enabling 
participants to answer questions and clarify issues arising, was a particular 
strength of the recruitment process.  
 
I sought and received ethical approval for this phase of work from St 
Thomas’ Hospital NHS Research Ethics Committee. I gained research 
governance approval separately from each of the four participating Trusts. 
As a result of this process, I received an honorary contract with each Trust to 
enable me to attend clinics to carry out the research.  
 
Recruitment period 
Recruitment to the study took place over two time periods. The first phase of 
recruitment took place over three months from 19 June to 13 September 2006. 
At this point, due to the personal reasons outlined in the Preface, I 
temporarily halted data collection. This interruption did, however, also have 
the benefit of enabling a new cohort of patients to come through; by 
September 2006 the majority of eligible patients attending clinics had 286 
 
participated in the study and recruitment numbers had therefore dropped. 
The second three month period of recruitment took place from 30 January to 
27 April 2007, at which point I ceased recruiting as I had achieve the desired 
sample size of 250. 
 
7.3 Study instruments and variables 
Participating patients and carers completed a semi-structured questionnaire 
compiled for the purposes of this study (see Appendix V, page 439 for the 
text of the patient questionnaire, and page 453 for the carer questionnaire). 
The patient questionnaire included 25 items covering their stated diagnosis 
and other illnesses, their use of health care services for lung cancer, and 
personal details (based on items developed for the National Survey of NHS 
Patients by the Picker Institute Europe and others). 451 In addition, the patient 
questionnaire included a validated HRQL instrument, the EORTC QLQ-C30, 
and its lung cancer module the LC-13. 431;452  
 
This was not the initial choice of HRQL instrument to use as an indicator of 
need for SPC following my systematic review and content appraisal 
described in Chapter 6. In the pilot study, I used the McMaster Quality of 
Life instrument, as this had the most comprehensive coverage of domains of 
need for SPC and enabled the calculation of a total score to use as an 
indicator of need for care. 428 However, the piloting process [described in full 
in Appendix IV, page 423] found this to be unsuitable for use in the main 
cross-sectional survey for four reasons: 
 
1.  There was a high proportion of missing data, with only 8/18 (44%) of 
respondents completing all items on the scale.  
2.  Patients had difficulty in understanding the 1 to 7 scoring system, 
often asking for assistance.  287 
 
3.  Items on being bedridden and on employment were seen as 
unsuitable by a number of pilot participants.  
4.  There was a tendency for respondents to use either anchor (1 or 7) as 
their response, leading to skewed distributions.  
 
For these reasons, I switched to using the EORTC-QLQ C30 with the LC13 
module in the main study. As outlined in Chapter 6, these instruments also 
had good coverage of domains of need for SPC. Whilst they do not enable 
the calculation of a total score, the developers of the QLQ-C30 recommend 
the use of the global quality of life scale score as a suitable indicator of 
overall quality of life. This is comprised of two items; a rating of overall 
health and of overall quality of life. This was used as an indicator of need for 
SPC, as described in full later in this Chapter. The time taken to complete the 
patient questionnaire ranged from ten to 30 minutes.  
 
The carer questionnaire comprised 13 items covering their relationship with 
the patient; help they gave to the attending patient; and their personal 
details. It also included the General Health Questionnaire 12 item version 
(GHQ-12) as an indicator of general psychological distress. The carer 
questionnaire took an average of five minutes to complete.  
 
Choice of outcome and explanatory variables 
Prior to the commencement of the study I chose and defined the outcome 
and key explanatory variables to investigate, based on previous research in 
the area and the results of the ethnographic study. These were derived from 
patient and carer questionnaires and medical records. These are outlined in 
Table 7.6, and explored in more detail below. 288 
 
 
Table 7.6 Explanatory variables 
Variable  Defined as  Categories  Source of data 
Need for SPC  EORTC-QLQ C30 global quality 
of life score 
Continuous 
score 
Patient 
questionnaire 
Age  Time between date of birth and 
date of study participation 
Over / under 
75  Medical records 
Gender  -  Male / female  Patient 
questionnaire 
Ethnicity  Census categories  White / non-
white 
Patient 
questionnaire 
Living alone  -  Alone / living 
with others 
Patient 
questionnaire 
Socioeconomic 
characteristics 
Index of Multiple Deprivation 
rank based on postcode of 
residence 
Tertiles  Patient 
questionnaire 
Extent of disease  Number and site of metastases  None / 1 or 
more  Medical records 
Treatment received  Current line of treatment  1
st / 2
nd or 3
rd   Medical records 
Known 
comorbidities 
Recorded as having one or more 
from seven groups of relevant 
comorbidities 
0, 1 or ≥ 2  Medical records 
Treating clinic  Current location of care  Clinic 1-4  Medical records 
Diagnosing clinic  Initial location of care  Clinic 1-7  Medical records 
Carer stress  GHQ-12  Continuous 
and binary 
Carer 
questionnaire 
 
Outcome: use of specialist palliative care 
The outcome of interest was use of SPC. I did not attempt to measure access 
to SPC, even though (as highlighted in Chapter 2) it is the facilitation of the 
equal opportunity to use health care, rather than just the equal use of health 
care, which is the ultimate goal of the NHS’s commitment to equality. 453 
However, a true assessment of access requires an investigation both of 
utilisation rates, and of factors which may affect these utilisation rates. For 
example, the offer of SPC to a patient who subsequently declines this service 
should be included within a measure of access to SPC, but obtaining data 
such as these would be challenging.  
 
I defined use as being on the caseload of a community SPC team, attending a 
hospice day care unit, or receiving SPC on an outpatient basis. Patients 289 
 
classified as using SPC were therefore currently receiving advice and 
support from clinical nurse specialists, clinicians and other members of the 
multidisciplinary SPC team, whether by telephone, at home or in the 
outpatient setting. Patients who had been discharged from SPC by the time 
of study participation were not classified as current users.  
 
Primary explanatory variable: Age of patient 
My primary explanatory variable was patient age, dichotomised as ‘younger’ 
and ‘older’. ‘Old age’ is frequently defined as being 65 years of age or older, 
as in the National Service Framework for Older People. 7 However, I chose 
75 as the threshold for older age, for two reasons. Firstly, previous research 
on the influence of age on lung cancer treatment has identified patients aged 
75 and above as the group least likely to receive active treatment, as well as 
those least likely to received SPC. 15;454 Secondly, lung cancer is frequently 
diagnosed at an older age, commonly between 70 and 74.  
 
Quality of life / need for specialist palliative care 
To measure need for SPC, I used two, linked patient-completed HRQL 
instruments, the EORTC QLQ-C30 and the LC13. Specifically, need for SPC 
was operationalised as global quality of life score derived from the QLQ-
C30. This is a continuous rather than a dichotomous measure, reflecting my 
ethnographic findings which suggested the strict categorisation of patients 
into ‘need’ and ‘no need’ for SPC may be problematic. Drawing on my 
ethnographic findings, I also chose particular dimensions of HRQL (physical, 
emotional and social functioning, fatigue, pain, nausea and vomiting, 
appetite loss and dyspnoea) as indicators of specific dimensions of need for 
SPC to examine in an exploratory analysis of the association of these with 
SPC use.  
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Extent of disease 
Extent and severity of disease may influence referral to SPC, as patients with 
advanced cancer may have the highest need for symptom control. 19 As 
NSCLC and SCLC are staged differently, I categorised extent of disease 
simply as the presence or absence of metastases at the time of participation 
in the study.  
 
Comorbidity 
Comorbidity is an important determinant of treatment outcome and survival 
in lung cancer, and older lung cancer patients are significantly more likely to 
have multiple comorbidities. 455 I classified comorbidity based on categories 
used by Janssen-Heijen et al, in turn adapted from Charlson et al 243;456 [Table 
7.7]. This classification system identifies seven comorbidities or groups of 
comorbidities which may impact on treatment decisions and prognosis in 
lung cancer patients. It provides a standardised, clinically-driven approach 
to measuring comorbidity. I used this to calculate the number of clinically 
relevant comorbidities for each participant (grouped as none, one, and two 
or more). 
 
The clinically relevant comorbidities indexed using the Charlson approach 
include dementia, one aspect of which is cognitive impairment. Recognising 
that the prevalence of cognitive impairment increases with age, and that it 
has been associated with poorer survival rates in cancer patients, I 
considered screening separately for cognitive impairment. 457;458 However, the 
most commonly used screening measure for cognitive impairment, the Mini 
Mental State Examination, is observer-rated and can take ten minutes to 
complete. 459 With consideration of respondent burden and the increase in 
sample size required to include additional covariates in the analysis, I 
decided against introducing a separate measure of this.  291 
 
 
Table 7.7 Classification of comorbidity 
1.  COPD 
2. 
Cardiovascular diseases: 
Myocardial infarction, cardiac decompensation, angina pectoris, intermittent 
claudication, abdominal aneurysm 
3.  Cerebrovascular diseases: 
Cerebrovascular accident, hemiplegia 
4.  Other malignancies (except basal cell skin carcinoma) 
5.  Hypertension 
6.  Diabetes mellitus (medically treated) 
7. 
Other: 
Soft tissue diseases (Besnier Boeck disease (sarcoidosis), Wegener’s 
granulomatosis, SLE (systemic lupus erythematosis) 
Rheumatoid arthritis (only severe) 
Kidney diseases (chronic glomerulonephritis, chronic pyelonephritis) 
Bowel diseases (Crohn’s disease, ulcerative colitis) 
Liver diseases (cirrhosis, hepatitis) 
Dementia 
Tuberculosis 
 
Current line of treatment 
Whether a patient is receiving first, second or third line treatment for their 
lung cancer is an additional indicator of the duration and extent of their 
disease. I defined first line treatment as the initial therapy received following 
a diagnosis of lung cancer. Second line treatment was defined as the 
treatment offered if or when the disease had failed to respond to initial 
treatment, or on recurrence of the disease. Finally, I classified third line 
treatment as the therapy given to patients on the failure of second line 
treatment, or following the second recurrence of disease.  
 
Gender 
As the NICE Guidance on Supportive and Palliative Care states, the 
palliative care needs of patients should be assessed and addressed regardless 
of a patient’s gender (19 p.26). I therefore included gender as an explanatory 
variable, although at present there is no research evidence linking this to use 
of SPC. 
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Living alone 
My ethnographic findings suggested the possibility that patients living 
alone, and patients with young children, may be given a higher priority to 
receive SPC. I therefore asked participants how many other adults and 
children (<18 years of age) they resided with. However, whilst I anticipated a 
sufficient proportion of respondents may be living alone to enable this 
variable to be included within analyses, I was less certain that this would be 
the case for the proportion with children.  
 
Deprivation 
Deprivation, measured at both an individual and an area level, is associated 
with variations in use of a wide spectrum of health care services. 460 Socio-
economic deprivation has been associated with lower rates of treatment, and 
subsequently higher mortality rates, in lung cancer. 461 Research on the 
influence of deprivation on end-of-life care has primarily focussed on 
variations in place of death, with lower home death rates in more deprived 
areas. 462 To capture any influence of deprivation on variations in use of SPC, 
I included this as a potential explanatory factor.  
 
I assigned deprivation level to patients using the Index of Multiple 
Deprivation (IMD) 2004. 463 This is a widely used indicator of deprivation 
within public health and health services research at both area and individual 
level, including studies on use of services by lung cancer patients. 247 The 
IMD is a summary measure of area level deprivation comprising weighted 
scores in seven deprivation domains (income, employment, health and 
disability, education, skills and training, barriers to housing and services, 
crime, and living environment). IMD data are available at the Super Output 
Area (SOA) lower layer, covering a mean of 1500 people (minimum 1000). 293 
 
There are 32,482 SOAs in England; each is assigned a score and rank for the 
total IMD 2004, as well as for the more detailed Domain Indices. 
 
Whilst using area-level data applied to individuals always risks ecological 
fallacy (the assumption that individuals have the same level of deprivation 
as that assigned to the area in which they live), there is some evidence that 
individual and area level deprivation measures correlate well. 464 I 
considered obtaining data on individual-level socioeconomic data using the 
National Statistics socio-economic classification (NS-SEC), as used for all 
official statistics. However, I considered this to be problematic for two 
reasons. Firstly, the NS-SEC is primarily an occupation-based classification 
system. This may not be appropriate in a population of lung cancer patients 
who are predominantly retired or on long-term sick leave. Secondly, the NS-
SEC requires a minimum of four detailed questions (compared to postcode 
alone for the IMD). This may considerably increase instrument length and 
resulting responder fatigue. As a result, I decided to use the IMD system.  
 
To assign a deprivation level to each participant, I used the rank of total IMD 
score to place each Super Output Area in England within a deprivation  
tertile (high, moderate and low). I then used postcode of residence to identify 
the correct SOA for each participant. Based on their SOA, I then assigned a 
deprivation tertile to each participant.  
 
Ethnicity 
There is little evidence on the influence of ethnicity on use of SPC. However, 
due to widespread concerns about variations in use of primary and 
secondary care between ethnic groups, I included patients’ ethnicity as a 
potential contributory factor in equity of use. 465;466 
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Carer stress 
As previously discussed, my ethnographic study identified carer stress as a 
potential contributory factor in referrals to SPC. I therefore obtained a 
validated measure of carer psychological stress, the GHQ-12, from those 
carers attending clinic with patients.  
 
Cancer clinic/hospital attending for treatment 
Variations in models of care, service availability and personnel at the 
different participating lung cancer clinics may impact on the likelihood of 
being referred to SPC services. I therefore included the site at which patients 
were recruited (corresponding to the site they were currently attending for 
care and/or treatment) as an explanatory factor. I also noted the site at which 
patients were diagnosed. Diagnosing site could differ from the 
recruiting/treating site due to referrals between hospitals, and particularly 
between cancer units and the cancer centre.  
 
Deteriorating condition 
My ethnographic findings highlighted the importance of a patient’s 
deteriorating condition in precipitating a need for SPC. The assessment of 
patients on referral to SPC, and throughout the provision of care to them, 
included whether the patient’s condition was continuing to decline. Stable 
disease and stable symptoms were frequently a reason for deciding a patient 
no longer had a need for SPC. However, within the cross-sectional survey, 
particularly with the EORTC QLQ-C30 as a measure of need for care, it was 
not possible to assess this dimension. This HRQL instrument did not include 
an assessment of how patients were changing over time, and it was not 
possible to construct a robust measure of this from medical records. Thus, 
whilst it remains an important component of need for SPC, it was not 
assessed within this survey.  295 
 
7.4 Study procedures 
Further details of the conduct of the study are outlined below.  
 
Data preparation 
Prior to the start of data collection, I drew up a data management plan to 
guide data collection, entry, and checking.  
 
Data entry 
I entered data into an SPSS database following my attendance at every clinic. 
I used single data entry with verification of a sample of records in preference 
to double data entry. 467 This approach has been shown to produce 
satisfactory levels of accuracy within the context of limited study resources. 
468  
 
Data checking 
Checks on data quality following completion of data collection are less 
effective than ensuring initial high quality data through careful collection 
techniques. 469 However, it is nonetheless essential to assess the nature and 
extent of inaccuracies arising from typographical and data extraction errors 
which may occur. Entering data immediately following every clinic meant I 
was able to swiftly resolve obvious data extraction errors, as participants’ 
medical records were easily revisited in subsequent clinics for clarification. 
Following the completion of recruitment to the study, I conducted secondary 
checking of the data to assess the potential error rate, and to correct a 
proportion of the data entry errors. This involved a sequence of four 
different checks, each applied to the entire data set (including both patient 
and carer records): 
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1.  Visual verification checks 
2.  Duplication checks 
3.  Range checks 
4.  Consistency checks 
 
Data checking: visual verification checks 
I carried out initial visual record verification checks on a random 10% 
sample of cases by comparing every variable in the selected records with the 
original questionnaires and data extraction forms. I generated samples using 
the ‘select cases’ function in SPSS; 30 cases from the patient database, and 21 
from the carer database were highlighted for checking in this way. I 
corrected any discrepancies on the database to match the data as recorded on 
the questionnaire and data extraction form. I kept an error log using an Excel 
spreadsheet to record the number of errors per record, the nature of the 
error, and the correction made.  
 
Out of the 30 patient records checked, I found a total of 8 typographical 
errors across 4680 entries (0.18% of entries). Three of these errors related to 
dichotomous variables, two to variables with more than 2 categories, and 
two errors involved dates. Out of the 21 carer records checked, I found a 
total of 6 typographical errors across 924 entries (0.65%). Four of these errors 
related to the same two, linked variables, with the wrong category value 
entered on each. One error was on a dichotomous variable (female gender 
was entered instead of male), and one related to a date. With a low 
proportion of errors (overall figures of greater than 0.5% have been 
commonly reported 467;468) further visual verification checks were not 
conducted. 
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Data checking: duplication checks.  
To ensure no records had the same unique identification number, I checked 
the frequency of ID codes. Two records were found to have the same ID 
number. On reference back to the original records, these were found to relate 
to two different patients. The ID code of one participant was amended, and 
all records updated. 
 
Data checking: range checks. 
To look for values falling outside of the expected range, I systematically 
examined the distribution of each variable using frequency tables. For 
categorical variables, I checked all observations to ensure they related to the 
permitted categories. For continuous variables, I performed frequency 
counts to ensure values fell within the expected range. Values which fell 
outside the permitted or likely range were checked against the original data 
collection sheets and amendments made as necessary. To record the range 
checks conducted, I created a table in Word listing every variable, its type 
(categorical or continuous), its permitted distribution (for categorical) or 
expected range (for continuous), the number of records for each variable, 
and, for errors, the number, nature and any corrections made. In checking 
the patient data, a total of two typographical errors were found across 97 
variables, both relating to categorical data. I amended these on the database. 
In checking the carer data, no errors were found across 28 variables. 
 
Data checking: consistency checks 
I conducted consistency checks to ensure key variables were consistent for 
each participant. There were no cross-clarification checks conducted outside 
of the completed patient HRQL instrument, as none of the other recorded 
variables were open to inconsistencies which required or necessitated 298 
 
clarification. However, I assessed the quality of data derived from the 
EORTC instruments, as explained below.  
 
The EORTC scoring manual does not include recommendations about 
investigating the coherence of responses within the instrument/s. However, 
within and between the QLQ-C30 and the LC13, responses to certain items 
can lead to logical inconsistencies. To investigate the potential quality of 
responses by individuals, I adapted the approach taken by the developers of 
the SF-36 quality of life instrument. 470 The SF-36 Response Consistency Index 
(RCI) uses 15 internal consistency checks based on pairs of SF-36 items – 
such as a report of being able to ‘walk more than one mile’ but not be able to 
‘walk one block’ – to evaluate response quality. 471 A value of 1 is assigned to 
each inconsistent response pair, and a value of 0 to each consistent response. 
These are then totalled to form an RCI score for each respondent ranging 
from 0 (excellent data quality) to 15 (poor data quality). Reference values 
provided for the SF-36 show that 90.3% (2234/2474) of respondents in the 
general US population had no inconsistent responses 471; however, a study in 
patients with laryngeal cancer found only 75% of respondents had no 
inconsistencies. 472 
 
Applying this approach to the EORTC QLQ-C30 and LC-13, I identified 
before data collection the following seven item pairs which could contain 
potentially inconsistent responses: 
 
1.  item 3 (taking a short walk) and item 2 (taking a long walk) 
2.  item 8 (short of breath) and item 33 (short of breath when rested) 
3.  item 8 (short of breath) and item 33 (short of breath when walked) 
4.  item 8 (short of breath) and item 33 (short of breath when climbed 
stairs) 299 
 
5.  item 40 (pain in chest) and item 9 (pain) 
6.  item 41 (pain in arm or shoulder) and item 9 (pain) 
7.  item 42 (pain in other parts of body) and item 9 (pain) 
 
The identification of inconsistencies within these response pairs can not in 
itself lead to the conclusion that individual responses are of a poor quality. 
Inconsistencies may arise through random error alone. Alternatively, 
respondents may react differently and give an apparently conflicting answer 
to stand alone items (such as ‘were you short of breath?’) compared to a run 
of similar items (such as ‘were you short of breath when you 
rested/walked/climbed stairs?’). However, by identifying response 
inconsistencies, we can estimate the level of potential problems with data 
quality, regardless of how these problems have arisen.  
 
For these data, I identified apparently inconsistent responses for each item 
pair. I then assigned a score of one for each inconsistent response pair, and 
calculated the proportion of respondents with any inconsistent response 
pairs [Table 7.8].  300 
 
 
Table 7.8 Analysis of inconsistent response pairs in EORTC instruments 
Item pair  Inconsistent answers 
Number of respondents 
with inconsistent 
responses 
A problem taking a short 
walk / A problem taking a 
long walk 
A little / Not at all 
Quite a bit / Not at all 
Quite a bit / A little 
Very much / Not at all 
Very much / A little 
Very much / Quite a bit 
0 
0 
0 
0 
0 
0 
Short of breath /  
Short of breath when 
resting 
Not at all / A little 
Not at all / Quite a bit 
Not at all / Very much 
A little / Quite a bit 
A little / Very much 
Quite a bit / Very much 
1 
0 
0 
0 
0 
0 
Short of breath /  
Short of breath when 
walking 
Not at all / Quite a bit 
Not at all / Very much 
A little / Very much 
0 
0 
1 
Short of breath /  
Short of breath when 
climbing stairs 
Not at all / Very much 
  0 
Pain in chest /  
Pain 
Quite a bit / Not at all 
Very much / Not at all 
Very much / A little 
1 
0 
0 
Pain in arm or shoulder /  
Pain 
Quite a bit / Not at all 
Very much / Not at all 
Very much / A little 
1 
0 
0 
Pain elsewhere /  
Pain 
Quite a bit / Not at all 
Very much / Not at all 
Very much / A little 
6 
1 
2 
Total    13 
 
13 respondents (13/254 = 5.1%) had one inconsistent response pair; none had 
more than one. I could not conclude that these are attributable to random 
error alone, but the low proportion of inconsistent responses suggests that 
items were commonly answered in a logical and consistent manner. 
 
Once data cleaning was complete, I re-examined the distribution of all 
variables to double-check for consistency and accuracy. I identified no 
further problems. 
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Data reduction, reclassification and scoring 
Following completion of data checking to identify data inaccuracies, I 
undertook a process of data reduction and reclassification to prepare the 
database for analysis. A primary focus of this was to transfer qualitative 
variables on participants’ treatment and disease status into quantitative 
variables suitable for descriptive analysis. This involved, for example, 
converting string data on comorbidities into coded variables on the nature of 
the comorbidity, and the number of comorbidities for each patient.  
 
During this phase, I also scored data from the EORTC QLQ-C30, the LC13 
and the GHQ-12. The EORTC QLQ-C30 has nine multi-item scales and six 
single-item measures; the EORTC QLQ-LC13 has one multi-item scale and 
nine single item measures. Scales are scored in the same manner. Firstly, the 
average of the items that contribute to the scale is estimated. This is known 
as the raw score. The raw score is then standardised using linear 
transformation; scores range from 0 to 100. A high score on the global quality 
of life scale and the functional scales represents high (good) levels of quality 
of life / functioning. By contrast, a high score on symptom scales represents a 
high (worse) level of symptoms. Missing data are dealt with in one of two 
ways. If at least half the items from a scale have been answered, the scale 
score is calculated as above, with missing items ignored. If less than half the 
items have been completed, the scale score is set to missing. All single-item 
measures are set to missing. The EORTC supplies the SPSS commands for 
scoring the QLQ-C30 and QLQ-LC13, including the suitable treatment of 
missing data. These were run as an SPSS syntax file to calculate the scores for 
each participant. 
 
The GHQ-12, contained within the carers’ questionnaire, uses a four-point 
response scale which can be scored in a variety of ways, although the 302 
 
developers recommend the use of their original binary method. 473 This 
approach assigns a score of 0 or 1 as follows:  
 
−  symptom present ‘not at all’ = 0,  
−  ‘same as usual’ = 0,  
−  ‘more than usual’ = 1, and  
−  ‘much more than usual’ = 1.  
 
Appropriate threshold scores for the GHQ-12, used to determine ‘caseness’, 
are known to vary according to setting, ranging from 1/2 to 6/7 out of a total 
possible score of 12. 474 In recent years, the use of stratum-specific likelihood 
ratios has been explored as an alternative to threshold values in the GHQ-12, 
although these do not assign caseness. 475;476 For the purposes of this study, 
the threshold value was set conservatively at 3/4 to avoid false positives. 438  
 
Data confidentiality and storage 
To safeguard the confidentiality of participants, I did not record patients' 
and carers’ personal details (name and address) on any questionnaires. I 
allocated an identifier code to each participant as they entered the study, 
recorded on all study documents. I noted participant details and codes in a 
handwritten code book, kept in a locked fire-proof filing cabinet separate to 
and away from the storage location of data. I transferred data to a computer 
database at regular intervals during data collection. These data were stored 
on password protected computers.  
 
Sample size 
The aim of the analysis was to assess whether there were differences in use 
of SPC services between older (≥ 75) and younger (< 75) lung cancer 
outpatients, after controlling for need and other explanatory factors. The 303 
 
most recent available data, from a survey of 913 bereaved carers of patients 
who died from cancer in 2003 and 2004, reported 60.0% of patients under 70 
and 38.9% of patients over 70 used community SPC. 477 Data for differences 
in use under and over 75 years of age were not available from this study, and 
therefore the sample size calculation had to be estimated from this slightly 
different age group categorisation. To detect a 20% difference in use of SPC 
services between under and over 75’s, with 95% confidence and 80% power, 
I would have to recruit 192 patients (96 in each age group).  
 
However, to ensure stable estimates in multivariable models, there should be 
a minimum of 10 of the rarer events being studied for each covariate in the 
model. 478;479 The complete list of potential coefficients to be included in the 
analysis is shown in Table 7.9; it includes ten variables representing 14 
coefficients. 304 
 
 
Table 7.9 Proposed coefficients to be included in multivariable analysis 
Variable  Data source  Categories  Number of coefficients 
contributing to model 
Age   Date of birth: 
Medical records 
Under 75 / 
Over 75  1 
Gender  Medical records  Male / 
Female  1 
Ethnicity  Patient report  White /  
Non-white  1 
Deprivation  Postcode: 
Medical records 
Low / 
Medium / 
High 
2 
Lives alone  Patient report  Yes / 
No  1 
Recruiting centre  n/a 
1 / 
2 / 
3 / 
4 
3 
Extent of disease  Medical records  No metastases / 
Metastases  1 
Current 
treatment  Medical records  1st line / 
2nd or 3rd line  1 
Comorbidities  Medical records 
None / 
One / 
Two or more 
2 
Need for SPC  Patient report 
Continuous: 
EORTC QLQ-C30 
global quality of life 
score 
1 
TOTAL  -  -  14 
 
Therefore, a sample of 250 would include an estimated 100 uses of SPC (at 
the rarest rate of 40% use), meaning a maximum number of 10 coefficients in 
multiple logistic regression models; a sample of 350 would include an 
estimated 140 uses of SPC, and be able to support a maximum number of 14 
coefficients in multiple logistic regression models. On the basis of this 
information, and with consideration of the time-consuming nature of data 
collection following the pilot study, it was decided to aim for a maximum 
sample of 250 patients. This would enable 10 coefficients to be used, to be 
chosen as a result of univariable analysis.  305 
 
Statistical analysis 
Once I had fully prepared the data, I transferred them to Stata for analysis 
(StataCorp. 2007. Statistical Software: Release 9.2. College Station, TX: Stata 
Corporation).  
 
Descriptive analyses 
Distributions of categorical variables were examined using relative 
frequencies, to consider the number of participants in each category, and the 
proportion of missing data. Ordinal variables (EORTC scores) were 
examined using frequency distributions as appropriate.  
 
Explanatory variables were then examined in relation to the outcome 
variable. Categorical variables were tabulated against use of SPC, and the 
proportions of patients in each category using or not using SPC calculated. 
For EORTC scores, median scores and inter-quartile range by use of SPC 
were calculated.  
 
Univariable analysis 
The associations between explanatory variables and use of SPC were then 
examined using univariable logistic regression to calculate crude odds ratios. 
Table 7.10 has details of each variable examined, and the coding used for 
each category.  306 
 
 
Table 7.10 Coding of key explanatory variables  
Variable  Coding 
Age  Under 75 = 0 
75 and over = 1 
Gender  Male = 0 
Female = 1 
Deprivation 
Least deprived = 0 
Mid deprived = 1 
Most deprived = 2 
Living alone  No = 0 
Yes = 1 
Recruiting centre 
Centre one = 0 
Centre two = 1 
Centre three = 2 
Centre four = 3 
Extent of disease  No metastases = 0 
Metastases = 1 
Current line of treatment  First line = 0 
Second or third line = 1 
Comorbidity 
None = 0 
One = 1 
Two or more = 2 
Need for SPC  Global quality of life score = continuous 
 
Multivariable analysis 
Multiple variable logistic regression was carried out to examine the adjusted 
associations between explanatory variables and use of SPC. To carry out 
robust analyses, the inclusion of up to 14 coefficients in a multiple logistic 
regression model requires there to be 140 events. The 14 coefficients chosen 
to be potentially included in the model prior to the commencement of data 
collection were based on existing literature, policy and the results of the 
ethnographic study conducted as a prelude to the survey. No interactions 
between variables were expected on the basis of prior knowledge, and thus 
interaction terms were not included in the coefficient list. To reduce the 
number of coefficients to be included within the model to the anticipated 
maximum of 10, univariable regression results were considered. All 
explanatory variables with a P value of greater than 0.5 were not taken 
forward into the multivariable analysis. A high value of 0.5 was chosen to 307 
 
ensure I could be confident that no important association was missed in the 
multivariable analysis.  
 
Backwards elimination was then used to build a parsimonious logistic 
regression model from the remaining variables. All remaining explanatory 
variables (with P < 0.5 at the univariable level) were placed in the model. The 
variable with the highest P-value was then removed, with the threshold 
value for removal set at P > 0.05. Elimination of variables continued until no 
more variables could be removed from the model. To assess whether the 
same model could be achieved using a different approach, forward selection 
procedures were used with the same set of variables. Likelihood Ratio Tests 
(LRT) were used to examine the statistical significance of the variables 
included within the full, compared to a reduced, model. (480 p. 313) Goodness 
of fit was assessed using the Hosmer-Lemeshow test. (481 p.140) It was not 
possible to undertake multi-level modelling to take account of the effect of 
the treating and diagnosing clinic due to sample size restrictions. 
 
Exploratory analysis of dimensions of quality of life 
Whilst global quality of life score was used as an indicator of need for SPC in 
the main analysis, it is useful to know which particular dimensions of global 
quality of life are associated with use of SPC. Such dimensions could not be 
included in our main analysis due to sample size constraints. Key functional 
and symptom scores were identified a priori, based on factors identified 
within the ethnographic study as contributing to need for SPC. These were: 
 
•  Physical functioning 
•  Role functioning 
•  Emotional functioning 
•  Social functioning 308 
 
•  Pain 
•  Nausea and vomiting 
•  Dyspnoea (measured using the more extensive LC-13 scale) 
•  Fatigue, and  
•  Appetite loss.  
 
Univariable logistic regression analysis was used to examine the relationship 
between these specific functional and symptom scales and use of SPC. 
Multivariable analysis was anticipated to be constrained by multicollinearity; 
in this situation, two or more dimensions of quality of life are so highly 
correlated that false associations between the explanatory and outcome 
variables may be obtained. 482 A correlation matrix (Spearman’s correlation 
coefficients r) was used to examine the degree of correlation between 
selected HRQL variables. The proportion of moderately (r = 0.4 to 0.7) and 
strongly (r = 0.7 to 0.9) correlated HRQL variable pairs was calculated. Weak 
pairwise correlation coefficients do not necessarily exclude multicollinearity 
in this situation, as collinearity may exist between three or more variables. 482 
Therefore, multivariable regression analyses were limited to examining the 
effect of each HRQL variable in turn on use of SPC, controlling for other 
significant factors. As a result, models only included one HRQL variable at a 
time. All EORTC variables were assessed for lack of conformity to a linear 
gradient by fitting each as a quadratic term.  
 
Exploratory analysis of impact of carer stress 
To assess the association of carer stress with use of SPC, an exploratory 
analysis was carried out using data from the sub-section of patients for 
whom carer GHQ-12 scores were available. Univariable analysis considered 
whether GHQ-12 score, as a continuous or dichotomous (caseness or not) 
variable, was associated with use of SPC. These variables were then added to 309 
 
the final regression model developed for the entire data set, to assess 
whether an association existed after controlling for other factors known to be 
associated with use.  
 
7.5  Results 
 
Recruitment 
A total of 842 patients attended the four participating outpatient clinics 
during the study recruitment period. I screened all patients against the 
eligibility criteria. Figure 7.4 shows the outcome of this process: 307 patients 
(36.5%) were eligible to be approached to participate in the study during the 
recruitment period, and 535 (63.5%) were ineligible.  
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Patients screened in outpatient chest and oncology clinics 
n = 842 
 
Eligible 
n = 307 
Approached 
n = 266 
Missed 
n = 41 
(13.4%) 
Refused 
n = 5 
Completed 
 
n = 252 
Agreed but 
not returned 
n = 9 
 
Ineligible 
n = 535 
Not lung 
cancer 
n = 159 
Lung cancer 
but ineligible 
n = 271 
Under 
investigation 
n = 105 
Curative 
treatment 
n = 72 
Too ill or 
distressed 
n = 31 
RCT 
participant 
n = 31 
Unaware of 
diagnosis 
n = 3 
Requires 
interpreter 
n = 13 
New 
diagnosis 
n = 53 
Receiving 
results 
n = 68 
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Of the 307 eligible patients, I approached 266 (87%) to introduce the study. I 
missed 41 patients as I was with other patients and unable to reach them 
before they left the clinic. Of those approached, 252 patients completed the 
study instruments (95% response rate), representing 82% of all eligible 
patients. Of those that did not complete the questionnaire, 9 stated they 
would prefer to post the completed study measures rather than completing 
them in the clinic but these were subsequently not received, and 5 declined 
participation in the study. An analysis of differences between responders 
and non-responders was not conducted. I did not have ethical permission to 
record data from the notes of non-responders or access any other source of 
information, so personal characteristics (such as age) were unknown.  
 
Out of 535 ineligible patients, 159 (30%) did not have lung cancer, but were 
attending clinic for the assessment and treatment of conditions including 
COPD and other cancers. 105 patients (20%) had been referred for suspected 
lung cancer but were still undergoing assessment during the study 
recruitment period, and thus had not been diagnosed with lung cancer as 
yet. Finally, 271 patients (51%) did have a diagnosis of lung cancer but were 
not eligible to be approached about the study. The largest group of these 
(n=72, 27%) were receiving treatment with a curative intent, classified as 
surgery with or without adjuvant (radiotherapy or chemotherapy) treatment. 
68 (25%) patients were attending clinic to receive results of investigations 
into the suspected progression of their disease, whilst 53 (20%) were 
attending clinic to receive their diagnoses of lung cancer, or for their first 
appointment to discuss treatment options following their diagnosis. The 
most diverse category were those lung cancer patients (n=31, 11% of 
ineligible patients) categorised as too ill or distressed to approach. This 
decision was taken in conjunction with clinic staff, and included patients 
with mental health or behavioural problems as well as those who attended 312 
 
clinic requiring urgent medical attention (including patients in severe pain, 
those who were vomiting, and those who were judged to require immediate 
inpatient admission).  
 
Of the 252 participants in the study, 178 (71%) attended clinic with at least 
one relative or friend [Figure 7.5]. Of these 178 carers, 4 were not asked to 
participate in the 
study as clinic staff 
identified they had a 
degree of cognitive 
impairment (all four 
were elderly spouses 
of patients). Of the 
remaining 174 carers, 
137 (79%) 
participated in the 
study. Seven carers 
(4%) approached 
about the study 
declined to 
participate, three of 
these stating that 
they did not feel it 
was relevant as they 
were a friend rather 
than a family member. The remaining 30 (17%) who were approached took 
the questionnaire but did not complete the study instruments. This was 
usually because they assisted the patient with completing their 
questionnaire, and subsequently did not have time to complete the carer 
Participating patients 
n = 252 
With carers 
n = 178 
Without 
carers 
n = 74 
Carers 
completed 
n = 137 
Agreed but 
not returned 
n = 30 
Carers not 
approached 
n = 4 
Refused 
n = 7 
Figure 7.5  
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questionnaire before they left the clinic; whilst as many as possible were 
requested to post the completed questionnaire back, none were received 
from this group.  
 
Participating clinics contributed very different numbers of patients to the 
study [Figure 7.6]. Site one contributed 121 patients (48%), site two 93 (37%), 
site three 24 (10%) and site four 14 patients (6%). This reflected differences in 
the numbers of patients attending each clinic. 
 
 
 Figure 7.6 Patient recruitment to the study by month and clinic 314 
 
Respondent characteristics 
 
Socio-demographic characteristics: patients 
Participating patients were aged from 42 to 92 years (mean age 69 (sd 9.9)) 
[Table 7.11]. Ethnicity was overwhelmingly white (95.2%); as a result of low 
numbers in non-white ethnic groups this variable was dropped from 
analyses. Additionally, only 5.2% of respondents (n=13) were living with 
children. This variable too was therefore not included in analyses.  
 
Table 7.11 Respondent characteristics: patients  
Characteristic  n (%) 
Age (years)  (n = 252) 
< 55  26 (10.3) 
55-64  55 (21.8) 
65-74  95 (37.7) 
≥ 75  76 (30.2) 
Gender  (n = 252) 
Male  139 (55.2) 
Female  113 (44.8) 
Ethnicity  (n = 251) 
White  239 (95.2) 
Black or Black British  8 (3.2) 
Asian or Asian British  2 (0.8) 
Mixed  1 (0.4) 
Other  1 (0.4) 
Marital status  (n = 251) 
Married/living with partner  152 (60.6) 
Divorced or separated  32 (12.8) 
Widowed  53 (21.1) 
Single  14 (5.6) 
Social situation   
Lives alone  80 (31.8) 
Children < 18 in household  13 (5.2) 
Area-level deprivation (IMD 2004)  (n = 251) 
Least deprived  47 (18.7) 
Mid deprived  68 (27.1) 
Most deprived  136 (54.2) 315 
 
Compared to the age distribution of lung cancer incidence in England in 
2004, patients age 75 and above were under-represented in the survey 
[Figure 7.7]. 483  
 
 
 
 
Socio-demographic characteristics: carers 
Of the 137 participating carers, the mean age was 54.7 (sd 12.9, range 19 to 
83) [Table 7.12]. The majority (78%) were female; 51% were the spouse of the 
patient, and 36% the patient’s son or daughter.  
Figure 7.7 Age group of participating lung cancer patients compared to lung 
cancer incidence in England, 2004 316 
 
 
Table 7.12 Respondent characteristics: carers  
Characteristic  n (%) 
Age (years)  (n = 135) 
< 35  8 (5.9) 
35-44  23 (17.0) 
45-54  38 (28.2) 
55-64  28 (20.7) 
65-74  30 (22.2) 
≥ 75  8 (5.9) 
Gender  (n = 137) 
Male  30 (21.9) 
Female  107 (78.1) 
Ethnicity  (n = 137) 
White  135 (98.5) 
Asian or Asian British  1 (0.7) 
Mixed  1 (0.7) 
Relationship to patient  (n = 136) 
Husband/wife/partner  69 (50.7) 
Son/daughter  49 (36.0) 
Brother/sister  4 (2.9) 
Other family member  10 (7.4) 
Friend  3 (2.2) 
Other  1 (0.7) 
 
Clinical characteristics: patients 
NSCLC was the most common type of lung cancer amongst participants 
(73.9%), compared to 24.5% with SCLC [Table 7.13]. Four participants did 
not receive a histological diagnosis and therefore the type of lung cancer 
remained unknown. These proportions reflect the proportions of lung cancer 
types in the UK, commonly accepted as being 75% NSCLC and 25% SCLC. 
(239 p.63)  
 
54.8% of participants had received their lung cancer diagnosis over six 
months ago. The median length of time between diagnosis and study 
participation was 7 months (inter-quartile range 3 to 19). Over half of 
participants (56.8%) had metastatic disease by the time of their participation 317 
 
in the study. The most common metastatic site was another lung tumour, 
followed by bone and liver.  
 
Table 7.13 Patient clinical characteristics 
Type of cancer 
SCLC  61 (24.5) 
NSCLC  184 (73.9) 
Not known  4 (1.6) 
Stage of cancer at diagnosis   
NSCLC:   
Stage I  18 (10.3) 
Stage II  12 (6.9) 
Stage III  79 (45.4) 
Stage IV  65 (37.4) 
SCLC:   
Limited  17 (29.3) 
Extensive  41 (70.7) 
Time since diagnosis   
In the past month  13 (5.2) 
In the past three months  61 (24.2) 
In the past six months  40 (15.9) 
More than six months ago  138 (54.8) 
Metastatic disease at participation   
No  109 (43.3) 
Yes  143 (56.8) 
Site of metastatic disease *   
Other lung  58 (33.1) 
Bone  35 (20.0) 
Liver  31 (17.7) 
Adrenal  22 (12.6) 
Brain  20 (11.4) 
Other  9 (5.1) 
 
* Totals add up to more than 143 as 28 patients had metastatic disease at two sites, and two 
patients had metastatic disease at three sites 
 
More than half (58.5%) of patients had relevant co-morbid disease recorded 
in their medical notes; of these, 90 (62.1%) had one additional disease, and 55 
(37.9%) had two or more. The most-common comorbidity was hypertension 
(28.4%), but 15.3% of patients had been previously diagnosed with an 318 
 
additional malignancy, and 20.9% had pulmonary disease including COPD 
[Figure 7.8].  
 
 
 
 
Treatment received 
All but 3 participants had received treatment for their disease. 8.7% had 
received surgery prior to the recurrence of their lung cancer, 55.4% had 
received radiotherapy and 83.1% chemotherapy [Table 7.14]. At the time of 
participation in the study over half of participants were on follow-up after 
the completion of their most recent treatment.  
Figure 7.8 Prevalence of comorbidities 319 
 
 
Table 7.14 Treatment received 
Received surgery   
Yes  22 (8.7) 
Lobectomy  17 (77.3) 
Pneumonectomy  2 (9.1) 
Wedge resection  3 (13.6) 
No  230 (91.3) 
Received radiotherapy   
Yes  138 (55.4) 
No  111 (44.6) 
Received chemotherapy   
Yes  207 (83.1) 
No  14 (16.9) 
Current or most recent treatment   
Chemotherapy  130 (53.5) 
Chemotherapy & radical radiotherapy  24 (9.9) 
Chemotherapy & palliative radiotherapy  57 (23.5) 
Radical radiotherapy  5 (2.1) 
Palliative radiotherapy  19 (7.8) 
None  3 (1.2) 
Other  5 (2.1) 
Treatment status at participation   
On treatment  92 (38.0) 
About to commence treatment  15 (6.2) 
On watch and wait  132 (54.6) 
No treatment received  3 (1.2) 
Nature of current or most recent treatment 
First line  195 (81.3) 
Second line  36 (15.0) 
Third line  9 (3.8) 
 
Quality of life 
EORTC QLQ-C30 and LC13 scores revealed a high prevalence of symptoms. 
According to the raw scores, pain (a little to a lot) was reported by 64%; 
dyspnoea by 85%, fatigue by 91% and nausea by 35% [Figure 7.9].  
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Despite this high symptom burden, 65% of respondents rated their overall 
health as being average to excellent, and 69% felt their overall quality of life 
was average to excellent [Figure 7.10].  
Figure 7.9 Raw QLQ-C30 scores for symptoms 321 
 
 
 
 
 
EORTC reference values are available by cancer site for transformed scores, 
enabling study samples to be compared against published data. 484 I 
compared mean scores on key functional and symptom scales with reference 
values for NSCLC and SCLC populations. NSCLC reference values are 
derived from 794 patients recruited from Europe (including the UK) and 
Canada, 44% with local/locoregional disease and 56% with distant/recurrent 
disease. SCLC reference values are derived from 478 patients from Europe 
(including the UK) and Canada, 43% with limited disease and 57% with 
advanced disease.  
 
Figures 7.11 and 7.12 show that mean symptom scores for the study sample 
closely follow those of the reference populations. NSCLC patients in the 
study have a slightly higher symptom burden than the reference population, 
Figure 7.10 Raw QLQ-C30 scores for global health and quality of life 322 
 
and SCLC patients a slightly lower burden. Mean functional scale scores, 
including global quality of life, also match closely between the study sample 
and the reference population [Figures 7.13 and 7.14].  323 
 
 
 
 
 
Abbreviations: NV, nausea and vomiting; DI diarrhoea; CO, constipation;  
DY, dyspnoea; SL, insomnia; PA, pain; AP, appetite loss; FA, fatigue;  
FI, financial difficulties 
Figure 7.11 QLQ-C30 profiles: symptoms in NSCLC patients 
Figure 7.12 QLQ-C30 profiles: symptoms in SCLC patients 
Abbreviations: NV, nausea and vomiting; DI diarrhoea; CO, constipation;  
DY, dyspnoea; SL, insomnia; PA, pain; AP, appetite loss; FA, fatigue;  
FI, financial difficulties 324 
 
 
 
 
 
 
 
 
Figure 7.13 QLQ-C30 profiles: function in NSCLC patients 
Abbreviations: QL, global quality of life; RF, role functioning; SF, social functioning;  
PF, physical functioning; EF, emotional functioning; CF, cognitive functioning 
Figure 7.14 QLQ-C30 profiles: function in SCLC patients 
Abbreviations: QL, global quality of life; RF, role functioning; SF, social functioning;  
PF, physical functioning; EF, emotional functioning; CF, cognitive functioning 325 
 
Carer GHQ-12 scores 
Figure 7.15 shows the distribution of GHQ-12 scores in family members and 
friends of participating patients (low (0) to high (12)). Using a threshold of 
3/4 to determine psychological distress, 52% of carers (70/135: 46.7% of males 
and 53.3% of females) were cases. This is comparable to a study of 280 
spouse carers of people with Alzheimer’s disease, which found 58% were 
designated ‘probable cases’ using the GHQ-12. 485 It is four times higher than 
the general population: data from the Health Survey for England, using the 
same threshold, reported that 11% of males and 15% of females had 
psychological distress. 486  
 
 
 
 
Use of SPC 
Confirmed use of SPC at the time of participation in the study, verified with 
local SPC services, was reported for 99 (39.3%) of participants. The median 
Figure 7.15 Carer GHQ-12 scores 326 
 
time from diagnosis to referral to SPC for the 96 patients for whom referral 
date was available was 2 months (interquartile range 0.2 to 12 months) 
[Figure 7.16]. 22 patients (23%) were referred to SPC during the process of, or 
on the day of, diagnosis; all of these 22 patients had metastatic disease by the 
time they were diagnosed.  
 
 
 
 
Key explanatory variables were examined by use of SPC, using proportions 
or medians as appropriate [Tables 7.15 and 7.16]. A slightly lower proportion 
of older patients (75 or over) were receiving SPC compared to those aged 
under 75. There were large differences in use of SPC by treating clinic, with 
proportions of patients under SPC at each clinic ranging from 23.7% to 
66.7%. When examined by diagnosing clinic, use of SPC ranged from 24.7% 
to 64.7%. Half of patients with metastatic disease (49.7%) were under SPC, 
Figure 7.16 Time from diagnosis to SPC referral 327 
 
compared to 25.7% of patients without metastatic disease. Finally, 53.3% of 
patients on second or third line treatment were receiving SPC, compared to 
36.9% of patients receiving their first treatment.  
 
Median global quality of life score was 41.7 in users of SPC, indicating a 
lower perceived quality of life compared to non-users (median score 58.3). 
Lower scores were also observed in SPC patients for physical, role, 
emotional and social functioning. Users of SPC reported higher symptom 
burdens for fatigue, pain and dyspnoea.  328 
 
 
Table 7.15 Use of SPC by demographic and disease variables 
  Use of SPC n (%) 
  Yes  No 
Age      
Under 75  71 (40.6)  104 (59.4) 
75 and over  28 (36.4)  49 (63.6) 
Gender     
Male  48 (34.5)  91 (65.5) 
Female  51 (45.1)  62 (54.9) 
Deprivation     
Least deprived  17 (36.2)  30 (63.8) 
Mid deprived  26 (38.2)  42 (61.8) 
Most deprived  56 (41.2)  80 (58.8) 
Living alone     
No  63 (36.6)  109 (63.4) 
Yes  36 (45.0)  44 (55.0) 
Treating clinic     
1  54 (44.6)  67 (55.4) 
2  22 (23.7)  71 (76.3) 
3  16 (66.7)  8 (33.3) 
4  7 (50.0)  7 (50.0) 
Metastatic disease     
No  28 (25.7)  81 (74.3) 
Yes  71 (49.7)  72 (50.4) 
Current/most recent treatment     
First line  72 (36.9)  123 (63.1) 
Second or third line  24 (53.3)  21 (46.7) 
Number of comorbidities     
None  42 (40.8)  61 (59.2) 
One  33 (36.7)  57 (63.3) 
Two or more  24 (43.6)  31 (56.4) 
 329 
 
 
Table 7.16 Use of SPC by HRQL scores 
  Use of SPC 
[Median score (inter-quartile range)] 
  Yes  No 
Global quality of life  41.7 (33.3 to 58.3) 
(n = 99) 
58.3 (41.7 to 75.0)  
(n = 150) 
Physical functioning  46.7 (26.7 to 73.3) 
(n = 99) 
60.0 (46.7 to 80.0) 
(n = 153) 
Role functioning  33.3 (0.0 to 66.7) 
(n = 98) 
66.7 (33.3 to 100.0) 
(n = 149) 
Emotional functioning  66.7 (41.7 to 91.7) 
(n = 99) 
75.0 (66.7 to 100.0) 
(n = 150) 
Social functioning  50.0 (16.7 to 83.3) 
 (n = 99) 
66.7 (33.3 to 100.0) 
(n = 150) 
Fatigue  55.6 (33.3 to 77.8) 
(n = 99) 
44.4 (33.3 to 66.7) 
(n = 150) 
Nausea and vomiting  0.0 (0.0 to 33.3) 
(n = 98) 
0.0 (0.0 to 16.7) 
(n = 151) 
Pain  33.3 (16.7 to 66.7) 
(n = 99) 
16.7 (0.0 to 33.3) 
(n = 1513) 
Dyspnoea  44.4 (22.2 to 77.8) 
(n = 91) 
33.3 (22.2 to 66.7) 
(n = 145) 
Appetite loss  33.3 (0.0 to 66.7) 
(n = 96) 
0.0 (0.0 to 33.3) 
(n = 150) 
 
Regression analyses 
Univariable logistic regression analysis found that the presence of metastatic 
disease, the treating clinic, the current or most recent line of treatment, and 
global quality of life score were significantly associated with use of SPC 
[Table 7.17]. Age (above/below 75) was not associated with use of SPC at a 
univariable level. 330 
 
 
Table 7.17 Univariable regression analysis 
  OR  95% CI  P value 
Age          
Under 75  1.00       
75 and over  0.84  0.48  1.46  0.53 
Gender         
Male  1.00       
Female  1.56  0.94  2.60  0.09 
Deprivation         
Least deprived  1.00       
Mid deprived  1.09  0.51  2.36   
Most deprived  1.24  0.62  2.45  0.81 
Living alone         
No  1.00       
Yes  1.42  0.83  2.43  0.21 
Treating clinic         
1  1.00       
2  0.38  0.21  0.70   
3  2.48  0.99  6.23   
4  1.24  0.41  3.75  <0.001 
Metastatic disease         
No  1.00       
Yes  2.85  1.66  4.90  <0.001 
Current/most recent 
treatment         
First line  1.00       
Second or third line  1.95  1.02  3.75  0.045 
Number of comorbidities         
None  1.00       
One  0.84  0.47  1.50   
Two or more  1.12  0.58  2.18  0.69 
Global quality of life         
One unit increase  0.97  0.96  0.99  <0.001 
 
On the basis of the univariable analysis gender, living alone, treating clinic, 
metastases, line of treatment and global quality of life were entered into a 
logistic regression model. Following backwards elimination, the final model 
contained treating clinic, quality of life and metastatic disease [Table 7.18]. 
This was confirmed using stepwise forward regression. LRTs indicated that 
all were significantly associated with use of SPC after adjusting for the other 331 
 
variables. Age (< 75 / ≥ 75 and as a continuous variable) remained not 
significant when forced into the final regression model. The Hosmer and 
Lemeshow's goodness-of-fit test for the final model gave a P-value of .84, 
showing that the model fits the data well. 
 
Table 7.18 Final model for multivariable regression analysis 
  OR  95% CI  P value 
Treating clinic         
1  1.00       
2  0.37  0.19  0.71   
3  2.43  0.90  6.52   
4  0.95  0.28  3.23  0.002 
Metastatic disease         
No  1.00       
Yes  2.60  1.44  4.68  0.002 
Global quality of life         
One unit increase  0.97  0.96  0.98  <0.001 
 
Further analysis was undertaken to investigate whether the association of 
treating clinic with use of SPC was also to be found by diagnosing clinic. 
Diagnosing clinic was significant both in univariable logistic regression 
analysis (P = 0.0033) and in multivariable analysis with global quality of life 
and metastatic disease (P = 0.0052). The Hosmer and Lemeshow's goodness-
of-fit test for this model gave a P-value of .99, indicating a good fit with the 
data. 
 
Exploratory analysis of use of SPC in relation to HRQL variables 
A correlation matrix for key HRQL variables found that over three-quarters 
(77.8%) of the correlations had an r > 0.4, with physical functioning, role 
functioning and fatigue having the greatest number of strong correlations 
[Table 7.19].  332 
 
 
Table 7.19 Correlation matrix for selected EORTC QLQ-C30 and LC13 variables 
(absolute values of Spearman correlation coefficients, n = 228) 
  QL2  PF2  RF2  EF  SF  FA  NV  PA  AP 
PF2  0.55                 
RF2  0.58  0.75               
EF  0.45  0.48  0.45             
SF  0.48  0.50  0.56  0.53           
FA  -0.64  -0.74  -0.68  -0.57  -0.60         
NV  -0.31  -0.39  -0.30  -0.39  -0.37  0.44       
PA  -0.44  -0.54  -0.47  -0.51  -0.48  0.54  0.38     
AP  -0.45  -0.44  -0.40  -0.43  -0.37  0.54  0.55  0.41   
LCDY  -0.47  -0.61  -0.53  -0.44  -0.36  0.57  0.21  0.43  0.34 
 
Abbreviations: QL2, global quality of life; PF2, physical functioning; RF2, role functioning; 
EF, emotional functioning; SF, social functioning; FA, fatigue; NV, nausea and vomiting; PA, 
pain; AP, appetite loss 
 
Univariable logistic regression analysis found that physical, role, emotional 
and social functioning were all significantly associated with use of SPC 
[Table 7.20]. The physical symptoms of fatigue, pain, appetite loss were also 
all associated with use; nausea and vomiting was not, and dyspnoea was of 
borderline association. Pain and fatigue showed the strongest association 
with receiving care from a SPC team, along with physical and role 
functioning. Adding treating clinic and metastatic disease into the regression 
model for each HRQL variable made little difference to the associations; 
nausea and vomiting remained the one HRQL variable with no clear 
association with SPC, whilst the association between dyspnoea and use 
strengthened. All terms were fitted as linear effects. 333 
 
 
Table 7.20 Exploratory regression analysis: use of SPC by key HRQL variables * 
  Univariable analysis 
Multivariable analysis: 
treating clinic and 
metastatic disease included 
  OR  95% CI  P  OR  95% CI  P 
                 
Physical functioning  0.98  0.97  0.99  <0.001  0.97  0.96  0.99  <0.001 
Role functioning  0.98  0.98  0.99  <0.001  0.98  0.97  0.99  <0.001 
Emotional functioning  0.98  0.97  0.99  0.001  0.98  0.97  0.99  <0.001 
Social functioning  0.99  0.98  1.00  0.002  0.99  0.98  1.00  0.005 
Fatigue  1.02  1.01  1.03  <0.001  1.02  1.01  1.03  <0.001 
Nausea and vomiting  1.01  0.99  1.02  0.202  1.01  1.00  1.02  0.184 
Pain  1.02  1.01  1.02  <0.001  1.02  1.01  1.03  <0.001 
Dyspnoea  1.01  1.00  1.02  0.038  1.02  1.00  1.03  0.006 
Loss of appetite  1.01  1.00  1.02  0.004  1.01  1.00  1.02  0.003 
 
* All figures are reported for one unit increase in the variable of interest 
 
Exploratory analysis of use of SPC in relation to carer distress 
Further exploratory analyses were conducted on data from 131 patients 
whose carers had also participated in the study and had completed the 
GHQ-12 instrument. Of these patients, 39.9% (53/133) were under the care of 
a SPC team at the time of participating in the study. On a univariable level, 
neither GHQ-12 score as a continuous variable, or dichotomised into 
cases/not cases, were associated with use of SPC [Table 7.21]. Forcing GHQ-
12 variables into the final regression model derived from the full data set did 
not alter the association.  334 
 
 
Table 7.21 Exploratory regression analysis: use of SPC by carer GHQ-12 score 
  Univariable analysis 
Multivariable analysis: 
treating clinic, metastatic 
disease and QL2 included 
  OR  95% CI  P  OR  95% CI  P 
GHQ-12 score (0-12)                 
One unit increase  0.99  0.90  1.10  0.900  1.00  0.89  1.13  0.953 
GHQ-12 case (1=yes)                 
No  1.00        1.00       
Yes  0.63  0.31  1.26  0.191  0.67  0.30  1.52  0.342 
 
7.6  Discussion 
I found no association between age and use of SPC. Receipt of such care was, 
however, associated with the presence of metastatic disease, global quality of 
life, and the treating cancer clinic. Exploratory analyses found that specific 
dimensions of quality of life, including both functional and symptom scales 
(for example, pain and fatigue) were also associated with use of SPC. 
Participating lung cancer patients had a high overall symptom burden, with 
pain, dyspnoea and fatigue reported by the majority of participants. In half 
of the informal carers surveyed psychological distress was elevated, but this 
was not associated with use of SPC. 
 
Limitations 
This is the first time an investigation of SPC use has controlled for need 
using a psychometrically validated instrument. I was able to gather a wide 
range of potential explanatory factors directly from patients, and to confirm 
use of SPC with providers of care. Another important strength of this study 
was the high recruitment rate, with 82% of eligible patients taking part. This 
increases the likely generalisability of our results. I excluded a proportion of 
attending patients primarily as they were receiving results concerning 
disease progression, or required immediate medical attention. This could 
have resulted in recruitment of patients with less extensive disease or 335 
 
symptoms. However, participants’ EORTC scores were comparable to, or 
worse than, reference values for NSCLC and SCLC patients, suggesting that 
their symptoms and functional status were representative of lung cancer 
patients as a whole. I was not able to record characteristics, such as age, from 
patients excluded from the study, and was thus unable to undertake an 
analysis of the differences between responders and non-responders.  
 
Due to the cross-sectional design, it was not possible to understand use of 
SPC within the context of patients’ disease trajectories. In particular, I do not 
know whether older cancer patients were referred to services at a later stage 
than younger patients. The design also means I cannot identify causal 
relationships. Thus, whilst I found an association between global quality of 
life (‘need’) and use of SPC, I cannot conclude that lower quality of life 
precipitates a referral to SPC. For example, it may be metastatic disease that 
triggers clinicians to refer to SPC, and the association of quality of life with 
SPC use is in fact a reflection of the association of poorer quality of life with 
more advanced disease. Additionally, I did not examine the role of 
deterioration in determining need for SPC, although this was an important 
dimension of need within my ethnographic findings.  
 
Patients were recruited from four lung cancer outpatient settings within one 
cancer network in London. Limited resources meant it was not possible to 
include an additional contrasting geographical area (such as a rural setting), 
and this may restrict the generalisability of the results to other locations. The 
inclusion of cancer units together with a cancer centre does, however, reflect 
the organisation of cancer services throughout England.  
 
In addition, the outpatient setting excluded lung cancer patients following 
other diagnostic and treatment routes, who may have different patterns of 336 
 
use of SPC. Referral guidelines recommend a common route of GP 
presentation, chest x-ray, and referral to a chest physician clinic following a 
positive result. 237 These guidelines were the basis for choosing respiratory 
outpatient clinics as the setting for the study. However, diagnosis and 
treatment patterns are unlikely to be the same for all patients. A cohort study 
of 246 lung cancer patients in Exeter, Devon diagnosed between 1998 and 
2002 found that, whilst 61% (n = 150) were referred by their GP for specialist 
investigation as outpatients, only 73% of these (n = 110) were referred to a 
respiratory physician. 487 23% (n = 56) were admitted to hospital as an 
emergency. Of the 210 patients referred to secondary care, 93 of these were 
before the publication of the NICE guidance on lung cancer, and 117 after. 
There were statistically significant differences in the route of referral 
following guidance publication, with 37% being referred to a respiratory 
physician before, and 64% afterwards. Whilst this is a substantial 
improvement, it remains likely that not all lung cancer patients are referred 
to designated lung cancer outpatient clinics. 
 
Patients over 75 years were under-represented in the study sample. This has 
important implications for the generalisability of the results, and particularly 
the finding that age was not associated with use of SPC in the study sample. 
It may be attributable to the contribution of 48% of participants by the cancer 
centre, many of whom travel large distances to attend. More elderly patients 
may choose not to travel such distances to receive their care. In addition, 
older patients may be more likely to be treated as inpatients; to be cared for 
under different specialties including medicine for the elderly; or to be 
diagnosed (if at all) much later in the disease course and to remain outside 
the lung cancer clinic setting. 488  
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Further, 95.2% of patient participants stated their ethnicity to be white. I was 
not therefore able to consider use of SPC in relation to ethnic group, due to 
the small numbers in non-white categories. Figures on cancer incidence in 
relation to ethnicity are sparse due to the under-recording of this variable: a 
survey by the Thames Cancer Registry of 2002 cancer registrations found 
that only 22.6% had a valid ethnic code. (489 p. 83) London Health 
Observatory data shows that in 2000/2001, the ethnicity of London residents 
admitted to hospital for lung cancer was unknown for 29% of males and 31% 
of females; of the remainder, 64% of males and 63% of females were reported 
to be white, and 6% of males and 5% of females from other ethnic groups. 490 
The 2001 census reported 75.3% of area residents to be white. Taking these 
figures together, it is likely ethnic minority lung cancer patients are not 
attending outpatient clinics in sufficient numbers, with a proportion being 
diagnosed and treated in other settings.  
 
Developing a rigorous and effective approach to the measurement of need 
was a major challenge for this study. As I discussed in Chapter 6, there are 
currently no psychometrically robust instruments with which to measure 
need for SPC within research. My choice and use of an existing HRQL 
instrument was guided by the aspiration of measuring provider-defined 
need. A number of limitations arise from this approach. 
 
Firstly, I chose an existing HRQL instrument based on domains of need 
developed through my ethnographic study, as well as psychometric 
considerations of reliability and validity. The choice therefore represents 
only my interpretation of need for SPC. Others may have derived different 
categories of import and reach different conclusions. An alternative measure 
of need may lead to different conclusions on the presence or absence of 
equitable care. Whilst age was not associated with use of SPC at a 338 
 
univariable level (even before controlling for need), this remains an 
important conceptual point.  
 
Secondly, the balance between ensuring psychometric robustness and 
establishing content validity meant that I was limited in the choice of 
available instruments, and in how these instruments could be used within an 
analysis of equity. Of particular concern, the EORTC-QLQ-C30 and LC-13 do 
not enable the calculation of a total scale score to reflect the multiple 
domains covered by the instruments. Therefore, I used global quality of life 
score as an indicator of SPC need. It is thus possible that, in spite of my 
extensive critical appraisal of available instruments and their relevance to 
domains of need for SPC, my measure of SPC need was not sufficiently 
comprehensive. However, I did conduct further exploratory analyses to 
investigate the association of particular dimensions of need (including pain, 
breathlessness and fatigue) with SPC use. 
 
Thirdly, due to time pressures relating to the requirements of gaining ethical 
approval, I was not able to assess providers’ views on my choice of 
instrument. Seeking the perspectives of SPC staff on my analysis of the 
domains of need and their mapping onto available HRQL instruments 
would have considerably strengthened the foundation on which my choice 
of instrument was based.   
 
Fourthly, I hoped that greater or lesser need as measured by the chosen 
HRQL instrument would reflect the prioritisation of patients by SPC 
providers. However, I did not investigate if patients’ scores on the EORTC-
QLQ C30 and LC13 reflected their prioritisation by SPC providers. This 
would be an interesting exercise in how the instrument relates to the 
decisions made by SPC providers.  339 
 
Finally, in spite of my best efforts to match the chosen HRQL instrument 
with a conceptualisation of need, it is unlikely that I can measure or capture 
every effect that SPC has.  
 
The final issue I wish to highlight is that this study confined itself to an 
assessment of horizontal equity, considering the association between quality 
of life (‘need’) and the presence or absence of SPC use. I did not collect data 
on intensity of use, covering the nature and level of contact each patient had 
with their SPC provider. Such data, together with a larger sample of patients, 
would enable a more detailed analysis of whether variations in need were 
associated with variations in use: for example, whether patients with a 
higher need for care received a greater level of input from SPC. An 
alternative approach would link stage of disease with the specific amount of 
SPC use, again to assess whether there was equal use of SPC at every level of 
need. Finally, consideration of vertical equity could also investigate the 
urgency with which patients are referred to SPC in response to quality of life 
or stage of disease, reflecting Mooney’s conceptualisation of this concept as 
one of prioritisation. 71 Whilst all of these approaches would considerably 
strengthen my examination of equity, the requirement for a much larger 
sample size and additional data on SPC use precluded this within the 
current study. 
 
The findings in context 
39.3% of participating patients were on the caseload of a local SPC service at 
the time of their completion of the study instruments. Comparable recent 
figures for use of SPC by cancer, and particularly lung cancer, patients are 
limited. A retrospective survey of relatives bereaved in 1990 found that 
27.8% of cancer patients (all sites) were reported to have received SPC at 
some point up until their death. 124 A separate analysis of the same study 340 
 
data reported 29% of lung cancer patients had received help from a palliative 
care nurse. 252 However, these figures are based on retrospective recall of 
relatives some months following death, and rely on the correct identification 
of palliative care professionals by respondents. In a survey of 50 NSCLC 
outpatients in one UK hospital in 2000, 30% reported receiving care from a 
Marie Curie nurse, Macmillan nurse or hospice centre, and 56% reported that 
they had been offered or were aware of these services. 253 Such figures must 
be approached cautiously; in my pilot study I found patients tended to over-
report SPC use compared to actual SPC use. In this study, usage at treating 
hospital sites ranged from 24% to 67%, a variation discussed in more detail 
later.  
 
Participating patients in this study reported a wide range of difficulties, both 
functional and symptomatic. In a survey of cancer outpatient attendees 
across eight tumour groups (including breast, gastrointestinal, head and 
neck and brain), lung cancer patients were identified as having the highest 
number of symptoms, and the most severe problems. 106 In this study, 50% of 
those with metastatic disease were not receiving SPC, suggesting that in 
spite of the presence of advanced disease and corresponding symptom 
burden, SPC usage is not widespread.  
 
Use in relation to age 
This study set out to consider use of SPC in relation to age. A systematic 
review conducted as background to this work found that, in previous studies 
conducted both in the UK and elsewhere, crude odds ratios for the use of 
SPC in older (primarily 75 and above) versus younger cancer patients ranged 
from 0.33 (0.15–0.72) to 0.82 (0.80–0.84). 15 The odds ratio for use of SPC in 
older (≥ 75) and younger (<75) patients in this study was 0.84 (0.48 to 1.46). 
Therefore, whilst there was a slightly lower use of SPC in older patients, the 341 
 
confidence intervals were wide and I found no statistically significant 
difference. There are a number of possible explanations for the discrepancy 
in findings between the current study and previous research. 
 
It is possible that the extensive reforms in cancer treatment and diagnosis 
from Calman Hine onwards have eliminated discriminatory practices within 
cancer clinics since the majority of previous studies were conducted. One of 
the consequences of the Calman-Hine cancer care reforms was an expansion 
in the numbers of palliative care consultants and nurses working as 
members of the lung cancer multidisciplinary team. This is likely to have 
raised the profile and understanding of SPC, and facilitated appropriate 
referrals to these services. 491  
 
Additionally, studies based on retrospective report (as much previous 
research is) may have inaccurate outcomes figures which lead to false 
conclusions of inequalities in care. I found that patients tended to over-
report use of SPC, perhaps due to confusion over the specific titles and roles 
of the doctors and nurses they saw during the course of treatment. As it is 
plausible that inaccuracies in such reports may vary with patient and carer 
age, this problem may become more acute in older respondents. 
 
Further, it is possible that over-75s are under-represented within the 
outpatient clinic compared to the population incidence of lung cancer. Whilst 
the evidence on treatment pathways is sparse, older patients may be more 
likely to be treated as inpatients; to be cared for under different specialties 
including medicine for the elderly; or to be diagnosed (if at all) much later in 
the disease course and remain outside the lung cancer clinic setting. 488 If this 
is the case, additional research is required to establish whether there is a 
difference in use of SPC by age and other important variables for patients 342 
 
treated in settings other than lung cancer specific outpatient clinics. It would 
also be important to examine differences in use of SPC between those treated 
within the outpatient compared to other settings, particularly care of the 
elderly.  
 
However, there are also a number of issues arising in the design and conduct 
of this study which may contribute to my findings. 
 
Firstly, the possibility of an under-powered study must be considered. The 
study was powered to detect a difference in use of 20% between older (≥ 75) 
and younger (<75) age groups, however: 
 
•  only 76 (30.2%) of participants were aged 75 and over 
•  the achieved sample size was 252. A maximum of 300 was the ideal 
target to enable the inclusion of more coefficients within the 
regression analysis, although only 192 were required to locate the pre-
specified difference in use 
•  the actual difference in use of SPC was 4.2%. 
 
As already noted, the sample size calculation was based on the most recent 
English usage data available. This was derived from retrospective carer 
report concerning cancer deaths in 2003 and 2004: reported use of 
community SPC services was 60.0% in under-70s and 38.9% in 70s and over. 
477 Alternative data sources on which to base calculations, located during the 
course of the background systematic review, were from older studies or 
other international contexts. 15 The review found widely varying differences 
in SPC use between age groups, which in part reflected different overall 
usage rates. For example, Italian data on use of home palliative care by 
cancer patients showed a difference in use of 3.3% between under and over 343 
 
75s, although the overall usage rate across all ages was only 4.4%, perhaps 
reflecting differences in the health care system from the UK. 129 By 
comparison, in Canada (which has more similar system to the UK), one 
study found a difference in use of a palliative care programme between 
under and over 75s of 15.1%, in the context of a 44.2% overall usage rate. 102  
 
On reflection, the choice of a 20% difference in use was perhaps over-
optimistic. This difference was derived from a population-based survey 
including all types of cancer deaths, reporting use of SPC up until death. My 
setting was cancer-site specific, setting-specific (attendees of outpatient 
clinics) and included only living patients. This situation reflects the 
difficulties of fitting sample size calculations to available data sets where 
truly relevant data is lacking. The alternative of setting a minimal clinically 
important difference between age groups on which to base sample size 
calculations was considered, but such a figure would be subjective and 
difficult to defend. 492 To increase sample size, I would have had to extend 
the period of data collection, or extend the number of settings for data 
collection, neither of which were possible.  
 
Secondly, previous figures for use of SPC by age are based on retrospective 
studies (cohort, proxy surveys and one case-control study). 15 All were 
sampled from cancer deaths, and all therefore considered use of SPC up until 
the last weeks of life. The cross-sectional design of the current study 
precluded the inclusion of total SPC use. If differences in SPC use between 
older and younger age groups become more pronounced closer to death, 
with older patients less likely to receive such services at this point in time, 
this may explain the discrepancy between the findings of this cross-sectional 
study design with retrospective studies. However, such a hypothesis would 
require factors leading to higher SPC use in younger patients (such as age 344 
 
discrimination) to become more influential in the period shortly before 
death. This seems unlikely.  
 
Thirdly, it is possible that older people are not under-represented in the 
clinics, but were under-represented in the study. There is strong evidence 
that older cancer patients are less likely to receive active treatment for cancer, 
including lung cancer. 247;454;493;494 Whilst I recruited from both chest and 
oncology clinics, there would be a reduced likelihood of recruiting patients 
attending chest clinics for six-monthly or twelve-monthly ‘watch and wait’ 
check-ups compared to patients attending oncology clinics every one to four 
weeks for treatment review. If older patients are more likely to be under 
‘watch and wait’, it is possible that I missed a substantial proportion of such 
patients as they were simply not attending clinic as frequently as younger 
patients.  
 
Finally, the choice of an age cut-off at 75 years may have influenced the 
result. It is possible that differences in use of SPC between older and younger 
patients in this sample do exist, but at an older age of 80 or 85. The choice of 
cut-off was made following careful review of the previous evidence on SPC 
use, and also with reference to the literature on definitions of old age. I felt a 
cut-off of 65 would be too ‘young’, especially as lung cancer is more usually 
diagnosed at an older age. Choosing an older age cut-off such as 85 would 
have resulted, in this current study, in too few participants in the older age 
group. 
 
Use in relation to diagnosing and treating centre 
I found that the hospital clinic within which patients were treated or 
diagnosed was an important determinant of SPC use. This suggests that a 
reduction in regional variations in access to care (a key aim of the Calman-345 
 
Hine reforms) has not been fully realised, at least in terms of access to SPC. 
Variation in the propensity of clinics to refer to SPC has been reported in the 
US health care system, where hospice enrolment for cancer patients varied 
from 50% to 80% between eleven participating health centres within one 
regional integrated health care system. 132 Whilst evidence from the UK 
shows there are geographical variations in access to lung cancer treatment 
(surgery, radiotherapy or chemotherapy) according to health authority 
region, 495 no other research has focussed on within regional differences in 
access to care, including palliative care.  
 
There are a number of factors which may explain variations in SPC use 
within the network. The propensity of clinics to refer to SPC may be 
dependent upon individual clinic staff’s attitudes towards and knowledge of 
SPC; the skills and availability of lung nurse specialists; and the integration 
of the clinic with local SPC services. 496 The clinics studied differed in their 
staff composition and skill-mix: thus, the presence of a lung nurse specialist 
with a palliative care background in one cancer unit may explain the lower 
proportion of palliative care referrals compared to a clinic without a lung 
nurse specialist available to support patients. Additionally, there were 
indications that differences in perceived availability of SPC between clinics 
(for example, known staffing problems within local SPC services, or poor 
provision within the local area) may impact on the likelihood of referrals. 
Staff at the cancer centre in particular may have poorer links with palliative 
care services within the diverse geographical areas patients may be referred 
from, and there may be confusion over whose responsibility (the treating 
centre’s or the diagnosing unit’s) it is to refer patients for care. An emphasis 
on aggressive treatment within a clinic may lead to a lower level of 
consideration of palliative care. Differences in the perceived availability of 
SPC between clinics (for example, if there are known staffing problems 346 
 
within local SPC services, or poor provision within the local area) may 
impact on the likelihood of referrals. There may also be differences in the 
care offered by local SPC services; some may be more likely to discharge 
patients from their care after a brief intervention, or decline to accept 
referrals.  
 
Use in relation to metastatic disease 
Given the emphasis of palliative care on care of patients with advanced, 
progressive illness, the association between metastatic disease and receipt of 
such services is to be expected. 27 SPC in particular focuses on those with 
complex and persistent problems which a generalist palliative care approach 
may not be able to deal with. 19 Advanced disease is typically associated with 
an increase in symptom burden. 240 As treatment options become more 
limited in the presence of metastatic disease, and the focus switches to 
control of symptoms rather than regression of disease, the consideration of 
referral to palliative care may become more pronounced. It is possible that 
the association between HRQL (‘need’) and SPC use, discussed below, may 
in fact reflect the association between HRQL and metastatic disease, and 
subsequently metastatic disease and SPC use, rather than quality of life in 
itself precipitating a referral to SPC. Alternatively, health care professionals 
may routinely perceive patients with advanced disease as having a greater 
need for SPC, regardless of their actual symptom burden.  
 
Use in relation to health-related quality of life 
Need for SPC was measured using a HRQL instrument, chosen following 
work in earlier phases on the conceptualisation of need and the most 
effective approach to measuring this. The primary indicator of need used 
was global quality of life measured using the EORTC QLQ-C30, an 
established and well-validated instrument used widely in cancer research. 497 347 
 
This measure, and by proxy need for SPC, was strongly associated with use; 
the odds of use increased as quality of life declined. The two items 
comprising the global quality of life scale ask respondents to rate their 
overall health, and their overall quality of life. Thus, half of the scale is 
focused on health, which may be interpreted as predominantly physical 
health. Its association with SPC use therefore reinforces the primacy of the 
physical domains of need for care.  
 
Specific dimensions of quality of life (physical functioning, role functioning, 
emotional functioning, social functioning, fatigue, pain, and loss of appetite) 
were also strongly associated with use at a univariable level, with lower 
functional status and higher symptom burdens associated with an increase 
in odds of use. Pain and fatigue, the two symptoms most strongly associated 
with SPC use, have previously been identified as the most distressing 
symptoms for lung cancer patients. 241 It is possible that nausea and vomiting 
among the sample was primarily induced by chemotherapy, rather than 
being associated with more advanced disease and subsequent use of SPC. It 
was not possible to fully examine the inter-relationships between palliative 
care use and functional and symptom scales due to multicollinearity.  
 
The aim of SPC is to achieve the highest possible quality of life for patients 
with progressive illness. One consideration at the beginning of this study 
was that patients receiving SPC may therefore have a better reported quality 
of life than patients not receiving such treatment, as a result of improved 
access to effective symptom control and psychological support. This was not 
the case. Higher symptom burden and poorer functional status indicated 
patients were more likely to be under SPC. However, this does not 
necessarily reflect ineffective care. It is possible that the poorer quality of life 
associated with use of SPC does improve on receipt of such services, but 348 
 
remains below that of patients not referred to (and thus deemed as not 
needing) the service.  
 
Summary and interpretation of findings 
My results are to some extent encouraging, suggesting that extent of 
patients’ disease and quality of life, rather than sociodemographic 
characteristics such as age, are associated with use of SPC within the 
specialist cancer care setting. However, outstanding questions remain to be 
resolved. The pathway to care for patients of all ages must be examined to 
determine whether these findings apply to patients treated in settings other 
than the specialist cancer care system, such as care of the elderly. The wide 
variation in use of SPC between clinics also requires further exploration, 
including the extent to which differences in clinic culture, provider 
relationships and service availability influence access to SPC.  
 
This survey has demonstrated the feasibility of gathering data directly from 
patients, rather than relying on retrospective approaches, in examining 
equity of use of SPC. It further emphasises the importance of including a 
measure of need to investigate use. However, future research must be 
broader in scope to include all patients regardless of their treatment setting 
to better examine the use of services in relation to need.  
 
This was the final phase of empirical work I undertook. In the concluding 
chapter which follows, I draw together findings from the qualitative and 
quantitative phases of this mixed methods study to present my inferences on 
need for and use of SPC. I return to the underlying themes of social justice 
and equity to consider how these results may be interpreted in the light of 
theories of inequalities in health care. Finally, I consider what further studies 349 
 
may be required to continue to develop methodology, research and practice 
in this field.  350 
 
Chapter 8 
 
Conclusions 
 
 
Below the surface stream, shallow and light, 
Of what we say we feel – below the stream, 
As light, of what we think we feel – there flows 
With noiseless current strong, obscure and deep, 
The central stream of what we feel indeed. 
 
Matthew Arnold. Untitled. 498 
 
 
In this study I investigated equity of use of SPC services by age within one 
cancer network. I had three core objectives: 
 
1.  To explore, using documentary evidence, qualitative observation and 
interviews, how SPC providers define and conceptualise patients' 
need for care. 
 
2.  To systematically identify HRQL instruments developed for use in 
palliative care and lung cancer patient populations, and to appraise 
their validity for use as indicators of need for SPC. 
 
3.  To conduct a cross-sectional survey to measure use of SPC in younger 
versus older lung cancer patients in relation to need. 
 
In this chapter, I draw together findings from the different phases of work to 
present an integrated interpretation of results. I consider strengths and 
weaknesses in both the conception and implementation of the study. I reflect 
on how inferences drawn from the study relate to theories of social justice, 351 
 
equity and need discussed earlier in the thesis, and consider methodological 
implications for investigations in this field. Finally, I present further 
questions raised by this work, and discuss their potential for future research 
and policy. 
 
8.1 Integration of findings 
The mixed methods design of this study was conceived to enable each phase 
of work to influence subsequent phases. Thus, I used findings from the 
ethnographic study to inform the design of the cross-sectional survey; to 
guide a choice of HRQL instrument as an indicator of need for SPC; to 
highlight variables to include in the primary analysis of the use of SPC; and 
to decide on further variables to include in exploratory analyses of the use of 
SPC in relation to specific dimensions of need. These inter-relationships 
between different aspects of the research are illustrated in Figure 8.1.  
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PHASE 1: 
PROVIDERS’ CONCEPTS 
OF NEED FOR SPC 
PHASE 2: 
EQUITY OF USE OF SPC 
Objective:  
To explore providers’ 
conceptualisations of need 
for SPC, and factors 
determining the offer of 
care 
Methods:  
Documentary analysis, 
qualitative observation and 
interviews with three SPC 
service providers.  
Analysis:  
Thematic and content 
analysis of transcripts of 
observed meetings; 
thematic analysis of 
interviews and fieldnotes 
Objective:  
To investigate equity of use 
of SPC by lung cancer 
patients in relation to age 
Methods:  
Cross-sectional survey of 
lung cancer patients and 
carers attending outpatient 
clinics at four hospitals 
Analysis:  
Statistical (multivariable) 
analysis of questionnaire 
and medical records data 
QUAL  QUAN 
Design: 
Ethnography 
Design: 
Cross-sectional survey 
Content analysis guides choice of 
McMaster Quality of Life instrument as 
indicator of need in pilot study. Problems 
with McMaster in piloting means choice 
switched to EORTC HRQL instruments. 
Global quality of life score from EORTC 
QLQ-C30 used as measure of need for 
SPC in main study: continuous scores 
rather than dichotomous need/no need 
used as a result of ethnographic findings  
PHASE 1b: 
MEASURING NEED FOR 
PALLIATIVE CARE 
Systematic literature review 
and critical appraisal of 
HRQL instruments used in 
cancer and palliative care 
Thematic analysis 
highlights importance 
of including carers in 
survey 
‘Living alone’ included 
as explanatory variable 
in main analysis as a 
result of ethnographic 
findings 
 
Figure 8.1 Study inter-relationships 
Ethnographic findings guide choice of 
explanatory variables in exploratory 
analysis of association of specific 
dimensions of SPC need with use: 
physical, emotional and social 
functioning, fatigue, pain, nausea and 
vomiting, appetite loss and dyspnoea 353 
 
My findings suggest that older age is not a barrier to the receipt of SPC for 
patients who are attending specialist cancer care clinics. Instead, the 
likelihood of referral to SPC for such lung cancer patients is associated with 
HRQL and disease severity [Figure 8.2]. In spite of a substantial proportion 
of carers reporting psychological distress, this is not associated with use of 
SPC. Whilst these findings demonstrate that referrals to SPC tend to respond 
to patients’ symptoms and disease stage, wide variations in the proportions 
of patients using SPC between clinics suggest an important role for clinic 
culture and individual staff practice in determining access. 354 
 
 
 
 
Presence of lung cancer 
Presence of need for SPC 
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Once a referral is made to a SPC service, the patient and their carers are 
assessed against a holistic concept of need, covering in particular the 
physical, psychological and social domains of care. Whilst spiritual concerns 
are documented as influencing the prioritisation of patients for care, in 
reality these are rarely fully assessed.  
 
For patients receiving SPC, an implicit idea of ongoing need is based on a 
model of acute reactive care. This focuses in particular on the physical, but 
may be shifted to concentrate on psycho-social issues where these are 
especially urgent. This model of need reflects the biomedical paradigm of 
care of a predominantly clinical and nursing staff, and the resource 
limitations within which they work. 
 
Whilst age is not related to use of SPC, and my ethnographic work suggested 
no explicit age discrimination, I do, however, have some concerns about the 
influence of age in access to and provision of care.  
 
Firstly, over-75s were under-represented in participating cancer clinics. 
Potential reasons for this were discussed in full in Chapter 7, including the 
impact of the inclusion of a cancer centre with a younger age profile, and the 
possibility of alternative care pathways as a result of patient age. In the 
absence of further research examining the locations of care and treatment 
received for all lung cancer patients in relation to age, my concerns are 
speculative. However, there remains the possibility that older lung cancer 
patients may be less likely to receive specialist oncology care, in 
contradiction of NICE guidance which state access should be provided 
regardless of age. 237  
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Secondly, my qualitative findings suggest that the nature of SPC may on 
occasion differ as a result of patient age, with older patients receiving lower 
quality care. I observed that older patients may be more likely to wait for an 
inpatient SPC bed, or were less likely to be offered a bed in a private room 
rather than on a ward. Younger patients may be regarded as ‘special’ or 
particularly tragic and thus deserving of different levels of care. However, I 
was not able to measure intensity of care (in terms of numbers of contacts 
with SPC staff and treatments received), or explore this matter more deeply 
with SPC staff, so this remains a speculative point.  
 
8.2 Limitations of the study 
A clear theoretical and methodological base underpins this study. Research 
into concepts of social justice, equity, need, access and use during the process 
of study design meant that I undertook data collection and analysis with a 
strong idea of the approaches I wished to draw upon. This sets the study 
apart from previous research in the field, which has either failed to define 
need for SPC, or has used a limited definition such as a diagnosis of cancer 
or the presence of pain. However, this approach also had its challenges, 
which I outline below.  
 
My attempt to operationalise the concept of capacity to benefit through 
ethnographic work in conjunction with a systematic review of HRQL 
instruments may be questioned on a number of levels. The findings from my 
ethnographic study and the models of need I derived from these may not be 
replicated by other researchers (due to differences in individual knowledge, 
experiences and approach), or in other settings (due to differences in 
practices and procedures). Using HRQL as a proxy for SPC need is only one 
option; alternative formulations may focus on specific key symptoms or 
indicators of disease severity such as stage of cancer. However, in my view 357 
 
these more limited approaches do not fit with the holistic aims of SPC. I 
matched domains of SPC need to existing HRQL instruments to assess 
content validity. However, due to the requirements of instrument scoring, in 
my primary analysis I used only global quality of life to approximate need. 
Thus, although I developed a comprehensive conceptualisation of need, this 
was not what I was able to examine in practice. However, the conduct of 
further exploratory analyses on specific dimensions of need and their 
association with SPC use goes some way to alleviating this. In spite of these 
concerns, the use of a HRQL instrument as a proxy for need is a step forward 
compared to previous work in this field.  
 
My primary outcome of interest was use of, rather than access to SPC. Whilst 
conceptually access is the more important of the two (reflecting the political 
commitment to equity of access, rather than simply use, of health care 453), in 
practice this is difficult to measure. Understanding whether patients have 
the opportunity to use SPC, rather than whether they have used SPC, 
requires an understanding of the true availability of these services, a 
measure which in practice is almost impossible to ascertain.  
 
I measured use of SPC as being on the caseload of a SPC provider. This 
provided a simple dichotomous outcome of ‘SPC’ or ‘no SPC’. I did not 
attempt to measure intensity of care, in relation to the nature and level of 
contact patients had received from the service up until their participation in 
the study. Such information may be able to give useful insights into how the 
care provided varied on the basis of patient characteristics such as age, and 
would have provided a more robust and detailed measure with which to 
investigate the presence or absence of equity. However, obtaining and using 
such information was outside the resources of this study. In addition, the 
sample size was not sufficiently powered to examine vertical equity. 358 
 
The use of mixed methods broadened the research questions I addressed, 
and deepened the inferences I drew. Using techniques drawn from 
qualitative and quantitative traditions meant I was able to weave together 
ideas about need with the measurement of need. The pragmatic grounding 
of the study enabled me to use whichever methods would best answer the 
question at hand, and freely draw upon all techniques when necessary (such 
as the quantification of some qualitative data) to develop my analysis. This 
was essential in developing a comprehensive picture of the organisation of 
SPC for lung cancer patients within the study area. 
 
The study is limited by its inclusion of only a proportion of the care 
providers within only one cancer network. The addition of all the cancer 
units within the network would have enabled me to develop a more 
complete picture of care. Further, the participating network is a mainly 
urban area with historically strong SPC provision and major teaching 
hospitals providing access to the latest lung cancer treatments. The study 
would have been strengthened by including a contrasting cancer network 
with different organisation and provision of SPC and lung cancer care. For 
example, patterns of access to and use of SPC may differ considerably in 
rural areas in England. Including additional participants would, of course, 
require additional research capacity, which study funding did not allow.  
 
The study could have been further enriched by the inclusion of the planned 
third phase of work, interviews with lung cancer patients and referring 
health care professionals to examine demand and supply side factors 
influencing referral to and uptake of SPC. These alternative perspectives on 
need for SPC and the decision-making process around referral to or 
acceptance of care are an important aspect of explaining variations in use. 
Their undertaking would bring greater understanding of the issues at hand, 359 
 
particularly the influence of age on patient pathways. For example, 
interviews across a diverse age range would have facilitated the exploration 
of patient attitudes towards the natural process of ageing, expectations of 
care in relation to age, and attitudes towards death, dying and specialist 
palliative care. Differences in attitudes may have an important impact on 
patient-defined need for care; interviews with referring professionals would 
have introduced further ideas about the relationship between age and need 
for care at the end of life. Patient interviews would also enable exploration of 
the particular experiences of lung cancer patients in their receipt of and 
desire for care, an important and currently under-researched topic.  
 
A number of the issues summarised above relate to the scale of the study. A 
larger funding application, building on the work presented here, would 
support a multi-centre cohort study to address issues of vertical and 
horizontal equity and patient experience across all settings. Yet the 
underlying conceptual difficulties are relevant to all sizes of study; how best 
to define, operationalise and measure need remains a challenge within this 
field. The work presented here represents a considerable step forward in 
addressing this issue, but more needs to be done at the theoretical level to 
inform the development of robust methodology to investigate inequities.  
 
I turn now to consider the inferences that may be drawn from my study 
findings. Drawing upon the theoretical underpinning of the work, I relate 
my results to dominant theories of need for health care and concepts of social 
justice.  
 
8.3 Need for specialist palliative care 
Need for health care may be assessed either at the level of the population or 
the individual [Figure 8.3]. Needs assessments are conducted for the 360 
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purposes of distributing health care resources at a macro level (in the form of 
health care planning), or at a micro level (in clinical decision making). The 
aim of needs assessments may be to ensure equity within a community, or 
prioritise those most in need, or (as we have seen with current Government 
policy 6), some mixture of the two. Assessments of need may use 
quantitative, qualitative or mixed approaches to achieve their goal. Whilst 
population-level assessments tend to draw upon epidemiological data, 
clinicians may use information from multiple sources to inform their 
decision on the nature of care to offer. Within this study, I was concerned 
with clinical decision-making and with identifying need at an individual 
level. However, I drew upon a primarily macro-level concept of need (that of 
capacity to benefit) to inform my approach.  
 
 
 
 
 
 
 
 
 
 
 
Drawing on the idea of capacity to benefit, I derived two models of need for 
SPC. The first, ‘aspirational’ model is holistic. It suggests a clear link between 
capacity to benefit and physical, psychological, social and spiritual domains 
of both the patient and their family. The second, ‘actual’ model is more 
restricted. It suggests the capacity to benefit is more closely aligned to 
physical aspects of care for the patient. 
Figure 8.3 The definition and assessment of need in health care planning and delivery 361 
 
These alternative formulations highlight the fluid nature of need, its 
‘infinitely contestable’ nature. 74 Sociological studies on clinical decision 
making have provided clear evidence that need for care is shaped through a 
discourse that incorporates implicit categorisations of patients and a wide 
range of social factors. 91;92;323 As I observed, prioritisation of patients was a 
subtle and fluid process; whilst a primarily biomedical model of need 
formed the backbone of a patient assessment, this was woven into an 
analysis of the available resources and an acknowledgement of 
characteristics including age. This complex reality must, however, be 
reduced to a measurable phenomenon if we are to research the equitable 
provision of care using quantitative methods. The move from qualitative to 
quantitative and from nuanced to clearly defined is challenging; some of the 
limitations have already been outlined above.  
 
I believe that the aspirational model of SPC need is a useful one. Firstly, it 
provides a strong conceptual framework for the design and implementation 
of SPC services. Secondly, it is the model SPC staff use to assess patients, 
even if their subsequent delivery of care is not as broad in scope. However, 
the evidence of effectiveness to support this model – particularly in the social 
and spiritual domains – is limited at present. 223 This is a weakness when 
concepts of need for health care stress the importance of that health care 
being effective. 24 Thus, the evidence base to support this model must be 
expanded. If there is evidence of effectiveness across all dimensions, more 
resources may be directed towards implementing comprehensive SPC 
services. 499  
 
In the light of current resource limitations, it may appear more sensible to 
use the primarily physical, ‘actual’ model of SPC for policy and planning 
purposes. A focus on the relief of physical suffering requires fewer resources 362 
 
than a holistic approach to care. Further, as the proportion of older people in 
our population expands and demand for end-of-life care subsequently 
increases, resources may become even more limited.  
 
However, there is a theoretical justification for SPC services to continue to 
strive to implement the ‘aspirational’ model of care, and improve the nature 
of the care provided to all their patients. Jennifer Prah Ruger, amongst 
others, has argued for the importance of the concept of ‘shortfall’ in assessing 
the equity and quality of health care. 500 I discuss this in more detail below, 
but the idea of assessing the gap between the care which is actually delivered 
and the highest attainable standard of care is relevant here. The aspirational 
model of SPC may be attainable with sufficient resources and an experienced 
multi-disciplinary team. As I have discussed in this thesis, patients are 
initially assessed against multiple domains of need, but the decision making 
process and the provision of ongoing care tends to be weighted toward the 
physical. Within the concept of ‘shortfall equality’, inequality results for 
anyone who receives less than the highest standard of care. The retention of 
an aspirational model of need thus serves to provide a gold standard against 
which to measure performance. This is a demanding measure to meet, but it 
lends support to continuing to set out what a sufficiently resourced service 
should achieve. 
 
I would argue that the continued existence of an ‘aspirational’ model of need 
does not imply that the ‘actual’ model of need is necessarily problematic at 
present. I did not undertake interviews with patients as planned, so I am not 
able to conclude whether a primary focus on physical needs is or is not 
acceptable from their perspective. Research suggests that satisfaction with 
SPC, particularly within hospices, is high, although there are concerns about 
the methodological rigour of studies conducted to date. 501 However, it 363 
 
remains likely that, in spite of the potentially reduced nature of care many 
patients receive against the ‘gold standard’ aspiration, benefit (in terms both 
of patient satisfaction and symptom relief) is still delivered. SPC is a 
relatively young movement within medicine and nursing, and continues to 
strive to improve its evidence base and models of care delivery. Within the 
UK, shifts in funding and Government policy have contributed to difficulties 
in fully achieving goals of care; this may change in the future. 502 Whilst 
services and evidence continue to develop and expand, the effective relief of 
physical symptoms for those in the last months of life remains an essential 
part of our health care system.  
 
The existence of both ‘aspirational’ and ‘actual’ models of need within one 
specialty, and the requirement to understand these both qualitatively and 
quantitatively, requires clarity about the purpose, level and nature of any 
needs assessment undertaken. Capacity to benefit is an instrumental theory 
of need, based on the idea that health care is required to achieve a particular 
end state, such as improved quality of life. However, in practice such 
instrumental concepts may be subsumed within normative assessments of 
need based simply on the belief of a SPC provider that care should be given 
to a particular patient, without reference to the goal of that care. Yet, I have 
demonstrated that capacity to benefit still has utility in guiding examinations 
of clinical decision-making. The greatest challenge in much research into 
need will be moving between the micro and the macro, between qualitative 
and quantitative assessments, whilst maintaining clarity about the 
phenomenon at hand. Below, I develop further the role of need within equity 
research and its relevance to theories of social justice.  
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8.4 Aspects of equity and priority 
The current Government’s drive for equal access to SPC, regardless of 
patient characteristics such as age, stems from their concern with social 
justice. In the background to this thesis, I outlined alternative theories of 
social justice, aligned to egalitarianism (opportunities approaches and the 
capabilities approach), prioritarianism, and sufficientism. Broadly, these are 
concerned either with the achievement of equality in access to health care; 
targeting access to health care for the worst off to raise them from the lowest 
level of health; or with ensuring adequate health care for everyone.  
To date, egalitarian ideals have dominated health policy and research, on the 
basis that everyone should have equal access to effective health care to 
achieve their full health potential. 503 However, there is evidence that within 
the context of limited resources the focus moves to prioritisation of the worst 
off at both the macro (population) and micro (individual) level. 322 Further, in 
circumstances of severely limited resources, ensuring that everyone receives 
a basic minimum standard of care may be the most pressing concern. 504 
Strict adherence to one theoretical ideal is therefore unlikely to happen in 
practice, as current Government concerns with both reducing inequities and 
improving the position of the worst off shows. 505  
 
I focus here on egalitarian theory, as my investigation was based on the 
policy goal of ensuring equal access to SPC on the basis of need. Whilst both 
opportunity and capability-based accounts support the goal of equal access 
to care, the reasons behind their support and the detailed formulation of 
what this entails differ. Opportunities-based theories, derived from the work 
of Rawls, justify the fair provision of health care on the basis that it secures 
opportunities for individuals within society. As loss of normal human 
functioning may be addressed by the provision of care, Rawlsian approaches 
associate an equal right to health care with the broader requirement to 365 
 
promote equal opportunity within society. 37 A capabilities-based defence of 
equal access to health care takes a broader approach, arguing the goal is not 
removing barriers to opportunity, but a deeper aim of ensuring the social 
conditions in which all individuals have the capability to be healthy. 48 It is 
the capabilities-based approach which I feel has particular relevance to the 
findings presented here.  
 
The capabilities-based approach provides a framework through which 
assessments of wellbeing, including investigations into inequalities, may be 
conducted. However, a capability theory of justice has not yet been fully 
developed within political philosophy; further, the capability approach lends 
itself to the development of more than one theory of justice. 506 Regardless of 
this, attempts have been made to draw upon the capability approach to 
assess inequalities. As outlined in Chapter 2, Wolff and de-Shalit have 
provided one formulation through which to assess injustice, suggesting that 
society should focus on ‘genuine opportunities for secure functioning’, 
which requires, in the context of limited resources, an initial prioritisation of 
the worst-off. 62 They suggest how this might relate to inequalities in health 
care; whilst decisions to offer care will be based on clinical need, these will 
be taken within a broader context aiming for the most efficient distribution 
of resources to improve the position of the most disadvantaged. Whilst this 
theory was specifically formulated to have direct policy relevance and 
provides a useful framework to guide strategy, it is another capabilities 
account, derived specifically to relate to health care, I find most useful here.  
 
The ‘health capability approach’ recently developed by Jennifer Prah Ruger 
incorporates health care quality, health agency, and health norms within 
assessments of health care inequalities [Figure 8.4]. 46;48 In formulating this 
theory, Ruger draws both on Sen’s capability approach and on Aristotle’s 366 
 
political theory. 48 Its broad approach to inequalities in part reflects Margaret 
Whitehead’s influential formulation of equity, which stressed the importance 
of considering access, use and quality in investigating variations in health 
care. 23 Below, I consider how the major concerns of the health capability 
account (the concept of shortfall equity and the principles of horizontal and 
vertical equity) and the three domains through which to assess inequalities 
under this account (health care quality, health agency and health norms) 
relate to the findings of this study. 367 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Firstly, Ruger’s account does not require equal outcomes amongst people in 
terms of achieving equal health or receiving equal amounts of healthcare. 
Instead, it concentrates on evaluating disparities in terms of ‘shortfall 
equality’. This concept considers the deficit in achievement from an 
individual’s potential for health, or from a health care services’ potential to 
deliver. 47;48;507 Thus, equity should be assessed by considering how far 
experiences of SPC fall short of the agreed standard of care all patients are 
expected to receive. Systematic differences between groups, such as older 
and younger patients, in gaps between expected and received care would 
suggest inequities. This pursuit of a ‘gold standards’ of care is challenging, 
although Ruger urges society to take this challenge on. 48 
 
‘Shortfall equality’ is a useful approach to considering the role of the 
‘aspirational’ model of SPC, and the ‘actual’ model of SPC I derived. The 
aspirational model serves to underpin efforts both to improve care, and to 
Health care quality  Health agency  Health norms 
GOAL: 
Ensure the social conditions in which all individuals have the 
capability to be healthy 
POLICY: 
Equal access to necessary and appropriate health care in proportion 
to health need 
ASSESSED IN RELATION TO 
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improve the evidence base for care. The actual model focuses attention on 
current experiences of care and whether these are agreed to be deficient or 
not. Under the concept of shortfall equality, all patients receiving a more 
restricted model of SPC may be disadvantaged, as there is a gap between the 
care they receive and the ‘gold standard’ of care.  
 
A second dimension of the health capability account is that the allocation of 
resources should follow the idea of proportional distribution derived from 
the Aristotelian principles of horizontal and vertical equity (like treatment 
for like, and unlike treatment for unlike). Thus, individuals with greater 
needs should receive more health care resources to restore their health 
functioning as far as possible, as long as other individuals with similar needs 
receive the same level of care. 48 Ruger suggests that health care should be 
offered only if it is necessary and appropriate, aspects which should be 
assessed by patients and their clinicians. This formulation of equity 
highlights the importance both of meeting the needs of all, whilst 
acknowledging that some needs are greater than others.  
 
The prioritisation of patients within SPC, and the subsequent devotion of 
greater resources to them, would thus be justified on the basis that 
‘individuals merit the resources they need to reach a medically determined 
level of health functioning’. 48 The complex discussions I observed at 
inpatient admissions meetings as to which patients should be admitted to a 
limited number of beds represent the efforts by SPC staff to understand and 
prioritise levels of need. For example, home care patients referred for 
inpatient care were prioritised over hospital patients, who were deemed to 
be in a ‘safe place’ and thus less requiring of care. Principles of vertical and 
horizontal equity are further reflected by my finding that the 22 survey 369 
 
participants referred to SPC on the day of diagnosis (23% of all those 
receiving SPC) all had metastatic disease by this time.  
 
What Ruger’s theory cannot do is provide insight into whether the 
formulation of need for SPC on which access is based is acceptable. She 
suggests that decisions about which health care services to provide, and to 
what level, should be taken using a decision-making framework integrating 
both clinical and economic considerations, and based on both procedural 
and substantive principles. 46 Thus, policy-makers, the public, patients and 
clinicians may agree that the provision of the ‘actual’ (predominantly 
physical) model of SPC may be the best approach within current resource 
limitations. As such, the current model of care identified here would be 
unproblematic. However, it is also likely that the health capability account 
would support the retention of the ‘aspirational’ view of need as an ideal to 
work towards. As noted above, interviews with patients and referrers to SPC 
services would here be useful to start to explore expectations of and 
satisfaction with models of care. 
 
The health capability account suggests three dimensions through which 
health care inequalities should be assessed. Firstly, it is concerned with the 
achievement of high quality care for all. Ruger argues that differences in 
health care quality are ‘morally troubling and unjust’. 48 Such differences 
undermine individual’s capability for health functioning. Thus, people with 
the same health condition should enjoy the same access to care. My 
observations that older people may wait longer for an inpatient hospice bed, 
or receive different levels of care once admitted, would thus highlight a 
breach of standards of equal access. A full examination of equity drawing 
upon the capability approach would demand a consideration not just of 370 
 
outcomes – whether a patient received SPC or not – but also what happened 
to each patient under the care of a SPC team.  
 
The second dimension, health agency, is concerned with the ability 
individuals have to use the high quality health care available to them to 
attain the highest possible health functioning. Health agency: 
 
...includes more than health knowledge, but effective decisional balance with respect 
to health, self-management and self-regulation skills, and ability to command control 
of personal and professional situations to pursue health, among other important 
qualities. 48 
 
Individuals may vary in the degree of health agency they enjoy, and the 
health capability account places a responsibility on society to nurture a 
minimal level of health agency for all. Older cancer patients may, for 
example, be less likely to recognise important symptoms, to negotiate access 
to health care, to communicate with health care providers, and to be able to 
self-care. 160;508 Reduced levels of health agency amongst older patients may 
thus be an important dimension of equitable access to SPC, including the 
level of service received once patients are on the caseload of a provider. 
However, without interviews with patients to explore this phenomenon, no 
further understanding of its impact on SPC access may be derived. 
 
The final dimension of the health capability account is a concern with health 
norms. Health norms are beliefs about health, ill-health and health care that 
influence choice at the individual and community level. 48 Societal norms 
may result in social exclusion and disadvantage. Here, an opportunities-
based account would focus on changing the situation of a disadvantaged 
individual (for example, an elderly cancer patient) through the provision of 371 
 
resources (for example, health care). A capabilities-based account, by 
contrast, would provide appropriate health care whilst also striving to 
change norm-based inequalities and improving opportunities for health 
agency. Thus, if social norms suggest older cancer patients do not have equal 
moral worth and are as a result excluded from aspects of care, the pursuit of 
equal access to health care must involve tackling deep-rooted attitudes 
across wider society.  
 
I observed that SPC attitudes towards older and younger patients may vary. 
Deaths of younger patients were commented on as particularly tragic or 
shocking, echoing previous findings that within SPC deaths occurring at a 
young age were seen as ‘bad’ deaths. 509 Concerns were expressed about the 
nature of care provided for older patients within SPC, and ensuring 
providers were not drawn into aspects of care deemed unsuitable for them; 
as one doctor cautioned ‘she is an elderly lady like a lot of elderly ladies out there’. 
One clinician directly acknowledged that the service was likely to make 
more of an effort for younger patients. These suggest the existence of norms 
within SPC, reflecting those of wider society, in which older patients are 
perceived as less deserving of care. Whilst the policy and legal context may 
strongly discourage age discrimination, changing implicit values and 
attitudes is more challenging. 8 
 
The under-specification of capability theory means that it should be 
partnered with additional or alternative theories in seeking to examine 
phenomena of interest. 510 Ruger does not specify how need for health care 
may be conceptualised, operationalised and measured, simply stating that 
within her approach equal access to care is based on need for necessary and 
appropriate health care. The concept of capacity to benefit from care is one 
that is used widely within the health economics and public health literature, 372 
 
and is useful here in providing an approach to determining the dimensions 
of import. Capacity to benefit may include multiple dimensions of care, as 
within SPC. 26 However, the requirement that care should additionally be 
effective highlights the need for an expansion of the SPC evidence base to 
enable the field to meet its aspirations.  
 
The capability approach has been adopted within a pragmatist perspective 
by Zimmermann. 292 As with pragmatism, Sen’s formulation of the capability 
approach rejects utilitarianism’s narrow conception of action as being 
motivated by the achievement of desires. Instead, both emphasise the 
importance of ability and freedom to achieve, rather than achievement itself. 
Further, Sen’s commitment to the role of human agency (including 
motivations, beliefs and emotions) and the influence of environmental and 
economic circumstances on that agency echoes the pragmatist conception of 
‘situated action’, the interaction between agency and the environment. 292 
Finally, the link made by Sen between knowledge and action is paralleled in 
the pragmatist approach to inquiry, seeking both to develop knowledge and 
to drive corresponding changes in political values and commitments.  
 
The ethical dimension to both pragmatism and the capability approach 
provide strong support for research into inequalities which is driven by a 
belief in the moral importance of understanding and taking action against 
disadvantage. Additionally, considerations of individual agency and context 
highlight the need to incorporate a temporal dimension to such research. 
Agency, opportunities, capabilities and environmental factors may vary 
throughout the course of an individual’s life, or throughout a disease 
trajectory, as well as a result of characteristics such as age. 292 Thus, factors 
which promote or impede access to care may differ between one time point 
and another, and between one individual and another. This supports the use, 373 
 
where possible, of methods which enable investigation into the whole 
patient journey. Finally, a pragmatic and capability-based understanding of 
agency and context supports the examination of the complex processes 
generated through the interplay between macro, meso and micro elements; 
of how inequalities may arise through the interaction of population-level 
policy with individual-level decision making. Mixed methods approaches 
provide a useful approach to investigating these multiple dimensions of care. 
 
In examining equity of health care access, I believe that Ruger’s framework 
of health agency, healthcare quality and health norms is an important 
development in building a comprehensive understanding of inequities. The 
use of both qualitative and quantitative methods enables investigation of 
each of these dimensions to achieve a holistic understanding of the processes 
and outcomes of care. Finally, a capabilities approach underpinned by a 
pragmatic philosophy enables researchers into inequalities to acknowledge 
the ethical and moral dimensions of their work. 
 
I would therefore conclude that, whilst I did not find disparities in use of 
SPC between older and younger patients, this is not sufficient to suggest 
inequities are not present. Regardless of age, patients with equal needs 
should receive the same level and quality of SPC, and should additionally be 
supported in recognising their needs. As already acknowledged, in this 
study I was not able to address every dimension of the health capability 
account required to comprehensively identify disadvantage. Below, I outline 
how future research may continue to add to our understanding of equitable 
SPC. 
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8.5 Recommendations for research and policy 
In this study I considered the experiences of patients within the specialist 
cancer care system. This setting is not representative of the experiences of all 
patients with a diagnosis of lung cancer. As my findings suggest, the age 
distribution within these clinics is unlikely to reflect the age distribution of 
lung cancer incidence within England as a whole. The question remains, 
therefore, whether access to SPC is equitable by age for all lung cancer 
patients regardless of treatment setting. This would require study of patient 
pathways to SPC (or not) across all potential locations of care. Ideally, 
recruitment would start within the primary care setting. More realistically, 
studies would encompass all potential locations of secondary care for lung 
cancer patients, including care of the elderly, general medicine, oncology, 
and A&E. This would enable a comprehensive understanding of the 
treatment received by all patients, and how this varied by age. 
 
Originally I set out with the aim of conducting a cohort study to investigate 
not only access to SPC, but also the nature and level of SPC received. This 
was not achievable with the resources available, but is an important next 
step if we are to obtain the best possible evidence on use of SPC, and 
particularly the presence or absence of vertical equity. As already outlined 
above, the ideal would be to follow patients from GP referral for 
investigation of lung cancer (or presentation within A&E) to death, with an 
additional assessment following death to determine the bereavement 
services family and friends receive. This would be resource intensive, but 
would form the most robust approach to examining both the full patient 
pathway and the nature of SPC received.  
 
Data on the precise amount and type of SPC received – telephone 
consultations, home visits, clinic appointments, inpatient stays – would 375 
 
enable a detailed examination of the proportionality of care. Do patients with 
similar needs (in terms of stage of disease or type and ‘troublesomeness’ of 
symptoms) receive similar levels of care? Are there disparities by age? This 
would provide greater understanding of whether equal quality of care was 
offered.  
 
The aspirational model of need I derived highlights the importance of 
understanding whether SPC approaches to the provision of psychological, 
social and spiritual support are effective. Building this evidence base would 
have implications for both policy and practice. Firstly, if there were positive 
evidence for the impact of SPC on these less tangible dimensions, providers 
would be able to shape their services around the most effective model of 
care. Researchers would better understand whether we are to assess equity 
in care delivery against a reduced or more holistic model of need. Finally, 
policy makers would be able to consider whether SPC should receive more 
resources to support their development of the holistic ‘physical, 
psychological, social and spiritual’ model of care.  
 
The tension between quantitative and qualitative accounts of need for health 
care, and SPC in particular, remains a challenge. Further exploration of the 
construction of patient need within clinical discourse would enable greater 
understanding of the processes by which use of health care is determined. 
Within SPC, attempts to develop a suitable measure of need for care are 
ongoing (see for example 511). Whilst this study used HRQL as an indicator of 
need, alternative formulations could incorporate known dimensions of the 
decision-making process to provide a more refined measure.  
 
Finally, the capabilities approach has interesting implications for 
assessments of equity. Methodological approaches to the fair provision of 376 
 
care have to date focused primarily on use of health care alone. 
Incorporating assessments of quality, agency and norms into research 
studies would require a wider scope to enquiries, including an 
understanding of how our culture contributes to health care provision, 
access and use. Mixed methods would be particularly suited to this task, 
facilitating the combination of quantitative measures of quality and access 
with qualitative explorations of social norms and health agency.  
 
It is difficult to make clear policy recommendations when much further 
research is required. If, for example, the holistic measure of need for SPC is 
demonstrated to have a robust evidence base, this will have implications for 
the resources required to enable patients at the end of life to receive the 
highest quality care, including psycho-social support. Additionally, more 
information about the care pathways of older lung cancer patients is needed 
before further action can be taken at a policy level to address any potential 
inequities of care.  
 
The health capability account, incorporating health quality, agency and 
norms, highlights the importance of formulating health care policy across all 
Government departments. In particular, changing potentially negative health 
norms about ageing requires action across the whole of society. Whilst the 
Equality Bill introduced in 2009 highlights the need to tackle deep-rooted 
attitudinal issues in all arenas, changing individual behaviour and 
organisational culture remains a challenge for policy makers keen to achieve 
equity. 9 377 
 
Summary 
In this thesis I have presented research drawing on theory and evidence 
from a range of sources, including philosophy, economics, and public health. 
The goal throughout has been to contribute to our understanding of the 
fairness of health care; to do so, I focused on the experiences of lung cancer 
patients, and the specialty of SPC. As I have outlined previously, fairness is a 
contested concept. So are need, use, quality of care, old age and other issues 
central to this work. Throughout my research, I have endeavoured to learn 
about, consider and critique the various approaches to these concepts, 
eventually drawing upon those that sat best with my research outlook and 
the subject at hand. Thus, I have utilised a pragmatic, mixed methods 
approach to guide the design and conduct of my studies. I have taken an 
instrumental concept of capacity to benefit to guide an operationalisation of 
need for SPC. I have chosen an existing to HRQL instrument to measure this 
need. Finally, I have drawn on a capability account of health to explain my 
findings of use and quality of care, and to highlight the need for more 
comprehensive examinations of pathways to care to inform policy.  
 
Previous research in this field has commonly concluded that older people are 
less likely to access SPC. However, this research has also neglected to 
conceptualise, operationalise and measure need for SPC. I did not find 
evidence of inequity of SPC in my study sample, but I did uncover some 
evidence that older people may be disadvantaged in their receipt of 
appropriate cancer and end-of-life care. This project demonstrates the 
feasibility of incorporating a measure of need into considerations of use, and 
of gathering data directly from patients and carers rather than relying on 
retrospective records or reports. It also highlights the strength of mixed 
methods in examining the multiple dimensions of health care equity 
necessary to develop a full understanding of variations in use and quality of 378 
 
care. I hope that it represents one small additional step towards achieving 
the goal shared by so many; the reduction of injustice and disadvantage in 
our society.  
 
What we call the beginning is often the end 
And to make an end is to make a beginning 
The end is where we start from 
 
TS Eliot. Four Quartets ‘Little Gidding’ 512 
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Appendix I 
 
Lung cancer diagnosis and treatment 
 
This appendix sets out full details of the current treatment regimes available 
to lung cancer patients within the UK, to provide context to the findings of 
the survey on SPC use by lung cancer patients. 
 
Staging and treatment 
Treatment options for lung cancer are determined by the stage of disease, 
along with performance status and the presence of relevant comorbidities. 
Disease stage is a clear indicator of expected prognosis. 513  
 
Non-small cell lung cancer (NSCLC) is staged using the TNM system: 
 
•  T to indicate the size and location of the primary tumour 
•  N to indicate spread to regional lymph nodes 
•  M for distant metastasis 
 
These are then classified into stage groupings ranging in severity from I to IV 
[Tables 1 and 2]. Whilst small-cell lung cancer (SCLC) can in theory also be 
classified using the TNM system, in practice it is grouped into two stages, 
limited or extensive disease. Limited disease is defined as being where all 
detectable tumour can be encompassed within a radiotherapy port. 
Extensive disease includes patients with metastatic lesions in the other lung, 
and those with distant metastatic involvement.  
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Table 1. The TNM staging system for NSCLC 
237 
Primary tumour (T) 
TX 
Primary tumour cannot be assessed, or tumour proven by presence of 
malignant cells in sputum of bronchial washings but not visualized by 
imaging or bronchoscopy. 
T0  No evidence of primary tumour. 
TIS  Carcinoma in situ.  
T1 
Tumour < 3cm in greatest dimension, surrounded by lung or visceral 
pleura, without bronchoscopic evidence of invasion more proximal than 
the lobar bronchus (that is, not in the main bronchus) 
T2 
Tumour with any of the following features of size or extent: 
- > 3cm in greatest dimension 
- involves main bronchus 
- > 2cm distal to the carina 
- invades the visceral pleura 
Associated with atelactasis or obstructive pneumonitis that extends to the 
hilar region but does not involve the entire lung 
T3 
Tumour of any size that directly invades any of the following: diaphragm, 
mediastinal pleura, parietal pericardium; or tumour in the main bronchus < 
2cm distal to the carina, but without involvement or the carina; or 
associated atelectasis or obstructive pneumonitis of the entire lung. 
T4 
Tumour of any size that invades any of the following: mediastinum, heart, 
great vessels, trachea, oesophagus, vertebral body, carina, or tumour with 
malignant pleural effusion or pericardial effusion or with satellite tumour 
nodules within the ipsilateral primary-tumour lobe of the lung.  
Regional lymph nodes (N) 
NX  Regional lymph nodes cannot be assessed. 
N0  No regional lymph node metastasis. 
N1 
Metastasis to ipsilateral peribronchial and / or ipsilateral hilar lymph nodes 
and intrapulmonary nodes involved by direct extension of the primary 
tumour. 
N2  Metastasis to ipsilateral mediastinal and/or sub-carinal lymph nodes. 
N3  Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or 
contralateral scalene or supraclavicular lymph nodes. 
Distant metastasis (M) 
MX  Presence of distant metastasis cannot be assessed. 
M0  No distant metastasis. 
M1  Distant metastasis present. 
 382 
 
 
Table 2. NSCLC staging – TNM subsets by stage 
Stage group  TNM subset 
Stage 0   Carcinoma in situ 
Stage IA  T1 - N0 - M0 
Stage IB  T2 - N0 - M0 
Stage IIA  T1 - N1 - M0 
Stage IIB  T2 - N1 - M0 
  T3 - N0 - M0 
Stage IIIA  T3 - N1 - M0 
  T1 - N2 - M0 
  T2 - N2 - M0 
  T3 - N2 - M0 
Stage IIIB  T4 - N0 - M0 
  T4 - N1 - M0 
  T4 - N2 - M0 
  T1 - N3 - M0 
  T2 - N3 - M0 
  T3 - N3 - M0 
  T4 - N3 - M0 
Stage IV  Any T Any N M1 
 
There are limited data on the proportion of patients at each stage of the 
disease at presentation. One UK study of referrals to a cancer unit reported 
that, of those patients whose disease was staged, 59% of SCLC patients had 
extensive disease, and 35% of NSCLC had Stage IV disease. 514 However, the 
high proportion of missing data in the more seriously ill patients in this 
study means that the actual proportion of patients with advanced disease is 
likely to be higher.  
 
NICE guidelines on the diagnosis and treatment of lung cancer set out 
recommended treatment approaches for patients. 237 These are dependent on 
the stage of disease and characteristics of each individual patient, and are 
summarised for NSCLC in Table 3. For SCLC, patients are routinely offered 
chemotherapy, with radiotherapy considered for some. All treatment 
approaches are described in more detail below. 383 
 
 
Table 3. Treatment of Non Small Cell Lung Cancer 
  Stage 
I 
Stage 
II 
Stage 
IIIA 
Stage 
IIIB 
Stage 
IV, 
WHO 
0-1 
Stage 
IV 
WHO 
2 
Stage 
IV 
WHO 
>2 
Surgery               
Radiotherapy followed by 
surgery               
Surgery followed by 
radiotherapy               
Pre-operative 
chemotherapy and 
surgery 
a  a  a         
Surgery followed by 
chemotherapy               
Surgery then chemo- and 
radiotherapy    a  a         
Radical radiotherapy               
Chemotherapy and radical 
radiotherapy        b       
Chemotherapy            a   
Symptomatic treatment, 
including palliative 
radiotherapy 
             
 
Key 
  First choice for eligible patients 
  Suitable for some patients 
  Not recommended 
a Except within a clinical trial 
b May be first choice of treatment for patients with good performance status and 
localised disease that can be safely encompassed in a radical radiotherapy 
treatment volume 
 
Surgery 
Surgery is the primary curative treatment available to patients with NSCLC, 
but only if they have early disease (stage I or II, occasionally IIIA) and good 
performance status. It is rare for surgery to be offered for SCLC, as by the 
time of diagnosis the disease has usually progressed beyond the stage where 
it is amenable to surgical intervention.  
 
Three different surgical approaches are possible, depending on the nature 
and location of the tumour [Figure 1]. Alongside considerations of the 
operability of the disease, guidelines set out clear recommendations on 384 
 
assessing the suitability of patients for surgery. 515 These highlight four areas 
for assessment: age, pulmonary function, cardiovascular fitness, and 
nutrition and performance status. The guidelines state that all patients 
should have equal access to care, regardless of their age. However, whilst it 
is concluded that limited surgery for both stage I and II disease is effective 
for patients aged between 70 and 79, for those aged over 80 surgery is only 
recommended in the context of stage I disease. More extensive surgery in the 
form of pneumonectomy is considered to be associated with higher mortality 
in the elderly, and therefore guidelines state that the age of the patient must 
be taken into account before performing this procedure. Finally, the 
guidelines draw attention to the importance of comorbidity in determining 
the likely success of surgery, and the relationship between increasing age 
and increasing comorbidity.  
 
UK figures show that only around 10% of lung cancer patients undergo 
surgical resection, although recently higher figures of 17% have been 
suggested. 516;517  
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Radical radiotherapy 
Radical radiotherapy is radiotherapy given with the intention of cure or 
long-term disease control. 237 It may be given in isolation, or in combination 
with chemotherapy. In stage I and II NSCLC, radical radiotherapy may be 
offered to those patients who are deemed to be unfit for surgery (due to 
1. Limited re-section 
 
A wedge resection involves 
the removal of a small part of 
the lung containing the tumour. 
A segmentectomy is similar, 
but involves the removal of a 
slightly larger area.  
2. Lobectomy 
 
In a lobectomy, one whole 
lobe of the lung which contains 
the tumour is removed. This is 
the most frequently conducted 
type of surgery for lung cancer, 
recommended for all patients if 
they are able to tolerate the 
procedure.  
3. Pneumonectomy 
 
A pneumonectomy involves 
the removal of an entire lung, 
and is carried out when the 
cancer involves more than one 
lobe. 
Figure 1. Types of surgery for lung cancer 386 
 
comorbidity, for example), or who decline surgery. Individuals with Stage III 
disease and a good performance status, whose disease is encompassable 
within a radiotherapy treatment volume, may also be offered radical 
radiotherapy. Evidence on the effect of age on survival following radical 
radiotherapy is currently conflicting; some studies have reported better 
survival in younger patients (defined as 80 or 70 and below, according to the 
study), whilst others have found no effect. 256 Older age is not, therefore, 
currently regarded as a contraindication to receiving radical radiotherapy. 
 
Radical radiotherapy regimens differ in the total dose of radiotherapy 
delivered (measured in Grays (Gy)), how this total dose is administered (the 
number of treatments (fractions) and the amount given in each fraction), and 
in whether treatments are given on consecutive days, or on Mondays to 
Fridays only.  
 
The conventional approach to radical radiotherapy in NSCLC offers a total 
dose of 64-66 Gy in 32-33 fractions over 6½ weeks (Monday to Friday) or 55 
Gy in 20 fractions over 4 weeks. However, NICE guidelines recommend an 
alternative regimen, called CHART, as the treatment of choice for NSCLC 
patients receiving radical radiotherapy alone. In CHART (Continuous 
Hyperfractionated Accelerated RadioTherapy) patients receive a total dose 
of 54 Gy, given in 36 fractions of 1.5 Gy, three times a day for 12 consecutive 
days – a regimen shown to have significant survival benefits over 
conventional approaches. 518 However, in spite of the acknowledged 
effectiveness of CHART, practical difficulties in its administration (requiring 
radiographers to be available seven days a week) mean that it is currently 
available in only a few centres in the UK. A subsequent proposed 
modification of the regimen is CHARTWEL (CHART – weekend-less), 387 
 
offering a total dose of between 54 and 60Gy three times a day Monday to 
Friday, 519 which is currently undergoing further trials.  
 
Palliative radiotherapy 
Palliative radiotherapy is offered to patients with both NSCLC and SCLC to 
offer relief from symptoms including chest pain, breathlessness, cough and 
haemoptysis. This usually consists of a short course of 10Gy in one fraction, 
or 16/17Gy in two fractions. A recent Cochrane review found that higher 
dose regimens of 36Gy in 12 fractions may lead to modest increases in 
survival, as well as providing effective symptom control, for patients who 
are fit enough to receive larger doses of radiotherapy. 520 
 
Chemotherapy 
Although NSCLC is not as chemosensitive as SCLC, chemotherapy is the 
recommended treatment for patients with Stage IIIB or IV disease and good 
performance status. In this context, the aim is not cure but symptom control 
and small improvements in life expectancy. It may also be used in 
conjunction with radical radiotherapy in patients with Stage IIIA disease. By 
contrast, chemotherapy is the treatment of choice for SCLC, which is 
regarded as a systemic disease usually requiring systemic treatment. In 
limited stage SCLC, chemotherapy may also be used alongside radiotherapy 
to improve local disease control.  
 
Chemotherapy is usually given on an outpatient basis as a course of three to 
six cycles, with three weeks in between each cycle. In advanced NSCLC, 
patients are recommended to receive a combination of third generation drug 
(docetaxel, gemcitabine, paclitaxel or vinorelbine) together with a platinum-
based drug (carboplatin or cisplatin). SCLC is also normally treated with 
combination-based therapy with a platinum based drug, such as etoposide 388 
 
alongside cisplatin. The choice of therapy will depend on the extent of the 
patient’s disease, comorbidity and frailty as well as the availability of such 
drugs within the treating hospital. For patients who may be unable to 
tolerate the more toxic platinum-based drugs, single agent therapy may be 
offered.  
 
Performance status is a key clinical consideration when judging eligibility for 
chemotherapy. Typically assessed using the Zubod/WHO scale (Table 4), 
only patients with a performance status of 0 or 1 are usually considered 
eligible for chemotherapy. Patients with a score of 2 or more who do receive 
chemotherapy have been found to have lower survival rates, and suffer 
greater toxicity; treatment is not therefore routinely offered to patients with 
poor performance status. 237  
 
Table 4. Zubod/WHO Scale of Performance Status  
Score  Definition 
0  Asymptomatic 
1  Symptomatic, but ambulatory (able to carry out light work) 
2  In bed < 50% of day (unable to work but able to live at home with 
some assistance) 
3  In bed >50% of day (unable to care for self)  
4  Bedridden  
 
 
Best supportive care 
Best supportive care is the name commonly given to the management of 
disease-related symptoms in lung cancer patients where cure is not possible. 
521 It may involve the receipt of both chemotherapy and radiotherapy where 
the aim is symptom control rather than prolongation of life. Patients are 
monitored and symptoms and other concerns addressed as they develop; it 
does not necessarily mean a referral to a SPC team has been made.  
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Appendix II 
 
Documentation for ethnography of specialist palliative care 
providers 
 
 
This appendix contains the documentation used in the ethnographic study of 
SPC providers, exploring their concepts of need for, and factors influencing 
use of, SPC for cancer patients. This comprises: 
 
•  Participant information sheet 
•  Participant consent form (observation) 
•  Participant consent form (interview) 
•  Interview topic guide 
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UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
 
 
 
Defining need for specialist palliative care 
Information sheet for participants 
 
 
 
You are being invited to take part in a research study. Before you decide whether to 
take part it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask me if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish to 
take part. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
One of the basic principles of healthcare in the UK is that it is provided on the basis 
of need, and need alone. Research into variations in the use of healthcare services 
therefore requires information on patients’ need for this care, as well as their use of 
it. This is so we can understand whether differences in patients’ use of healthcare 
are simply due to differences in those patients’ need for care, or whether differences 
in use are due to other factors such as gender or socio-economic status. 
 
This study forms one part of a Medical Research Council (MRC) funded research 
project looking at variations in the use of specialist palliative care services by lung 
cancer patients. In order to look carefully at how and why use of specialist palliative 
care varies in this group, it is important for us to develop an in-depth understanding 
of how need for this type of care can be defined and measured. However, at present 
there is little information on how need for specialist palliative care is perceived by 
providers of such care, and how it can be assessed within the context of a research 
study. Therefore, the aim of this study is to develop a conceptualization of need for 
specialist palliative care, and investigate whether any existing quality-of-life 
instruments can be used to measure this need. 
 
The study involves a comprehensive literature review, observation of meetings of 
specialist palliative care providers, and one-to-one interviews with specialist 
palliative care providers.  
 
This study will take place over the course of a year, although the wider programme 
of work will take place over the next three years. 391 
 
 
Why have I been chosen? 
You have been chosen to take part in this study because of your professional role 
within the specialist palliative care service. We wish to involve all those who take 
part in discussions about referrals and admissions to the service, to enable us to 
explore how concepts of need for specialist palliative care are applied in practice.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you do decide to take part you are still free to withdraw at any time and without 
giving a reason. A decision to withdraw at any time, or a decision not to take part, 
will not affect your work in any way. 
 
What will happen to me if I take part? 
We wish to gather information about need for care in two different ways.  
 
Firstly, the researcher will sit in on team meetings to observe discussions 
surrounding referrals made to the service. The researcher will not be an active 
participant in these meetings, but will simply take notes on aspects of patients’ 
needs for the service, as they are discussed. If all those present at each meeting 
consent, the researcher will also tape-record these meetings. These recordings will 
be transcribed and analysed to provide further detail on the important domains of 
need for care. In this part of the study, you will not be required to do anything 
outside of or in addition to your normal day-to-day responsibilities.  
 
In the second part of the study, the researcher will conduct face-to-face interviews 
with a selection of those who participate in the team meetings which have been 
observed. The purpose of these interviews is to probe in more detail how providers 
conceptualise need for their services. If you are approached to be interviewed, we 
will ask you to sign a further consent form. All information given during these 
interviews will be kept strictly confidential, and no names will be attached to the 
information provided. The interview will be conducted at a convenient time and 
place of your choosing. It will cover your views on need for specialist palliative care 
in cancer patients, and how this might differ from need for generalist palliative care. 
The interview should last for around thirty minutes. Interviews will be tape-recorded, 
if you consent, and transcribed. 
 
What are the possible disadvantages and risks of taking part? 
We realise that you have limited time available to you, and participation in this study 
will require your time for about half an hour to an hour. 
 
What are the possible benefits of taking part? 
By feeding back the results to participating specialist palliative care providers, we 
hope that this project will enhance understanding of how specialist palliative care 
needs of patients with cancer can be consistently defined and measured. The 
information gathered from this stage of the project will be used in a cohort study of 
lung cancer patients looking at variations in use of specialist palliative care. 392 
 
 
Will my taking part in this study be kept confidential? 
All information which is collected from you during the course of the research will be 
kept strictly confidential. Transcripts of meetings and interviews will have your name 
removed so that you cannot be recognised from them. Tape recordings will be 
stored securely in the University, and destroyed immediately after analysis has been 
completed. In publications and reports, the identity of participating palliative care 
services will not be revealed, although basic descriptive information about the 
service will be given. 
 
What will happen to the results of the research study? 
A summary of the findings of the study will be sent to all participants on completion 
of the research, likely to be at the end of 2005. Results will also be published in 
peer-review journals. Participating specialist palliative care providers and staff will 
not be identified in any report or publication arising from this study. 
 
Who is organising and funding the research? 
This project is being funded by the Medical Research Council (MRC). It is being 
conducted by researchers from the London School of Hygiene and Tropical 
Medicine. 
 
Who has reviewed the study? 
The study has been reviewed and approved from an ethical point of view by 
Bromley Local Research Ethics Committee. 
 
Your contacts 
Jenni Burt is the researcher who will be conducting the observation and interviews. 
If you have any concerns about any aspect of the study please do get in touch and I 
will be happy to answer any questions. 
 
Jenni Burt 
Research Fellow 
UCL Department of Epidemiology and Public Health 
1-19 Torrington Place 
London 
WC1E 6BT 
 
Phone: 020 7679 8283 
Email: jenni.burt@ucl.ac.uk 393 
 
UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
 
CONSENT FORM 
 
 
Title of Project:     Defining need for specialist palliative care:  
Non-participant observation 
 
Name of Researcher:  Jenni Burt 
 
Please initial box 
 
1.  I confirm that I have read and understand the information sheet  
dated 18/02/05 (version 1) for the above study and have had the  
opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free  
to withdraw at any time, without giving any reason, without my  
work or legal rights being affected. 
 
3.  I understand that all the information I provide for the purposes of  
this study will be kept strictly confidential. 
 
4.  I consent to the meetings being taped, and understand that these  
tapes will be stored securely and destroyed after analysis is  
complete. 
 
5.  I agree to being quoted anonymously in the results 
 
6.  I agree to take part in the above study 
 
 
 
____________________  ____________  ______________________ 
Name of Participant    Date      Signature 
 
 
____________________  ____________  ______________________ 
Researcher      Date      Signature 
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UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
 
CONSENT FORM 
 
 
Title of Project:     Defining need for specialist palliative care:  
Interview 
 
Name of Researcher:  Jenni Burt 
 
Please initial box 
 
1.  I confirm that I have read and understand the information sheet  
dated 18/02/05 (version 1) for the above study and have had the  
opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free  
to withdraw at any time, without giving any reason, without my  
work or legal rights being affected. 
 
3.  I understand that all the information I provide for the purposes of  
this study will be kept strictly confidential. 
 
4.  I consent to the interview being taped, and understand that this 
tape will be stored securely and destroyed after analysis is complete. 
 
5.  I agree to being quoted anonymously in the results 
 
6.  I agree to take part in the above study 
 
 
 
____________________  ____________  ______________________ 
Name of Participant    Date      Signature 
 
 
____________________  ____________  ______________________ 
Researcher      Date      Signature 
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Conceptualising need for specialist palliative care 
 
Interview topic guide 
 
 
FOR: Staff of specialist palliative care providers (medical, nursing, social 
work, professions allied to medicine, administrative, and other) who 
participate in decisions about services to offer to patients referred or made 
known to their service.  
 
ADMINISTRATION: Face-to-face in a private, convenient place of the 
participant’s choosing.  
 
Interview to be conducted following the receipt of written consent to 
participate. 
 
 
Introduction 
 
This interview is taking place as part of a project exploring concepts and 
definitions of need for specialist palliative care. We are very interested to 
know your views about cancer patients’ needs for specialist, rather than 
generalist palliative care, and which aspects of need you feel are particularly 
important. 
 
With your permission, this interview will be tape-recorded. This helps us to 
ensure that we have an accurate record of everything you say. If you would 
prefer that this interview is not tape-recorded, that is absolutely fine – I will 
make hand-written notes instead. All the information you give to us will be 
kept strictly confidential, and your name will not be attached to the transcript 
of or notes from this interview. 
 
Please remember, you are free to withdraw at any time from this interview – 
just tell me if you wish to stop. Also, if there is a particular question you do 
not wish to answer, please let me know.  
 
Do you have any questions before we start? 
 
[Ensure have obtained valid consent form including written permission to 
audio tape interview, if appropriate] 
 
[Notify the participant that the tape has been switched on and is recording] 
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Introductory topic 
 
•  Participant’s role in the palliative care service 
Briefly cover:   Involvement in patient care 
      Involvement in referral/admissions decisions 
      Other major areas of responsibility 
 
 
Topic one: Definitions 
 
•  Participant’s definitions of palliative care 
Cover:   Palliative care as a whole 
Specialist palliative care – what type of care is this? 
Generalist palliative care – what type of care is this? 
 
 
Topic two: Referrals and admissions 
 
•  Participant’s views on accepting referrals to specialist palliative care 
Cover:    Factors important in deciding to accept referral 
Factors important in deciding to reject referral / 
inappropriate referrals 
Probe:    Relative importance of: 
    Diagnosis        Prognosis 
Symptoms        Functional status 
Psychosocial issues      Place of care 
Informal carers      Availability of 
resources 
Demographics      Other services 
involved 
Source of referral      Other issues arising 
 
 
Topic three: Need for specialist palliative care 
 
Following on from and further developing discussions around topics one and 
two: 
 
•  Role of specialist palliative care in cancer: 
Cover:  What does specialist palliative care offer to patients that 
other services don’t? 
    How is it different from generalist palliative care? 
How does it fit with other healthcare services a cancer 
patient might receive? 
 
•  Need for specialist palliative care: 
Cover:    What type of patients have need for specialist care? 
Probe:   How might they benefit from this? 
Cover:  What type of patients don’t have need for specialist 
care? 397 
 
Probe:   Why wouldn’t they benefit from this? 
 
 
•  Participants’ conceptualization of need for specialist palliative care 
Probe:   Most important domains of need 
 
•  Any other comments 
 
 
Topic four: Variations in need for specialist palliative care 
 
Do you think that there may be occasions when a younger person has more 
need for specialist palliative care than an older person? 
 
OR - switch 
 
Do you think that there may be occasions when an older person has more 
need for specialist palliative care than a younger person? 
 
 
 
 
End 
 
Thank you for taking the time to participate in this interview. We shall ensure 
you receive a summary of our results arising from this work. 
 
Do you have any further questions arising from this interview? 
 
 
[Notify participant the tape recorder has been switched off and is no longer 
recording] 
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Appendix III 
 
Critical appraisal of HRQL instruments  
 
This appendix gives details of the 32 instruments I critically appraised but 
did not include in the short list for more detailed consideration of their use 
as an indicator of SPC need. The instruments are organised by target group 
(generic, cancer, lung cancer and palliative care) [Table 1]. I introduce the 
instruments, describe their appropriateness for use as an indicator of need 
for SPC, and then for each group summarise the outcome of my critical 
appraisal.  
 399 
 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
Generic instruments used in lung cancer or palliative care 
EQ-5D 
386 
5 
dimensions 
(mobility, 
self-care, 
usual 
activities, 
pain/discomf
ort and 
anxiety/depr
ession) plus 
global QL 
item 
Patient 
completion 
3 
stateme
nts to 
choose 
from in 
each 
dimensio
n; plus 
VAS (0 
to 100) 
for 
global 
QL 
rating 
- 
Test-retest 
correlation 
(general 
population) 
stated by 
authors to be 
“good”. 
Expert 
review. 
Pilot test. 
Reasonabl
e 
correlation 
with SF-36. 
Changed in 
anticipated 
direction 
during 
treatment in 
breast cancer 
patients. 
522 
Time: 8-10 
minutes. 
Acceptabil
ity: some 
low 
response 
rates in 
postal 
surveys.  
Mainly 
postal 
surveys of 
communit
y. 
Healthy 
and ill 
adults, 
including 
lung 
cancer 
patients. 
All ages. 
English 
and 
others.  
Fox Simple 
Quality of 
Life Scale 
387 
25 items; 
four 
dimensions: 
satisfaction, 
well-being, 
health and 
functional 
status.  
Patient 
completion 
Five-
point 
categoric
al scale 
Overall 
Cronbach’
s α .93.  
- 
Literatur
e review. 
Expert 
review. 
Patient 
interview
s.  
Correlated 
with FP-
QLI, FACT-
G, SF-36, 
General 
Well-being 
Scale.  
- 
Time: not 
stated. 
Acceptabil
ity: 
reading 
ease fine, 
low 
missing 
data 
Communit
y 
Cancer 
patients 
from 
support 
group. 
Age not 
stated. 
English 
NHP 
(Nottingha
m Health 
Profile) 
388 
38 items; 6 
domains: 
physical 
mobility, 
pain, social 
isolation, 
emotional 
reactions, 
energy, 
sleep. 
Patient 
completion 
Dichoto
mous 
yes/no 
Overall 
Cronbach’
s α (older 
adults) .82. 
523  
Test-retest 
correlations 
for subscales 
(older adults) 
ranged from  
.81 to .97. 
n=93 
Time=1 
month 
523 
Patient 
interview
s. Expert 
review. 
Pilot test.  
Correlated 
with 
physical 
performanc
e as 
predicted. 
523 
- 
Time: 5 to 
10 
minutes. 
Acceptabil
ity: good.  
Communit
y. 
Outpatien
t. 
Healthy 
and ill 
adults, 
including 
lung 
cancer 
patients. 
All ages. 
English 
and 
others 400 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
SEIQoL 
(Schedule 
for the 
Evaluation 
of Individual 
Quality of 
Life) 
389;390 
5 areas 
important to 
their QL 
listed by 
patient. Each 
area and 
overall QL 
rated. 
Finally, QL 
then rated 
for 30 
hypothetical 
profiles. 
Interviewer-
administered 
Visual 
analogu
e scale 
Overall r = 
.90 
389 
Test-retest 
correlation > 
.70. 
Overall r² 
=.88  -  - 
Time: 40 
minutes. 
Acceptabil
ity: 
Complete
d by 78% 
of 
patients. 
Outpatien
t 
Inpatient 
“Incurabl
e” 
cancer. 
Age 
range 34 
to 87. 
English. 
SEIQoL-
DW 
(Schedule 
for the 
Evaluation 
of Individual 
Quality of 
Life – direct 
Weighting) 
389;390 
5 areas 
important to 
their QL 
listed by 
patient. E   
ach area and 
overall QL 
rated. 
Finally, 5 
chosen 
areas 
weighted for 
importance. 
Interviewer-
administered 
Visual 
analogu
e scale 
Overall r = 
.90 
389  -  -  -  - 
Time: 15 
minutes. 
Acceptabil
ity: 
Complete
d by all 
patients.  
Outpatien
t 
Inpatient 
“Incurabl
e” 
cancer. 
Age 
range 34 
to 87. 
English. 401 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
SF-36 
(Short Form 
36) 
36 items; 8 
domains: 
physical 
functioning, 
social 
functioning, 
role 
limitations 
due to 
physical 
problems; 
role 
limitations 
due to 
emotional 
problems 
mental 
health; 
energy/vitalit
y, pain, 
general 
health 
perception 
Self-
administered.  
Categori
cal 
scales 
(yes/no, 
3-, 5- 
and 6-
point). 
Domain 
Cronbach’
s α 
(primary 
care 
population) 
.80 to .95 
524 
 
Test-retest 
correlations 
ranged from 
.43 to .90. 
337 
Previous 
QL 
instrume
nts.  
Discrimina
nt validity: 
differences 
in scores 
between 
well and 
unwell 
respondent
s. 
524 
Scores 
changed over 
time in 
expected 
direction for a 
number of 
diagnosis 
groups. 
337 
Time: 10-
15 
minutes. 
Acceptabil
ity: 78.5% 
of 
outpatient 
oncology 
patients 
completed 
all items. 
337  
Outpatien
t 
Inpatient 
Communit
y 
Healthy 
and ill 
adults, 
many 
cancer 
groups 
including 
lung 
cancer. 
All ages. 
English 
plus 
others.  
SIP 
(Sickness 
Impact 
Profile) 
391 
136 items; 2 
domains: 
physical and 
psychosocial 
covering 12 
dimensions 
Patient 
completion or 
interviewer-
administered 
Dichoto
mous 
(yes/no) 
Overall 
Cronbach’
s α (non-
cancer) 
.94. 
391 
Test-retest 
correlation 
(non-cancer) 
.92. 
391 
 
 
Correlated 
with clinical 
measures. 
(non-
cancer) 
391 
 
- 
Time: 20 
to 30 
minutes. 
Acceptabil
ity: 5% 
patients 
refused 
participati
on 
525 
Inpatient 
(cancer) 
525 
Advance
d 
cancer. 
Mean 
age 59.2 
525 
English 402 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
WHOQOL-
100 
392;393 
100 items; 4 
domains: 
physical 
health, 
psychologica
l, social 
relationships
, 
environment 
Patient 
completion 
Five-
point 
categoric
al scale 
Overall 
Cronbach’
s α .97: 
domains α 
.87 to 
.95.
393 
 
Overall 
Cronbach’
s α 
(cancer) 
.97. 
526 
Test-retest 
correlations 
good (non-
cancer). 
527 
Literatur
e. Focus 
groups. 
Expert 
review. 
Pilot test. 
Convergen
t and 
divergent 
validity 
between 
and within 
domains 
(non-
cancer). 
393 
Discrimina
nt validity: 
Inpatients 
poorer 
scores 
than others 
(non-
cancer). 
393 
Scores 
different by 
cancer 
treatment 
and patient 
expressed 
condition 
526 
- 
Time not 
known. 
Acceptabil
ity not 
known 
Outpatien
t 
Inpatient 
Communit
y 
Well 
adults 
and 
patients 
in 15 
countries
. 
392 
Cancer 
patients 
aged 
<30 to 
>70. 
526 
English 
and 
others 403 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
WHOQOL-
Bref 
394 
26 items; 4 
domains: 
physical 
health, 
psychologica
l, social 
relationships
, 
environment 
Patient 
completion 
Five-
point 
categoric
al scale 
Domains: 
Cronbach’
s (non-
cancer) α 
.68 to .82 
394 
Test-retest 
correlations 
.66 to .87 for 
domains. 
n=391, 
time=2 to 8 
weeks. (non-
cancer) 
528 
Items 
taken 
from 
WHOQO
L-100 
Domain 
scores 
correlated 
with overall 
QL item. 
Discrimina
nt validity: 
able to 
distinguish 
between 
patients 
and 
healthy 
adults.  
- 
Time: 5 
minutes 
(well 
adults). 
Acceptabil
ity: < 1% 
missing 
data 
except for 
sex like 
(6%) and 
mobility 
(1.4%) 
(non-
cancer). 
394 
Inpatient 
Outpatien
t 
Communit
y 
Healthy 
and ill 
adults, 
including 
patients 
receiving 
palliative 
care. 
Age 
range 12 
to 97. 
394 
English 
and 
others 
Cancer-specific instruments used in lung cancer or palliative care 
Care 
notebook 
395 
24 items; 3 
domains: 
physical 
wellbeing, 
mental 
wellbeing 
and life 
wellbeing 
Patient 
completion 
11 point 
categoric
al scale 
Domains 
Cronbach’
s α .86 to 
.93 
Test-retest 
correlations 
.40 to .68 for 
subscales. 
n=249, 
time=4 weeks 
Expert 
review. 
Pilot test.  
Correlated 
with 
EORTC 
QLQ-C30 
and 
FACIT-Sp-
12. 
Discrimina
nt validity: 
scores 
changed 
with 
performanc
e status.  
- 
Time: Not 
known. 
Acceptabil
ity: not 
known. 
Outpatien
t 
Cancer 
patients, 
all 
stages. 
Age 
range 
<49 to 
>70.  
Validate
d in 
Japanes
e. 
Translat
ed to 
English 404 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
CARES 
(Cancer 
Rehabilitati
on 
Evaluation 
System)  
396 
Maximum 
139 items. 6 
domains: 
physical, 
psychologica
l, medical 
interaction, 
marital, 
sexual, misc 
Patient 
completion 
Five-
point 
categoric
al scale 
Domains 
Cronbach’
s α .88 to 
.92  
Test-retest 
correlations 
.84 to .95 for 
subscales. 
n=71, time=1 
week 
Literatur
e. 
Interview
s with 
patients. 
Expert 
review. 
Correlated 
with SCL-
90, KPS, 
DAS. 
- 
Time 10 to 
45 
minutes. 
Acceptabil
ity: 
majority 
“easy to 
use” 
Inpatient 
Outpatien
t 
Communit
y 
  English 
CARES-SF 
(Cancer 
Rehabilitati
on 
Evaluation 
System –
Short Form) 
397 
Maximum 59 
items. 5 
domains: 
physical, 
psychologica
l, medical 
interaction, 
marital, 
sexual 
Patient 
completion 
Five-
point 
categoric
al scale 
Domains 
Cronbach’
s α .61to 
.85 
Test-retest 
agreement 
86% 
Expert 
review of 
CARES. 
Correlated 
with the 
CARES 
and FLIC. 
Divergent 
validity: 
between 
domains. 
Scores change 
over time 
(breast cancer 
patients 1, 7 
and 13 months 
post diagnosis) 
Time not 
known. 
Acceptabil
ity not 
known 
Inpatient 
Outpatien
t 
Communit
y 
Cancer 
patients. 
All ages. 
English 
QOL-CS 
(Quality of 
Life 
Instrument 
– Cancer 
Survivor 
Version) 
398;399 
41 items; 4 
domains: 
physical 
wellbeing, 
psychologica
l wellbeing, 
social 
wellbeing 
and spiritual 
wellbeing 
Patient 
completion 
Ten-
point 
categoric
al scales 
Overall 
Cronbach’
s α .93: 
subscales 
α .71 to 
.89 
Test-retest 
correlations 
.89 overall; 
for subscales 
.81 to .90. 
n=70 
time=2 weeks 
 
Expert 
review 
Correlated 
with FACT-
G as 
expected. 
- 
Time not 
known. 
Acceptabil
ity not 
known. 
Communit
y 
Cancer 
“survivor
s”. All 
ages.  
English. 405 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
QLI-C-FP 
(Ferrans 
and Power 
Quality of 
Life Index – 
Cancer 
version ) 
400;401 
66 items; 4 
domains 
plus overall 
QL: heath 
and 
functioning, 
socioecono
mic, 
psychologica
l/spiritual, 
family. 
Patient 
completion 
Six-point 
categoric
al scale 
Overall 
Cronbach’
s α .95. 
Subscales 
α .66 to 
.93 
401 
Test-retest 
correlations 
whole index: 
.87 (non-
cancer) 
time=1 week 
400 
 
.78 (cancer) 
time=3 to 4 
weeks. 
529 
Literatur
e.  
Convergen
t validity: 
correlated 
with a 
measure of 
satisfaction 
with life. 
Discrimina
nt validity: 
able to 
distinguish 
between 
patients 
with less 
pain, 
depression 
and stress 
coping. 
Factor 
analysis 
demonstrat
ed four 
sub-scales. 
Not 
demonstrated 
in cancer; 
scores 
changed 
before and 
after 
intervention for 
e.g. cardiac 
patients.  
Time: not 
known. 
Acceptabil
ity: not 
known. 
Inpatient. 
Outpatien
t. 
Breast 
and 
other 
cancer 
patients. 
All ages. 
English. 
FLIC 
(Functional 
Living Index 
– Cancer) 
402 
22 items; 5 
domains: 
physical, 
psychologica
l, social, 
family and 
symptoms 
Patient 
completion 
Seven-
point 
visual 
analogu
e scale 
Subscales 
Cronbach’
s α .65 to 
.87 
530  
- 
Panel 
review. 
Pilot test. 
Correlated 
as 
expected 
with KPS, 
Katz ADL, 
GHQ and 
MPQ. 
- 
Time: 
Less than 
15 
minutes 
Outpatien
t 
Cancer 
patients 
US 
English 406 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
Quick-FLIC 
403 
11 items; 5 
domains: 
physical, 
psychologica
l, social, 
family and 
symptoms 
Patient 
completion 
Seven-
point 
categoric
al scale 
Overall 
Cronbach’
s α .86  
Test-retest 
correlations 
.76 overall. 
n=327, 
time=4 weeks 
Expert 
review of 
FLIC 
Correlated 
with FLIC, 
FACT-G 
and 
EORTC 
QLQ-C30. 
Discrimina
nt validity: 
scores 
differed 
according 
to ECOG 
and 
treatment 
status. 
Scores 
changed with 
declining 
ECOG status 
over 4 weeks. 
Time not 
known. 
Acceptabil
ity not 
known. 
Outpatien
t 
Cancer 
patients. 
Mean 
age 
48.4.  
English 
and 
Chinese 
Padilla’s 
Quality of 
Life Index  
14 items; 3 
domains: 
symptom 
control, 
physical 
well-being, 
psychologica
l wellbeing.  
Patient 
completion 
Visual 
analogu
e scale 
Overall 
Cronbach’
s α .93 
Test-retest 
correlations 
>.60. 
- 
Discrimina
nt validity: 
scores 
varied 
between 
health 
adults and 
cancer 
patients.  
- 
Time: 5 to 
10 
minutes 
Inpatient 
Outpatien
t 
Cancer 
patients 
undergoi
ng 
treatmen
t plus 
healthy 
adults. 
Age not 
stated.. 
English 
Rotterdam 
Symptom 
Checklist 
404 
38 items; 4 
domains: 
physical 
symptom 
distress, 
psychologica
l distress, 
activity level, 
and overall 
quality of life 
Self 
completion 
Four-
point 
categoric
al scales 
Domains α 
.71 to .86 
(English 
sample) 
- 
Literatur
e. Expert 
review. 
Discrimina
nt validity: 
differentiat
es between 
different 
disease 
and 
treatment 
states.  
- 
Time: 
Less than 
ten 
minutes. 
Acceptabil
ity: not 
known 
Outpatien
t 
Inpatient 
Communit
y 
Cancer 
patients 
all 
stages 
English 
plus 
other 
languag
es 
Lung cancer specific instruments 407 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
LCSS 
(Lung 
Cancer 
Symptom 
Scale) 
405-
407 
9 items: 
symptoms 
plus 
summary 
items. Plus 6 
item 
observer 
scale 
Patient 
completion 
(initially 
interviewer-
administered)
. Observer 
completion 
Eleven-
point 
categoric
al scale. 
531  
Overall 
Cronbach’
s α .82 
Test-retest 
correlations 
>.75 n=52, 
time=one 
hour 
Expert 
review. 
Patient 
review. 
Correlated 
with KPS, 
American 
Thoracic 
Society 
Questionna
ire 
subscales, 
McGill Pain 
Questionna
ire, Profile 
of Mood 
States, SIP 
-  Time: 8 
minutes.  
Outpatien
t 
Late 
stage 
lung 
cancer. 
English. 
Palliative care specific instruments 
AQEL 
(Assessme
nt of Quality 
of Life at 
the End of 
Life 
Instrument) 
408 
19 items; 5 
domains: 
physical, 
psychologica
l, social, 
existential, 
medical 
care; plus 
global quality 
of life. 3 
additional 
complement
ary 
questions. 
Patient 
completion 
Visual 
analogu
e scale 
marked 
1 to 10 
- 
Test-retest 
correlations 
.52 to .90 for 
items. 
n=30, time=3 
days 
Literatur
e. 
Clinical 
experien
ce 
Physical 
and 
psychologi
cal items 
correlated 
with CIPS. 
Poor 
correlation 
for social 
items. 
Total score 
correlated 
with KPS 
Scores 
declined with 
approaching 
death. 
Time not 
known. 
Acceptabil
ity not 
known 
Communit
y. 
“Incurabl
e” 
cancer. 
Age 
range 31 
to 88.  
Develop
ed in 
Swedish.  408 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
Brief 
Hospice 
Inventory 
409 
17 items; 2 
‘sub-scales’: 
symptoms 
and ‘quality 
of life’ 
Patient 
completion; 
optional 
professional 
version 
Ten-
point 
categoric
al scale 
Domains 
Cronbach’
s α 
symptom 
subscale 
.88; quality 
of life .94 
Test-retest 
correlations 
.58 to .63 for 
subscales. 
N=145, 
time=1 week 
Clinical 
experien
ce 
Factor 
analysis 
showed 
two sub-
scales; 
symptoms 
and ‘quality 
of life’.  
 
Time not 
known. 
Acceptabil
ity not 
known. 
Communit
y 
Patients 
under 
palliative 
care 
service. 
All 
diagnose
s. Age 
range 37 
to 98 
US 
English. 
EORTC 
QLQ-C15-
PAL 
410 
15 items; 
physical and 
emotional 
function, 
pain, fatigue, 
nausea/vomi
ting, 
appetite, 
dyspnoea, 
constipation, 
sleeping 
difficulties, 
overall QL. 
Patient 
completion 
Four- 
and 
seven-
point 
categoric
al scales 
-  - 
Items 
from 
EORTC 
QLQ-
C30. 
Chosen 
by 
interview
s. Item 
response 
theory. 
-  -  - 
Inpatient 
Outpatien
t 
Communit
y 
Anticipat
ed 
suitable 
for 
patients 
with 
advance
d, 
incurable 
and 
symptom
atic 
cancer. 
English 
HQLI 
(Hospice 
Quality of 
Life Index) 
411;412 
28 items; 3 
subscales: 
psycho 
physiological
, functional, 
social/spiritu
al wellbeing 
Patient 
completion 
Ten-
point 
categoric
al scale 
Overall 
Cronbach’
s α .88. 
Subscales 
α .82 to 
.84 
- 
Literatur
e. Expert 
review. 
Interview
s with 
patients. 
Weak but 
significant 
correlation 
with 
ECOG. 
Discrimina
nt validity: 
able to 
distinguish 
between 
cancer 
patients 
and 
healthy 
adults. 
 
Time not 
known. 
Acceptabil
ity not 
known 
Communit
y 
Cancer 
patients 
under 
palliative 
care 
service. 
Mean 
age 71.1 
US 
English 409 
 
Table 1. Critical appraisal of HRQL instruments used in lung cancer and palliative care 
Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
Initial 
Assessmen
t of 
Suffering in 
Terminal 
Illness 
413 
43 items 
(reduced to 
20 after 
testing); 5 
domains: 
mood, 
symptoms, 
fears and 
family 
worries, 
knowledge 
and 
involvement, 
support 
Patient 
completion or 
by interview 
Five 
point 
categoric
al scale 
- 
Test-retest 
anova of 
mean scores 
no difference 
found. N=50, 
time= 3 to 5 
weeks 
Focus 
groups 
with 
experts. 
Pilot test. 
Physical 
symptom 
domain 
correlated 
with 
Spitzer QLI 
- 
Time: 30 
minutes. 
Acceptabil
ity: 95% of 
patients 
reported it 
to be 
“relevant” 
Inpatient 
Advance
d cancer 
patients. 
Age not 
stated 
English 
(Australi
an)  
Missoula-
VITAS 
Quality of 
Life index 
339 
25 items 
plus single-
item global 
scale; 5 
domains: 
symptoms, 
functional, 
interpersonal
, well-being, 
transcendent 
Patient 
completion 
Five 
point 
categoric
al scale 
Overall 
Cronbach’
s α .77 
-  Expert 
review. 
Correlated 
with the 
single-item 
QL 
measure. 
Divergent 
validity; 
poorly 
correlated 
with KPS. 
- 
Time not 
known. 
Acceptabil
ity: 
Complete
d by 87% 
of patients 
who had 
agreed to 
participate
. 
Inpatient.  
Communit
y. 
Patients 
under 
palliative 
care 
service. 
All 
diagnose
s. Age 
range 29 
to 91 
US 
English 
POS 
(Palliative 
Care 
Outcome 
Scale) 
414 
10 items; 
physical 
symptoms, 
psychologica
l symptoms, 
spiritual 
consideratio
ns, practical 
concerns, 
emotional 
concerns, 
psychosocial 
needs. 
Patient 
completion. 
Observer 
completion. 
Five 
point 
categoric
al scale 
Overall 
Cronbach’
s α .65. 
Test-retest: 
proportion 
agreement 
within one 
score per 
item 0.74 to 
1. 
n=34, 
time=varied. 
Literatur
e. Expert 
review. 
Patient 
interview
. Pilot 
test. 
Correlated 
with 
EORTC 
QLQ-C30. 
Severe scores 
improved over 
time. 
Time 7 
minutes. 
Acceptabil
ity not 
known. 
Inpatient. 
Outpatien
t. 
Communit
y 
Patients 
under 
palliative 
care 
services. 
Age 
range 
not 
known. 
English. 410 
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domains 
Administrati
on 
Respon
se 
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Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
PQLI 
(Palliative 
Care 
Quality of 
Life 
Instrument) 
415 
28 items 
plus single-
item global 
scale; 7 
domains: 
activity, self-
care, health 
status, 
choice of 
treatment, 
support, 
communicati
on , 
psychologica
l affect 
Patient 
completion 
Three 
point 
categoric
al scale 
Overall 
Cronbach’
s α .79. 
Subscales 
α .77 to 
.92 
Test-retest 
correlations 
.73 to .99 for 
items; for 
subscales .84 
to .98 
 
Literatur
e. Expert 
review. 
Pilot test. 
Correlated 
with 
ECOG, 
AQEL and 
EORTC 
QLQ-C30 
-  Mean time 
8 minutes.  
Outpatien
t 
Cancer 
patients 
under 
palliative 
care 
service. 
Age 
range 19 
to 88 
Validate
d in 
Greek. 
Translat
ed to 
English.  
Patient 
Evaluated 
Problem 
Score 
416 
Unlimited list 
of problems; 
plus single-
item global 
scale 
Patient 
completion 
Problem
s: rated 
on a 
three 
point 
categoric
al scale. 
Global 
QL: ten 
point 
categoric
al scale 
-  -  -  -  - 
A few 
minutes. 
Complete
d by 73% 
of 
admitted 
patients  
Inpatient 
Patients 
under 
palliative 
care 
service. 
Most 
cancer. 
Age 
unknown 
English. 411 
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Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
PNPC 
(Problems 
and Needs 
in Palliative 
Care) 
328 
138 items; 
13 domains: 
activities of 
daily living, 
physical 
symptoms, 
role 
activities, 
financial 
issues, 
social 
issues, 
psychologica
l issues, 
spiritual 
issues, 
autonomy, 
problems in 
consultations
, quality of 
care, GP 
care, 
specialist 
care, 
informational 
needs 
Patient 
completion 
Each 
item 
asked if 
a 
problem 
(yes/som
ewhat/no
) and if 
want 
help for 
this (yes, 
more/as 
much as 
now/no) 
Domains 
Cronbach’
s α .67 to 
0.89 
- 
Literatur
e. 
Patient 
interview
s. Expert 
interview
. Pilot 
test. 
Correlated 
with 
EORTC 
QLQ-C30 
and 
COOP-
WONCA 
charts. 
- 
Time: Not 
known 
Acceptabil
ity: 
Response 
by item 
ranged 
from 12% 
to 90% 
Communit
y 
Cancer 
patients 
under 
palliative 
care. 
Age 
range 30 
to 87 
Validate
d in 
Dutch. 
Translat
ed to 
English. 
QUAL-E 
(Quality of 
life at the 
End of Life) 
417;418 
26 items; 4 
domains: life 
completion, 
relationship 
with health 
care 
provider, 
symptoms 
impact, 
preparation 
for end of 
life. 
Interview-
administered. 
Five-
point 
categoric
al scale 
Domains 
Cronbach’
s α .68 to 
0.87. 
Test-retest 
correlations 
.23 to .74 for 
subscales. 
N=248, 
time=1 week 
Focus 
groups 
and 
interview
s with 
patients, 
carers, 
experts. 
Patient 
survey. 
Pilot test. 
Correlated 
with 
FACIT-SP, 
Missoula-
VITAS 
QOL Index 
and 
Participator
y Decision 
Making as 
expected.  
Not yet tested 
Time: not 
known. 
Acceptabil
ity: not 
known. 
Outpatien
t 
Outpatie
nts with 
advance
d 
disease. 
Cancer 
and non-
cancer. 
Age 
range 28 
to 88. 
English. 412 
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Instrument  Items and 
domains 
Administrati
on 
Respon
se 
format 
Reliability  Validity 
Responsive-
ness  Burden 
Appropriateness 
Internal 
consist-
ency 
Reproduc-
ibility  Content  Construct  Setting 
Groups 
tested 
in 
Lang-
uage 
Supportive 
Care Needs 
Survey 
419 
61 items; 5 
domains: 
psychologica
l, health 
system and 
information, 
physical and 
daily living, 
patient care 
and support, 
sexuality. 
Patient 
completion 
Five-
point 
categoric
al scale 
Subscales 
Cronbach’
s α .87 to 
.97 
- 
Adapted 
from 
Cancer 
Needs 
Question
naire. 
Expert 
review. 
Patient 
review.  
Factor 
analysis 
identified 
five factors 
supporting 
underlying 
constructs 
- 
Time: 20 
minutes. 
Acceptabil
ity: 
Minimum 
reading 
age. 
Outpatien
t. 
Cancer 
patients. 
Age 
range 18 
to 85. 
English 
(Australi
an) 
Therapy 
Impact 
Questionnai
re 
(Tamburini 
1997) 
36 items; 4 
domains: 
physical 
symptoms, 
functional 
status, 
emotional 
and 
cognitive 
issues, 
social 
interaction 
Patient 
completion, 
or observer 
completion 
Four-
point 
categoric
al scale 
Not known  Not known 
Literatur
e. Expert 
review. 
Pilot test.  
Not known  Not known 
Time: Not 
known. 
Acceptabil
ity: 87% 
response 
rate.  
Inpatient 
Outpatien
t 
Communit
y.  
Advance
d cancer 
patients 
under 
palliative 
care 
service. 
Age not 
stated.  
Validate
d in 
Italian. 
Translat
ed to 
English. 
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Critical appraisal of generic instruments 
Seven generic instruments, plus two additional shortened versions, were 
identified as having been used with lung cancer or palliative care patient 
populations, although their use was mainly confined to oncology rather than 
palliative care settings. These were the EQ-5D, developed by the EuroQol 
group; the Fox Simple Quality of Life Scale; the Nottingham Health Profile; 
the SEIQoL (Schedule for the Evaluation of Individual Quality of Life), and 
its shorter version the SEIQoL-DW; the SF-36; the Sickness Impact Profile; 
and the WHOQOL-100 and its shortened version the WHOQOL-Bref.  
 
EQ-5D 
The EQ-5D is a non-disease specific health outcome measure developed 
simultaneously in a number of European languages, including English. 386 It 
is very brief, with only five questions (mobility, self-care, “usual activities”, 
pain/discomfort and anxiety/depression) and one rating of global health 
status, measured using a visual analogue scale. Whilst more widely used in 
surveys of the general population, 532 it has also been used to assess quality of 
life in lung cancer patients, 533 particularly in the context of clinical trials (e.g. 
534). It has been criticised for having poor response rates, for being skewed, 
and for having poor sensitivity. 337 p.13 The response statements for each 
dimension give only three options (for example, I have no problems in 
walking about, I have some problems in walking about, I am confined to 
bed). These may be inappropriate in disease-based research, leading to poor 
differentiation between respondents. The instrument has additionally been 
criticised for using a 0 to 100 score in its visual analogue scale for global 
health status; in one study 7.3 of respondents aged 75 and above failed to 
complete this “thermometer”; and 63.5% of respondents chose a score 
ending in zero, negating the assertion that a 0 to 100 scale enables greater 
score precision. 535  414 
 
Fox Simple Quality of Life Scale 
Developed as a generic HRQL instrument, but validated in a cancer 
population, the Fox Simple Quality of Life Scale is a 25-item instrument 
covering satisfaction, wellbeing, health and functional status. 387 Items do not 
include physical symptoms. It is still in the early stages of development and 
data on reproducibility and responsiveness has yet to be published.  
 
Nottingham Health Profile 
The Nottingham Health Profile, widely used in cardiovascular disease, has 
also on occasion been applied to lung cancer patient populations. 536-538 This 
38-item instrument covers physical mobility, pain, social isolation, emotional 
reactions, energy and sleep, using a dichotomous (yes/no) response format. 
This format has been criticised for restricting the available answer options to 
only yes or no, with no grading of e.g. severity – leading to lower response 
rates and a high proportion of missing data. 539 Of particular concern to this 
study, there is evidence that the domains of pain and mobility are not 
distinct, with many pain questions set in the context of mobility (e.g. “I’m in 
pain when I walk”). 540;541 For lung cancer patients, pain may be present 
regardless of movement – items on pain must take this into account to be 
relevant.  
 
SEIQoL/SEIQoL-DW 
The SEIQoL and SEIQoL-DW ask respondents to nominate five domains 
important to their quality of life; the weighting system varies according to 
whether the long or short form is used. The SEIQoL was first used in 
gastroenterology and hip replacement patients and demonstrated good 
acceptability and validity. 542;543 Its suitability for use in oncology and 
palliative care patients is disputed; whilst some authors claim that it is best 
restricted to relatively healthy individuals, others have reported good 415 
 
feasibility in patients with palliative care needs. 389;544;545 The instruments 
must be interviewer-administered and their length and complexity mean 
their practicality in larger scale studies is poor. 390  
 
SF-36 
The SF-36 is one of the most widely used generic HRQL instruments, with 
well recorded reliability and validity across disease groups. It includes 36 
items in 8 domains, covering physical and social functioning, role limitation, 
mental health, energy, pain and perception of general health. It has been 
used in a number of studies of lung cancer patients, 546-548 but its use in 
palliative care has been less well documented. As a generic instrument, it 
covers few symptoms aside from pain.  
 
SIP 
The Sickness Impact Profile is a 136 item, self- or interviewer-administered 
instrument covering physical and psychological domains. Its psychometric 
properties in cancer are uncertain, despite its widespread use in other clinical 
areas. 391  
 
WHOQOL-100 and WHOQOL-Bref 
The WHOQOL-100 is a reliable and valid instrument developed and tested 
simultaneously in 15 countries, including the UK. 392;393;527 Its use in cancer 
patients was validated in Japan, although its acceptability in advanced 
cancer patients is unreported. 526 The WHOQOL-Bref is a 26 item version 
recently developed to reduce respondent burden; its use within lung cancer 
or palliative care has yet to be reported. 394 
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Generic instruments – summary 
Whilst some of the generic instruments reviewed above are extensively used 
within cancer research, particularly the SF-36, there are a number of 
limitations to their use as an indicator of need for palliative care. Firstly, their 
ability to discriminate between lung cancer patients with and without a need 
for specialist palliative care is likely to be low; few include symptoms other 
than pain and few have fine enough response formats to generate a range of 
responses in this group. Secondly, despite their use in lung cancer trials, the 
inclusion of domains such as work or the ability to walk long distances is 
redundant when applied in advanced disease. Thirdly, few include domains 
specific to the assessment of need for specialist palliative care, such as 
existential issues including concepts self, death and dying, and meaning of 
life. For these reasons, none were short listed for further consideration. 
 
Critical appraisal of cancer-specific instruments 
Eight cancer-specific HRQL instruments, and two additional shortened 
versions, were identified for full critical appraisal. The shortlisted instrument 
in this group was the EORTC QLQ-C30 (European Organization for 
Research and Treatment of Cancer Core Quality of Life questionnaire), 
described in full in Chapter 6. The non-shortlisted instruments were the Care 
Notebook; CARES (the Cancer Rehabilitation Evaluation System) and its 
short form CARES-SF; the Quality of Life Instrument – Cancer Survivor 
Version;; the Ferrans and Power Quality of Life Index – Cancer version; FLIC 
(the Functional Living Index-Cancer) and its short form Quick-FLIC; the 
Multi-dimensional Quality of Life Scale – Cancer (MQOLS-CA); and the 
Rotterdam Symptom Checklist. 
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The Care Notebook 
The care notebook is a 24-item HRQL instrument designed primarily for 
clinical, rather than research use. 395 Reliability and validity were tested in a 
population of Japanese cancer outpatients; whilst it has been translated into 
English, it has not been psychometrically tested in this language.  
 
CARES and CARES-SF 
CARES (139 items) and the more widely used short form CARES-SF (59 
items) are reliable and valid instruments developed to measure the 
rehabilitation needs of cancer patients. 396;397 Respondents are asked to rate a 
list of cancer-related problems they might encounter on a daily basis, 
including physical changes and marital relationships. The use of CARES in 
advanced cancer patients has been questioned due to its inclusion of items 
on work and sexual activity, deemed to be inappropriate in this population, 
as well as its length. 549 Additionally, the instrument is commercially licensed 
and a fee must be paid to use it within research studies; for this reason, the 
full item wording is difficult to obtain for assessment purposes.  
 
The Quality of Life Instrument – Cancer Survivor Version (QOL-CS) 
The QOL-CS was developed by researchers at the City of Hope National 
Medical Center in the USA to assess physical, psychological, social and 
spiritual wellbeing. 398;399 It is aimed mainly at “cancer survivors” – those 
who have received successful treatment for an incidence of cancer – and 
includes items such as the extent to which respondents are fearful of a 
recurrence or spread of cancer. This limits its application to patients at all 
stages of cancer. 
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FLIC and Quick-FLIC 
Another widely-used instrument is the 22-item FLIC, 402 which also has a 
shortened version, the Quick-FLIC. The FLIC has been criticised for using 
visual analogue scales as its response format, which not all patients find easy 
to use. 337 The Quick-FLIC, validated in English and Chinese speaking cancer 
patients in Hong Kong, adapted a categorical scale response format for this 
reason. 403 However, the major concern for this study is the reported 
problems in its use with lung cancer patients – with low response rates and a 
lack of relevant functional and psychosocial items. 337;550  
 
Padilla’s Quality Life Index 
The 14 item Quality of Life Index developed by Padilla and colleagues is 
aimed at cancer patients undergoing treatment, and was validated in adults 
receiving chemotherapy or radiotherapy. It has not been tested in patients 
with advanced cancer and its suitability for application in patients at all 
stages of disease therefore remains uncertain.  
 
The Rotterdam Symptom Checklist 
The Rotterdam Symptom Checklist is a 38 item instrument developed for 
cancer patients, covering physical symptoms, psychological distress, activity 
level and overall quality of life. It has good psychometric properties, but its 
focus on symptoms and functional status to the exclusion of the social and 
spiritual dimensions of quality of life raises concerns over its coverage of 
health-related quality of life, rather than just physical symptoms. 549 
Additionally, it has been found to have very low acceptability and 
completion rates in inpatient hospice patients. 551  
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Cancer-specific instruments – summary 
Of the cancer-specific instruments reviewed, the CARES, the QOL-CS and 
Padilla’s Quality of Life Index have not proved suitable for administration in 
advanced cancer patients, limiting their utility in a cross-sectional survey of 
all stages of disease. The FLIC and Rotterdam Symptom Checklist excluded a 
number of important dimensions of HRQL, particularly psychosocial items. 
Finally, the Care Notebook has not been psychometrically tested in English 
speaking populations and is thus unsuitable for use until its validity and 
reliability have been confirmed in this language. 
 
Lung-cancer specific instruments 
Three lung-cancer specific instruments were identified; the EORTC QLQ-
LC13 (part of the EORTC modular HRQL system), the Functional 
Assessment of Cancer Therapy – Lung (FACT-L), part of the Functional 
Assessment of Chronic Illness Therapy (FACIT) measurement system; and 
the Lung Cancer Symptom Scale (LCSS). Two of these – the EORTC QLQ-
LC13 and the FACT-L were shortlisted for full content appraisal. The LCSS is 
briefly discussed below.  
 
LCSS 
Designed for repeated use within the context of clinical trials, the LCSS is a 
very brief scale comprising only 9 items. 405;407 Its focus is on symptoms 
(appetite loss, fatigue, cough, dyspnoea, haemoptysis, pain), with only 
summary items of other aspects of quality of life (total symptom distress, 
normal activity status and overall quality of life). An alternative response 
format for the LCSS was recently developed, enabling a choice between the 
original visual analogue scale or a categorical scale, appropriate for the 
computer scanning of instruments often used in large scale trials. 
Psychometric properties of the instrument remained adequate with this 420 
 
change in format. 531 The VAS approach requires initial interviewer 
administration to explain the response format; the categorical format was 
also administered in this way. The LCSS is commercially copyrighted, and a 
fee is payable for its use. Advantages include its brevity, and it has proved 
suitable for use in patients with advanced disease.  
 
Lung-cancer specific instruments – summary 
The LCSS, whilst it has shown good reliability and validity, is limited in its 
coverage of non-symptom concerns, which were shown to be important in 
the ethnographic study undertaken. It additionally relies on being 
interviewer-administered; for these reasons it does not appear suitable to use 
in the planned cross-sectional survey.  
 
Palliative care specific instruments 
The largest group of instruments identified were developed for use 
specifically in palliative care populations. However, this group also showed 
the greatest variation in the extent to which instruments had been 
psychometrically tested, with some showing little or no evidence of their 
reliability and validity. 
 
Assessment of Quality of Life at the End of Life 
The Assessment of Quality of Life at the End of Life instrument comprises 19 
items with a VAS response format. 408 Tests on validity showed there were 
problems with the social domain; internal consistency has not been reported. 
It was originally validated in Swedish; whilst it has been back-translated to 
English its properties in this language are unknown.  
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Brief Hospice Inventory 
Developed specifically for patients receiving palliative care, each of the 17 
items in the Brief Hospice Inventory uses a ten-point categorical scale 
anchored by opposing descriptors (e.g. No pain / worse possible pain). 409 It 
has reasonable psychometric properties and is quick to complete. However, 
the inclusion of items such as “hospice has been of greater help than I could 
have imagined /no help at all” preclude its use in patients not receiving 
palliative care. 
 
EORTC QLQ-C15-PAL 
A shortened version of the EORTC QLQ-C30, this instrument has been 
developed specifically for palliative care populations. 410 It is still in its early 
stages of psychometric testing, although items were taken systematically 
from the robustly evaluated longer core instrument. As the authors explain, 
its utility is likely to be in patients with particularly symptomatic progressive 
cancer who are unable to complete the QLQ-C30, which already has 
demonstrated acceptability in advanced cancer patients.  
 
Hospice Quality of Life Index 
Devised for and validated in hospice patients in the USA, the Hospice 
Quality of Life Index covers three domains of HRQL: psycho physiologic 
well-being, functional well-being and social and spiritual well-being. It has 
been found to have internal consistency and construct validity, but its 
reproducibility and responsiveness have not been tested. 411;412 As with the 
Brief Hospice Inventory, however, its inclusion of questions related to the 
hospice care respondents are receiving precludes its administration to 
patients who are not under palliative care.  
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Initial Assessment of Suffering 
Aimed at patients with advanced cancer, the Initial Assessment of Suffering 
instrument covers mood, symptoms, fears and family worries, knowledge 
and involvement and perceived support. 413 A 43-item version was initially 
tested and limited data on reliability and validity given. As a result of these 
tests the instrument was reduced to 20 items, but psychometric data on the 
shortened version has not been published.  
 
Missoula-Vitas Quality of Life Index 
The Missoula-Vitas Quality of Life Index was developed for use in 
terminally ill patients and originally validated in a hospice population. 339;552 
The five domains (across 26 items) of the instrument cover symptoms, 
function, interpersonal, wellbeing and spirituality. Whilst it has good 
psychometric properties for palliative care patients, it is not suitable for use 
in earlier stages of disease; for example, items include “As the end of my life 
approaches, I am comfortable with the thought of my own death/I am 
uneasy with the thought of my own death.” Additionally, it does not cover 
the assessment of symptoms in detail.  
 
Palliative Care Outcome Scale (POS) 
POS was developed in the UK as an outcomes measure for palliative care 
services. 414 It has ten items covering physical and psychological symptoms 
and practical issues such as time spent waiting for hospital appointments, 
over a time scale of the previous three days. A corresponding instrument is 
available for completion by health care professionals. It has demonstrated 
adequate psychometric properties in patients under palliative care services, 
but its application and relevance to wider groups of cancer patients is 
uncertain. Additionally, its content in relation to assessment of symptoms – a 
key indicator of need for specialist palliative care – is limited. 423 
 
Palliative Care Quality of Life Instrument 
The 28-item Palliative Care Quality of Life Instrument was developed and 
validated in another language (Greek) and translated to English for 
publication. 415 Whilst the authors reported it to have good reliability and 
validity, testing has not been extensive and its responsiveness and 
applicability in all settings of palliative care are unknown. Additionally, an 
examination of the English language version raises questions about the 
quality of the translation, and the instruments comprehensibility to English 
palliative care populations.  
 
Patient Evaluated Problem Score 
The Patient Evaluated Problem Score is similar to the SEIQoL in being a 
patient-led instrument in which they are able to list and rate the problems 
they are facing. 416 It has proved acceptable to even very ill hospice 
inpatients, and is used in clinical practice within the UK, but has undergone 
no psychometric testing. It is therefore not suitable to use as a HRQL 
instrument within research studies.  
 
Problems and Needs in Palliative Care (PNPC) 
Developed and validated in Dutch, and subsequently translated to English, 
the Problems and Needs in Palliative Care instrument covers 138 items of 
both quality of life and quality of care. 328 It has not been psychometrically 
tested in English. 
 
QUAL-E (Quality of Life at the End of Life) 
A recently developed measure of HRQL in patients with life-threatening 
illness, the 31-item QUAL-E has reasonable psychometric properties in 
patients with advanced disease. 417;418 It covers life completion, relationships 
with health care providers, the impact of symptoms and preparation for end 424 
 
of life. However, domains are slanted in particular towards US hospice 
patients, who have enrolled in a very specific program of terminal care. It is 
designed to be administered by an interviewer. 
 
Supportive Care Needs Survey 
The Supportive Care Needs Survey is a combined health-related quality of 
life and quality of care instrument, developed and validated in Australia. Its 
domains cover psychological, health system and information, physical and 
daily living, patient care and support and sexual issues over 61 items. It has 
been validated in outpatient clinics settings with cancer patients in Australia, 
but has not been tested on UK populations. 
 
Palliative-care specific instruments – summary 
Instruments developed for use in palliative care populations varied widely 
in their content. A number – such as the Missoula-Vitas QLI and the Hospice 
Quality of Life Index – include items very specific to patients with a terminal 
illness, and are therefore unlikely to be suitable for use in patients in earlier 
stages of cancer. Furthermore, instruments were frequently poorly 
psychometrically tested, with little evidence of reliability and validity.  425 
 
Appendix IV 
 
Pilot study of equity of use of specialist palliative care 
 
This appendix contains full details of the methods and results of the pilot 
survey I conducted prior to the commencement of the main cross-sectional 
survey of lung cancer patients. The pilot had the following objectives: 
 
1.  To establish the study within participating clinics and raise awareness 
amongst all staff. 
2.  To pilot the anticipated method of recruitment and gain information 
on expected recruitment rates. 
3.  To assess the clarity, acceptability and feasibility of the patient and 
carer questionnaires developed for the study. 
4.  To assess the comprehensiveness and ease of use of the medical 
record data extraction form developed for the study. 
 
The methods and results of this pilot are reported in full below. 
 
Pilot sample 
A convenience sample of patients with a diagnosis of lung cancer attending 
two of the four participating lung cancer outpatient clinics, and their carers, 
were approached.  
 
Recruitment and consent 
On arrival in the clinic, patients and carers attending with them were 
approached to introduce the study. I explained the study and the pilot 
process, and gave patients and their carers a study information pack 
containing an information sheet, consent form and the study questionnaire. 
Patients and carers were asked to read through the information about the 426 
 
study and, if they wished to participate, complete the consent form and 
study measures whilst in the clinic.  
 
During this pilot period, I noted the number of people I approached, the 
number who agreed to take part in the pilot, and the responses of those 
approached who chose not to participate. I also kept notes on the running of 
the clinic, the opportunities for approaching potential participants, and the 
barriers to recruitment.  
 
Pilot patient questionnaire 
The patient questionnaire was compiled for the purposes of this study. In 
four sections, questions covered: 
 
1.  Diagnosis 
2.  Use of health care services for this diagnosis, including SPC services  
3.  HRQL (as an indicator of need for SPC) 
4.  Personal details  
 
The first two sections, covering the patient’s stated diagnosis and other 
illnesses, and their use of health care services for lung cancer, were devised 
for this study. The use of health care questions covered patients’ contacts 
with nurses, doctors, (including those from SPC services), and professions 
allied to medicine for the treatment and care of their lung cancer. It also 
asked whether they had sought further information on their diagnosis from 
literature, the internet or telephone advice lines. In the piloted version of the 
questionnaire, the HRQL instrument used was the McMaster Quality of Life 
Instrument, chosen using methods described in full in Chapter 6 [see end of 
Appendix for text]. Finally, the personal details section was based on 427 
 
questions used in a National Survey of NHS Patients developed by the 
Picker Institute and others. 451 
 
Prior to piloting, the draft questionnaire, information sheet and consent form 
were sent to four cancer patients recruited through the CancerVOICES 
‘Opportunities for involvement’ scheme for their comments. The 
questionnaire was slightly adapted following their feedback, with some 
amendments made to question wording (no amendments in wording or 
layout were made to the validated HRQL instrument).  
 
Pilot carer questionnaire 
A brief instrument was also developed for family and friends attending 
clinics with participating patients. This comprised three sections: 
 
1.  Relationship with and help given to the attending patient 
2.  The General Health Questionnaire 12 item version (GHQ-12) 
3.  Respondent’s personal details.  
 
Pilot medical records data extraction form 
A form was developed to obtain data from participants’ medical records in a 
standardised format [appendix V]. Participating clinics maintain written, 
hospital-based notes for each patient, which were used to gather further 
information on demographic details, diagnosis and subsequent disease 
progression, treatment received (surgery, radiotherapy, chemotherapy), past 
medical history, and recorded use of SPC.  
 
Questionnaire and data extraction form piloting 
Whilst patients and carers were completing the questionnaire, I timed length 
of completion, and answered any questions as they arose. Once the 428 
 
questionnaires were completed, I undertook a brief interview with 
participants to address the following questions: 
 
1.  Did they understand the purpose of the research? 
2.  Were the questionnaire instructions clear? 
3.  Were any questions unclear or ambiguous? 
4.  Were any questions missing? 
5.  Did they object to answering any questions? 
6.  Was the layout clear and attractive? 
7.  Did they understand how to return the questionnaire? 
 
Completed questionnaires were entered onto the pilot database to check for 
suitability of coding and data entry procedures. 
 
For a sub-sample of the patients who took part in the questionnaire piloting, 
I explored the process of accessing and extracting data from their medical 
notes using the standardized form developed for this purpose.  
 
Results of pilot study 
 
Recruitment 
18 patients and 17 carers were approached to participate in the pilot study. 
There were no patient refusals to participate; one carer refused to participate, 
and one patient attended clinic alone. The pilot study was therefore based on 
18 patients and 16 carers. Recruitment procedures were piloted in full at one 
clinic session; 13 of 14 patients booked to attend clinic did so, and all 13 
attending patients were recruited to the study and completed the 
questionnaire whilst in the clinic.  
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Participants 
Descriptive statistics obtained from the pilot survey are shown in Tables 1 
and 2.  
 
Table 1. Pilot study results: patients 
  n (%) 
Age 
< 55  3 (16.7) 
55 to 64  3 (16.7) 
65 to 74  7 (38.9) 
≥ 75  5 (27.8) 
Gender 
Male  7 (38.9) 
Female  11 (61.1) 
Diagnosis 
SCLC  3 (16.7) 
NSCLC  10 (55.6) 
Unknown  5 (27.8) 
Date diagnosed 
In the past month  1 (5.6) 
In the past three months  2 (11.1) 
In the past six months  4 (22.2) 
More than six months ago  11 (61.1) 
Reported use of SPC 
From questionnaire  10/18 (55.6) 
From notes audit  3/13 (23.1) 
HRQL score 
Range  118 to 221 
Mean  163 (sd 31) 
Quartiles   
25  140.25 
50  163.00 
75  190.25 
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Table 2. Pilot study results: carers 
  n (%) 
Age 
< 45  3 (18.8) 
45 to 64  9 (56.3) 
65 to 74  4 (25.0) 
≥ 75  0 (0.0) 
Gender 
Male  6 (37.5) 
Female  10 (62.5) 
Relationship to patient 
Husband/wife/partner  6 (37.5) 
Son/daughter  7 (43.8) 
Other family member  1 (6.3) 
Friend  2 (12.5) 
Number of children in household 
0  13 (81.3) 
1 to 2  2 (12.5) 
3 or more  1 (6.3) 
GHQ score 
0 to 3  5 (35.7) 
4 or more  9 (64.3) 
 
 
Patient questionnaire 
Sections A (reason for hospital visit), B (your use of health care) and C 
(personal details) of the patient questionnaire were completed in full by all 
patients, apart from one missing response to the question asking about 
contact with a palliative care doctor. However, 25 of 32 items in the HRQL 
scale had missing values. The highest proportion of missing values was 5/18 
(28%) for mobility, and 4/18 (22%) for both oedema and employment, with 
an overall missing value percentage of 8% (45/576). Only 8/18 (44%) of 
respondents completed all items on the scale.  
 
Difficulties with the HRQL scale were as follows: 431 
 
 
1.  Patients did not understand how best to rank their situation using the 
1 to 7 scoring system, and frequently asked for assistance. 
2.  A number of participants felt that the instrument included 
inappropriate questions. For example, a question on mobility uses an 
anchor which states “bedridden”, which is not relevant to an 
outpatient population. Additionally, many respondents were retired, 
with no such option given by the “employment” question. 
3.  Responses to a large number of items were poorly distributed, and 
skewed towards extreme scores (e.g. 41% of respondents scored 7 for 
pain). Whilst this may reflect the clinical reality of this population, it is 
also possible that difficulties with the scale led respondents to use 
either anchor (1 or 7) as their responses – a phenomenon noted on 
several completed questionnaires.  
 
39% (7/18) patients had assistance from their family or friends in completing 
the questionnaire. The time taken for patients to complete the whole 
questionnaire ranged from approximately 10 to 30 minutes.  
 
Carer questionnaire 
Sections A (reason for hospital visit) and C (personal details) of the carer 
questionnaire were well completed. Section A had only 2 responses missing 
overall, both for the same respondent; these related to living with and 
looking after the patient. Discussion with the respondent clarified the reason 
for non-completion was the complexity of the situation between her and her 
husband (the patient). Section C had no missing items. Section B, the GHQ-
12, was not completed by two respondents. Both were friends, rather than 
relatives, of the patient. One felt it would not produce relevant results as she 
was herself ill, having recently had surgery; it was not possible to clarify 432 
 
with the other respondent the reason for not completing this section. Of the 
remaining 14 respondents, 2/168 items were missing from the GHQ (1.2%). 
 
There were no reported problems for the carers in completing the 
questionnaire; average time of completion was five minutes. 
 
Medical notes data extraction form 
The data extraction form designed for use with patient’s medical records was 
found to be comprehensive in its content, but the layout was not always 
appropriate to the information being extracted. For example, there was no 
space to accurately record the development of the disease. These were 
particularly important data as stage at diagnosis was frequently different to 
the disease stage at the time the respondent participated in the study. 
 
There were discrepancies between patient report and medical records on 
SPC use. According to responses on the patient questionnaire, 56% had used 
SPC services; from medical records data this figure was 23%. It was decided 
prior to the pilot that if there were inconsistencies between patient report 
and medical records, use would be determined based on medical records 
alone, as patient recall and recognition of SPC input was unlikely to be as 
reliable. However, the level of inconsistency gave rise to the question of 
whether either source was an accurate record of use of SPC. 
 
Pilot conclusions and changes made to study design 
As a result of the pilot, I determined that recruitment of patients could be 
undertaken successfully within the clinic setting, with a high participation 
rate (at pilot 100% of patients and 94% of carers approached). However, 
there were three major areas of concern in which changes were made to the 
planned study design. 433 
 
Firstly, the HRQL instrument chosen as an indicator of patients’ need for 
SPC, the McMaster Quality of Life Instrument, proved unsuitable in this 
population. One of the reasons for the original choice of the McMaster over 
the EORTC instruments (which also relate closely to the identified domains 
of need for SPC) was the ability to calculate a summary score to be used in 
the analysis of use in relation to need. The EORTC instruments, by contrast, 
do not enable the calculation of a summary score derived from all items, 
although a global quality of life score can be derived from items on overall 
quality of life and health. However, the EORTC QLQ-C30 and LC13 are used 
extensively in cancer research, and have excellent psychometric properties.  
 
I therefore decided to use the EORTC-QLQ C30 and LC-13 as the indicator of 
need for SPC, with the global quality of life score as the primary explanatory 
variable of interest. The revised questionnaire including the EORTC 
instruments was piloted in a further two patients. No problems were 
identified, and additional piloting of the revised questionnaire was not 
undertaken due to the extensive use of the EORTC in the UK outpatient 
setting. Other sections of the questionnaire remained unchanged following 
the pilot study. 
 
Secondly, during the pilot a number of patients required or requested 
physical assistance to complete the study instruments. I therefore decided to 
offer assistance with questionnaire completion where necessary in the main 
study. To accomplish this, verbal explanation of the study would stress the 
importance of participants answering questions themselves, whilst stating 
that questions could be read out, and answers written down, by a carer or 
the researcher. In this way, eligible patients who were physically unable to 
complete a questionnaire would be offered the opportunity to participate.  
 434 
 
Finally, I resolved the issue of accurate outcome ascertainment. As 
previously described, during the course of piloting I found discrepancies 
between SPC use reported by patients and recorded within hospital notes. In 
addition, my review of notes for patients receiving care at the cancer centre 
found that these were often sparse, with little detail of previous or current 
care. 
 
To ensure complete ascertainment of the outcome, I decided that use of SPC 
in the final analysis would be determined directly from SPC providers’ 
records, rather than from hospital notes or patient report. As I would have 
written consent from all participants to access their medical records, I 
approached all SPC providers in the study area to ask if they would check 
their records to determine whether patients had been under their care or not 
at the time of their study participation. All providers agreed with this 
request.  435 
 
McMaster Quality of Life Questionnaire 
 
Many people experience changes in one or more areas of their lives during their illness. 
Below, please describe how you have generally felt during the last week. Please circle the 
number that best describes your experience for each item. 
 
If your illness causes no problems in this area, that is no change has occurred due to your 
illness, please check the box under “Does Not Apply” and do not rate the item. 
 
 
 
 
Does 
Not 
Apply 
  Rating of your experience 
(Circle one number for each area please) 
￿  Pain  Seldom  1  2  3  4  5  6  7  Almost constant 
￿  Appetite  Normal  1  2  3  4  5  6  7  No appetite 
￿ 
Insomnia 
(Sleeplessness)  None  1  2  3  4  5  6  7  Major problem/unable to 
sleep 
￿  Nausea  Cannot stand 
the sight of food  1  2  3  4  5  6  7  Not nauseated 
￿  Restlessness  Very agitated  1  2  3  4  5  6  7  Normal 
￿  Breathing  Very short of 
breath  1  2  3  4  5  6  7  Not short of breath 
￿  Pain  Very mild/no 
pain  1  2  3  4  5  6  7  Severe 
￿  Diarrhoea  None   1  2  3  4  5  6  7  Frequent 
￿  Vomiting  Never  1  2  3  4  5  6  7  Very often 
￿  Cough 
Severe, 
persistent 
coughing spells 
1  2  3  4  5  6  7  Seldom cough 
￿ 
Oedema 
(swelling)  None  1  2  3  4  5  6  7  Unable to move normally 
￿  Constipation  Severe  1  2  3  4  5  6  7  None 
￿  Sore Mouth  Severe  1  2  3  4  5  6  7  None 
￿  Employment  Unable to work  1  2  3  4  5  6  7  Maintain previous 
employment 
 
 
Please turn over to the next section 
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  Rating of your experience 
(Circle one number for each area please) 
Mood  Not depressed  1  2  3  4  5  6  7  Very depressed 
Fatigue/tiredness  Usual 
energy/Not tired  1  2  3  4  5  6  7  Exhausted 
Mobility  Bedridden  1  2  3  4  5  6  7  Normal activities (pre 
illness) 
Interest in Others  Very interested  1  2  3  4  5  6  7  Not interested 
Future planning  Limited to days  1  2  3  4  5  6  7  Months or more 
Confusion  Never confused  1  2  3  4  5  6  7  Very often confused 
Drowsiness  Not drowsy  1  2  3  4  5  6  7  Very drowsy 
Meaning of life  Find life very 
meaningful  1  2  3  4  5  6  7  See no purpose 
Anxiety  Very anxious  1  2  3  4  5  6  7  Not anxious 
Well-being  Calm/relaxed  1  2  3  4  5  6  7  Very worried and fearful 
Concentration  Cannot 
concentrate  1  2  3  4  5  6  7  Usual / normal 
Appearance  Getting worse  1  2  3  4  5  6  7  Improving 
Personal comfort  Very 
uncomfortable  1  2  3  4  5  6  7  Comfortable 
Household management  Participate as 
usual  1  2  3  4  5  6  7  Cannot take part 
Social interaction  Very limited  1  2  3  4  5  6  7  Interact daily with 
relatives/friends 
Self care  Independent  1  2  3  4  5  6  7  Must rely entirely on 
others 
Decision making  Take part 
actively  1  2  3  4  5  6  7  Completely rely on 
others 
 
                 
Overall, your quality  
of life  Very poor  1  2  3  4  5  6  7  Excellent 
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Appendix V 
 
Documentation for cross-sectional survey of lung cancer patients 
and carers 
 
This appendix contains the documentation used in the cross-sectional survey 
of lung cancer patients and carers, investigating equity of use of specialist 
palliative care in relation to age. This comprises: 
 
•  Patient information sheet 
•  Patient consent form 
•  Patient questionnaire 
•  Carer information sheet 
•  Carer consent form 
•  Carer questionnaire 
•  Medical notes data extraction form 
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UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
The use of health care services study 
 
Participant Information Sheet 
 
I would like to invite you to take part in a research study. Please take time to 
read the following information carefully and discuss it with others if you wish. 
 
My name is Jenni Burt and I am a researcher supported by a grant from the 
Medical Research Council. I work for University College London (UCL). 
Please ask me if there is anything that is not clear or if you would like more 
information.  
 
Thank you for reading this. 
 
Purpose 
In this study we would like to find out more about what type of health care 
patients with lung illnesses receive. We want to know if there are differences 
between particular groups of patients in the care they receive, and why this 
might be happening. It is important for us to include family members and 
friends, as well as patients, in this study so we can know how the treatment 
and care patients receive also affects those who support them. 
 
What is involved? 
If you would like to take part, you need to do two things. 
First, fill in the consent form in this pack to say you are happy to answer the 
questionnaire. 
Second, fill in the questionnaire in this pack and hand it back to me or the 
clinic receptionist. Filling in the questionnaire should take up to 10 minutes. 
Your family member or friend who you have attended clinic today with will 
also be asked to fill in a separate questionnaire (if they wish to).  
 
Participation 
It is up to you to decide whether or not to take part. You do not have to 
answer any questions you do not want to. You are free to withdraw from the 
study at any time. Please tell me about any concerns you may have 
 
Who will have access to the details? 
All the information about your participation in this study will be kept 
confidential to the research team. 
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My contact details 
I am in clinic today. If you want to get in touch with me at another time, I can 
be contacted at:  
 
Department of Epidemiology and Public Health 
UCL 
1-19 Torrington Place 
London 
WC1E 6BT.  
 
My phone number is 020 7679 8283, and my email address is 
jenni.burt@ucl.ac.uk 
 
Thank you very much for taking the time to read this sheet 440 
 
UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
 
 
Centre number: 
Study number: 
Patient Identification Number for this study: 
 
 
CONSENT FORM 
 
 
Title of project:    The use of health care services study 
Name of researchers:  Professor Rosalind Raine 
        Ms Jenni Burt 
 
 
Please initial box 
 
 
1.  I confirm that I have read and understand the information sheet dated 
15 December 2005 (version 1) for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily.  
 
2.  I understand that my participation is voluntary. I also understand that I 
am free to withdraw at any time, without giving any reason, and 
without my medical care or legal rights being affected. 
 
3.  I understand that sections of my medical notes may be looked at by 
the researcher from University College London. I give permission for 
this individual to have access to my records. 
 
4.  I agree to take part in this study 
 
 
 
___________________    ____________  __________________ 
Name of Patient      Date      Signature 
 
 
___________________    ____________  __________________ 
Researcher        Date      Signature
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The use of health care services questionnaire 
 
 
Thank you for agreeing to complete this questionnaire. 
 
 
 
There are four sections to the questionnaire: 
 
A. Your reason for this hospital visit 
B. Your use of health care 
C. Your current health 
D. Some general questions about you 
 
 
 
 
 
 
 
 
 
 
 
Centre ID:   ................................................ 
 
Participant ID:   …………………………… 
 
Date:   ………………………………………. 442 
 
 
 
Instructions for completion 
 
 
Please read each question carefully and answer ALL of the 
questions. 
 
Where there are boxes next to the responses, please tick the appropriate 
box or boxes: 
 
e.g.   ￿   Yes   ￿   No    
 
Where there are several responses next to each other, please circle your 
answer: 
 
e.g.   Not at all  A little   Quite a bit    Very much 
 
Where you are asked to give your own response, please write clearly in 
the space provided. 
 
All your answers will be kept in the strictest confidence and used for 
research purposes only.  
 
When you have completed the questionnaire, please hand it back to the 
researcher – Jenni Burt – who is in clinic, or to the clinic receptionist.  
If you do not manage to complete it whilst in clinic, please send it back to 
Jenni in the envelope included. You do not need to use a stamp. 
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A. Your reason for this hospital visit 
 
Firstly, we would like to ask some questions about your diagnosis. For the 
condition for which you are being treated or examined during this hospital 
visit: 
 
1.  How long ago were you diagnosed with this condition or illness?  
(please tick one box) 
 
￿  In the past month 
￿  In the past three months 
￿  In the past six months 
￿  More than six months ago 
 
2.  What was your diagnosis? (Please write it down in the space below) 
   
………………………………………………………………………………… 
   
………………………………………………………………………………… 
 
3.   Apart from this current illness, do you have any other long-standing 
illnesses or disabilities? 
 
￿  Yes 
￿  No 
If YES, please say what these are: 
 
  ………………………………………………………… 
 
  ………………………………………………………… 
 
  ……………………………………………………….... 
 
B. Your use of health care 
 
We are interested in finding out what kind of health care you have received 
for your current illness (the condition for which you are being treated or 
examined during this hospital visit).  
 
The following questions ask about the health professionals who may have 
treated you or who may have cared for you, since you were diagnosed with 
your illness.  
 
Please remember, this does not mean you should have seen every one as 
part of your care.  
 
Please turn over to the next section 444 
 
1. Nurses 
 
1.  Lung clinical nurse specialist 
Lung nurses have specialist training and experience in lung illnesses, 
and are based at the hospital. They provide continuing support to 
patients and families during and following treatment. 
 
I have seen a lung clinical nurse specialist  
about my illness: (please tick box)     ￿  Yes 
￿  No 
￿  Not sure 
￿  Not applicable 
 
2.  Chemotherapy nurse 
Chemotherapy nurses are hospital nurses who explain and give 
chemotherapy treatment to patients. 
 
I have seen a chemotherapy nurse  
about my illness: (please tick box)     ￿  Yes 
￿  No 
￿  Not sure 
￿  Not applicable 
 
3.  District nurse 
District Nurses visit and care for patients in their own homes. They do 
a whole variety of tasks, including dressing wounds, removing 
stitches, taking blood and giving drug treatments at home.  
 
I have seen a district nurse about my illness:  
(please tick box)           ￿  Yes 
￿  No 
￿  Not sure 
￿  Not applicable 
 
4.  Specialist palliative care nurse  
(sometimes called Macmillan, Ellenor or Hospice nurses) 
Palliative care nurses are specialists in supporting patients and 
families facing illnesses such as cancer. They offer advice on pain 
and symptom control, and also emotional support for the patient and 
family. However, they do not provide ‘hands-on’ nursing care like the 
District Nurses. They often visit people in their own homes, but they 
may also see patients when they come as hospital outpatients, or 
whilst they are on a hospital ward.  
 
I have seen a palliative care nurse  
about my illness: (please tick box)     ￿  Yes 
￿  No 
￿  Not sure 
￿  Not applicable 445 
 
5.  Research nurse 
Research nurses are hospital nurses who explain participation in 
research studies to patients. (This question does not refer to the 
researcher who gave you this questionnaire) 
 
I have seen a research nurse  
about my illness: (please tick box)     ￿  Yes 
￿  No 
￿  Not sure 
￿  Not applicable 
 
 
6.  Other nurses 
If you want to, please tell us about any other types of nurses you have 
seen about your illness. (please write in the space below) 
 
  ………………………………………………………………………………… 
 
  ………………………………………………………………………………… 
 
  ………………………………………………………………………………… 
 
  ………………………………………………………………………………… 
 
 
 
 
Please turn over to the next section 446 
 
2. Doctors 
 
1.  Chest doctor  
A chest (respiratory) doctor specialises in caring for patients with 
illnesses related to their lungs (breathing).  
 
I have seen a chest doctor about my illness:   ￿  Yes 
(please tick box)          ￿  No 
￿  Not sure 
￿  Not applicable 
 
2.  Oncologist 
Oncologists are doctors who specialise in treating patients with 
cancer. They advise patients on chemotherapy (drug) treatment, often 
in the outpatient clinic. Some oncologists specialise in radiotherapy (x-
ray) treatment. 
 
I have seen an oncologist about my illness:   ￿  Yes 
(please tick box)          ￿  No 
￿  Not sure 
￿  Not applicable 
 
3.  Palliative care doctor 
Palliative care doctors are specially trained in the control of pain and 
other symptoms such as difficulties with breathing, or feeling sick 
(nausea) and vomiting. These doctors may see patients in the hospital 
outpatient clinic, on a hospital ward, or even visit some patients at 
home.  
 
I have seen a palliative care doctor about   ￿  Yes 
my illness: (please tick box)      ￿  No 
￿  Not sure 
￿  Not applicable 
 
4.  Other doctors 
If you want to, please tell us about any other types of doctors you 
have seen about your illness. (please write in the space below) 
 
  ………………………………………………………………………………… 
 
  ……………………………………………………………………………….... 
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3. Other sources of support 
 
1.  Below we have listed other professionals who may have supported 
you during your current illness. Please tick all those that you have 
seen. 
 
  I have seen this professional about my illness 
 
    Yes  No  Not 
sure 
Not 
applica
ble 
1.  GP  ￿  ￿  ￿  ￿ 
2.  Social worker  ￿  ￿  ￿  ￿ 
3.  Dietician  ￿  ￿  ￿  ￿ 
4.  Physiotherapist  ￿  ￿  ￿  ￿ 
5.  Occupational therapist  ￿  ￿  ￿  ￿ 
6.  Counsellor / psychotherapist  ￿  ￿  ￿  ￿ 
7.  Complementary therapist  ￿  ￿  ￿  ￿ 
8.  Information worker  ￿  ￿  ￿  ￿ 
9.  Radiographer  ￿  ￿  ￿  ￿ 
10.  Spiritual leader  ￿  ￿  ￿  ￿ 
11.  Other (please state) 
 
……………………………………… 
 
……………….................................. 
 
2.  Finally, have you used any of the following to get information or 
support about your illness? 
 
  I have used this for my illness 
    Yes  No  Not 
sure 
Not 
applica
ble 
1. 
A telephone helpline  
(for example, Cancer 
Backup) 
￿  ￿  ￿  ￿ 
2.  The internet  ￿  ￿  ￿  ￿ 
3.  Information leaflets  ￿  ￿  ￿  ￿ 
4.  Other (please state)  ………………………………………… 
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C. Your health 
 
We are interested in some things about you and your health. Please answer 
all of the questions yourself by circling the number that best applies to you. 
There are no “right” or “wrong” answers. The information that you provide will 
remain strictly confidential.  
 
    Not  
at All 
A 
Little 
Quite 
a Bit 
Very 
Much 
1.  Do you have any trouble doing 
strenuous activities like carrying a 
heavy shopping bag or a suitcase? 
1  2  3  4 
2.  Do you have any trouble taking a 
long walk? 
1  2  3  4 
3.  Do you have any trouble taking a 
short walk outside of the house? 
1  2  3  4 
4.  Do you need to stay in bed or a 
chair during the day? 
1  2  3  4 
5.  Do you need help with eating, 
dressing, washing yourself or using 
the toilet? 
1  2  3  4 
           
During the past week:  Not 
at All 
A 
Little 
Quite 
a Bit 
Very 
Much 
6.  Were you limited in doing either 
your work or other daily activities? 
1  2  3  4 
7.  Were you limited in pursuing your 
hobbies or other leisure time 
activities? 
1  2  3  4 
8.  Were you short of breath?  1  2  3  4 
9.  Have you had pain?  1  2  3  4 
10.  Did you need to rest?  1  2  3  4 
11.  Have you had trouble sleeping?  1  2  3  4 
12.  Have you felt weak?  1  2  3  4 
13.  Have you lacked appetite?  1  2  3  4 
14.  Have you felt nauseated?  1  2  3  4 
15  Have you vomited?  1  2  3  4 449 
 
 
During the past week:  Not 
at All 
A 
Little 
Quite 
a Bit 
Very 
Much 
16.  Have you been constipated?  1  2  3  4 
17.  Have you had diarrhea?  1  2  3  4 
18.  Were you tired?  1  2  3  4 
19.  Did pain interfere with your daily 
activities? 
1  2  3  4 
20.  Have you had difficulty in 
concentrating on things, like reading 
a newspaper or watching 
television? 
1  2  3  4 
21.  Did you feel tense?  1  2  3  4 
22.  Did you worry?  1  2  3  4 
23.  Did you feel irritable?  1  2  3  4 
24.  Did you feel depressed?  1  2  3  4 
25.  Have you had difficulty 
remembering things? 
1  2  3  4 
26.  Has your physical condition or 
medical treatment interfered with 
your family life? 
1  2  3  4 
27.  Has your physical condition or 
medical treatment interfered with 
your social activities? 
1  2  3  4 
28.  Has your physical condition or 
medical treatment caused you 
financial difficulties? 
1  2  3  4 
 
For the following questions please circle the number between 1 and 7 
that best applies to you 
 
9.  How would you rate your overall health during the past week? 
  1  2  3  4  5  6  7 
  Very poor  Excellent 
 
29.  How would you rate your overall quality of life during the past 
week? 
  1  2  3  4  5  6  7 
  Very poor  Excellent 
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Patients sometimes report that they have the following symptoms or 
problems. Please indicate the extent to which you have experienced these 
symptoms or problems during the past week. Please answer by circling the 
number that best applies to you. 
 
 
During the past week: 
 
Not 
at All 
A 
Little 
Quite 
a Bit 
Very 
Much 
31.  How much did you cough?  1  2  3  4 
32.  Did you cough up blood?  1  2  3  4 
33.  Were you short of breath when you 
rested? 
1  2  3  4 
34.  Were you short of breath when you 
walked? 
1  2  3  4 
35.  Were you short of breath when you 
climbed stairs? 
1  2  3  4 
36.  Have you had a sore mouth or 
tongue? 
1  2  3  4 
37.  Have you had trouble swallowing?  1  2  3  4 
38.  Have you had tingling hands or 
feet? 
1  2  3  4 
39.  Have you had hair loss?  1  2  3  4 
40.  Have you had pain in your chest?  1  2  3  4 
41.  Have you had pain in your arm or 
shoulder? 
1  2  3  4 
42.  Have you had pain in other parts of 
your body?  
1  2  3  4 
  If yes, where 
__________________________ 
       
43.  Did you take any medicine for pain?         
  1  No  2  Yes         
  If yes, how much did it help?  1  2  3  4 
 
 
 
© QLQ-C30-LC13 Copyright 1994 EORTC Study Group on Quality of Life. All rights reserved. 
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D. Finally, we would like to ask some general questions about you 
 
1.   Are you…?    ￿    Male    ￿   Female 
 
2.   How old are you?   Please write in:  Years: ……………… 
 
3.   Are you…? (please tick one box) 
￿  Married or living with a partner 
￿  Divorced or separated 
￿  Widowed 
￿  Or single (never married, and not living with a partner) 
 
4.   Apart from yourself, how many other adults live in your household 
(aged 18 or over)? 
 
Write in number:  ……………… 
 
5.   How many children live in your household (aged under 18)? 
 
Write in number:  ……………… 
 
6.  To which of the following ethnic groups would you say you belong? 
(please tick one box) 
 
￿  White          ￿  Asian or Asian British 
￿  Black or Black British     ￿  Chinese 
￿  Mixed         ￿  Other (please specify:) 
……………… 
 
7.  What is your postcode?  
(please note, we will not use this to contact you – it is for information 
only). 
 
        Write in full postcode: ……………… 
 
8.  Do you look after, or give special help to, anyone who is ill, disabled or 
elderly, other than in a professional capacity? (Please tick all that 
apply) 
 
￿  Yes, a person in this household 
￿  Yes, a person in another household 
￿  No 
 
If yes, please give details if you wish:  
 
…………………………………………………..................................................... 
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9.  And does anyone look after or give special help to you because of 
illness, disability or old age, other than in a professional capacity? 
(Please tick all that apply) 
 
￿  Yes, a person in this household 
￿  Yes, a person in another household 
￿  No 
 
If yes, please give details if you wish:  
 
…………………………………………………..................................................... 
 
………………………………………………………………………………………… 
 
 
10.   Did you complete this form by yourself, or did someone help you with 
any of it? (Please tick all that apply) 
 
￿  I completed it by myself 
￿  Someone read the questions to me 
￿  Someone wrote down the answers I gave 
￿  Someone answered the questions for me 
￿  Someone translated the questions into my own language 
￿  Someone helped in some other way (please write below) 
 
………………………………………………………………………… 
 
……………………………………………………………………....... 
 
Thank you very much for completing the questionnaire. Please return it to the 
researcher (Jenni) in the clinic, or to the staff at the clinic reception desk. 
Alternatively, you can return it in the envelope provided – no stamp is 
needed. 
 
If there is anything else you would like to tell us in writing, please feel free to 
write it down in the space below or on a separate sheet of paper and return it 
to us with this questionnaire. We would be very interested in what you have 
to say. 
 
………………………………………………………………………………………… 
 
………………………………………………………………………………………… 
 
………………………………………………………………………………………… 
 
Thank for your help. 
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UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
The use of health care services study 
 
Participant Information Sheet 
 
I would like to invite you to take part in a research study. Please take time to 
read the following information carefully and discuss it with others if you wish. 
 
My name is Jenni Burt and I am a researcher supported by a grant from the 
Medical Research Council. I work for University College London (UCL). 
Please ask me if there is anything that is not clear or if you would like more 
information.  
 
Thank you for reading this. 
 
Purpose 
In this study we would like to find out more about what type of health care 
patients with lung illnesses receive. We want to know if there are differences 
between particular groups of patients in the care they receive, and why this 
might be happening. It is important for us to include family members and 
friends, as well as patients, in this study so we can know how the treatment 
and care patients receive also affects those who support them. 
 
What is involved? 
If you would like to take part, you need to do two things. 
First, fill in the consent form in this pack to say you are happy to answer the 
questionnaire. 
Second, fill in the questionnaire in this pack and hand it back to me or the 
clinic receptionist. Filling in the questionnaire should take up to 10 minutes. 
Your family member or friend who you have attended clinic today with will 
also be asked to fill in a separate questionnaire (if they wish to).  
 
Participation 
It is up to you to decide whether or not to take part. You do not have to 
answer any questions you do not want to. You are free to withdraw from the 
study at any time. Please tell me about any concerns you may have 
 
Who will have access to the details? 
All the information about your participation in this study will be kept 
confidential to the research team. 
 
My contact details 
I am in clinic today. If you want to get in touch with me at another time, I can 
be contacted at: the Department of Epidemiology and Public Health, UCL, 1-
19 Torrington Place, London, WC1E 6BT. My phone number is 020 7679 
8283, and my email address is jenni.burt@ucl.ac.uk 
 
Thank you very much for taking the time to read this sheet454 
 
UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
 
 
Centre number: 
Study number: 
Participant Identification Number for this study: 
 
CONSENT FORM 
 
 
Title of project:    The use of health care services study 
Name of researchers:  Professor Rosalind Raine 
        Ms Jenni Burt 
 
 
Please initial box 
 
 
1.  I confirm that I have read and understand the information 
sheet dated 15 December 2005 (version 1) for the above study.  
I have had the opportunity to consider the information, ask  
questions and have had these answered satisfactorily.  
 
2.  I understand that my participation is voluntary. I also 
understand that I am free to withdraw at any time, without  
giving any reason, and without our medical care or legal rights  
being affected. 
 
3..  I agree to take part in this study 
 
 
 
 
 
_____________________ _______________  ______________________ 
Name of Participant     Date      Signature 
 
 
_____________________ _______________  ______________________ 
Researcher        Date      Signature 
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The experiences of family and friends  
questionnaire 
 
 
Thank you for agreeing to complete this questionnaire.  
 
There are three sections to the questionnaire:  
 
A. Your reason for this hospital visit 
B. Your experiences as a family member or friend 
C.. Some general questions about you 
 
 
 
 
 
 
 
 
 
 
Centre ID:   ................................................ 
 
Participant ID:   …………………………… 
 
Date:   ……………………………………….  
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Instructions for completion 
 
 
Please read each question carefully and answer ALL of the 
questions. 
 
Where there are boxes next to the responses, please tick the appropriate 
box or boxes: 
 
e.g.   ￿   Yes   ￿   No    
 
Where there are several responses next to each other, please circle your 
answer: 
 
e.g.   Not at all  A little   Quite a bit    Very much 
 
Where you are asked to give your own response, please write clearly in 
the space provided. 
 
All your answers will be kept in the strictest confidence and used for 
research purposes only.  
 
When you have completed the questionnaire, please hand it back to the 
researcher – Jenni Burt – who is in clinic, or to the clinic receptionist.  
If you do not manage to complete it whilst in clinic, please send it back to 
Jenni in the envelope included. You do not need to use a stamp. 
 
.  
457 
 
A. Your reason for this hospital visit 
 
Firstly, we would like to ask some questions about you and the reason for 
your visit to hospital today.  
 
1.   What is your relationship to the patient you are accompanying to the 
outpatient clinic today? 
 
￿  Husband/wife/partner 
￿  Son/daughter 
￿  Brother/sister 
￿  Other family member (please describe) 
 
……………………………………………… 
￿  Friend 
￿  Other (please describe) 
 
 ……………………………………………… 
 
 
2.   Do you normally live in the same house as your family member/friend 
who is attending clinic today? 
 
￿  Yes  
￿  No 
 
 
3.   Do you look after, or give special help to, your family member/friend 
you have attended clinic with today, as a result of their illness? 
 
      ￿  Yes  
￿  No 
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4.   What care or support do you provide to your family member/friend?  
(Please tick all boxes that apply) 
   
    ￿  Household tasks (such as cleaning) 
￿  Shopping / collecting benefits / prescriptions 
￿  Accompanying to medical appointments 
￿  Personal care (help to wash and dress, use the toilet)  
￿  Nursing/medical care 
￿  Emotional support  
￿  Regular night care 
￿  Help with money 
￿  Other (please give details) 
 
…………………………………………………… 
 
……………………………………………………  
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B. Your experiences as a family member or friend 
 
We want to know how your health has been in general over the last few 
weeks. Please read the questions below and each of the four possible 
answers. Circle the response that best applies to you. Thank you for 
answering all the questions.  
 
Have you recently? 
 
1. Been able to concentrate 
on what you’re doing 
Better 
than usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
2. Lost much sleep over 
worry 
Not at all  No more 
than usual 
Rather 
more than 
usual 
Much 
more than 
usual 
3. Felt you were playing a 
useful part in things 
More so 
than usual 
Same as 
usual 
Less 
useful 
than usual 
Much less 
than usual 
4. Felt capable of making 
decisions about things 
More so 
than usual 
Same as 
usual 
Less so 
than usual 
Much less 
capable 
5. Felt constantly under 
strain 
Not at all  No more 
than usual 
Rather 
more than 
usual 
Much 
more than 
usual 
6. Felt you couldn’t 
overcome your difficulties 
Not at all  No more 
than usual 
Rather 
more than 
usual 
Much 
more than 
usual 
7. Been able to enjoy your 
normal day-to-day activities 
More so 
than usual 
Same as 
usual 
Less so 
than usual 
Much less 
than usual 
8. Been able to face up to 
your problems 
More so 
than usual 
Same as 
usual 
Less so 
than usual 
Much less 
able 
9. Been feeling unhappy 
and depressed  
Not at all  No more 
than usual 
Rather 
more than 
usual 
Much 
more than 
usual 
10. Been losing confidence 
in yourself 
Not at all  No more 
than usual 
Rather 
more than 
usual 
Much 
more than 
usual 
11. Been thinking of 
yourself as a worthless 
person. 
Not at all  No more 
than usual 
Rather 
more than 
usual 
Much 
more than 
usual 
12. Been feeling 
reasonably happy, all 
things considered 
More so 
than usual 
About the 
same as 
usual 
Less so 
than usual 
Much less 
than usual 
 
General Health Questionnaire (GHQ-12) © David Goldberg 1978; reproduced by permission of NFER-NELSON. All 
rights reserved.  
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3. Finally, we would like to ask some general questions about you 
 
 
1.   Are you…? (please tick one box) 
   
￿    Male 
    ￿   Female 
 
2.   How old are you? 
   
Please write in:  Years: …………………. 
 
3.   Are you…? (please tick one box) 
   
￿  Married or living with a partner 
￿  Divorced or separated 
￿  Widowed 
￿  Or single (never married, and not living with a partner) 
 
4.   Apart from yourself, how many other adults live in your household 
(aged 18 or over)? 
 
Write in number:  ………………. 
 
5.   How many children live in your household (aged under 18)? 
 
Write in number:  ………………. 
 
6.  To which of the following ethnic groups would you say you belong? 
(please tick one box) 
 
￿  White 
￿  Asian or Asian British 
￿  Black or Black British  
￿  Chinese 
￿  Mixed 
￿  Other (please specify):  
 
……………………………………. 
 
7.  What is your postcode? (please note, we will not use this to contact 
you – it is for information only). 
 
    Write in full postcode: ……………………… 
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8.  Not including the person you attended clinic with today, do you look 
after, or give special help to, anyone who is ill, disabled or elderly, 
other than in a professional capacity? (Please tick all that apply) 
 
￿  Yes, a person in this household 
￿  Yes, a person in another household 
￿  No 
 
9.  And does anyone look after or give special help to you because of 
illness, disability or old age, other than in a professional capacity? 
(Please tick all that apply) 
 
￿  Yes, a person in this household 
￿  Yes, a person in another household 
￿  No 
 
If yes, please give details if you wish: ……………………………………………. 
 
 
10.   Did you complete this form by yourself, or did someone help you with 
any of it? (Please tick all that apply) 
 
￿  I completed it by myself 
￿  Someone read the questions to me 
￿  Someone wrote down the answers I gave 
￿  Someone answered the questions for me 
￿  Someone translated the questions into my own language 
￿  Someone helped in some other way (please write below) 
 
………………………………………………………………… 
 
………………………………………………………………… 
 
 
Thank you very much for completing the questionnaire. Please return it to the 
researcher (Jenni) in the clinic, or to the staff at the clinic reception desk. 
Alternatively, you can return it in the envelope provided – no stamp is 
needed. 
 
If there is anything else you would like to tell us in writing, please feel free to 
write it down on in the space below or on a separate sheet of paper and 
return it to us with this questionnaire. We would be very interested in what 
you have to say. 
 
……………………………………………………………………………………… 
 
…………………………………………………………………………………………  
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UCL DEPARTMENT OF EPIDEMIOLOGY  
AND PUBLIC HEALTH 
HEALTH CARE EVALUATION GROUP 
 
 
Use of health care services study 
Data extraction form 
 
Patient details 
1  Patient identification 
number:   
2  Date recruited:  …… / …… / …… 
3  Site recruited from:   
  Originating site:   
4  Sex (circle):  F   M 
5  Date of birth: 
…… / …… / …… 
6.  Postcode:   
7.  Name of GP:   
8.  Address of GP:   
     
     
9.  Referred to DN (circle)  Yes   No 
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Diagnosis 
1  Date of diagnosis: 
…… / …… / …… 
2  Type:  NSCLC  SCLC   unknown 
3  Site and type:   
4  Stage at diagnosis:  T …  N …  M 
…   Limited  Extensive 
5  How staged (circle):  histological  clinical 
6.  Disease progression:   
  Date: …… / …… / …… 
CT     PET      X-ray 
Bone scan      Other   
 
Date: …… / …… / …… 
CT     PET      X-ray 
Bone scan      Other   
  Date: …… / …… / …… 
CT     PET      X-ray 
Bone scan      Other   
 
Date: …… / …… / …… 
CT     PET      X-ray 
Bone scan      Other   
 
Date: …… / …… / …… 
CT     PET      X-ray 
Bone scan      Other   
  Date: …… / …… / …… 
CT     PET      X-ray 
Bone scan      Other   
7.  Metastases:   
  Date: …… / …… / ……  Site: 
 
Date: …… / …… / ……  Site: 
 
Date: …… / …… / ……  Site: 
 
Date: …… / …… / ……  Site: 
8.  Notes:   
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Treatment: surgery 
1.  Surgery (circle):  Yes   No  
  Date:   …… / …… / …… 
  Site:   
2.  Further surgery (circle):  Yes   No 
  Date:  
…… / …… / …… 
  Site:   
3.  Notes:   
     
 
 
Treatment: radiotherapy 
1.  Radiotherapy (circle):  Yes   No  
  Date commenced:   …… / …… / …… 
  Date completed: 
…… / …… / …… 
  Type (circle):  Radical     Palliative     Unknown 
  Site:  Course (strength/#): 
2.  Further RT:  Yes   No  
  Date commenced:   …… / …… / …… 
  Type (circle):  Radical     Palliative     Unknown 
  Site:  Course (strength/#): 
3.  Notes:   
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Treatment: chemotherapy 
1.  Chemotherapy (circle):  Yes   No  
  Date commenced:   …… / …… / …… 
  Date completed: 
…… / …… / …… 
  Type (circle):  Adjuvant     Palliative     Unknown 
  Type (circle):  Cisplatin  Etoposide 
    Gemcitabine  Paclitaxel 
    Vinorelbine  Carboplatin 
    Cisplatin  Docetaxel 
    Other: 
……………………………………………… 
  Number of cycles  ..…. planned     …... received 
2.  Further CT (circle):  Yes   No  
  Date commenced:  
…… / …… / …… 
  Date completed:  …… / …… / …… 
  Type (circle):  Cisplatin  Etoposide 
    Gemcitabine  Paclitaxel 
    Vinorelbine  Carboplatin 
    Cisplatin  Docetaxel 
    Other: 
……………………………………………… 
  Number of cycles  ..…. planned     …... received 
3.  Notes:   
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Other relevant past medical history 
Date  Diagnosis/disease progression/investigation 
…… / …… / ……   
…… / …… / …… 
 
…… / …… / …… 
 
…… / …… / …… 
 
…… / …… / …… 
 
…… / …… / ……   
…… / …… / …… 
 
…… / …… / ……   
…… / …… / …… 
 
…… / …… / …… 
 
…… / …… / ……   
…… / …… / …… 
 
…… / …… / ……   
…… / …… / …… 
 
…… / …… / …… 
 
…… / …… / …… 
 
…… / …… / …… 
 
Notes:   
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Use of SPC 
1.  Referral to SPC (circle):  Yes   No 
2.   Date of first referral:   …… / …… / …… 
3.  Referred by:  ￿ Lung CNS   
    ￿ Chest consultant  ￿ Chest SPR 
    ￿ Oncology consultant  ￿ Oncology SPR 
    ￿ Other: 
…………………………………………… 
4.   Type of service (tick):  ￿ Community  ￿ Day hospice 
    ￿ Inpatient hospice  ￿ Inpatient 
hospital 
5.  Reason for referral  ￿ Pain/symptom control 
    ￿ Emotional/psychological support 
    ￿ Social/financial 
    ￿ Assessment for hospice admission 
    ￿ Carer support 
    ￿ Other reason (e.g. spiritual/lymphoedema) 
6.  Urgent referral (circle):  Yes   No 
7.  Referrer’s expectations 
of current treatment  ￿ Symptom control  ￿ Life prolonging 
    ￿ Curative   
8.  Estimated prognosis  ￿ Days  ￿ Weeks 
    ￿ Months   ￿ Years 
9.  Notes:   
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Appendix VI 
 
Journal papers arising from this work  
 
This appendix contains the text of two published papers arising so far from 
this work: 
 
1.  Burt J, Raine R. The effect of age on referral to and use of specialist 
palliative care services in adult cancer patients: a systematic review. 
Age and Ageing 2006 35(5): 469-476 
2.  Burt J, Plant H, Omar R, Raine R. Equity of use of specialist palliative 
care by age: cross-sectional study of lung cancer patients. Palliative 
Medicine 2010 
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The effect of age on referral to and use of specialist palliative care 
services in adult cancer patients: a systematic review 
 
 
Abstract 
 
Objective 
To investigate variations in the use of specialist palliative care services for 
adult cancer patients, in relation to age. 
 
Design 
Systematic review of studies examining use of or referral to specialist 
palliative care services in adult cancer patients.  
 
Search strategy and selection criteria 
Five electronic databases (Medline, Embase, Web of Science, HMIC, SIGLE 
and AgeInfo) were searched for studies published between 1966 to March 
2005, and references in the articles identified were also examined. Inclusion 
criteria were all studies which provided data on age in relation to use of, or 
referral to specialist palliative care. Two reviewers independently selected 
studies, extracted data and assessed methodological quality according to 
defined criteria. 
 
Main outcome measures 
Use of or referral to specialist palliative care services, determined from all 
sources of report (patient, informal carer, healthcare professional, healthcare 
records).  
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Results 
14 studies were identified. All reported a statistically significant lower use of 
specialist palliative care among older cancer patients (65 and above or older) 
at a univariate level (crude odds ratios ranged from 0.33 (0.15 to 0.72) to 0.82 
(0.80 to 0.82)). However, there were important methodological weaknesses in 
all of the studies identified; most crucially, studies failed to consider 
variations in use in relation to need for specialist palliative care. 
 
Conclusions 
There is some evidence that older people are less likely to be referred to, or 
use specialist palliative care. These findings require confirmation in studies 
using prospectively collected data which control for patient’s need for 
specialist palliative care. 
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Introduction 
As populations age and disease patterns change, the need for access to high 
quality palliative care at the end of life is becoming of increasing public 
health concern. (1) For the growing numbers of older people with advanced, 
progressive illnesses, poor access to effective symptom control and 
psychosocial support as they near the end of life can lead to an increased risk 
of hospital admission and death in hospital. (2) Older people frequently 
present with complex needs as a result of comorbidities, social isolation, frail 
older care-givers, and economic hardship. They may respond well to the 
expertise offered by specialist palliative care providers across all settings. (2) 
However, recent UK policy documents including the NHS Cancer Plan and 
the National Service Framework for Older People report that that older 
people have poorer access to palliative care compared with younger people. 
(3;4)  
 
The debate about the appropriateness of rationing health care provision by 
age has been fuelled recently by a National Institute for Clinical Excellence 
(NICE) consultation document on social value judgments, which concluded 
that “where age is an indicator of benefit or risk, age discrimination is 
appropriate.” (5) The concept of a “fair innings” has also been used to justify 
the prioritisation of health care resources to younger people. (6) However, 
these arguments refer to health care aimed at prolonging life, and are not 
applicable to palliative care, an intervention which improves the quality, 
rather than the length of life. (7)  
 
Two previous reviews have investigated variations in access to specialist 
palliative care (SPC). (8;9)  On the basis of seven studies published between  
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1997 and 2003, Ahmed et al concluded that there was some evidence that 
patients aged 65 and over have a reduced likelihood of referral to SPC. (8) 
Grande et al reviewed 14 studies and found that that older patients were less 
likely to receive home SPC. (9) However, neither review quantified the 
difference in use by younger and older patients to enable estimation of the 
scale of the problem. In addition, neither review applied a quality 
assessment to the included studies, which limits the confidence that can be 
placed in the conclusions.  
 
This review is the first to critically appraise published quantitative research 
on the effect of age on referral to and use of SPC for patients with cancer, and 
to quantify the impact of age on use. Cancer patients were chosen because 
they represent 95% of specialist palliative care users in the UK. (10) 
 
Review methods 
 
Search strategy and selection criteria 
We searched Medline, Embase, Web of Science, HMIC, SIGLE and AgeInfo 
from 1966 to March 2005 for all studies which included quantitative data on 
referral to and/or use of specialist palliative care (SPC) by adult cancer 
patients (at any site and stage of disease), across all clinical settings. Settings 
included in-patient care in a designated palliative care unit (e.g. hospice), 
day care in a designated palliative care unit, home care received from a SPC 
team and hospital care received from a SPC team. Studies of care not 
provided by a dedicated SPC team, including generalist palliative care 
provided by e.g. family doctors and palliative radiotherapy, were excluded. 
Retrospective or prospective cohort studies, case-control studies and cross- 
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sectional surveys were eligible for inclusion if they provided data on and 
included age within their analysis, even if age was not their primary 
predictor variable. All sources of report of referral or use (patient, informal 
carer, healthcare professional, healthcare records) were eligible for inclusion. 
There were no restrictions on the country of research, but the language of 
publication was restricted to English.  
 
A combination of text words and thesaurus terms were used for two major 
search concepts and their synonyms – referral/use and specialist palliative care 
(Appendix 1 for full strategy). The search strategy was developed in Medline 
and then adapted for other databases. Bibliographies of full-text articles 
identified through database searching and included in the review were 
scrutinized for further relevant studies. The lists of titles, abstracts and then 
full texts were scrutinized independently by two reviewers (JB and RR) to 
determine whether they met the inclusion criteria. 
 
Data extraction, appraisal and synthesis 
Extraction of data from each paper was performed by one reviewer (JB) and 
checked by a second (RR). Discrepancies were resolved by referral to the 
original studies. A checklist was used to extract data on the methods 
(including design, completeness of outcome ascertainment, analysis); size of 
study; study population (region, subjects and inclusion/exclusion criteria); 
outcomes of interest; and proportions of users/non-users by age. 
Components for quality assessment were adapted from the methodology 
checklists developed by the Scottish Intercollegiate Guidelines Network 
(SIGN) and used by organisations including the National Institute for Health 
and Clinical Excellence (NICE). (11) These series of questions, published for  
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study designs including cohort and case-control studies, guide assessment of 
the internal validity of a study. Each study-design specific checklist covers 
details on the selection of subjects, the assessment of outcome, confounding, 
and statistical analysis. Criteria are answered on a scale from ‘Not reported’ 
to ‘Well covered’, and an overall assessment of the study is then made based 
on how many of the criteria are met. Cross-sectional studies were appraised 
using a modified version of the cohort study checklist. 
 
Due to the diverse nature of the included study populations and of the 
outcomes, statistical synthesis of study findings was inappropriate. Where 
data allowed, crude odds ratios and 95% confidence intervals for the use of 
specialist palliative care in older versus younger cancer patients were 
calculated. We used an age cut-off of over and under 75 where original age 
categories allowed. Extracted data are presented in tabular form and a 
narrative synthesis conducted.  
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Results 
 
Description of studies 
Of 2652 citations initially identified, fourteen articles (which related to 
thirteen studies) met the inclusion criteria. (12-25)  
 
 
 
Nine of the thirteen studies were retrospective cohort studies which used 
administrative data and ranged in size from 521 (18) to 170,136 participants. 
(23) Two studies were cross-sectional surveys using retrospective reports of 
service use from proxy respondents (usually carers). They included 96 (24) 
and 2074 (12;13) participants respectively. One study used a retrospective 
case-control design (17) and one was a retrospective review of a palliative 
Not meeting inclusion criteria (n = 12) 
 
Not restricted to cancer patients (n=3) 
No data on age of patients (n=2) 
Includes only patients already receiving 
palliative care (n =3) 
No direct measurement of use of 
specialist palliative care (n=3) 
Duplicate paper (n=1) 
Full text studies retrieved for more 
detailed evaluation (n = 26)  
Studies meeting inclusion criteria and 
included in review (n = 14) 
Studies identified through searches and 
screened against inclusion criteria (n = 
2652)  
Not meeting inclusion criteria (n = 2626) 
Fig 1. Flowchart of literature search and study selection  
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care service’ records, with comparisons to the wider population of cancer 
deaths. (16) Studies covered deaths occurring from 1979 to 1999. Two studies 
restricted participants to patients aged 65 years and above at death, and one 
to 67 years and above; the remaining restricted participants to adults, or had 
no stated age restrictions (Table 1). 
 
Four articles focused specifically on the receipt of SPC at home. (13;15;17;24) 
The remaining included one or more services providing SPC across a range 
of settings (e.g. home, hospital, and hospice). Studies based their outcome 
ascertainment on records kept or provided by the SPC service of interest, 
except the two surveys of proxy respondents, which relied on participant’s 
reports of the deceased’s use of services  
 
Use of specialist palliative care in relation to age 
All of the studies reported a statistically significant lower use of SPC among 
older cancer patients at a univariate level. Crude odds ratios for the use of 
SPC in older versus younger cancer patients ranged from 0.37 (0.23 to 0.60) 
to 0.82 (0.80 to 0.84) (Table 2). 
 
Eight studies included a multivariate regression analysis to investigate the 
effect of age on referral to or use of SPC, after controlling for potential 
confounding factors. (12-14;17;19-21;23) Of these, six reported older adults 
were significantly less likely to use specialist palliative care services. (12-
14;19-21) However, age group cut-offs and variables included in regression 
models varied between studies, making direct comparison between them 
difficult. In Grande et al’s (2002) case control study, the effect of age 
disappeared after controlling for other variables, including use of cancer and  
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district nursing services. (17) As the author’s acknowledged, if age is related 
to use of other health care services, its relationship with hospice use may 
have been disguised in their analysis. The final study reported that, 
following multiple regression analysis, the effect of age (as a continuous 
variable) on the use of hospice care increased over the period of their study, 
1991 to 1999. (23) 
 
Discussion 
Our findings suggest that patients’ age may be an influential factor in use of 
or referral to SPC, with older patients less likely to receive these services 
than younger patients. However, important weaknesses in the studies 
reviewed limit the certainty of the findings. 
 
Crucially, these studies did not explicitly explore the issue of inequality 
versus inequity of use. Inequality and inequity are related, but not equivalent, 
concepts. Inequities in the use of health care are inequalities (differences) in 
use which are considered to be unfair or unjust. (26) The judgement as to 
what is unfair or unjust is usually based on consideration of the need for 
health care and the extent to which health care inequalities are avoidable.  
An equitable health care system is one in which there is equal use of health 
care for equal need. Therefore, the measurement of need is fundamental to 
studies of the fair use of health care. (27) This concept of fairness, rather than 
simply of equality, is widely recognised when the distribution of NHS care is 
considered. For example, standard one of the National Service Framework 
(NSF) for Older People states that “NHS services will be provided, 
regardless of age, on the basis of clinical need alone.” (4) Specialist palliative  
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care is designed to meet only the most complex or persistent needs of cancer 
patients – and therefore not all patients require this care. (28)  
 
Unequal use of health care between particular population groups is not 
inequitable if it reflects an unequal need for care.  These findings may 
therefore reflect a reduced need for specialist palliative care amongst older 
people. It is not yet clear whether this is indeed the case, for two reasons.  
First, although it has been agreed that specialist palliative care should be 
reserved for those with “complex and persistent” needs, there has been little 
examination on how this definition of need should be operationalised, 
resulting in a lack of agreement between medical and nursing staff as to 
which hospital inpatients require such care. (29)  Secondly, the  evidence on 
variations in the need for care by age, based upon the presence and impact of 
symptoms, is limited and conflicting. For example, one post-bereavement 
survey of carers found that patients over 85 years had a greater number of 
symptoms than patient under 65, but symptoms in the older group were less 
likely to “very distressing”. (30) By contrast, a secondary analysis of a 
retrospective survey of cancer patient carers suggested that both the number 
of symptoms and the proportion perceived to be “very distressing” declined 
with age, whilst the level of functional dependency did not vary. (31)  
 
It is argued that the need for specialist palliative care should be determined 
by social, emotional and spiritual concerns as well as by health status. (1)  
Across a life span, patients’ health, social and economic status (including the 
presence of dependent children or partners, the likelihood of living alone 
and employment status) fluctuates. It is therefore possible that the need for 
specialist palliative care will vary with age.  However, in the absence of  
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explicit definitions of the needs that can be addressed by specialist palliative 
care, it is not possible to explore the extent to which they differ with age. 
Only one of the studies included in this review attempted to define patients’ 
need for specialist palliative care, and this was limited to a consideration of 
symptoms. (12;13)  
 
An alternative explanation for lower use of specialist palliative care by older 
patients is that their needs are being met elsewhere. Perhaps health or social 
care services “fill the gap” for older cancer patients.  It may be that  a 
palliative care approach is used by generalist or care of the elderly services 
and that these meet the needs of older cancer patients. (28) The high 
proportion of older cancer patients dying in care homes may also reflect 
another effective approach to meeting the needs of these patients. (32) 
However, until a greater understanding of need is developed, it is difficult to 
judge how far specialist palliative care needs are met by alternative care 
sources.  
 
Some further limitations of the studies included in this review should be 
pointed out. Firstly, four studies gave an inadequate description of SPC 
services that were included, their setting, and the care offered, limiting their 
generalisability. (14;20;22;23) Secondly, the quality of the outcomes data was 
often poor. All the studies were based on retrospective investigations of 
service use, relying on routine administrative data or recall of service use by 
proxy respondents. It is understandable why such data sources are used in 
preference to prospectively collected data from patients themselves. In this 
field prospective data collection is challenging, due to the terminal nature of 
illness, and risk of loss of data due to participants’ incapacity or death.  
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However, the limitations of retrospective methods should be recognised. For 
example, referral to, or use of SPC has been shown to be inconsistently 
recorded in patient records; (33) the validity of responses about service use 
and subjective symptoms from proxies such as carers is uncertain; (34) and 
questions asked of proxy respondents to determine use of SPC are often 
insufficiently comprehensive. (24) The sensitive nature of terminal illness 
research  should not exclude the use of prospective studies.  Instead 
discerning methods of data collection should be designed, which may 
include, for example, flexibility in data collection intervals and settings. If 
retrospective methods continue to be used, validation methods should 
ascertain the accuracy of their outcomes data. These could include 
prospective investigation of the completeness and accuracy of medical 
records, or cross-validation of respondent reports with data from SPC 
services.  
 
Implications 
This review highlights the requirement to investigate the use of SPC in 
relation to the need for such care to understand whether the objectives of the 
NHS Cancer Plan and the NSF for Older People are being fulfilled in line 
with the principles of the NHS. Sensitive and flexible prospective methods 
should be developed to examine the extent to which the use of specialist 
palliative care is fair. This review also highlights wider issues about how 
need for SPC may be defined. Although this paper is restricted to cancer 
patients, the ongoing debate about SPC for non-cancer patients may present 
an opportunity to focus on and clarify what SPC actually is and offers, and 
who has a need for such care.   
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Table 1. Characteristics and quality appraisal of studies 
Study 
(location)  Age of patients  Participants  Outcome  SIGN score* 
Retrospective cohort studies       
Burge 2002 
(Canada) (14)  No stated restrictions 
4376 cancer deaths (1992 to 1997) identified 
from death certificates in one municipality. No 
stated age restrictions. 
Referral to the municipality palliative care 
programme. Not stated how determined.  2- 
Costantini 
1993 (Italy)  
(15) 
18+  12,343 cancer deaths (1986 to 1990) identified 
from local department of statistics in one city.  
Use of the palliative home care service. 
Determined from clinical records of the 
service. 
2- 
Evans 1984 
(UK) (16)  No stated restrictions 
125 patients (referred between May 1982 and 
June 1983) identified from the clinical records 
of the service and who received continuing 
care. 437 cancer deaths (1982) in one district 
identified from the death records of the Office 
of Population Censuses and Surveys.  
Receipt of continuing care from the 
multidisciplinary terminal care support team.  2- 
Gray 1997 
(UK) (18)  16+ 
521 cancer deaths (1991) identified from death 
register held by the Director of Public Health. 
Participants included if postcode of residence 
within District Health Authority; cancer 
recorded as a causal or contributory factor in 
death. 16 years and over. 
Receipt of care from one or more specialist 
palliative care agencies, last 12 months of 
life. Determined from in-patient and day 
hospice records; Marie Curie and Macmillan 
nurse' case load diaries 
2- 
Hunt 1996 
(Australia) 
(19) 
No stated restrictions 
2800 cancer deaths (1990) identified from 
Central Cancer Registry (CCR) database. 
Deaths attributable to a non-cancer cause – 
based on State death records – excluded. No 
stated age restrictions. 
Use of one of South Australia's inpatient 
hospice or outreach palliative care services. 
Determined from lists provided by all hospice 
and palliative care services of their patients 
who died in 1990. 
2-  
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Table 1. Characteristics and quality appraisal of studies 
Study 
(location)  Age of patients  Participants  Outcome  SIGN score* 
Hunt 2002 
(Australia) 
(20) 
No stated restrictions 
3086 cancer deaths (1999) identified from 
State Cancer Registry database. No stated 
age restrictions. 
Use of one of South Australia's inpatient 
hospice or outreach palliative care services. 
Determined from lists provided by all hospice 
and palliative care services of their patients 
who died in 1999. 
2- 
Johnston 
1998 
(Canada) (21) 
20+ 
14,494 cancer deaths (1988 to 1994) identified 
from death certificate data included in the 
Cancer Registry in one region. 20 years and 
over. 
Referral  to a comprehensive Palliative Care 
Program (PCP) based in one Infirmary. 
Inpatient unit, hospital consultation, clinic 
follow-up, home consultation and 
bereavement support. Determined from 
clinical records of the service. 
2- 
Lackan 2003 
(USA) (22)  65+ 
25,161 breast cancer deaths (1991 to 1996) 
identified from Surveillance, Epidemiology and 
End Result (SEER) Medicare databases - 
population-based registry for incident cancer 
cases. SEER areas represent about 14% of 
the US population. Diagnosed with breast 
cancer between 1986 and 1996. Aged 65 
years and over. 
Receipt of hospice care. Determined by 
existence of a hospice claim in the hospice 
standard analytic file [Medicare claims]. 
2- 
Lackan 2004 
(USA) (23)  67+ 
170,136 breast, colorectal, lung and prostate 
cancer deaths (1991 to 1999) identified from 
Surveillance, Epidemiology and End Result 
(SEER) Medicare databases - population-
based registry for incident cancer cases. 
SEER areas represent about 14% of the US 
population. Diagnosed with cancer between 
1991 and 1996. Aged 67 years and over. 
Receipt of hospice care. Determined by 
existence of a hospice claim in the hospice 
standard analytic file [Medicare claims]. 
2- 
Virnig 2002 
(USA) (25)  65+ 
388,511 deaths from one of seven cancers 
(1996) identified from the National Center for 
Health Statistics’ Report of Final Mortality 
Statistics. Aged 65 years and over.  
Use of hospice care. Determined from 1996 
hospice claims data submitted to the Health 
Care Financing Administration.  
2-  
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Table 1. Characteristics and quality appraisal of studies 
Study 
(location)  Age of patients  Participants  Outcome  SIGN score* 
Retrospective surveys of proxy respondents     
Addington-
Hall 1998 
(UK) (12) 
No stated restrictions 
2074 of 2094 (71% response rate) cancer 
deaths randomly sampled from 20 self-
selected health authorities. Deaths occurring 
in last quarter of 1990. For each death, the 
best informant about the deceased’s last 12 
months of life sought, and interviewed using a 
structured questionnaire. 
Receipt of hospice inpatient care. 
Determined by respondent’s recollection of 
the names of hospitals and hospices to 
which the deceased was admitted. Names 
cross-checked with the 1990 Directory of 
Hospice Services. 
2- 
Addington-
Hall 2000 
(UK) (13) 
No stated restrictions 
2074 of 2094 (71% response rate) cancer 
deaths randomly sampled from 20 self-
selected health authorities. Deaths occurring 
in last quarter of 1990. For each death, the 
best informant about the deceased’s last 12 
months of life sought, and interviewed using a 
structured questionnaire. 
Receipt of CSPC nursing. Determined by 
respondent’s reports of use of these services 
– no further details. 
2- 
McCusker 
1985 (USA) 
(24) 
No stated restrictions 
133 cancer deaths randomly selected from 
deaths in one county, December 1979 to 
January 1980. Surviving relatives contacted 
and interviewed (96/133 – 72% response 
rate). 
Use of the county home-hospice programme.   2- 
Retrospective case-control study       
Grande 2002 
(UK) (17)  No stated restrictions 
121 cancer patients referred to HAH from June 
1994 to June 1995 (cases) and 206 cancer 
deaths randomly sampled from the area 
Cancer Registry who were not referred to HAH 
(control). 
Referral to the Hospital at Home palliative 
care service. Not stated how determined.  2+ 
 
* Based on the SIGN methodological quality checklists. Code 2 ++ (High quality case-control, cohort or cross-sectional studies with a very low risk of confounding, 
bias, or chance and a high probability that the relationship is causal), 2+ (Well conducted case control, cohort or cross-sectional studies with a low risk of 
confounding, bias, or chance and a moderate probability that the relationship is causal), 2 - (Case control, cohort or cross-sectional studies with a high risk of 
confounding, bias, or chance and a significant risk that the relationship is not causal). NB: retrospective studies can only score + or -.  
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Table 2: Estimates of use of specialist palliative care by age group 
Study  Results: 
Use of SPC by age 
Extracted results: 
Crude (unadjusted) odds ratios  Multivariate analysis 
    Comparison 
group 
Odds 
ratio  95% CI   
Retrospective cohort studies 
Burge 2002 
(14) 
< 65 = 75% 
65-74 = 70% 
75-84 = 53% 
≥85 = 38% *  
* NB: No numerator or denominator 
data shown 
 
-  -  - 
Patients older than 65 less likely to receive SPC than patients 
under 65. Controlled for sex, cancer type, year of death and receipt 
of palliative radiotherapy. Odds ratios (OR): 
< 65 = 
65-74 = 
75-84 = 
≥85 = 
1.00 
0.72 (0.60, 0.85) 
0.44 (0.37, 0.53) 
0.21 (0.17, 0.27) 
Costantini 
1993 (15) 
<55 = 8.1% 
55-64 = 6.1% 
65-74 = 5.0% 
75-84 = 2.8% 
≥85 = 1.6% 
(92/1142) 
(139/2287) 
(179/3590) 
(110/4005) 
(21/1319) 
Over / under 
75 
 
0.41  
  0.33 to 0.50 
Multivariate analysis not conducted to investigate use of SPC 
(investigated predictors of home death for patients receiving care 
from SPC home care service) 
Evans 1984 
(16) 
<44 = 75.0% 
45-54 = 66.7% 
55-64 = 30.9% 
65-74 = 28.7% 
75-84 = 19.3% 
≥ 85 = 9.5% 
(9/12) 
(18/27) 
(29/94) 
(41/143) 
(23/119) 
(4/42) 
Over / under 
75 
 
0.37  0.23 to 0.60  Multivariate analysis not conducted 
Gray 1997 
(18) 
Mean age at death: 
Use SPC: 66.6 (SD 11.9) 
No use SPC: 73.0 (SD 10.6) 
-  -  -  Multivariate analysis not conducted 
Hunt 1996 
(19) 
<40 = 56.7% 
40-59 = 66.3% 
60-79 = 58.1% 
≥80 = 41.2% 
 
 
(51/90) 
(299/451) 
(963/1657) 
(248/602) 
Over / under 
80  0.47  0.39 to 0.57 
Patients older than 80 less likely to receive SPC compared to 
patients under 40. Controlled for area of residence, site, survival, 
place of birth, other variables uncertain/not stated. ORs:  
<40 = 
40-59 = 
60-79 = 
≥80 = 
1.00 
1.26 (0.78, 2.03) 
0.89 (0.57, 1.39) 
0.41 (0.26, 0.65)  
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Table 2: Estimates of use of specialist palliative care by age group 
Study  Results: 
Use of SPC by age 
Extracted results: 
Crude (unadjusted) odds ratios  Multivariate analysis 
    Comparison 
group 
Odds 
ratio  95% CI   
Hunt 2002 
(20) 
<60 = 73.3% 
60-69 = 73.6% 
70-79 = 70.9% 
≥80 = 58.3% 
 
(356/486) 
(457/621) 
(778/1097) 
(514/882) 
Over / under 
80  0.54  0.46 to 0.63 
Patients older than 80 less likely to receive SPC compared to 
patients under 60. Controlled for area of residence, country of 
birth, primary cancer site, survival from diagnosis. ORs: 
<60 = 
60-69 = 
70-79 = 
≥80 = 
1.00 
0.96 (0.72, 1.27) 
0.83 (0.64, 1.07) 
0.50 (0.39, 0.65) 
Johnston 1998 
(21) 
20-74 = 50.1 % 
≥75 = 35.0% 
 
(409/817) 
(182/520) 
Over / under 
75  0.54  0.43 to 0.67 
Older patients less likely to receive SPC compared to younger 
patients. Controlled for sex, cancer cause of death, provision of 
palliative radiation, year of death, time between diagnosis and 
death, place of residence. ORs: 
20-54 = 
55-64 =  
65-74 =  
75-84 =  
≥85 =  
4.9 (3.2, 7.6) 
3.4 (2.2, 5.1) 
3.1 (2.1, 4.5) 
2.1 (1.4, 3.1) 
1.0 
Lackan 2003 
(22) 
67-74 = 25.4% 
75-84 = 22.8% 
85-89 = 18.1% 
≥90 = 12.3% 
 
(1383/5443) 
(2432/10666) 
(861/4756) 
(528/4293) 
Over / under 
75  0.71  0.66 to 0.76  Effect of age in multivariate analysis not reported 
Lackan 2004 
(23) 
67-74 = 33.1% 
75-84 = 31.2% 
≥85 = 24.3% 
 
(18377/55520) 
(23411/75035) 
(9557/39329) 
Over / under 
75  0.82  0.80 to 0.84 
Multivariate analysis showed the effect of age (as a continuous 
variable) on use of hospice increased between 1991 and 1999 – 
adjusted odds ratios for use of hospice in 1991 were 0.99 (0.99–
1.00), and in 1999 0.98 (0.97–0.98) 
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Table 2: Estimates of use of specialist palliative care by age group 
Study  Results: 
Use of SPC by age 
Extracted results: 
Crude (unadjusted) odds ratios  Multivariate analysis 
    Comparison 
group 
Odds 
ratio  95% CI   
Virnig 2002 
(25) 
65-69 = 41.8 
70-74 = 45.0 
75-79 = 45.3 
80-84 = 45.0 
85-89 = 43.1 
90-94 = 41.0 
≥95 = 38.2 
 
Rate per 100 
deaths, 
standardised 
for sex and 
race 
-  -  -  Multivariate analysis not conducted (rates standardised for sex and 
race) 
Proxy surveys 
Addington-Hall 
1998 (12) 
<55 = 17.9% 
55-64 = 20.9% 
65-74 = 19.5% 
75-84 = 15.3% 
≥85 = 7.9% 
(37/207) 
(67/321) 
(111/570) 
(105/686) 
(22/277) 
 
Over / under 
75  0.62  0.49 to 0.79 
Being under the age of 85 years was significantly associated with 
an increased likelihood of receiving inpatient hospice care. Under 
85 odds ratio 2.82 (1.59 – 5.00). Variables included in model not 
explicitly stated. 
Addington-Hall 
2000 (13) 
<55 = 43.0% 
55-64 = 39.3% 
65-74 = 31.1% 
75-84 = 21.1% 
≥85 = 13.4% 
(89/207) 
(126/321) 
(177/570) 
(145/686) 
(37/277) 
 
Over / under 
75 
 
0.42  0.34 to 0.51 
Being under the age of 75 years was significantly associated with 
an increased likelihood of receiving community specialist palliative 
care nursing. Under 75 odds ratio 1.77 (1.4 – 2.3). Variables in 
model – 23, including type of respondent, marital status, whether 
had living children and symptoms.  
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Table 2: Estimates of use of specialist palliative care by age group 
Study  Results: 
Use of SPC by age 
Extracted results: 
Crude (unadjusted) odds ratios  Multivariate analysis 
    Comparison 
group 
Odds 
ratio  95% CI   
McCusker 
1985 (24) 
<65 = 61.9% 
65-74 = 35.9% 
≥75 = 34.1% 
(26/42) 
(14/39) 
(14/41) 
 
Over / under 
75  0.53  0.25 to 1.15  Multivariate analysis not conducted 
Retrospective case-control study 
Grande 2002 
(17) 
Users mean 
age 
Non-users 
mean age 
70.5 (SD 13.8) 
74.7 (SD 12.0) 
 
-  -  - 
Effect of age significant at a univariate level (difference in mean 
age between Hospice at Home and control groups P=.006); 
disappeared in multivariate logistic regression analysis. Variables 
in the final model predicting membership of the Hospice at Home 
group included non-cancer causes of death, cancer diagnosis, 
contact with oncologist, late start for acute hospital care, late start 
for district nursing input, and receipt of Marie Curie nursing care.  
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Appendix – search strategy 
 
  Medline example search strategy 
  1966 to March 2005 Week 1 
#1  Explode “Palliative Care” / all SUBHEADINGS 
#2  “Terminal Care” / all SUBHEADINGS 
#3  “Hospice Care” / all SUBHEADINGS 
#4  palliat* adj (care or treat* or nurs* or medic*) 
#5  terminal adj (care or nurs* or medic*) 
#6  hospice adj (inpatien* or care or treat* or nurs*) 
#7  end*of*life adj care 
#8  Macmillan adj nurs* 
#9  #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 
#10  “Referral and Consultation” / all SUBHEADINGS 
#11  Explode “Health Services Accessibility” / all SUBHEADINGS 
#12  referral 
#13  utili*ation 
#14  access 
#15  #10 or #11 or #12 or #13 or #14 
#16  #9 and #15 
#17  #16 Limit to English Language 
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Equity of use of specialist palliative care by age: cross-sectional 
study of lung cancer patients 
 
 
Abstract 
The equitable provision of care is a core principle of the NHS. Previous 
research has suggested that older cancer patients may be less likely to use 
specialist palliative care, but such research has been limited by retrospective 
design and the failure to measure clinical need. The objective of this study 
was to examine the extent to which the use of specialist palliative care in 
lung cancer patients varies by age, after accounting for need. A cross-
sectional survey of patients and their carers attending four hospital lung 
cancer clinics in London was conducted between June 2006 and April 2007. 
252 patients and 137 carers participated in the study. 39% of participants 
received specialist palliative care. Metastatic disease, global quality of life 
and the clinic where treatment was provided were associated with use of 
specialist palliative care. Age, gender, deprivation, living alone, current or 
most recent line of treatment, number of comorbidities and carer stress were 
not associated with receipt of such services. This suggests that, for patients 
within the specialist cancer care system, access to specialist palliative care is 
offered on the basis of need. 
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Introduction 
The provision of health care to all those in need, irrespective of their social 
characteristics, is a central tenet of the NHS. The NHS Constitution for 
England reinforces the principle that services should be available regardless 
of socioeconomic characteristics, gender, ethnicity, disability, age, sexual 
orientation, religion or belief. (1) This commitment to equity of access to all 
services is enshrined in NHS policies including the NHS Cancer Plan and the 
National Service Frameworks (NSFs). Thus, the NSF for Older People 
outlines steps to tackle age discrimination throughout the NHS (2) .  
 
The NSF for Older People highlighted concerns that older people may have 
limited access to specialist palliative care (SPC) services compared to 
younger patients. Systematic reviews conclude that there is evidence of 
inequalities in referral to and use of SPC services for older patients. (3-5) This 
does not seem to reflect patient choice or a lower need for care. (6;7) 
However, previous research has not comprehensively investigated and 
controlled for patients’ clinical and psycho-social needs for care. Therefore, 
we cannot draw reliable conclusions about the extent to which use of SPC is 
equitable (i.e. reflects the need for care) for older patients. (8) Furthermore, 
studies have rarely considered the needs of carers as well as patients in 
determining use, in spite of the stated aim of SPC to improve quality of life 
for patients and their families. (9)  
 
The aim of this research was to examine the clinical, psychosocial and socio-
demographic factors associated with receipt of SPC to investigate the extent 
to which older patients receive the care they need. We conducted our 
research amongst lung cancer patients: the high incidence, short prognosis, 
and frequently heavy symptom burden associated with this condition makes 
it particularly suitable for assessment of SPC provision.   
  495
Methods 
 
Study design 
We undertook a cross sectional survey of lung cancer patients attending 
chest or oncology outpatient clinics at four NHS Trusts in south London 
between June 2006 and April 2007. We developed eligibility criteria for 
participation following a pilot study and in consultation with clinic staff. 
Inclusion criteria were: adult patients with a clinical or histological diagnosis 
of primary lung cancer (non-small cell (NSCLC) and small cell (SCLC)) and 
the ability to fully understand consent procedures and complete study 
instruments in English. Patients were excluded if they had received surgery 
with curative intent, were not aware of their cancer diagnosis, or were 
participating in a clinical trial. In addition, patients attending clinic for 
immediate medical attention or receiving results concerning disease 
progression were not approached at that time. These criteria were designed 
to avoid distressing patients at particularly sensitive times. Informal carers 
attending clinic with participants were also invited to take part in the study 
to assess the association of carer stress with SPC use. All participants 
received written information about the study, and gave written informed 
consent. 
 
Ethical approval was sought and received from St Thomas’ Hospital NHS 
Research Ethics Committee. Research governance approval was sought and 
received separately from each of the four participating Trusts. 
 
Study instruments 
Participating patients and carers completed a semi-structured questionnaire 
whilst waiting for their clinic appointment. The patient questionnaire 
included 25 items covering their stated diagnosis and other illnesses, their  
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use of health care services for lung cancer, and personal details (based on 
items developed for the National Survey of NHS Patients by the Picker 
Institute and others). (10) In addition, the patient questionnaire included a 
validated quality of life instrument, the EORTC QLQ-C30 and its lung cancer 
module, the LC-13. (11;12) The EORTC QLQ-C30 includes five functional 
scales (physical, role, emotional, cognitive, and social), a global 
health/quality of life scale, and single measures of symptom severity (fatigue, 
nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, 
diarrhoea, and financial difficulties). The LC-13 module has one multi-item 
scale for dyspnoea, and single measures to assess symptoms associated with 
lung cancer, including dysphagia and chest pain. All scales and single items 
on the QLQ-C30 and LC-13 are scored from 0 to 100. High scores on the 
symptom scales represent a high level of symptoms, whilst high scores on 
the functional scales indicating a high (good) level of functioning. The time 
taken to complete the questionnaire ranged from ten to 30 minutes.  
 
The carer questionnaire comprised 13 items covering their relationship and 
help given to the attending patient and their personal details. It also included 
the General Health Questionnaire 12 item version (GHQ-12). The GHQ was 
developed as a self-administered screening instrument to detect general 
psychological distress, and is used worldwide in both healthy and ill 
populations. (13) It comprises twelve questions covering the respondent’s 
experience of anxiety and depression, general level of happiness, and sleep 
disturbance within the last few weeks. It uses a four-point response scale 
which can be scored in a variety of ways. (14) We scored responses using the 
0011 binary method, which rates each problem as either present or absent. 
The threshold value to determine cases of psychological distress was set 
conservatively at 3/4 (four problems present) to avoid false positives. (15) 
The carer questionnaire took an average of five minutes to complete.  
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Defining and measuring need for SPC 
To evaluate equity of use of a health care service (where equity is defined as 
equal use for equal need for health care), need for that care must be defined 
and measured. Need for health care is defined as a person’s capacity to 
benefit from use of that health care. (16) Capacity to benefit from SPC, 
typically reserved for those with ‘complex and persistent’ needs, is likely to 
encompass not just physical, but also social, psychological and spiritual 
domains. (17;18) However, there is little research evidence on how need for 
SPC is operationalised by referrers to and providers of these services. This is 
essential if we are to develop a comprehensive measure of need, rather than 
relying on common proxies such as diagnosis or the presence of physical 
symptoms. (3)  
 
The survey reported here formed one aspect of a wider programme of 
research investigating need for and use of SPC. (19) This included an 
ethnographic study of three SPC services to explore conceptualisations of 
need for care. We found that providers used an aspirational model of need in 
assessing referrals to their service, which encompassed a patient’s physical 
symptoms, psychological and spiritual issues, and social situation, as well as 
carer stress. 
 
Measures of need for SPC must reflect this holistic approach. We appraised 
existing instruments to measure palliative care need (20-22) but found they 
were not designed for patient-completion, were unsuitable for an outpatient 
setting, or did not reach accepted standards of psychometric robustness.  
 
The domains of need for SPC that we identified reflected definitions of 
health-related quality of life (HRQL) in palliative care, covering physical 
comfort, psychological wellbeing, social functioning and wellbeing, spiritual  
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wellbeing and meaningfulness of life, physical functioning, cognitive 
functioning, overall perceived quality of life and quality of dying. (23;24) 
HRQL has been used to approximate patients’ need for healthcare where 
validated health care needs questionnaires are not available. (25;26) This 
approach also enables access to an abundance of existing, psychometrically 
robust HRQL instruments. We therefore chose to use HRQL as an indicator 
of need for SPC.  
 
We conducted a systematic review and critical appraisal of HRQL 
instruments used in lung cancer and palliative care to consider the 
psychometric properties, conceptual relevance, and applicability of 65 
possible instruments to approximate need for care. (19) On the basis of this 
review we chose the EORTC QLQ-C30 and the LC-13 as our proxy measures 
of need for SPC. The primary indicator of need for SPC in our analysis was 
the global health/quality of life scale score.  
 
Additional explanatory factors 
Other potential explanatory factors obtained from questionnaire data were 
patient gender and ethnicity, whether the patient lived alone, and 
socioeconomic characteristics (SEC). We derived these from post code of 
residence, from which we obtained an Index of Multiple Deprivation (IMD) 
rank. (27) The IMD is a well established small-area measure widely used as a 
proxy indicator of SEC, including in lung cancer patients. (28) We divided 
IMD ranks into tertiles of deprivation (where 1 = least deprived, 2 = mid-
deprived and 3 = most deprived).  
 
In addition we obtained data from patients’ medical records and records of 
local service providers. Potential explanatory factors derived from medical 
records were patient’s date of birth, extent of disease (number and location  
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of metastases), current and previous treatment (surgery, chemotherapy, 
radiotherapy), known comorbidities, and clinics attended for both diagnosis 
and treatment. We calculated age by subtracting date of birth from date of 
study participation, categorised into four groups (<55, 55–64, 65–74, and 75+ 
years). Extent of disease was categorised as metastatic or not; line of 
treatment as first-line versus second or third line. Classification of 
comorbidity was based on seven comorbidities or groups of comorbidities 
which may impact on treatment decisions and prognosis in lung cancer 
patients (pulmonary disease, cardiovascular disease, cerebrovascular 
disease, other malignancies, hypertension, diabetes mellitus, and other 
including severe rheumatoid arthritis, ulcerative colitis and cirrhosis) (29;30). 
We classified patients as having 0, 1 or ≥ 2 comorbidities. Within the cancer 
network, patients may be diagnosed at one clinic (usually a cancer unit), but 
attend a different clinic for some or all of their treatment (usually the cancer 
centre). To assess the impact of the location of care on use of SPC, we used 
medical records to identify diagnosing and treating clinics (defined as the 
clinic patients were attending at the time of their participation in the study).  
 
We defined use of SPC as being on the caseload of a community palliative 
care provider or attending palliative care outpatient clinics at the time of 
participation. Patients classified as using SPC were therefore currently 
receiving advice and support from clinical nurse specialists, clinicians and 
other members of the multidisciplinary SPC team, whether by telephone, at 
home or in the outpatient setting. Our pilot study found disparities between 
palliative care use as reported by patients, hospital records and SPC 
providers. As patients may not always know or understand the affiliations of 
those caring for them, or be accurate in their recall of services received, and 
as hospital records do not necessarily reflect referrals made in the primary 
care setting, we  confirmed use of SPC directly from all SPC providers.   
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Sample size 
We estimated that within the available time frame we could recruit around 
250 patients. We predicted a 40% use of SPC, giving us 100 events available 
for analysis. (31) This would allow estimation of 10 parameters at a time with 
adequate precision in any multivariable regression model.  (32) We therefore 
decided to use univariable regression with a high significance level (p<=0.5) 
to first eliminate the weak explanatory variables, before entering the 
remaining explanatory variables in the multivariable regression model. 
 
Statistical analysis 
Potential explanatory variables chosen a priori for our main analysis were 
global quality of life, age, gender, deprivation, living alone, treating clinic, 
metastatic disease, current or most recent treatment, and number of 
comorbidities. We undertook logistic regression to investigate univariable 
and multivariable associations between these and use of SPC. Based on the 
univariable results, only explanatory variables with a P value of less than 0.5 
were included in multivariable analysis. We used backwards elimination 
with the threshold value for removal set at P > 0.05. To assess whether the 
same model could be achieved using a different approach, we used forward 
selection procedures with the same set of variables as part of a sensitivity 
analysis. Goodness-of-fit was assessed using the Hosmer-Lemeshow test. 
(33)  
 
Other explanatory variables of interest (diagnosing clinic, carer GHQ-12 
score, and additional EORTC QLQ-C30 and LC-13 scores) were not included 
in our main analysis as (a) they were secondary to our main hypothesis and 
(b) due to sample size constraints. Instead, we conducted two additional 
exploratory analyses. First, we identified key functional and symptom scores 
a priori to examine the association between particular dimensions of quality  
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of life and use of SPC. These were physical, role, emotional and social 
functioning, pain, nausea and vomiting, dyspnoea (measured using the more 
extensive LC-13 scale), fatigue, and appetite loss. We anticipated that the 
multivariable analysis would be constrained by multicollinearity. We used a 
correlation matrix (Spearman’s correlation coefficients r) to examine the 
degree of correlation, and calculated the proportion of moderately (r = 0.4 to 
0.7) and strongly (r = 0.7 to 0.9) correlated HRQL variable pairs. Weak 
pairwise correlation coefficients do not necessarily exclude multicollinearity 
in this situation, as collinearity may exist between three or more variables. 
(34) We therefore limited multivariable regression analyses to examining the 
effect of each HRQL variable in turn on use of SPC, controlling for other 
significant factors. As a result, models only included one HRQL variable at a 
time.  
 
Secondly, we assessed the association of carer stress with use of SPC, using 
data from patients for whom carer GHQ-12 scores were available. We 
examined univariable associations between GHQ-12 score (both as a 
continuous and as a dichotomous (case or not) variable) and use of SPC. We 
then added GHQ-12 score to the multivariable model developed for the 
entire data set, to assess whether an association existed after controlling for 
other factors found to be associated with use.  
 
We conducted all analyses using Stata (StataCorp. 2007. Statistical Software: 
Release 9.2. College Station, TX: Stata Corporation). 
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Results 
 
Recruitment 
307 eligible patients attended participating clinics during the study 
recruitment period, of whom 252 (82%) consented and completed the study 
instruments (Figure 1). Of the 252 participants, 178 (71%) attended clinic 
with at least one relative or friend, of whom 137 (79%) participated in the 
study. Table 1 summarises the demographic and clinical characteristics of the 
patients. In view of the small proportion (4.8%) of non-white patients, we 
excluded ethnicity from further analyses. A comparison of national data on 
lung cancer incidence (35) suggests that patients aged 75 and above were 
under-represented in our survey (30.2% vs. 42.5%) (Figure 2). 
 
Use of SPC 
99 (39.3%) of participants had confirmed use of SPC at the time of 
participation in the study. 22 patients (23%) were referred to SPC on the day 
of diagnosis. All of these patients had metastatic disease.  
 
 
Associations between patients’ clinical and demographic characteristics and 
their use of SPC 
Univariable analyses indicated that metastatic disease, global quality of life, 
current or most recent line of treatment, and treating clinic were associated 
with use of SPC (Table 2). Patient age, gender, deprivation, living alone and 
the number of comorbidities were not associated with SPC. 
 
Physical, role, emotional and social functioning dimensions of HRQL and 
symptoms of pain, fatigue and appetite loss were all associated with use of 
SPC at the 5% level of significance. 
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52% of carers who completed the GHQ-12 (70/135) were psychologically 
distressed. Complete data were available for 131 patient-carer pairs, of 
whom 53 (39.9%) were under SPC. For this group, GHQ-12 scores were not 
associated with SPC use.  
 
In multivariable analyses, backwards and forwards elimination produced a 
final model containing three variables: metastatic disease, global quality of 
life and treating clinic (Table 3). Age (< 75 / ≥ 75 and as a continuous 
variable) remained not significant when forced into the final regression 
model. The Hosmer-Lemeshow goodness of fit test for the final model 
produced a P value of 0.84, indicating the model fitted the data well. In our 
exploratory analysis, diagnosing clinic was also significant at a univariable 
(P = 0.003) and multivariable level (P = 0.005).  
 
Multivariable analysis of specific dimensions of HRQL in relation to SPC use 
was constrained by multicollinearity: a correlation matrix for key HRQL 
variables demonstrated that over three-quarters (77.8%) of the correlations 
had an r > 0.4. In separate models with treating clinic and metastatic disease, 
pain and fatigue showed the strongest association with receiving SPC, along 
with physical and role functioning (Table 4).  
 
Discussion 
We found no association between patient age and use of SPC. Receipt of 
such care was, however, associated with metastatic disease, patient’s global 
quality of life, and treating (and diagnosing) cancer clinic. Patients had a 
high overall symptom burden, with pain, dyspnoea and fatigue reported by 
the majority of participants. In half of the informal carers surveyed, 
psychological distress was elevated, although this was not associated with 
use of SPC.  
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Strengths and weaknesses 
This is the first time an investigation of SPC use has controlled for need 
using a psychometrically validated instrument. Furthermore, we have 
demonstrated the feasibility of gathering data directly from this vulnerable 
group of patients, rather than relying on routine data sources or carer 
perceptions. Our methodology enabled us to gather a wide range of potential 
explanatory factors directly from patients, and to confirm use of SPC with 
providers of care. We are therefore confident of the validity of our findings. 
 
Another important strength of our study was the high recruitment rate, with 
82% of eligible patients taking part. This increases the likely generalisability 
of our results. However, 46.9% of patients (n=271) attending clinic during the 
recruitment period were ineligible to participate in the study, primarily 
because they were  receiving results concerning disease progression, or 
required immediate medical attention (56.1% of those ineligible). This 
decision was taken following the study pilot to ensure patients were not 
disturbed at a sensitive time, and could have resulted in recruitment of 
patients with less extensive disease or symptoms. However, participants’ 
EORTC scores were comparable to, or worse than, reference values for 
NSCLC and SCLC patients, suggesting they were representative of lung 
cancer patients as a whole. (36) 
 
Our inclusion of three cancer units and one cancer centre within one network 
in London reflects the re-organisation of cancer services throughout England 
since the implementation of the NHS Cancer Plan. Whilst this increases the 
likelihood that our findings are generalisable to other metropolitan areas, 
they may not apply to less urban areas with different models of SPC 
provision. In addition, the outpatient setting excluded lung cancer patients  
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following other diagnostic and treatment routes, who may have different 
patterns of use of SPC – this is discussed further below.  
 
Patients over 75 years were under-represented in our sample. This may be 
attributable to the contribution of 48% of participants by the cancer centre, 
many of whom travel large distances to attend. More elderly patients may 
choose not to travel such distances to receive their care. In addition, older 
patients may be more likely to be treated as inpatients; to be cared for under 
different specialties including medicine for the elderly; or to be diagnosed (if 
at all) much later in the disease course and to remain outside the lung cancer 
clinic setting. (37) The consequence is that we cannot draw conclusions about 
the equity of SPC provision for all patients over 75 years. Additionally, we 
have not investigated whether timeliness of SPC referral varies by age. 
 
Comparison with other studies 
Systematic reviews of access to SPC have concluded that older patients are 
less likely to receive SPC compared with their younger counterparts. (3-5) 
However, these reviews include studies from countries outside the UK with 
different funding and organisation of care. The UK based research reporting 
lower use of palliative care services among older patients (38-40) relied on 
retrospective data using reports from bereaved carers and routine data 
sources, thus reducing the validity of the outcomes measured. (3) Previous 
studies also differ from this study by their inclusion of cancer, non-cancer 
and non-site specific cancer patients who may have followed a number of 
different treatment paths. (38-40) 
 
We found that half of participating carers had significant levels of 
psychological distress. This figure is comparable to that found amongst 
carers of people with another debilitating chronic disease (Alzheimer’s  
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disease) (41), and four times higher than that found in the general population 
(42), thus suggesting that our findings are valid. 
 
Explanations for findings 
Our findings suggest that, once patients are within the specialist cancer care 
system, SPC is made available regardless of patient age. The association of 
poorer global quality of life, as well as symptoms such as pain and fatigue, 
with SPC use suggest that referrals are responsive to patient need for care. 
However, we have demonstrated association rather than causation, and our 
data do not enable us to assess the reasons for referral to care. For example, it 
may be that referrers respond to the presence of advanced, metastatic disease 
rather than the symptoms this causes. (43) One of the consequences of the 
Calman-Hine cancer care reforms was an expansion in the numbers of 
palliative care consultants and nurses working as members of the lung 
cancer multidisciplinary team. This is likely to have raised the profile and 
understanding of SPC, and facilitated appropriate referrals to these services. 
(44) However, the lack of association between carer distress and use of SPC 
may reflect a narrow focus within participating clinics on patient need alone. 
Staff may not be aware of the extent of carers’ distress or may not feel 
referral to SPC is an appropriate response. Further work is needed in this 
area to assess how the needs of carers can be best met. (45) 
 
We also found that the hospital clinic within which patients were treated or 
diagnosed was an important determinant of SPC use. This suggests that a 
reduction in regional variations in access to care (a key aim of the Calman-
Hine reforms) has not been fully realised, at least in terms of access to SPC. 
Variation in the propensity of clinics to refer to SPC has been reported 
elsewhere (46) and may be dependent upon individual clinic staff’s attitudes 
towards and knowledge of SPC; the skills and availability of lung nurse  
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specialists; and the integration of the clinic with local SPC services. (47) The 
clinics studied differed in their staff composition and skill-mix: thus, the 
presence of a lung nurse specialist with a palliative care background in one 
cancer unit may explain the lower proportion of palliative care referrals 
compared to a clinic without a lung nurse specialist available to support 
patients. Additionally, there were indications that differences in perceived 
availability of SPC between clinics (for example, known staffing problems 
within local SPC services, or poor provision within the local area) may 
impact on the likelihood of referrals  
 
Finally our results diverge from other studies which demonstrate the 
influence of age on the likelihood of lung cancer treatment. (48). The 
different results may be explained by different decision making criteria for 
referral to care which improves quality of life (such as SPC), compared to 
care which extends length of life. (49;50) Denial of life-extending treatments 
for older people may be perceived to be acceptable (e.g. on the basis of 
beliefs about ‘good innings’ or ‘normal’ ageing (51)), whilst age related 
criteria for referral to quality of life enhancing care may be perceived to be 
inhumane. (52) This may explain why clinicians and nursing staff are willing 
to refer patients to SPC regardless of age, in spite of continuing evidence of 
ageism in access to lung cancer treatments.  
 
Conclusions and recommendations for further research 
Our results are to some extent encouraging, suggesting that extent of 
patients’ disease and quality of life, rather than sociodemographic 
characteristics such as age, are associated with SPC referral decisions within 
the specialist cancer care setting. However, outstanding questions remain to 
be resolved. The pathway to care for patients of all ages must be examined to 
determine whether our results apply to patients treated in settings other than  
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the specialist cancer care system (such as care of the elderly). Research into 
the SPC referral decision-making process would further understanding of 
concepts of need for SPC, and how variations in referrals may arise. The 
wide variation in use of SPC between clinics also requires further 
exploration, including the extent to which differences in clinic culture, 
provider relationships and service availability influence access to SPC.  
 
  
  509
 
References 
 
  (1)  Department of Health. The NHS Constitution. London: Department of 
Health; 2009.  
  (2)  DoH. National Service Framework for Older People. London: 
Department of Health; 2001.  
  (3)  Burt J, Raine R. The effect of age on referral to and use of specialist 
palliative care services in adult cancer patients: a systematic review. 
Age Ageing 2006;35(5):469-76. 
  (4)  Walshe C, Todd C, Caress A, Chew-Graham C. Patterns of Access to 
Community Palliative Care Services: A Literature Review. J Pain 
Symptom Manage 2009 May;37(5):884-912. 
  (5)  Ahmed N, Bestall JC, Ahmedzai SH, Payne S, Clark D, Noble B. 
Systematic review of the problems and issues of accessing specialist 
palliative care by patients, carers and health and social care 
professionals. Palliat Med 2004;18(6):525-42. 
  (6)  Catt S, Blanchard M, Addington-Hall JM, Zis M, Blizard R, King M. 
Older adults' attitudes to death, palliative treatment and hospice care. 
Palliat Med 2005;19(5):402-10. 
  (7)  Teunissen SC, de Haes HC, Voest EE, de Graeff A. Does age matter 
in palliative care? Critical Reviews in Oncology/Hematology 2006 
November;60(2):152-8. 
  (8)  Raine R. Bias measuring bias. J Health Serv Res & Policy 
2002;7(1):65-7. 
  (9)  WHO. National Cancer Control Programmes: Policies and guidelines. 
Geneva: World Health Organization; 2002.  
 (10)  National Centre for Social Research, Picker Institute Europe, and 
Imperial College School of Science, Technology and Medicine. The 
National Survey of NHS Patients Questionnaire. London: Department 
of Health; 2007.  
 (11)  Aaronson NK, Ahmedzai SH, Bergman B, Bullinger M, Cull A, Duez 
NJ et al. The European Organization for Research and Treatment of 
Cancer QLQ-C30: a quality-of-life instrument for use in international 
clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-76. 
 (12)  Bergman B, Aaronson NK, Ahmedzai SH, Kaasa S, Sullivan M. The 
EORTC QLQ-LC13 - a Modular Supplement to the Eortc Core Quality-
of-Life Questionnaire (QLQ-C30) for Use in Lung-Cancer Clinical-
Trials. Eur J Cancer 1994;30A(5):635-42.  
  510
 (13)  Goldberg, D. P. and Williams, P. A user's guide to the General Health 
Questionnaire. Windsor: NFER-Nelson; 1998.  
 (14)  Goldberg, D. P. and Williams, P. A user's guide to the General Health 
Questionnaire. Windsor: NFER-Nelson; 1988.  
 (15)  Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O 
et al. The validity of two versions of the GHQ in the WHO study of 
mental illness in general health care. Psychol Med 1997;27(1):191-7. 
 (16)  Culyer AJ, Wagstaff A. Equity and equality in health and health care. J 
Health Econ 1993;12(4):431-57. 
 (17)  Goddard M, Smith P. Equity of access to health care services: Theory 
and evidence from the UK. Soc Sci Med 2001;53(9):1149-62. 
 (18)  WHO. Palliative Care - The Solid Facts. Copenhagen: WHO Regional 
Office for Europe; 2004.  
 (19)  Burt J. Equity, need and access in health care: a mixed methods 
investigation of specialist palliative care use in relation to age 
[Unpublished PhD Thesis] UCL; 2010. 
 (20)  Ewing G, Todd C, Rogers M, Barclay S, McCabe J, Martin A. 
Validation of a symptom measure suitable for use among palliative 
care patients in the community: CAMPAS-R. J Pain Symptom Manage 
2004;27(4):287-99. 
 (21)  Bruera E, Kuehn N, Miller MJ, et.al. The Edmonton symptom 
assessment system (ESAS): a simple method for the assessment of 
palliative care patients. J Palliat Care 1991;7:6-9. 
 (22)  Higginson IJ. Audit methods: A community schedule. In: Higginson IJ, 
editor. Clinical audit in palliative care.Oxford: Radcliffe Medical Press; 
1993. p. 34-7. 
 (23)  Stewart AL, Teno J, Patrick DL, Lynn J. The concept of quality of life 
of dying persons in the context of health care. J Pain Symptom 
Manage 1999;17(2):93-108. 
 (24)  Cella DF. Quality-of-Life - Concepts and Definition. J Pain Symptom 
Manage 1994;9(3):186-92. 
 (25)  Asadi-Lari M, Packham C, Gray D. Is quality of life measurement likely 
to be a proxy for health needs assessment in patients with coronary 
artery disease. Health Qual Life Outcomes 2003;1:50. 
 (26)  Carr AJ, Gibson B, Robinson PG. Measuring quality of life - Is quality 
of life determined by expectations or experience? BMJ 
2001;322(7296):1240-3.  
  511
 (27)  Office of the Deputy Prime Minister. The English Indices of 
Deprivation 2004 (revised). London: Office of the Deputy Prime 
Minister; 2004.  
 (28)  Patel N, Adatia R, Mellemgaard A, Jack R, Moller H. Variation in the 
use of chemotherapy in lung cancer. Br J Cancer 2007;96(6):886-90. 
 (29)  Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development 
and validation. Journal of Chronic Diseases 1987;40:373-83. 
 (30)  Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin 
MA, Coebergh JWW. Prevalence of comorbidity in lung cancer 
patients and its relationship with treatment: A population-based study. 
Lung Cancer 1998;21(2):105-13. 
 (31)  Addington-Hall, J. M., Shipman, C., Burt, J., Ream, E., Beynon, T., 
and Richardson, A. Evaluation of the education and support 
programme for district and community nurses in the principles and 
practice of palliative care. London: King's College London; 2006.  
 (32)  Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A 
simulation study of the number of events per variable in logistic 
regression analysis. J Clin Epidemiol 1996 December;49(12):1373-9. 
 (33)  Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: 
John Wiley & Sons; 1989. 
 (34)  Van Steen K, Curran D, Kramer J, Molenberghs G, Van Vreckem A, 
Bottomley A et al. Multicollinearity in prognostic factor analyses using 
the EORTC QLQ-C30: identification and impact on model selection. 
Stat Med 2002;21(24):3865-84. 
 (35)  Office for National Statistics. Cancer Statistics registrations: 
Registrations of cancer diagnosed in 2004, England. London: National 
Statistics; 2005.  
 (36)  Fayers, P., Weeden, S., and Curran, D. EORTC QLQ-C30 Reference 
Values. Brussels: EORTC Quality of Life Study Group; 1998.  
 (37)  Melling PP, Hatfield AC, Muers MF, Peake MD, Storer CJ, Round CE 
et al. Lung cancer referral patterns in the former Yorkshire region of 
the UK. Br J Cancer 2002;86(1):36-42. 
 (38)  Grande GE, Farquhar MC, Barclay SIG, Todd CJ. The influence of 
patient and carer age in access to palliative care services. Age Ageing 
2006;35(3):267-73. 
 (39)  Addington-Hall JM, Altmann D. Which terminally ill cancer patients in 
the United Kingdom receive care from community specialist palliative 
care nurses? J Adv Nurs 2000;32(4):799-806.  
  512
 (40)  Grande GE, McKerral A, Todd CJ. Which cancer patients are referred 
to Hospital at Home for palliative care? Palliat Med 2002;16(2):115-
23. 
 (41)  Schneider J, Murray J, Banerjee S, Mann A. EUROCARE: a cross-
national study of co-resident spouse carers for people with 
Alzheimer's disease: I - factors associated with carer burden. Int J 
Geriatr Psychiatr 1999;14(8):651-61. 
 (42)  Joint Health Surveys Unit, National Centre for Social Research and 
Department of Epidemiology and Public Health at the Royal Free and 
University College Medical School. Health Survey for England 2003. 
Summary of key findings. London: National Statistics; 2004.  
 (43)  Cooley ME, Short TH, Moriarty HJ. Symptom prevalence, distress, 
and change over time in adults receiving treatment for lung cancer. 
Psycho-Oncology 2003;12(7):694-708. 
 (44)  Jack B, Oldham J, Williams A. A stakeholder evaluation of the impact 
of the palliative care clinical nurse specialist upon doctors and nurses, 
within an acute hospital setting. Palliat Med 2003 April 1;17(3):283-8. 
 (45)  Soothill K, Morris SM, Harman JC, FRANCIS B, Thomas C, 
McIllmurray MB. Informal carers of cancer patients: what are their 
unmet psychosocial needs? Health and Social Care in the Community 
2001;9(6):464-75. 
 (46)  Keating NL, Herrinton LJ, Zaslavsky AM, Liu L, Ayanian JZ. Variations 
in Hospice Use Among Cancer Patients. J Natl Cancer Inst 2006 
August 2;98(15):1053-9. 
 (47)  Walshe C, Chew-Graham C, Todd C, Caress A. What influences 
referrals within community palliative care services? A qualitative case 
study. Soc Sci Med 2008 July;67(1):137-46. 
 (48)  Peake MD, Thompson S, Lowe D, Pearson MG. Ageism in the 
management of lung cancer. Age Ageing 2003;32(2):171-7. 
 (49)  Williams A. The rationing debate: Rationing health care by age: The 
case for. BMJ 1997;314:820. 
 (50)  Evans JG. The rationing debate: Rationing health care by age: The 
case against. BMJ 1997;314:822. 
 (51)  Williams A. Intergenerational equity: An exploration of the 'fair innings' 
argument. Health Econ 1997;6(2):117-32. 
 (52)  Callahan D, Topinkova E. Age, Rationing and Palliative Care. In: 
Morrison RS, Meier DE, editors. Geriatric Palliative Care.USA: Oxford 
University Press; 2003. p. 46-78. 
  
  513
Fig 1. Recruitment flow chart 
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Fig 2: Age group of participating lung cancer patients compared to lung cancer 
incidence in England 2004
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Data for England from: Office for National Statistics. Cancer Statistics registrations: 
Registrations of cancer diagnosed in 2004, England. London: National Statistics; 2005  
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Table 1: Demographic and clinical characteristics of patients 
  n (%) 
Age (years)  (n = 252) 
< 55  26 (10.3) 
55-64  55 (21.8) 
65-74  95 (37.7) 
≥ 75  76 (30.2) 
Gender  (n = 252) 
Male  139 (55.2) 
Female  113 (44.8) 
Ethnicity *  (n = 251) 
White  239 (95.2) 
Other  12 (4.8) 
Social situation   
Lives alone  80 (31.8) 
Children < 18 in household  13 (5.2) 
Carer for another person  30 (12.0) 
Area-level deprivation (IMD 2004)  (n = 251) 
Least deprived  47 (18.7) 
Mid deprived  68 (27.1) 
Most deprived  136 (54.2) 
Type and stage of cancer at diagnosis    
NSCLC:  184 (73.9) 
Stage I  18 (10.3) 
Stage II  12 (6.9) 
Stage III  79 (45.4) 
Stage IV  65 (37.4) 
SCLC:  61 (24.5) 
Limited  17 (29.3) 
Extensive  41 (70.7) 
Not known  4 (1.6) 
Time since diagnosis   
< 1 month  13 (5.2) 
1 to < 3 months  61 (24.2) 
3 to < 6 months  40 (15.9) 
≥ 6 months  138 (54.8) 
Metastatic disease at participation   
No  109 (43.3) 
Yes  143 (56.8) 
Site of metastatic disease **   
Other lung  58 (33.1)  
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Bone  35 (20.0) 
Liver  31 (17.7) 
Adrenal  22 (12.6) 
Brain  20 (11.4) 
Other  9 (5.1) 
Treating clinic   
1  121 (48.0) 
2  93 (36.9) 
3  24 (9.5) 
4  14 (5.6) 
 
 
      * Excluded from analysis due to small numbers in non-white groups 
** Totals add up to more than 143 as 28 patients had metastatic disease at two 
sites, and two patients had metastatic disease at three sites 
      NSCLC (Non-small cell lung cancer); SCLC (Small cell lung cancer)  
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Table 2: Univariable regression analysis 
  OR  95% CI  P value 
Age          
Under 75  1.00       
75 and over  0.84  0.48  1.46  0.53 
Gender         
Male  1.00       
Female  1.56  0.94  2.60  0.09 
Deprivation         
Least deprived  1.00       
Mid deprived  1.09  0.51  2.36   
Most deprived  1.24  0.62  2.45  0.81 
Living alone         
No  1.00       
Yes  1.42  0.83  2.43  0.21 
Treating clinic         
1  1.00       
2  0.38  0.21  0.70   
3  2.48  0.99  6.23   
4  1.24  0.41  3.75  <0.001 
Metastatic disease         
No  1.00       
Yes  2.85  1.66  4.90  <0.001 
Current/most recent 
treatment         
First line  1.00       
Second or third line  1.95  1.02  3.75  0.045 
Number of 
comorbidities         
None  1.00       
One  0.84  0.47  1.50   
Two or more  1.12  0.58  2.18  0.69 
Global quality of life         
One unit increase  0.97  0.96  0.99  <0.001 
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Table 3: Final model for use of SPC 
  OR  95% CI  P value 
Treating clinic         
1  1.00       
2  0.37  0.19  0.71   
3  2.43  0.90  6.52   
4  0.95  0.28  3.23  0.002 
Metastatic disease         
No  1.00       
Yes  2.60  1.44  4.68  0.002 
Global quality of life         
One unit increase  0.97  0.96  0.98  <0.001 
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Table 4: Exploratory regression analysis – use of SPC by key HRQL variables 
  Univariable analysis 
Multivariable analysis: 
recruiting site and 
metastatic disease included 
  OR  95% CI  P  OR  95% CI  P 
Physical functioning                 
One unit increase  0.98  0.97  0.99  <0.001  0.97  0.96  0.99  <0.001 
Role functioning                 
One unit increase  0.98  0.98  0.99  <0.001  0.98  0.97  0.99  <0.001 
Emotional functioning                 
One unit increase  0.98  0.97  0.99  0.001  0.98  0.97  0.99  <0.001 
Social functioning                 
One unit increase  0.99  0.98  1.00  0.002  0.99  0.98  1.00  0.005 
Fatigue                 
One unit increase  1.02  1.01  1.03  <0.001  1.02  1.01  1.03  <0.001 
Nausea and vomiting                 
One unit increase  1.01  0.99  1.02  0.202  1.01  1.00  1.02  0.184 
Pain                 
One unit increase  1.02  1.01  1.02  <0.001  1.02  1.01  1.03  <0.001 
Dyspnoea                 
One unit increase  1.01  1.00  1.02  0.038  1.02  1.00  1.03  0.006 
Loss of appetite                 
One unit increase  1.01  1.00  1.02  0.004  1.01  1.00  1.02  0.003 
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